https://www.spreaker.com/podcast/longevity-technology--7312602esLeisureCopyright saderhttps://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/3213a135d5523647024c90a15c3fb0af.jpghttps://www.spreaker.com/podcast/longevity-technology--7312602Wed, 02 Sep 2026 18:53:33 +0000sadersaderfeeds@spreaker.comLongevity.Technologyfalse73f979aa-3831-5b62-809a-2aaad14697e0episodichttps://www.spreaker.com/episode/are-longevity-clinics-actually-evidence-based--74818012
Founder & CEO of Longevity Center and Longevity Academy
LinkedIn: https://www.linkedin.com/in/joanna-bensz-205b315/
Website: https://longevity-academy.com/, https://longevity-center.eu/

----------
What happens when longevity becomes a global industry before the medical system has agreed on what good longevity medicine actually looks like?

Phil Newman sits down with Joanna Bensz, entrepreneur, founder of the International Institute of Longevity, Longevity Academy and Round Table of Longevity Clinics, to explore how a rapidly expanding sector can develop credible standards while keeping pace with commercialization. They discuss the growth of longevity clinics, from premium destinations and telehealth platforms to sports centres and preventive health providers, and why Joanna estimates that only around 20% of the clinics she knows genuinely focus on diagnostics and interventions.

The conversation examines peptides, biological-age testing, clinical education and the need for protocols that connect biomarkers with appropriate interventions rather than simply adding more treatments. Joanna explains how Longevity Academy evolved from an internal doctor-training programme into an educational platform for clinicians, drawing on real-world clinic experience, biomarkers, testing and treatment decisions.

The episode goes beyond the clinic itself, examining the growing role of sports centres, retreats, AI, mental health, nervous-system regulation, nutrition and family health. Joanna argues that longevity should not be reduced to peptides or expensive interventions, but should include the everyday environments and behaviours that shape health across the lifespan.

In this episode, you’ll learn:

- Why rapid commercialization could outpace the development of clinical standards
- Why Joanna estimates only around 20% of longevity clinics genuinely focus on diagnostics and interventions
- How Longevity Academy is helping doctors bridge gaps in conventional medical education
- Why peptides illustrate the regulatory differences between the US and Europe
- Why longevity clinics need doctors, nutritionists, psychologists, coaches and other specialists working together
- How biomarkers can be used to track changes before and after interventions

Ultimately, this episode asks whether longevity medicine can become a credible part of healthcare without losing scientific and clinical rigor as the market scales. For Joanna, the path forward involves better education, clearer standards, measurable outcomes, collaboration and a more integrated approach to health that extends beyond the traditional doctor-patient relationship.

Subscribe for weekly episodes exploring longevity science, preventative medicine, healthcare innovation and the systems shaping how we live longer and better.
----------

Host:

Phil Newman: https://qrco.de/bgXpNY
----------

Timestamps:

00:00:01 - The Longevity Standards Problem
00:03:25 - Clinics Enter A New Era
00:08:22 - Commercialization vs. Clinical Rigor
00:09:50 - The Peptide Problem
00:13:33 - Educating The Modern Patient
00:14:49 - Training Longevity Doctors
00:17:40 - Building Clinical Standards
00:21:33 - Only 20% Meet The Bar
00:25:00 - Longevity Beyond The Clinic
00:28:38 - Can Standards Become Reality?
00:31:14 - Longevity Beyond Shortcuts
00:35:39 - The Multidisciplinary Clinic
00:37:53 - Longevity For Families
00:40:52 - The Future Of Independent Clinics
00:49:44 - Inside The Longevity Round Table]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987256647954436Mon, 31 Aug 2026 09:41:57 +0000saderGuest: Joanna Bensz Founder & CEO of Longevity Center and Longevity Academy LinkedIn: https://www.linkedin.com/in/joanna-bensz-205b315/ Website: https://longevity-academy.com/, https://longevity-center.eu/ ---------- What happens when longevity...
Founder & CEO of Longevity Center and Longevity Academy
LinkedIn: https://www.linkedin.com/in/joanna-bensz-205b315/
Website: https://longevity-academy.com/, https://longevity-center.eu/

----------
What happens when longevity becomes a global industry before the medical system has agreed on what good longevity medicine actually looks like?

Phil Newman sits down with Joanna Bensz, entrepreneur, founder of the International Institute of Longevity, Longevity Academy and Round Table of Longevity Clinics, to explore how a rapidly expanding sector can develop credible standards while keeping pace with commercialization. They discuss the growth of longevity clinics, from premium destinations and telehealth platforms to sports centres and preventive health providers, and why Joanna estimates that only around 20% of the clinics she knows genuinely focus on diagnostics and interventions.

The conversation examines peptides, biological-age testing, clinical education and the need for protocols that connect biomarkers with appropriate interventions rather than simply adding more treatments. Joanna explains how Longevity Academy evolved from an internal doctor-training programme into an educational platform for clinicians, drawing on real-world clinic experience, biomarkers, testing and treatment decisions.

The episode goes beyond the clinic itself, examining the growing role of sports centres, retreats, AI, mental health, nervous-system regulation, nutrition and family health. Joanna argues that longevity should not be reduced to peptides or expensive interventions, but should include the everyday environments and behaviours that shape health across the lifespan.

In this episode, you’ll learn:

- Why rapid commercialization could outpace the development of clinical standards
- Why Joanna estimates only around 20% of longevity clinics genuinely focus on diagnostics and interventions
- How Longevity Academy is helping doctors bridge gaps in conventional medical education
- Why peptides illustrate the regulatory differences between the US and Europe
- Why longevity clinics need doctors, nutritionists, psychologists, coaches and other specialists working together
- How biomarkers can be used to track changes before and after interventions

Ultimately, this episode asks whether longevity medicine can become a credible part of healthcare without losing scientific and clinical rigor as the market scales. For Joanna, the path forward involves better education, clearer standards, measurable outcomes, collaboration and a more integrated approach to health that extends beyond the traditional doctor-patient relationship.

Subscribe for weekly episodes exploring longevity science, preventative medicine, healthcare innovation and the systems shaping how we live longer and better.
----------

Host:

Phil Newman: https://qrco.de/bgXpNY
----------

Timestamps:

00:00:01 - The Longevity Standards Problem
00:03:25 - Clinics Enter A New Era
00:08:22 - Commercialization vs. Clinical Rigor
00:09:50 - The Peptide Problem
00:13:33 - Educating The Modern Patient
00:14:49 - Training Longevity Doctors
00:17:40 - Building Clinical Standards
00:21:33 - Only 20% Meet The Bar
00:25:00 - Longevity Beyond The Clinic
00:28:38 - Can Standards Become Reality?
00:31:14 - Longevity Beyond Shortcuts
00:35:39 - The Multidisciplinary Clinic
00:37:53 - Longevity For Families
00:40:52 - The Future Of Independent Clinics
00:49:44 - Inside The Longevity Round Table]]>3112falsefullhttps://www.spreaker.com/episode/the-51m-bet-to-make-the-doctor-obsolete--74818016
The Longevity Investors Conference brings together the scientists working at the root of aging, the clinicians translating research into practice, the founders building the next generation of longevity companies, and the investors deciding what gets funded next.

The seventh edition takes place from 14 to 17 September 2026 at Le Grand Bellevue in Gstaad, Switzerland. Participation is limited and applications are reviewed individually.

Click the link below to apply for LIC 2026.

Link: https://www.longevityinvestors.ch/lic-2026

----------

Guests:

Max Marchione
Founder & CEO of Superpower, Speaker at Longevity Investors Conference Gstaad 2026
LinkedIn and X: ⁠https://www.linkedin.com/in/maxmarchione/⁠,⁠ https://x.com/maxmarchione⁠
Website: ⁠https://superpower.com/⁠

----------
What if the future of healthcare is not a better hospital, but a system designed to keep you out of one?

Phil Newman sits down with Max Marchione, co-founder and CEO of Superpower, to explore his vision for a preventive health platform combining advanced diagnostics, longitudinal health data, wearables, AI and clinicians in one continuous system.

Recorded as a Longevity Investors Conference special, the conversation examines why healthcare remains largely reactive and episodic, and what it would take to create an experience that continuously monitors health, connects biological signals and intervenes before problems become disease.

Max explains how Superpower uses AI to examine data across blood tests, medical records and wearables, identifying patterns that may be difficult to uncover during a short medical appointment. They also discuss where human clinicians remain essential, particularly when decisions involve prescriptions, hormone therapy or other higher-risk interventions.

The conversation explores the limitations of conventional blood-test reference ranges, the growing interest in peptides, including GLP-1 therapies and the controversial BPC-157, and why promising anecdotes must still be tested through rigorous clinical research.

They also discuss Superpower’s direct-to-consumer and employer-funded models, the observational health dataset the company is building, the regulatory debate around right-to-try laws and Max’s much larger ambition to help create healthier cities.

In this episode, you’ll learn:

- Why Max believes healthcare will become more preventive, continuous and software-driven.
- How AI could connect patterns across blood tests, wearables, medical records and reported symptoms.
- Why being within a “normal” blood-test range does not necessarily mean a result is optimal for long-term health.
- Where AI may support medical reasoning and why physicians remain responsible for important treatment decisions.
- How Superpower aims to make elements of high-cost concierge medicine accessible at a lower price.
- Why employers and insurers may have a financial incentive to invest in preventive healthcare.
- Why peptides could become an increasingly important medical modality, and where the evidence remains uncertain.
- How repeated testing, treatment data and symptom tracking could contribute to longitudinal observational research.
- What right-to-try laws could mean for medical autonomy, regulation and clinical innovation.
- What a health-first city might look like and why infrastructure, community and culture matter as much as policy.

If you want to understand how AI, continuous diagnostics and longitudinal data could shift healthcare from episodic treatment toward proactive health management, this episode connects an ambitious technological vision with the clinical, commercial and regulatory realities of building a new healthcare system.

Subscribe for weekly episodes exploring longevity science, preventive medicine and the systems shaping how we live longer and better.
----------

Host:

Phil Newman: https://qrco.de/bgXpNY
----------

Timestamps:

00:00:00 - Could Healthcare Exist Without Hospitals?
00:00:30 - A Longevity Investors Conference Special
00:00:58 - Meet Max Marchione And Superpower
00:02:22 - Building Against Healthcare Convention
00:05:05 - Will AI Make Doctors Obsolete?
00:07:09 - Fixing Healthcare’s Financial Incentives
00:09:10 - Consumer Health And Employer Coverage
00:10:53 - What “Normal” Blood Results Can Miss
00:13:20 - How AI Connects Health Data
00:15:27 - Making Concierge Medicine Accessible
00:17:59 - The Future And Risks Of Peptides
00:20:40 - Building A Longitudinal Medical Dataset
00:21:59 - Right-To-Try And Medical Innovation
00:23:51 - Balancing Innovation With Clinical Oversight
00:26:47 - Who Will Build The Consumer Health System?
00:29:16 - Why A $30 Billion Exit Would Be A Failure
00:31:38 - Celebrity Investors And Brand Awareness
00:32:47 - Max’s Vision For Health-First Cities
00:35:06 - The Longevity Investors Conference
00:36:01 - The Investment Case For Consumer Health
00:37:26 - Where To Follow Max]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987256647954460Mon, 24 Aug 2026 14:28:49 +0000saderSponsor: Longevity Investors Conference The Longevity Investors Conference brings together the scientists working at the root of aging, the clinicians translating research into practice, the founders building the next generation of longevity...
The Longevity Investors Conference brings together the scientists working at the root of aging, the clinicians translating research into practice, the founders building the next generation of longevity companies, and the investors deciding what gets funded next.

The seventh edition takes place from 14 to 17 September 2026 at Le Grand Bellevue in Gstaad, Switzerland. Participation is limited and applications are reviewed individually.

Click the link below to apply for LIC 2026.

Link: https://www.longevityinvestors.ch/lic-2026

----------

Guests:

Max Marchione
Founder & CEO of Superpower, Speaker at Longevity Investors Conference Gstaad 2026
LinkedIn and X: ⁠https://www.linkedin.com/in/maxmarchione/⁠,⁠ https://x.com/maxmarchione⁠
Website: ⁠https://superpower.com/⁠

----------
What if the future of healthcare is not a better hospital, but a system designed to keep you out of one?

Phil Newman sits down with Max Marchione, co-founder and CEO of Superpower, to explore his vision for a preventive health platform combining advanced diagnostics, longitudinal health data, wearables, AI and clinicians in one continuous system.

Recorded as a Longevity Investors Conference special, the conversation examines why healthcare remains largely reactive and episodic, and what it would take to create an experience that continuously monitors health, connects biological signals and intervenes before problems become disease.

Max explains how Superpower uses AI to examine data across blood tests, medical records and wearables, identifying patterns that may be difficult to uncover during a short medical appointment. They also discuss where human clinicians remain essential, particularly when decisions involve prescriptions, hormone therapy or other higher-risk interventions.

The conversation explores the limitations of conventional blood-test reference ranges, the growing interest in peptides, including GLP-1 therapies and the controversial BPC-157, and why promising anecdotes must still be tested through rigorous clinical research.

They also discuss Superpower’s direct-to-consumer and employer-funded models, the observational health dataset the company is building, the regulatory debate around right-to-try laws and Max’s much larger ambition to help create healthier cities.

In this episode, you’ll learn:

- Why Max believes healthcare will become more preventive, continuous and software-driven.
- How AI could connect patterns across blood tests, wearables, medical records and reported symptoms.
- Why being within a “normal” blood-test range does not necessarily mean a result is optimal for long-term health.
- Where AI may support medical reasoning and why physicians remain responsible for important treatment decisions.
- How Superpower aims to make elements of high-cost concierge medicine accessible at a lower price.
- Why employers and insurers may have a financial incentive to invest in preventive healthcare.
- Why peptides could become an increasingly important medical modality, and where the evidence remains uncertain.
- How repeated testing, treatment data and symptom tracking could contribute to longitudinal observational research.
- What right-to-try laws could mean for medical autonomy, regulation and clinical innovation.
- What a health-first city might look like and why infrastructure, community and culture matter as much as policy.

If you want to understand how AI, continuous diagnostics and longitudinal data could shift healthcare from episodic treatment toward proactive health management, this episode connects an ambitious technological vision with the clinical, commercial and regulatory realities of building a new healthcare system.

Subscribe...]]>2342falsefullhttps://www.spreaker.com/episode/from-k-beauty-to-k-longevity-south-korea-s-new-health-model-longevity-news-roundup-week-34-2026--74818024
- South Korea is attracting international patients with comprehensive preventive screening that can combine bloodwork, imaging, cardiovascular assessment, cancer screening and physician consultation in a highly compressed pathway.
- Network Bio has launched with $50 million in financing, using patient tissue, paired blood samples, molecular data and longitudinal outcomes to search for biological signals that transfer across diseases.
- Utah is building a different kind of longevity hub, with physician-led practices, fitness and recovery businesses, diagnostics, consumer health brands and wellness companies clustering around Salt Lake City and Park City.
- GenBio AI has launched AIDO Cell, a stateful virtual cell designed to connect DNA, RNA, proteins and cellular behavior while retaining the effects of previous interventions.
- Longevica Therapeutics has appointed Dr. Prasun Mishra as CEO, bringing Genentech, Roche and NIH experience into a company attempting to move large-scale mammalian longevity research toward drug development.

----------
News & References:

- ‘The barriers aren’t clinical, they’re structural’ → https://longevity.technology/news/the-barriers-arent-clinical-theyre-structural/
- Network Bio launches with $50m for biological AI → https://longevity.technology/news/network-bio-launches-with-50m-for-biological-ai/
- Utah is building America’s longevity capital → https://longevity.technology/news/utah-is-building-americas-longevity-capital/
- Can AI put the cell back together? → https://longevity.technology/news/can-ai-put-the-cell-back-together/
- Longevica appoints ex-Genentech biotech veteran as CEO → https://longevity.technology/news/longevica-appoints-ex-genentech-biotech-veteran-as-ceo/

----------
Host:

Phil Newman: https://qrco.de/bgXpNY]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987256647954474Fri, 21 Aug 2026 09:52:46 +0000saderIn this week’s Longevity News Roundup, Phil Newman examines South Korea’s emerging health tourism model, Network Bio’s biological data platform, Utah’s growing longevity economy, GenBio AI’s virtual cell system, and Longevica’s push toward clinical...
- South Korea is attracting international patients with comprehensive preventive screening that can combine bloodwork, imaging, cardiovascular assessment, cancer screening and physician consultation in a highly compressed pathway.
- Network Bio has launched with $50 million in financing, using patient tissue, paired blood samples, molecular data and longitudinal outcomes to search for biological signals that transfer across diseases.
- Utah is building a different kind of longevity hub, with physician-led practices, fitness and recovery businesses, diagnostics, consumer health brands and wellness companies clustering around Salt Lake City and Park City.
- GenBio AI has launched AIDO Cell, a stateful virtual cell designed to connect DNA, RNA, proteins and cellular behavior while retaining the effects of previous interventions.
- Longevica Therapeutics has appointed Dr. Prasun Mishra as CEO, bringing Genentech, Roche and NIH experience into a company attempting to move large-scale mammalian longevity research toward drug development.

----------
News & References:

- ‘The barriers aren’t clinical, they’re structural’ → https://longevity.technology/news/the-barriers-arent-clinical-theyre-structural/
- Network Bio launches with $50m for biological AI → https://longevity.technology/news/network-bio-launches-with-50m-for-biological-ai/
- Utah is building America’s longevity capital → https://longevity.technology/news/utah-is-building-americas-longevity-capital/
- Can AI put the cell back together? → https://longevity.technology/news/can-ai-put-the-cell-back-together/
- Longevica appoints ex-Genentech biotech veteran as CEO → https://longevity.technology/news/longevica-appoints-ex-genentech-biotech-veteran-as-ceo/

----------
Host:

Phil Newman: https://qrco.de/bgXpNY]]>985falsefullhttps://www.spreaker.com/episode/the-longevity-tests-that-actually-matter--74818069Phil Newman: ⁠https://qrco.de/bgXpNY⁠
Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠


----------
Sponsor: YEARS


YEARS is a physician-led longevity clinic in Berlin that takes a proactive approach to health. Combining advanced diagnostics, biomarkers, imaging, and longitudinal data, YEARS helps identify health risks earlier and build personalized strategies designed to support healthier, longer lives.

Link: https://www.years.co/en


----------
Guests:

Jürgen Mehrtens
Co-Founder & CEO of YEARS
LinkedIn: https://www.linkedin.com/in/j%C3%BCrgen-mehrtens-116303b1/
Website: https://www.years.co/en

Alexandru Ardelean, MD
Specialist in Internal Medicine of YEARS
LinkedIn: https://www.linkedin.com/in/alexandru-c-ardelean-md-aba522109/
Website: https://www.years.co/en

----------
What if the future of preventive medicine is not simply better treatment, but knowing what is changing in the body years before disease appears?

Phil Newman and Dr. Nina Patrick sit down with Dr. Alexandru Ardelean, internal medicine specialist at YEARS, and Jürgen Mehrtens, CEO of YEARS, to explore how predictive biomarkers and longitudinal health data could reshape the way we understand aging and prevention.

Together they unpack the growing role of biomarkers such as GDF-15 and P-tau217. GDF-15 can reflect processes including mitochondrial dysfunction, hypoxia, oxidative stress, and chronic inflammation, while longitudinal measurements may reveal patterns that a single test cannot. They also discuss why these biomarkers are not yet used to prescribe specific treatments, but can help measure whether lifestyle interventions are working.

The conversation also explores how YEARS is building a standardized longitudinal dataset by requiring clients to undergo the same diagnostic framework over time, creating data that could eventually help researchers and pharmaceutical companies better understand aging.

They discuss biomarker variability, false negatives, patient adherence, community-based interventions, the role of partner gyms, YEARS' upcoming app, and the potential for private preventive medicine models to influence broader healthcare systems.

In this episode, you’ll learn:


- Why GDF-15 is emerging as a marker of cellular stress and how it relates to mitochondrial dysfunction, oxidative stress, hypoxia, and chronic inflammation.
- Why P-tau217 and other predictive biomarkers still require careful interpretation, longitudinal measurement, and clinical context before they can guide primary prevention.
- How YEARS is building longitudinal datasets through standardized diagnostics repeated annually or every two years.
- Why lifestyle interventions remain the foundation of prevention, even as increasingly sophisticated biomarkers become available.
- How community events, partner gyms, and digital monitoring can help patients stay engaged between clinical visits.

If you want to understand how predictive biomarkers could move healthcare from reacting to disease toward continuously measuring and managing risk, this episode connects emerging biomarker science with the practical realities of preventive medicine, patient behavior, and the future of longevity clinics.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
Timestamps:

00:00:00 - The Predictive Biomarker Era
00:00:55 - From Reactive To Preventive
00:03:58 - The Biomarker Gap
00:07:09 - Why GDF-15 Matters
00:11:05 - YEARS' Biomarker Strategy
00:12:52 - Measuring Treatment Success
00:15:09 - False Positives And Negatives
00:17:32 - The Cellular Stress Reserve
00:20:42 - Building Longitudinal Data
00:24:40 - Community And Adherence
00:27:51 - Berlin's Changing Clinic Landscape
00:29:54 - Tracking Patients Between Visits
00:31:57 - Changing Healthcare Systems
00:33:02 - Biomarkers As Aging Clocks
00:35:36 - The Future Of YEARS]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987256647954466Mon, 17 Aug 2026 09:23:48 +0000saderHosts: Phil Newman: ⁠https://qrco.de/bgXpNY⁠ Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠ ---------- Sponsor: YEARS YEARS is a physician-led longevity clinic in Berlin that takes a proactive approach to health. Combining advanced diagnostics,...Phil Newman: ⁠https://qrco.de/bgXpNY⁠
Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠


----------
Sponsor: YEARS


YEARS is a physician-led longevity clinic in Berlin that takes a proactive approach to health. Combining advanced diagnostics, biomarkers, imaging, and longitudinal data, YEARS helps identify health risks earlier and build personalized strategies designed to support healthier, longer lives.

Link: https://www.years.co/en


----------
Guests:

Jürgen Mehrtens
Co-Founder & CEO of YEARS
LinkedIn: https://www.linkedin.com/in/j%C3%BCrgen-mehrtens-116303b1/
Website: https://www.years.co/en

Alexandru Ardelean, MD
Specialist in Internal Medicine of YEARS
LinkedIn: https://www.linkedin.com/in/alexandru-c-ardelean-md-aba522109/
Website: https://www.years.co/en

----------
What if the future of preventive medicine is not simply better treatment, but knowing what is changing in the body years before disease appears?

Phil Newman and Dr. Nina Patrick sit down with Dr. Alexandru Ardelean, internal medicine specialist at YEARS, and Jürgen Mehrtens, CEO of YEARS, to explore how predictive biomarkers and longitudinal health data could reshape the way we understand aging and prevention.

Together they unpack the growing role of biomarkers such as GDF-15 and P-tau217. GDF-15 can reflect processes including mitochondrial dysfunction, hypoxia, oxidative stress, and chronic inflammation, while longitudinal measurements may reveal patterns that a single test cannot. They also discuss why these biomarkers are not yet used to prescribe specific treatments, but can help measure whether lifestyle interventions are working.

The conversation also explores how YEARS is building a standardized longitudinal dataset by requiring clients to undergo the same diagnostic framework over time, creating data that could eventually help researchers and pharmaceutical companies better understand aging.

They discuss biomarker variability, false negatives, patient adherence, community-based interventions, the role of partner gyms, YEARS' upcoming app, and the potential for private preventive medicine models to influence broader healthcare systems.

In this episode, you’ll learn:


- Why GDF-15 is emerging as a marker of cellular stress and how it relates to mitochondrial dysfunction, oxidative stress, hypoxia, and chronic inflammation.
- Why P-tau217 and other predictive biomarkers still require careful interpretation, longitudinal measurement, and clinical context before they can guide primary prevention.
- How YEARS is building longitudinal datasets through standardized diagnostics repeated annually or every two years.
- Why lifestyle interventions remain the foundation of prevention, even as increasingly sophisticated biomarkers become available.
- How community events, partner gyms, and digital monitoring can help patients stay engaged between clinical visits.

If you want to understand how predictive biomarkers could move healthcare from reacting to disease toward continuously measuring and managing risk, this episode connects emerging biomarker science with the practical realities of preventive medicine, patient behavior, and the future of longevity clinics.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
Timestamps:

00:00:00 - The Predictive Biomarker Era
00:00:55 - From Reactive To Preventive
00:03:58 - The Biomarker Gap
00:07:09 - Why GDF-15 Matters
00:11:05 - YEARS' Biomarker Strategy
00:12:52 - Measuring Treatment Success
00:15:09 - False Positives And Negatives
00:17:32 - The Cellular Stress Reserve
00:20:42 - Building...]]>1994falsefullhttps://www.spreaker.com/episode/the-longevity-industry-is-building-its-own-rules-longevity-news-roundup-week-33-2026--74818013
FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week’s Longevity News Roundup, Phil Newman examines how longevity is developing the clinical standards, biological models and infrastructure needed to move from promising technology toward real-world medicine.

- Viome’s acquisition of Circulate Health brings therapeutic plasma exchange into a platform built around diagnostics, nutrition and coaching. Circulate’s network spans more than 200 partner clinics, creating a “measure, act, remeasure” model, while recent data on microplastics and biological age highlight the gap between measurable changes and proven healthspan outcomes.
- Longevity Clinics World and the Healthy Longevity Medicine Society have signed an MOU focused on evidence-based medicine, shared terminology, education, quality improvement and standardization. The collaboration also emphasizes that future accreditation must have separate governance and independent oversight.
- Kailera Therapeutics reported an active IND for ribupatide oral, with initiation of global Phase 3 obesity trials planned for the first half of 2027, and says its ribupatide injection Phase 2b high-dose obesity trial is fully enrolled with data anticipated in mid-2027; global Phase 3 KaiNETIC enrollment is on track for more than 4,700 participants with data expected in 2028.
- Immorta Bio proposes combining multi-omics, AI, digital twins and secure patient-owned data into a continuously learning precision-medicine system. Exploratory metabolomic data from more than 2,000 individuals identified nine metabolites associated with age.
- Insilico Medicine is developing its Virtual Aging Cell platform to model biological change across six interconnected scales, making biological age a core variable rather than simply an output. The key question is whether these simulations can generate predictions that survive experimental and clinical validation.

----------
News & References:

- Virtual cells learn to grow old → https://longevity.technology/news/virtual-cells-learn-to-grow-old/
- Immorta Bio maps out AI’s next move in longevity → https://longevity.technology/news/immorta-bio-maps-out-ais-next-move-in-longevity/
- Kailera Therapeutics reports Q2 2026 results, updates progress on obesity trials → https://longevity.technology/news/kailera-therapeutics-reports-q2-2026-results-updates-progress-on-obesity-trials/
- HLMS and Longevity Clinics World join forces on standards → https://longevity.technology/news/hlms-and-longevity-clinics-world-join-forces-on-standards/
- Is blood filtering the new wellness flex? → https://longevity.technology/news/is-blood-filtering-the-new-wellness-flex/

----------
Hosts:

Phil Newman: https://qrco.de/bgXpNY]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987256647954446Sat, 15 Aug 2026 11:10:46 +0000saderSponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more...
FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week’s Longevity News Roundup, Phil Newman examines how longevity is developing the clinical standards, biological models and infrastructure needed to move from promising technology toward real-world medicine.

- Viome’s acquisition of Circulate Health brings therapeutic plasma exchange into a platform built around diagnostics, nutrition and coaching. Circulate’s network spans more than 200 partner clinics, creating a “measure, act, remeasure” model, while recent data on microplastics and biological age highlight the gap between measurable changes and proven healthspan outcomes.
- Longevity Clinics World and the Healthy Longevity Medicine Society have signed an MOU focused on evidence-based medicine, shared terminology, education, quality improvement and standardization. The collaboration also emphasizes that future accreditation must have separate governance and independent oversight.
- Kailera Therapeutics reported an active IND for ribupatide oral, with initiation of global Phase 3 obesity trials planned for the first half of 2027, and says its ribupatide injection Phase 2b high-dose obesity trial is fully enrolled with data anticipated in mid-2027; global Phase 3 KaiNETIC enrollment is on track for more than 4,700 participants with data expected in 2028.
- Immorta Bio proposes combining multi-omics, AI, digital twins and secure patient-owned data into a continuously learning precision-medicine system. Exploratory metabolomic data from more than 2,000 individuals identified nine metabolites associated with age.
- Insilico Medicine is developing its Virtual Aging Cell platform to model biological change across six interconnected scales, making biological age a core variable rather than simply an output. The key question is whether these simulations can generate predictions that survive experimental and clinical validation.

----------
News & References:

- Virtual cells learn to grow old → https://longevity.technology/news/virtual-cells-learn-to-grow-old/
- Immorta Bio maps out AI’s next move in longevity → https://longevity.technology/news/immorta-bio-maps-out-ais-next-move-in-longevity/
- Kailera Therapeutics reports Q2 2026 results, updates progress on obesity trials → https://longevity.technology/news/kailera-therapeutics-reports-q2-2026-results-updates-progress-on-obesity-trials/
- HLMS and Longevity Clinics World join forces on standards → https://longevity.technology/news/hlms-and-longevity-clinics-world-join-forces-on-standards/
- Is blood filtering the new wellness flex? → https://longevity.technology/news/is-blood-filtering-the-new-wellness-flex/

----------
Hosts:

Phil Newman: https://qrco.de/bgXpNY]]>1169falsefullhttps://www.spreaker.com/episode/are-glp-1-drugs-costing-you-muscle-the-truth-about-protein-weight-loss--74818033Phil Newman: ⁠https://qrco.de/bgXpNY⁠
Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠


----------
Sponsor: YEARS


YEARS is a physician-led longevity clinic in Berlin that takes a proactive approach to health. Combining advanced diagnostics, biomarkers, imaging, and longitudinal data, YEARS helps identify health risks earlier and build personalized strategies designed to support healthier, longer lives.

Link: https://www.years.co/en


----------
Guest:

Tom Rifai MD FACP DipABLM
Founder and CEO at Reality Meets Science®
LinkedIn: https://www.linkedin.com/in/flex5/
Website: https://realitymeetsscience.com/

Cristopher Gardner, PhD
Professor of Medicine and Director at Stanford Nutrition Studies Research Group
LinkedIn: https://www.linkedin.com/in/christopher-gardner-phd/
Website: https://med.stanford.edu/profiles/christopher-gardner

Stuart Phillips, PhD
Professor; Director, PACE and Professor, Kinesiology, Faculty of Science at McMaster University
LinkedIn: https://www.linkedin.com/in/stuartmphillips/
Website: https://mira.mcmaster.ca/our-faculty/stuart-phillips/


----------
What if the biggest advances in longevity have less to do with finding the perfect diet, and more to do with preserving muscle, improving movement, and building habits that last?

Phil Newman and Dr. Nina Patrick sit down with Dr. Christopher Gardner, Professor of Medicine at Stanford University and one of the world's leading nutrition researchers, Dr. Stuart Phillips, internationally recognized expert in skeletal muscle, aging, exercise, and protein metabolism, and Dr. Tom Rifai, lifestyle medicine physician and nutrition specialist, to separate nutrition science from social media hype.

Together they unpack why popular diet labels often distract from what truly matters, why muscle is emerging as one of the most important predictors of healthy aging, and how exercise, dietary quality, and sustainable behavior change consistently outperform quick fixes. From Mediterranean and vegan diets producing remarkably similar health outcomes when built around whole foods, to the growing challenges of preserving muscle during GLP-1 driven weight loss, the discussion highlights where the evidence is strongest and where public perception has drifted away from the science.

The panel also explores whether most people really need more protein, why resistance training matters far more than simply increasing protein intake, how clinicians should approach muscle preservation in older adults, and why food policy, environment, and long-term coaching may ultimately have a greater impact on population health than the latest nutrition trend.

In this episode, you’ll learn:


- Why the quality of your diet matters far more than choosing keto, vegan, carnivore, or Mediterranean
- How skeletal muscle supports mobility, glucose regulation, metabolic health, and healthy aging
- What current evidence actually says about protein requirements for longevity and muscle maintenance
- Why GLP-1 medications should ideally be paired with resistance training, nutrition guidance, and lifestyle support
- How small, sustainable behavior changes consistently outperform restrictive diets and short-term fixes
- Why whole foods, vegetables, legumes, and minimally processed diets remain the strongest common ground across nutrition research

Whether you're trying to make sense of conflicting nutrition advice, optimize healthy aging, or understand where longevity science is actually headed, this conversation brings together decades of clinical research, practical medicine, and real-world experience to reveal the bigger picture.

Subscribe for weekly conversations exploring longevity science, preventative medicine, biotechnology, and the innovations shaping how we live longer, healthier lives.

----------
Timestamps:

00:00:00 - Nutrition's Big Question
00:02:14 - Diet Myths Explained
00:07:46 - Why Extreme Diets Win
00:10:28 - The Protein Debate
00:16:05 - Why Muscle Matters
00:18:02 - Are We Overdoing Protein?
00:25:20 - GLP-1s and Muscle Loss
00:30:53 - Protein During Weight Loss
00:41:54 - Measuring Strength
00:44:41 - Building Better Habits
00:51:28 - The Longevity Industry
00:59:05 - Lessons from Blue Zones
01:01:52 - Final Nutrition Takeaways
01:03:48 - Behavior Over Perfection
01:05:06 - Closing Thoughts]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987256647954457Mon, 10 Aug 2026 09:32:15 +0000saderHosts: Phil Newman: ⁠https://qrco.de/bgXpNY⁠ Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠ ---------- Sponsor: YEARS YEARS is a physician-led longevity clinic in Berlin that takes a proactive approach to health. Combining advanced diagnostics,...Phil Newman: ⁠https://qrco.de/bgXpNY⁠
Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠


----------
Sponsor: YEARS


YEARS is a physician-led longevity clinic in Berlin that takes a proactive approach to health. Combining advanced diagnostics, biomarkers, imaging, and longitudinal data, YEARS helps identify health risks earlier and build personalized strategies designed to support healthier, longer lives.

Link: https://www.years.co/en


----------
Guest:

Tom Rifai MD FACP DipABLM
Founder and CEO at Reality Meets Science®
LinkedIn: https://www.linkedin.com/in/flex5/
Website: https://realitymeetsscience.com/

Cristopher Gardner, PhD
Professor of Medicine and Director at Stanford Nutrition Studies Research Group
LinkedIn: https://www.linkedin.com/in/christopher-gardner-phd/
Website: https://med.stanford.edu/profiles/christopher-gardner

Stuart Phillips, PhD
Professor; Director, PACE and Professor, Kinesiology, Faculty of Science at McMaster University
LinkedIn: https://www.linkedin.com/in/stuartmphillips/
Website: https://mira.mcmaster.ca/our-faculty/stuart-phillips/


----------
What if the biggest advances in longevity have less to do with finding the perfect diet, and more to do with preserving muscle, improving movement, and building habits that last?

Phil Newman and Dr. Nina Patrick sit down with Dr. Christopher Gardner, Professor of Medicine at Stanford University and one of the world's leading nutrition researchers, Dr. Stuart Phillips, internationally recognized expert in skeletal muscle, aging, exercise, and protein metabolism, and Dr. Tom Rifai, lifestyle medicine physician and nutrition specialist, to separate nutrition science from social media hype.

Together they unpack why popular diet labels often distract from what truly matters, why muscle is emerging as one of the most important predictors of healthy aging, and how exercise, dietary quality, and sustainable behavior change consistently outperform quick fixes. From Mediterranean and vegan diets producing remarkably similar health outcomes when built around whole foods, to the growing challenges of preserving muscle during GLP-1 driven weight loss, the discussion highlights where the evidence is strongest and where public perception has drifted away from the science.

The panel also explores whether most people really need more protein, why resistance training matters far more than simply increasing protein intake, how clinicians should approach muscle preservation in older adults, and why food policy, environment, and long-term coaching may ultimately have a greater impact on population health than the latest nutrition trend.

In this episode, you’ll learn:


- Why the quality of your diet matters far more than choosing keto, vegan, carnivore, or Mediterranean
- How skeletal muscle supports mobility, glucose regulation, metabolic health, and healthy aging
- What current evidence actually says about protein requirements for longevity and muscle maintenance
- Why GLP-1 medications should ideally be paired with resistance training, nutrition guidance, and lifestyle support
- How small, sustainable behavior changes consistently outperform restrictive diets and short-term fixes
- Why whole foods, vegetables, legumes, and minimally processed diets remain the strongest common ground across nutrition research

Whether you're trying to make sense of conflicting nutrition advice, optimize healthy aging, or understand where longevity science is actually headed, this conversation brings together decades of clinical research, practical medicine, and real-world experience to reveal the bigger picture.

Subscribe for weekly conversations exploring longevity science, preventative medicine,...]]>3828falsefullhttps://www.spreaker.com/episode/why-women-may-need-a-completely-different-longevity-playbook-longevity-news-roundup-week-32-2026--74818025
FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week's Longevity News Roundup, Phil Newman explores whether aging research has overlooked half the population, why supplement quality is becoming a scientific issue, how NAD+ science is moving into pharmaceutical development, and what superagers reveal about the limits of genetic prediction.

- A new $7.5 million NIH-funded center at USC will investigate sex differences in aging after decades of male-biased research. The initiative could reshape biomarkers, clinical trials, and personalized longevity interventions.
- Swiss longevity company Timeline won a $5.3 million judgment against sellers falsely marketing products as containing urolithin A. The ruling reinforces that scientific evidence depends on products containing the same ingredient and dose used in clinical research.
- Niagen Bioscience has partnered with Evotec to advance NB4168, an oral NAD+ small molecule for a rare pediatric neurodegenerative disease. The collaboration highlights how longevity companies are increasingly translating supplement science into regulated drug development.
- Researchers found that superagers shared similar Alzheimer's genetic risk profiles with cognitively average older adults. Rather than supporting a DNA destiny narrative, the findings point toward resilience mechanisms that future studies will explore through biomarkers, immune profiling, brain imaging, and lifestyle.

----------
News & References:

- What if aging research has been studying the wrong sex? → https://longevity.technology/news/what-if-aging-research-has-been-studying-the-wrong-sex/
- Timeline wins $5.3m in fake urolithin A case → https://longevity.technology/news/timeline-wins-5-3m-in-fake-urolithin-a-case/
- Niagen Bioscience teams up with Evotec to prepare rare disease drug for human trials → https://longevity.technology/news/niagen-bioscience-teams-up-with-evotec-to-prepare-rare-disease-drug-for-human-trials/
- SuperAgers challenge the DNA destiny narrative → https://longevity.technology/news/superagers-challenge-the-dna-destiny-narrative/

----------
Hosts:

Phil Newman: https://qrco.de/bgXpNY]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987256647954450Fri, 07 Aug 2026 09:44:36 +0000saderSponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more...
FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week's Longevity News Roundup, Phil Newman explores whether aging research has overlooked half the population, why supplement quality is becoming a scientific issue, how NAD+ science is moving into pharmaceutical development, and what superagers reveal about the limits of genetic prediction.

- A new $7.5 million NIH-funded center at USC will investigate sex differences in aging after decades of male-biased research. The initiative could reshape biomarkers, clinical trials, and personalized longevity interventions.
- Swiss longevity company Timeline won a $5.3 million judgment against sellers falsely marketing products as containing urolithin A. The ruling reinforces that scientific evidence depends on products containing the same ingredient and dose used in clinical research.
- Niagen Bioscience has partnered with Evotec to advance NB4168, an oral NAD+ small molecule for a rare pediatric neurodegenerative disease. The collaboration highlights how longevity companies are increasingly translating supplement science into regulated drug development.
- Researchers found that superagers shared similar Alzheimer's genetic risk profiles with cognitively average older adults. Rather than supporting a DNA destiny narrative, the findings point toward resilience mechanisms that future studies will explore through biomarkers, immune profiling, brain imaging, and lifestyle.

----------
News & References:

- What if aging research has been studying the wrong sex? → https://longevity.technology/news/what-if-aging-research-has-been-studying-the-wrong-sex/
- Timeline wins $5.3m in fake urolithin A case → https://longevity.technology/news/timeline-wins-5-3m-in-fake-urolithin-a-case/
- Niagen Bioscience teams up with Evotec to prepare rare disease drug for human trials → https://longevity.technology/news/niagen-bioscience-teams-up-with-evotec-to-prepare-rare-disease-drug-for-human-trials/
- SuperAgers challenge the DNA destiny narrative → https://longevity.technology/news/superagers-challenge-the-dna-destiny-narrative/

----------
Hosts:

Phil Newman: https://qrco.de/bgXpNY]]>831falsefullhttps://www.spreaker.com/episode/why-normal-blood-results-could-be-misleading--74818038
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: https://www.getstride.com/unlocked/

----------
Guest: Andrew Steele

Co-Founder & CEO of Stride
LinkedIn: https://www.linkedin.com/in/andrewsteeleathlete/
Website: https://www.getstride.com/eu/

----------
What if the future of healthcare isn't about finding disease earlier, but preventing it from developing in the first place?

Phil Newman and Dr. Nina Patrick sit down with Andrew Steele, founder and CEO of Stride and former Olympic sprinter, to explore how personalized health is evolving beyond wearables, blood tests, and genetic reports into a truly integrated model of prevention. Drawing on his experience as an elite athlete and entrepreneur, Andrew explains why collecting more health data isn't enough, and why the real challenge is helping people make better decisions that actually change long term behavior.

The conversation explores how Stride combines genetics, microbiome testing, advanced blood biomarkers, wearable data, and practitioner coaching into a single preventive health platform designed to prioritize the actions that matter most. Rather than overwhelming people with hundreds of recommendations, Andrew argues that sustainable health improvement comes from identifying a few highly personalized interventions that create momentum for broader lifestyle change.

They also discuss how longitudinal testing can reveal patterns that traditional healthcare often misses. Instead of relying on whether a biomarker sits inside or outside a population reference range, Andrew explains why understanding an individual's direction of travel over time may provide much earlier signals of future health risks. The discussion explores how integrating multiple biological data layers could eventually allow AI powered systems to identify preclinical risk years before disease develops.

The episode also examines the growing role of consumer health technologies, the limitations of existing healthcare systems, and why prevention increasingly sits outside traditional medicine. Andrew shares why he believes younger generations are embracing longevity as part of their identity, how behavioral psychology influences successful health interventions, and why human coaching remains essential even in an AI driven future.

In this episode, you’ll learn:

- Why personalized health requires more than DNA tests or wearable devices
- How combining genetics, microbiome data, blood biomarkers, and lifestyle creates a more complete picture of health
- Why focusing on three meaningful actions is more effective than dozens of recommendations
- How longitudinal biomarker tracking may detect risk before conventional clinical thresholds are reached
- Why AI works best when combined with experienced healthcare practitioners

If you want to understand where personalized medicine is heading, how AI could transform prevention, and why the next generation of healthcare may be built around continuous, individualized guidance rather than reactive treatment, this episode offers an insightful look at the future of longevity.

Subscribe for weekly conversations exploring longevity science, precision medicine, biotechnology, AI, and the innovations shaping healthier, longer lives.

----------
Timestamps:

00:00:00 - Beyond Health Data
00:01:24 - Ice Bath Lessons
00:04:41 - Athlete to Founder
00:08:04 - The Olympic Turning Point
00:12:29 - Building Stride
00:15:19 - Why Multiomics Matters
00:18:38 - Humans + AI
00:21:00 - Prioritizing Health
00:24:44 - Biomarkers Over Time
00:27:12 - Consumer vs Healthcare
00:32:03 - Predicting Future Risk
00:34:44 - The Future of Prevention
00:39:06 - Rapid Fire
00:42:21 - Biological Age Challenge
00:45:31 - Final Thoughts]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079307Mon, 03 Aug 2026 11:38:06 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Stride Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing,...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: https://www.getstride.com/unlocked/

----------
Guest: Andrew Steele

Co-Founder & CEO of Stride
LinkedIn: https://www.linkedin.com/in/andrewsteeleathlete/
Website: https://www.getstride.com/eu/

----------
What if the future of healthcare isn't about finding disease earlier, but preventing it from developing in the first place?

Phil Newman and Dr. Nina Patrick sit down with Andrew Steele, founder and CEO of Stride and former Olympic sprinter, to explore how personalized health is evolving beyond wearables, blood tests, and genetic reports into a truly integrated model of prevention. Drawing on his experience as an elite athlete and entrepreneur, Andrew explains why collecting more health data isn't enough, and why the real challenge is helping people make better decisions that actually change long term behavior.

The conversation explores how Stride combines genetics, microbiome testing, advanced blood biomarkers, wearable data, and practitioner coaching into a single preventive health platform designed to prioritize the actions that matter most. Rather than overwhelming people with hundreds of recommendations, Andrew argues that sustainable health improvement comes from identifying a few highly personalized interventions that create momentum for broader lifestyle change.

They also discuss how longitudinal testing can reveal patterns that traditional healthcare often misses. Instead of relying on whether a biomarker sits inside or outside a population reference range, Andrew explains why understanding an individual's direction of travel over time may provide much earlier signals of future health risks. The discussion explores how integrating multiple biological data layers could eventually allow AI powered systems to identify preclinical risk years before disease develops.

The episode also examines the growing role of consumer health technologies, the limitations of existing healthcare systems, and why prevention increasingly sits outside traditional medicine. Andrew shares why he believes younger generations are embracing longevity as part of their identity, how behavioral psychology influences successful health interventions, and why human coaching remains essential even in an AI driven future.

In this episode, you’ll learn:

- Why personalized health requires more than DNA tests or wearable devices
- How combining genetics, microbiome data, blood biomarkers, and lifestyle creates a more complete picture of health
- Why focusing on three meaningful actions is more effective than dozens of recommendations
- How longitudinal biomarker tracking may detect risk before conventional clinical thresholds are reached
- Why AI works best when combined with experienced healthcare practitioners

If you want to understand where personalized medicine is heading, how AI could transform prevention, and why the next generation of healthcare may be built around continuous, individualized guidance rather than reactive treatment, this episode offers an insightful look at the future of longevity.

Subscribe for weekly conversations exploring longevity science, precision medicine, biotechnology, AI, and the innovations shaping healthier, longer lives.

----------
Timestamps:

00:00:00 - Beyond Health Data
00:01:24 - Ice Bath Lessons
00:04:41 - Athlete to...]]>2851falsefullhttps://www.spreaker.com/episode/one-shot-gene-therapies-peptides-longevity-news-roundup-week-31-2026--74818028
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine new Alzheimer's therapies, the growing debate around experimental peptides, expanding access to investigational treatments, rapid advances in metabolic disease and encouraging progress in longevity gene therapy.

- Voyager Therapeutics reported that its investigational gene therapy VY1706 reduced tau protein by up to 75% in non-human primates for six months after a single intravenous dose, using a novel blood-brain barrier delivery approach.
- An advisory panel to the US Food and Drug Administration recommended broader access to compounded wellness peptides despite concerns over limited human evidence, highlighting the growing tension between consumer demand, regulatory oversight and the need for robust clinical trials.
- Vandria announced that its oral mitochondrial therapy VNA-318  safely reached the brain in its first human study, supporting once-daily dosing ahead of planned Alzheimer's trials.
- Montana advanced Right to Try legislation that could expand patient access to investigational therapies beyond traditional approval pathways, raising new questions about evidence, transparency and responsible implementation.
- D&D Pharmatech reported that its once-weekly dual GLP-1/glucagon receptor agonist zabopegdutide rapidly reduced liver fat and stiffness, with benefits seen even among participants who experienced minimal weight loss.
- Genflow Biosciences reported positive early results from its SIRT6 gene therapy trial in aging dogs, supporting the growing use of companion animals as a bridge toward future human longevity therapies

----------
News & References:

- Voyager’s single-dose gene therapy cuts tau by 75% → https://longevity.technology/news/voyagers-single-dose-gene-therapy-cuts-tau-by-75/
- FDA panel backs peptides over its own scientists → https://longevity.technology/news/fda-panel-backs-peptides-over-its-own-scientists/
- Vandria’s experimental Alzheimer’s pill proves safe, reaches target in first human study → https://longevity.technology/news/vandrias-experimental-alzheimers-pill-proves-safe-reaches-target-in-first-human-study/
- Montana takes next step on experimental therapies → https://longevity.technology/news/montana-takes-next-step-on-experimental-therapies/
- Zabopegdutide shows rapid, weight-independent liver benefits in Phase 2 → https://longevity.technology/news/zabopegdutide-shows-rapid-weight-independent-liver-benefits-in-phase-2/
- Genflow reports positive early results in aging-dog gene therapy trial → https://longevity.technology/news/genflow-reports-positive-early-results-in-aging-dog-gene-therapy-trial/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079341Fri, 31 Jul 2026 09:36:11 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable,...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine new Alzheimer's therapies, the growing debate around experimental peptides, expanding access to investigational treatments, rapid advances in metabolic disease and encouraging progress in longevity gene therapy.

- Voyager Therapeutics reported that its investigational gene therapy VY1706 reduced tau protein by up to 75% in non-human primates for six months after a single intravenous dose, using a novel blood-brain barrier delivery approach.
- An advisory panel to the US Food and Drug Administration recommended broader access to compounded wellness peptides despite concerns over limited human evidence, highlighting the growing tension between consumer demand, regulatory oversight and the need for robust clinical trials.
- Vandria announced that its oral mitochondrial therapy VNA-318  safely reached the brain in its first human study, supporting once-daily dosing ahead of planned Alzheimer's trials.
- Montana advanced Right to Try legislation that could expand patient access to investigational therapies beyond traditional approval pathways, raising new questions about evidence, transparency and responsible implementation.
- D&D Pharmatech reported that its once-weekly dual GLP-1/glucagon receptor agonist zabopegdutide rapidly reduced liver fat and stiffness, with benefits seen even among participants who experienced minimal weight loss.
- Genflow Biosciences reported positive early results from its SIRT6 gene therapy trial in aging dogs, supporting the growing use of companion animals as a bridge toward future human longevity therapies

----------
News & References:

- Voyager’s single-dose gene therapy cuts tau by 75% → https://longevity.technology/news/voyagers-single-dose-gene-therapy-cuts-tau-by-75/
- FDA panel backs peptides over its own scientists → https://longevity.technology/news/fda-panel-backs-peptides-over-its-own-scientists/
- Vandria’s experimental Alzheimer’s pill proves safe, reaches target in first human study → https://longevity.technology/news/vandrias-experimental-alzheimers-pill-proves-safe-reaches-target-in-first-human-study/
- Montana takes next step on experimental therapies → https://longevity.technology/news/montana-takes-next-step-on-experimental-therapies/
- Zabopegdutide shows rapid, weight-independent liver benefits in Phase 2 → https://longevity.technology/news/zabopegdutide-shows-rapid-weight-independent-liver-benefits-in-phase-2/
- Genflow reports positive early results in aging-dog gene therapy trial → https://longevity.technology/news/genflow-reports-positive-early-results-in-aging-dog-gene-therapy-trial/]]>1818falsefullhttps://www.spreaker.com/episode/can-longevity-become-public-policy--74818019
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
Guests: Dylan V. Livingston

Founder and CEO of The Alliance for Longevity Initiatives (A4LI)
LinkedIn: https://www.linkedin.com/in/dylan-v-livingston/
Website: https://a4li.org/

----------
What if the biggest barrier to longer, healthier lives isn't scientific discovery, but public policy?

In this episode, Phil Newman and Dr. Nina Patrick sit down with Dylan V. Livingston, founder and CEO of the Alliance for Longevity Initiatives (A4LI), to explore how Washington is becoming one of the most important frontiers in healthy aging.

Based on his unusual journey from political campaigning to longevity advocacy, Dylan explains why extending healthy lifespan requires more than innovative biotechnology. It also requires regulatory reform, stronger public investment, and policymakers who understand the biology of aging. From his work advancing state-level Right to Try legislation to proposals for new FDA pathways that recognize therapies targeting multiple age-related diseases, he shares how policy could dramatically accelerate the translation of longevity science into clinical practice.

The conversation explores the growing role of biomarkers, surrogate endpoints, and ARPA-H's PROSPR program in creating clearer regulatory pathways for aging interventions. Dylan also discusses proposals for expanding NIH support for aging biology research, why the current funding landscape remains misaligned with the burden of age-related disease, and how advocacy organizations can help bridge the gap between researchers, biotech companies, regulators, and elected officials.

They also examine whether the United States can maintain its leadership in longevity innovation as countries around the world invest in their own longevity ecosystems, and why creating the right incentives today could determine who leads the next generation of medicine.

In this episode, you’ll learn:

- Why public policy may become the biggest accelerator, or bottleneck, for longevity science.
- How a proposed multi-disease therapeutic designation could speed the development of aging interventions.
- Why validated biomarkers and surrogate endpoints are essential for future FDA approval pathways.
- How Right to Try legislation could expand safe access to experimental longevity therapies while generating valuable clinical data.
- Why stronger NIH investment, regulatory reform, and grassroots advocacy are all needed to bring longevity medicine into mainstream healthcare.

If you want to understand how longevity is evolving from a scientific discipline into a healthcare and public policy movement, this episode explores the people, institutions, and regulatory decisions that could shape the future of healthy aging for decades to come.

Subscribe for weekly conversations exploring longevity science, biotechnology, preventative medicine, and the innovations transforming how we live longer and better.

----------
Timestamps:

00:00:00 - From Politics to Longevity
00:01:29 - Dylan's Origin Story
00:06:42 - Why A4LI Was Created
00:12:29 - Longevity Reaches Washington
00:18:20 - The FDA Opportunity
00:22:53 - A Bigger Vision
00:25:45 - Building an Aging Pathway
00:28:59 - ARPA-H's Role
00:32:29 - Right to Try 2.0
00:37:51 - State-by-State Innovation
00:39:38 - Can America Stay Ahead?
00:42:53 - The Longevity Race
00:43:24 - Growing the Movement
00:45:26 - Why Policy Matters
00:46:40 - How to Get Involved]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079379Mon, 27 Jul 2026 11:14:13 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable,...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
Guests: Dylan V. Livingston

Founder and CEO of The Alliance for Longevity Initiatives (A4LI)
LinkedIn: https://www.linkedin.com/in/dylan-v-livingston/
Website: https://a4li.org/

----------
What if the biggest barrier to longer, healthier lives isn't scientific discovery, but public policy?

In this episode, Phil Newman and Dr. Nina Patrick sit down with Dylan V. Livingston, founder and CEO of the Alliance for Longevity Initiatives (A4LI), to explore how Washington is becoming one of the most important frontiers in healthy aging.

Based on his unusual journey from political campaigning to longevity advocacy, Dylan explains why extending healthy lifespan requires more than innovative biotechnology. It also requires regulatory reform, stronger public investment, and policymakers who understand the biology of aging. From his work advancing state-level Right to Try legislation to proposals for new FDA pathways that recognize therapies targeting multiple age-related diseases, he shares how policy could dramatically accelerate the translation of longevity science into clinical practice.

The conversation explores the growing role of biomarkers, surrogate endpoints, and ARPA-H's PROSPR program in creating clearer regulatory pathways for aging interventions. Dylan also discusses proposals for expanding NIH support for aging biology research, why the current funding landscape remains misaligned with the burden of age-related disease, and how advocacy organizations can help bridge the gap between researchers, biotech companies, regulators, and elected officials.

They also examine whether the United States can maintain its leadership in longevity innovation as countries around the world invest in their own longevity ecosystems, and why creating the right incentives today could determine who leads the next generation of medicine.

In this episode, you’ll learn:

- Why public policy may become the biggest accelerator, or bottleneck, for longevity science.
- How a proposed multi-disease therapeutic designation could speed the development of aging interventions.
- Why validated biomarkers and surrogate endpoints are essential for future FDA approval pathways.
- How Right to Try legislation could expand safe access to experimental longevity therapies while generating valuable clinical data.
- Why stronger NIH investment, regulatory reform, and grassroots advocacy are all needed to bring longevity medicine into mainstream healthcare.

If you want to understand how longevity is evolving from a scientific discipline into a healthcare and public policy movement, this episode explores the people, institutions, and regulatory decisions that could shape the future of healthy aging for decades to come.

Subscribe for weekly conversations exploring longevity science, biotechnology, preventative medicine, and the innovations transforming how we live longer and better.

----------
Timestamps:

00:00:00 - From Politics to Longevity
00:01:29 - Dylan's Origin Story
00:06:42 - Why A4LI Was Created
00:12:29 - Longevity Reaches Washington
00:18:20 - The FDA Opportunity
00:22:53 - A Bigger Vision
00:25:45 - Building an Aging Pathway
00:28:59 -...]]>2910falsefullhttps://www.spreaker.com/episode/the-first-real-longevity-drugs-are-getting-closer-longevity-news-roundup-week-30-2026--74818018
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine major advances in Alzheimer's research, growing investment in national longevity infrastructure, the challenges facing longevity clinics, and why microbiome science is becoming increasingly important for brain and women's health.

- Biogen and Ionis reported encouraging Phase II results for a tau-targeting Alzheimer's therapy. While the trial missed its primary endpoint, the treatment reduced tau biomarkers and slowed clinical decline, supporting plans for a Phase III study.
- Lighthouse Pharmaceuticals presented new data showing its gingipain inhibitor reduced agitation, caregiver distress, and cognitive decline in Alzheimer's patients who tested positive for p. gingivalis. The discussion explores what these findings could mean for the growing evidence linking oral health and neurodegeneration.
- Nova Capital committed $100 million to build a UAE longevity platform integrating clinics, preventive healthcare, digital health, and wellness services. Phil also explores what this investment could signal for the future geography of the global longevity industry.
- Eternal announced the closure of its longevity clinics, prompting a discussion about why data, defensible technology, and scalable business models may become increasingly important as the sector matures.
- Juno Bio raised $3.8 million to launch a CLIA-certified sequencing laboratory and expand provider-led vaginal microbiome diagnostics, moving precision women's healthcare beyond traditional symptom-based testing.

----------
News & References:

- Biogen, Ionis therapy slows early Alzheimer’s progression in Phase 2 trial → https://longevity.technology/news/biogen-ionis-therapy-slows-early-alzheimers-progression-in-phase-2-trial/
- Lighthouse Pharma’s Alzheimer’s drug reduces agitation, caregiver distress in clinical trial → https://longevity.technology/news/lighthouse-pharmas-alzheimers-drug-reduces-agitation-caregiver-distress-in-clinical-trial/
- Nova Capital commits $100m to back UAE longevity platform → https://longevity.technology/news/nova-capital-commits-100m-to-back-uae-longevity-platform/
- Eternal calls time on its longevity clinics → https://longevity.technology/news/eternal-calls-time-on-its-longevity-clinics/
- Startup Juno Bio raises $3.8m for smarter women’s diagnostics → https://longevity.technology/news/startup-juno-bio-raises-3-8m-for-smarter-womens-diagnostics/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079330Fri, 24 Jul 2026 10:42:30 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable,...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine major advances in Alzheimer's research, growing investment in national longevity infrastructure, the challenges facing longevity clinics, and why microbiome science is becoming increasingly important for brain and women's health.

- Biogen and Ionis reported encouraging Phase II results for a tau-targeting Alzheimer's therapy. While the trial missed its primary endpoint, the treatment reduced tau biomarkers and slowed clinical decline, supporting plans for a Phase III study.
- Lighthouse Pharmaceuticals presented new data showing its gingipain inhibitor reduced agitation, caregiver distress, and cognitive decline in Alzheimer's patients who tested positive for p. gingivalis. The discussion explores what these findings could mean for the growing evidence linking oral health and neurodegeneration.
- Nova Capital committed $100 million to build a UAE longevity platform integrating clinics, preventive healthcare, digital health, and wellness services. Phil also explores what this investment could signal for the future geography of the global longevity industry.
- Eternal announced the closure of its longevity clinics, prompting a discussion about why data, defensible technology, and scalable business models may become increasingly important as the sector matures.
- Juno Bio raised $3.8 million to launch a CLIA-certified sequencing laboratory and expand provider-led vaginal microbiome diagnostics, moving precision women's healthcare beyond traditional symptom-based testing.

----------
News & References:

- Biogen, Ionis therapy slows early Alzheimer’s progression in Phase 2 trial → https://longevity.technology/news/biogen-ionis-therapy-slows-early-alzheimers-progression-in-phase-2-trial/
- Lighthouse Pharma’s Alzheimer’s drug reduces agitation, caregiver distress in clinical trial → https://longevity.technology/news/lighthouse-pharmas-alzheimers-drug-reduces-agitation-caregiver-distress-in-clinical-trial/
- Nova Capital commits $100m to back UAE longevity platform → https://longevity.technology/news/nova-capital-commits-100m-to-back-uae-longevity-platform/
- Eternal calls time on its longevity clinics → https://longevity.technology/news/eternal-calls-time-on-its-longevity-clinics/
- Startup Juno Bio raises $3.8m for smarter women’s diagnostics → https://longevity.technology/news/startup-juno-bio-raises-3-8m-for-smarter-womens-diagnostics/]]>1746falsefullhttps://www.spreaker.com/episode/are-you-taking-too-many-supplements-gut-health-blood-tests-personalized-longevity--74818071
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
Guests:

Aaron Deere
Health and Performance Director of HOOKE London
LinkedIn: https://www.linkedin.com/in/aaron-deere-129079128/
Website: https://www.hooke.london/

Dr Jean-Marc Sobczyk
Integrative Medicine & Longevity Physician of HOOKE London
LinkedIn: https://www.linkedin.com/in/jean-marc-sobczyk/
Website: https://www.hooke.london/

----------
What if the future of longevity isn't about taking more supplements, but taking fewer, better ones?

In this episode, Phil Newman and Dr. Nina Patrick are joined by HOOKE London experts Aaron Deere, Health and Performance Director, and Dr. Jean-Marc Sobczyk, an integrative longevity physician, to explore how personalized nutrition, biomarker testing, and gut health are reshaping the future of preventive healthcare.

Drawing on years of clinical experience, they challenge the growing culture of "stacking" supplements without evidence, explaining why many people unknowingly oversupplement certain nutrients while remaining deficient in others. Through real-world case studies, they discuss why comprehensive blood testing should come before supplementation, how personalized formulations outperform generic multivitamins, and why regular monitoring is essential as your health, lifestyle, and physiology evolve over time.

The conversation also explores one of the most exciting frontiers in longevity: the microbiome. Aaron and Dr. Sobczyk explain why gut health is far more complex than simply taking probiotics, why the same stool sample can produce completely different results when analyzed by different laboratories, and how emerging AI-powered research could unlock more targeted microbiome therapies for inflammation, cognitive health, mood, skin aging, and disease prevention.

Throughout the conversation, one message remains clear: longevity isn't about chasing every new technology or buying every trending supplement. It's about understanding your unique biology and making informed decisions based on data, evidence, and continuous monitoring rather than marketing claims or social media advice.

In this episode, you’ll learn:

- Why taking more supplements can increase the risk of nutrient overload and unnecessary expense.
- How blood biomarkers can uncover hidden deficiencies like iron, vitamin D, and omega-3 insufficiency while identifying oversupplementation.
- Why microbiome testing remains useful despite inconsistent laboratory results, and how to interpret those findings in clinical practice.
- How GLP-1 therapies can support healthspan when combined with strength training, adequate protein intake, and lifestyle change.
- Why sleep, nutrition, cardiovascular fitness, muscle health, and consistent monitoring still outperform the latest longevity trends.

Whether you're building your first supplement protocol or refining an advanced longevity strategy, this conversation offers a practical framework for moving beyond guesswork and toward truly personalised health optimisation. It connects emerging science with real-world clinical experience, showing why testing, monitoring, and individualisation are becoming the new foundation of preventive medicine.

Subscribe for weekly episodes exploring longevity science, precision medicine, preventative healthcare, and the innovations shaping how we live longer, healthier lives.

----------
Timestamps:

00:00:00 - Too Many Supplements?
00:00:51 - Meet The Experts
00:01:36 - Personalized Blood Testing
00:08:51 - Electrolyte Hype
00:10:03 - Over Optimization
00:16:19 - Microbiome Reality Check
00:22:06 - Building Personalized Protocols
00:31:34 - Gut Health Foundations
00:35:14 - Biggest Longevity Mistakes
00:39:52 - NAD And GLP-1s
00:46:15 - The Next Frontier
00:50:05 - Quickfire Questions
00:53:53 - Overrated Biomarkers
00:54:00 - Future Longevity Technologies
00:55:49 - Final Takeaways]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079286Mon, 20 Jul 2026 09:58:25 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable,...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
Guests:

Aaron Deere
Health and Performance Director of HOOKE London
LinkedIn: https://www.linkedin.com/in/aaron-deere-129079128/
Website: https://www.hooke.london/

Dr Jean-Marc Sobczyk
Integrative Medicine & Longevity Physician of HOOKE London
LinkedIn: https://www.linkedin.com/in/jean-marc-sobczyk/
Website: https://www.hooke.london/

----------
What if the future of longevity isn't about taking more supplements, but taking fewer, better ones?

In this episode, Phil Newman and Dr. Nina Patrick are joined by HOOKE London experts Aaron Deere, Health and Performance Director, and Dr. Jean-Marc Sobczyk, an integrative longevity physician, to explore how personalized nutrition, biomarker testing, and gut health are reshaping the future of preventive healthcare.

Drawing on years of clinical experience, they challenge the growing culture of "stacking" supplements without evidence, explaining why many people unknowingly oversupplement certain nutrients while remaining deficient in others. Through real-world case studies, they discuss why comprehensive blood testing should come before supplementation, how personalized formulations outperform generic multivitamins, and why regular monitoring is essential as your health, lifestyle, and physiology evolve over time.

The conversation also explores one of the most exciting frontiers in longevity: the microbiome. Aaron and Dr. Sobczyk explain why gut health is far more complex than simply taking probiotics, why the same stool sample can produce completely different results when analyzed by different laboratories, and how emerging AI-powered research could unlock more targeted microbiome therapies for inflammation, cognitive health, mood, skin aging, and disease prevention.

Throughout the conversation, one message remains clear: longevity isn't about chasing every new technology or buying every trending supplement. It's about understanding your unique biology and making informed decisions based on data, evidence, and continuous monitoring rather than marketing claims or social media advice.

In this episode, you’ll learn:

- Why taking more supplements can increase the risk of nutrient overload and unnecessary expense.
- How blood biomarkers can uncover hidden deficiencies like iron, vitamin D, and omega-3 insufficiency while identifying oversupplementation.
- Why microbiome testing remains useful despite inconsistent laboratory results, and how to interpret those findings in clinical practice.
- How GLP-1 therapies can support healthspan when combined with strength training, adequate protein intake, and lifestyle change.
- Why sleep, nutrition, cardiovascular fitness, muscle health, and consistent monitoring still outperform the latest longevity trends.

Whether you're building your first supplement protocol or refining an advanced longevity strategy, this conversation offers a practical framework for moving beyond guesswork and toward truly personalised health optimisation. It connects emerging science with real-world clinical experience, showing why testing, monitoring, and individualisation are becoming the new foundation of preventive medicine.

Subscribe for weekly episodes exploring...]]>3400falsefullhttps://www.spreaker.com/episode/is-longevity-becoming-the-next-global-race-longevity-news-roundup-week-29-2026--74818049
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine BioAge's inflammation therapy, Alzheimer's advances, China's growing biotech influence, protein repair research, menopause science and US longevity policy.

- BioAge dosed the first patient in the Phase 2 QUELL-CV trial of BGE-102, an oral NLRP3 inflammasome inhibitor discovered through human longevity datasets rather than traditional disease-first drug discovery.
- Alzheon presented new analyses showing reduced brain swelling, preserved brain structure and encouraging biomarker and cognitive signals for valiltramiprosate, despite the original Phase 3 trial missing its primary endpoint. Confirmation studies are still needed.
- Kailera licensed its entire GLP-1 pipeline from China's Jiangsu Hengrui, highlighting growing US concerns over China's expanding role in drug innovation and obesity therapeutics.
- Revel Pharmaceuticals enzymatically removed advanced glycation end product (CML) damage from aged human tissues ex vivo, challenging long-held assumptions that some forms of molecular aging are irreversible.
- Elysium reported early pilot data suggesting its NAD+ supplement Basis reduced several menopause symptoms within seven days while also shifting estrogen metabolism biomarkers. Larger randomized trials are now needed.
- US policymakers and regulators outlined new frameworks supporting geotherapeutics, aging biomarkers and reimbursement, signalling growing federal momentum behind healthspan-focused medicine.

----------
News & References:

- BioAge doses first patient in Phase 2 trial of new cardiovascular drug → https://longevity.technology/news/bioage-doses-first-patient-in-phase-2-trial-of-new-cardiovascular-drug/
- Fresh analyses reshape Alzheon’s oral Alzheimer’s drug → https://longevity.technology/news/fresh-analyses-reshape-alzheons-oral-alzheimers-drug/
- Kailera’s oral obesity pill posts Phase 3 gains → https://longevity.technology/news/kaileras-oral-obesity-pill-posts-phase-3-gains/
- When irreversible no longer means forever → https://longevity.technology/news/when-irreversible-no-longer-means-forever/
- Elysium pilot study links Basis to reduced menopause symptoms → https://longevity.technology/news/elysium-pilot-study-links-basis-to-reduced-menopause-symptoms/
- US longevity policy takes center stage in Washington → https://longevity.technology/news/us-longevity-policy-takes-center-stage-in-washington/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079325Fri, 17 Jul 2026 10:51:47 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable,...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine BioAge's inflammation therapy, Alzheimer's advances, China's growing biotech influence, protein repair research, menopause science and US longevity policy.

- BioAge dosed the first patient in the Phase 2 QUELL-CV trial of BGE-102, an oral NLRP3 inflammasome inhibitor discovered through human longevity datasets rather than traditional disease-first drug discovery.
- Alzheon presented new analyses showing reduced brain swelling, preserved brain structure and encouraging biomarker and cognitive signals for valiltramiprosate, despite the original Phase 3 trial missing its primary endpoint. Confirmation studies are still needed.
- Kailera licensed its entire GLP-1 pipeline from China's Jiangsu Hengrui, highlighting growing US concerns over China's expanding role in drug innovation and obesity therapeutics.
- Revel Pharmaceuticals enzymatically removed advanced glycation end product (CML) damage from aged human tissues ex vivo, challenging long-held assumptions that some forms of molecular aging are irreversible.
- Elysium reported early pilot data suggesting its NAD+ supplement Basis reduced several menopause symptoms within seven days while also shifting estrogen metabolism biomarkers. Larger randomized trials are now needed.
- US policymakers and regulators outlined new frameworks supporting geotherapeutics, aging biomarkers and reimbursement, signalling growing federal momentum behind healthspan-focused medicine.

----------
News & References:

- BioAge doses first patient in Phase 2 trial of new cardiovascular drug → https://longevity.technology/news/bioage-doses-first-patient-in-phase-2-trial-of-new-cardiovascular-drug/
- Fresh analyses reshape Alzheon’s oral Alzheimer’s drug → https://longevity.technology/news/fresh-analyses-reshape-alzheons-oral-alzheimers-drug/
- Kailera’s oral obesity pill posts Phase 3 gains → https://longevity.technology/news/kaileras-oral-obesity-pill-posts-phase-3-gains/
- When irreversible no longer means forever → https://longevity.technology/news/when-irreversible-no-longer-means-forever/
- Elysium pilot study links Basis to reduced menopause symptoms → https://longevity.technology/news/elysium-pilot-study-links-basis-to-reduced-menopause-symptoms/
- US longevity policy takes center stage in Washington → https://longevity.technology/news/us-longevity-policy-takes-center-stage-in-washington/]]>1852falsefullhttps://www.spreaker.com/episode/the-genetic-clues-that-could-predict-how-you-age--74818072
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
Guests: Professor Ronjon Nag, OBE

President of the R42 Group, CEO and Founder of Agemica and Board Advisor at Genomelink and YourRoots
LinkedIn: https://www.linkedin.com/in/ronjonnag/
Website: https://www.r42group.com/, https://agemica.com/home, https://app.superbio.ai/, https://genomelink.io/, https://yourroots.com/

----------
What if your DNA and AI could become one of the most powerful tools for preventing disease, optimizing health, and extending healthy lifespan?

Phil Newman and Dr. Nina Patrick sit down with Ronjon Nag, OBE, President of R42, CEO of Aegemica and Superbio.ai, and Adjunct Professor in Genetics at the Stanford School of Medicine, to explore how artificial intelligence is reshaping genomics and why we're entering a new era of personalized healthcare.

Ronjon explains why most diseases are far more complex than single-gene mutations, and why understanding biology increasingly requires combining genetics with biomarkers, clinical records, lifestyle, and AI. He shares why genetics should be viewed as a lifelong health blueprint rather than a one-time report, and how future AI systems may allow people to interact with their own biology in entirely new ways.

The conversation also explores why medicine is shifting toward prediction rather than reaction, how AI is helping researchers identify disease patterns hidden inside massive biological datasets, and why better data could dramatically accelerate drug discovery and preventative healthcare.

Ronjon also discusses one of his boldest projects yet: developing peptide-based vaccines that target multiple aging pathways simultaneously. By combining AI with large-scale biological datasets, his team hopes to train the immune system to recognize and eliminate damaged cells before they contribute to age-related disease.

In this episode, you’ll learn:

- Why most diseases are influenced by thousands of genes, not just one
- How AI is making genetics more useful for everyday healthcare
- Why combining genetics with biomarkers creates better health insights
- How preventative medicine is moving toward personalized risk prediction
- The science behind peptide vaccines targeting aging pathways
- Why AI may soon let you "talk" to your own biology

If you're interested in AI, biotechnology, longevity science, and the future of healthcare, this episode offers an inside look at the technologies that could fundamentally change how we prevent disease and extend healthy lifespan.

Subscribe for weekly conversations exploring longevity science, biotechnology, and the innovations helping people live healthier, longer lives.

----------
Timestamps:

00:00:00 - Why DNA Matters
00:01:19 - Why Isn't Everyone Doing It?
00:05:38 - Why Doctors Lag Behind
00:08:42 - DNA Beyond Ancestry
00:13:37 - Genetics Explained Simply
00:17:27 - AI Meets Your Biology
00:22:17 - The Privacy Debate
00:25:43 - Talking To Your Genome
00:30:28 - Making Genetics Useful
00:33:00 - Genetics And Longevity
00:37:14 - The Aging Vaccine
00:45:22 - What Must Change
00:47:54 - AI's Healthcare Future
00:52:30 - Rapid Fire Round
00:57:02 - Where To Learn More]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079361Mon, 13 Jul 2026 09:44:29 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable,...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
Guests: Professor Ronjon Nag, OBE

President of the R42 Group, CEO and Founder of Agemica and Board Advisor at Genomelink and YourRoots
LinkedIn: https://www.linkedin.com/in/ronjonnag/
Website: https://www.r42group.com/, https://agemica.com/home, https://app.superbio.ai/, https://genomelink.io/, https://yourroots.com/

----------
What if your DNA and AI could become one of the most powerful tools for preventing disease, optimizing health, and extending healthy lifespan?

Phil Newman and Dr. Nina Patrick sit down with Ronjon Nag, OBE, President of R42, CEO of Aegemica and Superbio.ai, and Adjunct Professor in Genetics at the Stanford School of Medicine, to explore how artificial intelligence is reshaping genomics and why we're entering a new era of personalized healthcare.

Ronjon explains why most diseases are far more complex than single-gene mutations, and why understanding biology increasingly requires combining genetics with biomarkers, clinical records, lifestyle, and AI. He shares why genetics should be viewed as a lifelong health blueprint rather than a one-time report, and how future AI systems may allow people to interact with their own biology in entirely new ways.

The conversation also explores why medicine is shifting toward prediction rather than reaction, how AI is helping researchers identify disease patterns hidden inside massive biological datasets, and why better data could dramatically accelerate drug discovery and preventative healthcare.

Ronjon also discusses one of his boldest projects yet: developing peptide-based vaccines that target multiple aging pathways simultaneously. By combining AI with large-scale biological datasets, his team hopes to train the immune system to recognize and eliminate damaged cells before they contribute to age-related disease.

In this episode, you’ll learn:

- Why most diseases are influenced by thousands of genes, not just one
- How AI is making genetics more useful for everyday healthcare
- Why combining genetics with biomarkers creates better health insights
- How preventative medicine is moving toward personalized risk prediction
- The science behind peptide vaccines targeting aging pathways
- Why AI may soon let you "talk" to your own biology

If you're interested in AI, biotechnology, longevity science, and the future of healthcare, this episode offers an inside look at the technologies that could fundamentally change how we prevent disease and extend healthy lifespan.

Subscribe for weekly conversations exploring longevity science, biotechnology, and the innovations helping people live healthier, longer lives.

----------
Timestamps:

00:00:00 - Why DNA Matters
00:01:19 - Why Isn't Everyone Doing It?
00:05:38 - Why Doctors Lag Behind
00:08:42 - DNA Beyond Ancestry
00:13:37 - Genetics Explained Simply
00:17:27 - AI Meets Your Biology
00:22:17 - The Privacy Debate
00:25:43 - Talking To Your Genome
00:30:28 - Making Genetics Useful
00:33:00 - Genetics And Longevity
00:37:14 - The Aging Vaccine
00:45:22 - What Must Change
00:47:54 - AI's Healthcare Future
00:52:30 - Rapid Fire Round
00:57:02 - Where To Learn More]]>2429falsefullhttps://www.spreaker.com/episode/is-luxury-longevity-coming-to-an-end-longevity-news-roundup-week-28-2026--74818034
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine mRNA plaque reversal, affordable longevity clinics, laser-driven skin rejuvenation, immune rejuvenation, cuffless blood pressure monitoring, and peptide evidence.

- Repair Biotechnologies received FDA pathway eligibility for its investigational mRNA therapy targeting intracellular cholesterol, a novel approach that aims to reverse arterial plaque rather than simply lower LDL or slow cardiovascular disease progression.
- Fountain Life launched a new $595 annual membership, signaling a strategic shift beyond luxury longevity medicine toward employer benefits, insurance integration, and broader access to advanced preventive care.
- Researchers from Nature’s Scientific Reports has found that Candela’s Nordlys fractional laser treatment produced sustained epigenetic changes associated with younger skin biology, raising the possibility that aesthetic procedures could influence the biology of aging rather than just appearance.
- United Therapeutics acquired Thymmune Therapeutics for $140 million, highlighting growing confidence in thymus regeneration, immune rejuvenation, and the commercial potential of therapies targeting age-related immune decline.
- Sky Labs presented its ring-type cuffless blood pressure monitor, CART BP pro, that has entered a large Korean cohort study, potentially making continuous cardiovascular monitoring more practical than traditional inflatable cuffs.
- Evipedia launched transparent, AI-supported evidence reviews covering 24 peptides, providing clinicians and consumers with an up-to-date resource as regulators continue scrutinizing peptide safety, efficacy, and clinical evidence.

----------
News & References:

- Repair Bio advances plaque regression program with FDA nod → https://longevity.technology/news/repair-bio-advances-plaque-regression-program-with-fda-nod/
- Fountain Life makes longevity accessible with $595 membership → https://longevity.technology/news/fountain-life-makes-longevity-accessible-with-595-membership/
- Laser treatment found to reverse skin aging markers → https://longevity.technology/news/laser-treatment-found-to-reverse-skin-aging-markers/
- United Therapeutics buys Thymmune Therapeutics for $140m → https://longevity.technology/news/united-therapeutics-buys-thymmune-therapeutics-for-140m/
- Evipedia expands evidence reviews to cover peptides → https://longevity.technology/news/evipedia-expands-evidence-reviews-to-cover-peptides/
- Sky Labs’ blood pressure ring adopted for large-scale national health study → https://longevity.technology/news/sky-labs-blood-pressure-ring-adopted-for-large-scale-national-health-study/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079317Fri, 10 Jul 2026 09:57:08 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable,...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine mRNA plaque reversal, affordable longevity clinics, laser-driven skin rejuvenation, immune rejuvenation, cuffless blood pressure monitoring, and peptide evidence.

- Repair Biotechnologies received FDA pathway eligibility for its investigational mRNA therapy targeting intracellular cholesterol, a novel approach that aims to reverse arterial plaque rather than simply lower LDL or slow cardiovascular disease progression.
- Fountain Life launched a new $595 annual membership, signaling a strategic shift beyond luxury longevity medicine toward employer benefits, insurance integration, and broader access to advanced preventive care.
- Researchers from Nature’s Scientific Reports has found that Candela’s Nordlys fractional laser treatment produced sustained epigenetic changes associated with younger skin biology, raising the possibility that aesthetic procedures could influence the biology of aging rather than just appearance.
- United Therapeutics acquired Thymmune Therapeutics for $140 million, highlighting growing confidence in thymus regeneration, immune rejuvenation, and the commercial potential of therapies targeting age-related immune decline.
- Sky Labs presented its ring-type cuffless blood pressure monitor, CART BP pro, that has entered a large Korean cohort study, potentially making continuous cardiovascular monitoring more practical than traditional inflatable cuffs.
- Evipedia launched transparent, AI-supported evidence reviews covering 24 peptides, providing clinicians and consumers with an up-to-date resource as regulators continue scrutinizing peptide safety, efficacy, and clinical evidence.

----------
News & References:

- Repair Bio advances plaque regression program with FDA nod → https://longevity.technology/news/repair-bio-advances-plaque-regression-program-with-fda-nod/
- Fountain Life makes longevity accessible with $595 membership → https://longevity.technology/news/fountain-life-makes-longevity-accessible-with-595-membership/
- Laser treatment found to reverse skin aging markers → https://longevity.technology/news/laser-treatment-found-to-reverse-skin-aging-markers/
- United Therapeutics buys Thymmune Therapeutics for $140m → https://longevity.technology/news/united-therapeutics-buys-thymmune-therapeutics-for-140m/
- Evipedia expands evidence reviews to cover peptides → https://longevity.technology/news/evipedia-expands-evidence-reviews-to-cover-peptides/
- Sky Labs’ blood pressure ring adopted for large-scale national health study → https://longevity.technology/news/sky-labs-blood-pressure-ring-adopted-for-large-scale-national-health-study/]]>1582falsefullhttps://www.spreaker.com/episode/this-ai-can-detect-disease-before-symptoms--74818106
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Viome

Viome is a personalized health platform that uses RNA analysis and AI to provide insights into your microbiome, cellular health, and nutrition. By identifying what's happening inside your body in real time, Viome delivers tailored food, supplement, and lifestyle recommendations designed to support your long-term health and wellness journey.

Click the link below to learn more.

Link: https://viomehq.sjv.io/BX74XL

----------
Guests: Naveen Jain

Founder and CEO at Viome Life Sciences
Instagram: www.instagram.com/naveenjainceo/?hl=en
Website: www.viomelifesciences.com/

----------
What if the biggest breakthrough in longevity isn't changing your DNA, but understanding what your genes are doing right now?

Phil Newman and Dr. Nina Patrick sit down with Naveen Jain, entrepreneur, innovator, and founder of Viome, to explore why RNA biology, AI, and the microbiome are reshaping the future of preventative healthcare. While DNA tells us what is possible, Jain argues that RNA reveals what is actually happening inside the body in real time, creating opportunities to detect dysfunction years before symptoms appear.

From analyzing more than 400 quadrillion biological data points across 1.5 million biological samples to using AI to interpret millions of microbial and human gene expression signals, the conversation explores how precision diagnostics are moving beyond traditional blood testing. Jain explains why two people can eat the same foods and experience completely different biological outcomes, why there may be no such thing as a universally healthy food, and how personalized nutrition could become one of the most powerful tools for extending healthspan.

The discussion also examines the rise of longevity medicine, the consumerization of healthcare, the growing role of AI in clinical decision making, and why early disease detection may become one of the defining advances of this decade. Jain shares how Viome is developing RNA-based diagnostics for conditions including oral cancer, pancreatic cancer, inflammatory bowel disease, and metabolic dysfunction, while also discussing the importance of scientific validation and evidence-based recommendations.

In this episode, you’ll learn:

- How AI can interpret millions of biological signals that humans cannot analyze manually.
- Why personalized nutrition may outperform generalized dietary advice.
- How the microbiome influences inflammation, metabolism, cognition, and biological aging.
- Why foods like broccoli, spinach, avocado, almonds, and red meat can produce very different effects depending on your biology.
- How Viome's research is advancing early detection for pancreatic cancer, oral cancer, and metabolic disease.

If you want to understand how AI, molecular biology, and the microbiome are changing the future of preventative medicine, this episode connects cutting-edge science with practical insights for extending healthspan and longevity.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the innovations shaping how we live longer and better.

----------
Timestamps:

00:00:00 - Beyond DNA
00:01:15 - Meet Naveen Jain
00:02:39 - Defining Longevity
00:07:12 - DNA vs RNA
00:12:19 - AI Meets Biology
00:17:57 - We Are Microbial
00:21:11 - Predicting Disease
00:29:22 - Personalized Nutrition
00:35:04 - Food As Medicine
00:36:36 - Why Foods Differ
00:41:06 - Changing Your Microbiome
00:45:51 - The Future Of Diagnostics
00:50:29 - Longevity Goes Mainstream
00:54:47 - Detecting Cancer Earlier
01:02:09 - Looking Ahead]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079337Mon, 06 Jul 2026 10:13:25 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Viome Viome is a personalized health platform that uses RNA analysis and AI to provide insights into your microbiome, cellular health, and...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Viome

Viome is a personalized health platform that uses RNA analysis and AI to provide insights into your microbiome, cellular health, and nutrition. By identifying what's happening inside your body in real time, Viome delivers tailored food, supplement, and lifestyle recommendations designed to support your long-term health and wellness journey.

Click the link below to learn more.

Link: https://viomehq.sjv.io/BX74XL

----------
Guests: Naveen Jain

Founder and CEO at Viome Life Sciences
Instagram: www.instagram.com/naveenjainceo/?hl=en
Website: www.viomelifesciences.com/

----------
What if the biggest breakthrough in longevity isn't changing your DNA, but understanding what your genes are doing right now?

Phil Newman and Dr. Nina Patrick sit down with Naveen Jain, entrepreneur, innovator, and founder of Viome, to explore why RNA biology, AI, and the microbiome are reshaping the future of preventative healthcare. While DNA tells us what is possible, Jain argues that RNA reveals what is actually happening inside the body in real time, creating opportunities to detect dysfunction years before symptoms appear.

From analyzing more than 400 quadrillion biological data points across 1.5 million biological samples to using AI to interpret millions of microbial and human gene expression signals, the conversation explores how precision diagnostics are moving beyond traditional blood testing. Jain explains why two people can eat the same foods and experience completely different biological outcomes, why there may be no such thing as a universally healthy food, and how personalized nutrition could become one of the most powerful tools for extending healthspan.

The discussion also examines the rise of longevity medicine, the consumerization of healthcare, the growing role of AI in clinical decision making, and why early disease detection may become one of the defining advances of this decade. Jain shares how Viome is developing RNA-based diagnostics for conditions including oral cancer, pancreatic cancer, inflammatory bowel disease, and metabolic dysfunction, while also discussing the importance of scientific validation and evidence-based recommendations.

In this episode, you’ll learn:

- How AI can interpret millions of biological signals that humans cannot analyze manually.
- Why personalized nutrition may outperform generalized dietary advice.
- How the microbiome influences inflammation, metabolism, cognition, and biological aging.
- Why foods like broccoli, spinach, avocado, almonds, and red meat can produce very different effects depending on your biology.
- How Viome's research is advancing early detection for pancreatic cancer, oral cancer, and metabolic disease.

If you want to understand how AI, molecular biology, and the microbiome are changing the future of preventative medicine, this episode connects cutting-edge science with practical insights for extending healthspan and longevity.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the innovations shaping how we live longer and better.

----------
Timestamps:

00:00:00 - Beyond DNA
00:01:15 - Meet Naveen Jain
00:02:39 - Defining Longevity
00:07:12 - DNA vs RNA
00:12:19 - AI Meets Biology
00:17:57 - We Are Microbial
00:21:11 - Predicting Disease
00:29:22 - Personalized Nutrition
00:35:04 - Food As Medicine
00:36:36 - Why Foods Differ
00:41:06 - Changing Your Microbiome
00:45:51 - The Future Of Diagnostics
00:50:29 - Longevity Goes Mainstream
00:54:47 - Detecting Cancer Earlier
01:02:09 - Looking Ahead]]>3855falsefullhttps://www.spreaker.com/episode/why-klotho-is-becoming-longevity-s-biggest-bet-longevity-news-roundup-week-27-2026--74818022
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine CRISPR heart therapies, AI-guided Alzheimer's care, GLP-1 ecosystem expansion, biological age testing, Klotho programs, and regenerative medicine.

- Scribe Therapeutics secured more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance two CRISPR-based gene editing therapies toward human trials. The one-time treatments, STX-1200 and STX-1400, target inherited cardiovascular risk factors with the goal of durably reducing genetically driven heart disease risk.
- Eli Lilly's LillyDirect and ŌURA announced a collaboration to support people using prescribed GLP-1 therapies by combining access to treatment with wearable-based behavioral support. The initiative integrates sleep, activity, readiness, and other biometric insights to help reinforce healthy habits alongside obesity care, without sharing user data between the companies.
- NeuroXT and Beth Israel Deaconess Medical Center (BIDMC) expanded their collaboration to explore how AI could help identify the right treatment for the right Alzheimer’s patient. The research aims to identify which patients are most likely to benefit from emerging Alzheimer's therapies using imaging that is already widely available.
- Generation Lab launched SystemAge 2.1, describing it as the first biological age test to offer dedicated female and male versions. The platform analyzes more than 460 biomarkers across 21 organ systems from a needle-free blood sample, adding sex-specific assessments and organ-level tracking to monitor responses to longevity interventions.
- GARM Clinic debuted what it describes as the world's first Klotho Longevity Residency, a four-day educational program focused on Klotho-based gene therapy and regenerative medicine. Hosted in Roatán, Honduras, the residency brings together clinicians and researchers to explore translational longevity therapies in a more flexible regulatory setting.
- LyGenesis received a research award to expand its regenerative medicine platform into type 1 diabetes, to support a thymus program exploring immune tolerance to pancreatic islet transplantation. The funding will support preclinical development of a novel approach for tolerance induction following allogeneic pancreatic islet transplantation for type 1 diabetes, according to the company.

----------
News & References:

- Scribe lands $25m to advance heart disease gene therapies → https://longevity.technology/news/scribe-lands-25m-to-advance-heart-disease-gene-therapies/
- ŌURA-LillyDirect collab highlights new GLP-1 care model → https://longevity.technology/news/oura-lillydirect-collab-highlights-new-glp-1-care-model/
- AI and Alzheimer’s: NeuroXT, BIDMC aim to personalize care → https://longevity.technology/news/ai-and-alzheimers-neuroxt-bidmc-aim-to-personalize-care/
- Generation Lab launches SystemAge 2.1 as the first gender-specific biological age test → https://longevity.technology/news/generation-lab-launches-systemage-2-1-as-the-first-gender-specific-biological-age-test/
- GARM Clinic debuts world’s first Klotho longevity residency → https://longevity.technology/news/garm-clinic-debuts-worlds-first-klotho-longevity-residency/
- LyGenesis wins research award to advance type 1 diabetes cell therapy → https://longevity.technology/news/lygenesis-wins-research-award-to-advance-type-1-diabetes-cell-therapy/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079270Fri, 03 Jul 2026 09:45:44 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable,...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine CRISPR heart therapies, AI-guided Alzheimer's care, GLP-1 ecosystem expansion, biological age testing, Klotho programs, and regenerative medicine.

- Scribe Therapeutics secured more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance two CRISPR-based gene editing therapies toward human trials. The one-time treatments, STX-1200 and STX-1400, target inherited cardiovascular risk factors with the goal of durably reducing genetically driven heart disease risk.
- Eli Lilly's LillyDirect and ŌURA announced a collaboration to support people using prescribed GLP-1 therapies by combining access to treatment with wearable-based behavioral support. The initiative integrates sleep, activity, readiness, and other biometric insights to help reinforce healthy habits alongside obesity care, without sharing user data between the companies.
- NeuroXT and Beth Israel Deaconess Medical Center (BIDMC) expanded their collaboration to explore how AI could help identify the right treatment for the right Alzheimer’s patient. The research aims to identify which patients are most likely to benefit from emerging Alzheimer's therapies using imaging that is already widely available.
- Generation Lab launched SystemAge 2.1, describing it as the first biological age test to offer dedicated female and male versions. The platform analyzes more than 460 biomarkers across 21 organ systems from a needle-free blood sample, adding sex-specific assessments and organ-level tracking to monitor responses to longevity interventions.
- GARM Clinic debuted what it describes as the world's first Klotho Longevity Residency, a four-day educational program focused on Klotho-based gene therapy and regenerative medicine. Hosted in Roatán, Honduras, the residency brings together clinicians and researchers to explore translational longevity therapies in a more flexible regulatory setting.
- LyGenesis received a research award to expand its regenerative medicine platform into type 1 diabetes, to support a thymus program exploring immune tolerance to pancreatic islet transplantation. The funding will support preclinical development of a novel approach for tolerance induction following allogeneic pancreatic islet transplantation for type 1 diabetes, according to the company.

----------
News & References:

- Scribe lands $25m to advance heart disease gene therapies → https://longevity.technology/news/scribe-lands-25m-to-advance-heart-disease-gene-therapies/
- ŌURA-LillyDirect collab highlights new GLP-1 care model → https://longevity.technology/news/oura-lillydirect-collab-highlights-new-glp-1-care-model/
- AI and Alzheimer’s: NeuroXT, BIDMC aim to personalize care → https://longevity.technology/news/ai-and-alzheimers-neuroxt-bidmc-aim-to-personalize-care/
- Generation Lab launches SystemAge 2.1 as the first gender-specific biological age test → https://longevity.technology/news/generation-lab-launches-systemage-2-1-as-the-first-gender-specific-biological-age-test/
- GARM Clinic debuts world’s first Klotho longevity residency → https://longevity.technology/news/garm-clinic-debuts-worlds-first-klotho-longevity-residency/
- LyGenesis wins research award to...]]>1598falsefullhttps://www.spreaker.com/episode/the-longevity-discovery-hidden-in-dolphins--74818047
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://fatty15.com/UNLOCKED

----------
Guests:

Stephanie Venn-Watson, DVM, MPH
Co-Founder, Chief Executive Officer, Fatty15
LinkedIn: https://www.linkedin.com/in/stephanievennwatson/
Website: https://fatty15.com/

Nicholas J. Schork, PhD, MA
Co-Founder, Senior Sciencist, Fatty15
Research: https://www.researchgate.net/profile/Nicholas-Schork
Website: https://fatty15.com/

----------
What if one of the most influential nutrition recommendations of the last 50 years overlooked a nutrient essential for long-term health?

Phil Newman and Dr. Nina Patrick sit down with Dr. Stephanie Venn-Watson, veterinary epidemiologist, public health scientist, inventor, and co-founder of Fatty15, alongside Dr. Nicholas Schork, distinguished professor and leading researcher in quantitative medicine and longevity science, to explore the emerging evidence behind C15 and the future of nutrition research.

Together they examine how dietary guidelines introduced in 1977 led to widespread reductions in saturated fat consumption, while rates of obesity, metabolic disease, fatty liver disease, and type 2 diabetes continued to climb. Drawing on evidence from population studies, molecular biology, and animal research, they discuss why not all saturated fats behave the same way and how advances in metabolomics are helping researchers identify specific nutrients that may play critical roles in health and aging.

The conversation traces the remarkable discovery of C15 from aging Navy dolphins, where researchers found that higher C15 levels were associated with healthier aging and lower rates of metabolic dysfunction. They explore why C15 is emerging as a candidate essential fatty acid, how it may support cell membrane stability, mitochondrial function, AMPK activation, inflammation regulation, and metabolic resilience, and why some researchers now view it as a promising geroprotector.

They also discuss childhood nutrition, dairy consumption trends, grass-fed dairy, personalized versus essential nutrition, anemia, metabolic disease, and the challenges of translating emerging science into public health recommendations.

In this episode, you’ll learn:

- Why researchers believe saturated fats should no longer be treated as a single category
- How Navy dolphin research led to the discovery of C15's potential health benefits
- Why every 0.1% increase in circulating C15 has been associated with a 32% lower risk of developing type 2 diabetes
- What makes C15 a potential geroprotector that may influence multiple hallmarks of aging
- How future dietary guidelines may evolve as evidence around C15 continues to grow

If you want to understand how advances in nutrition science, aging biology, and public health research are reshaping our understanding of dietary fat, this episode offers a thought-provoking look at one of the most debated topics in longevity today.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
Timestamps:

00:00:00 - Why C15 Matters
00:00:53 - Finding C15 In Food
00:04:04 - Did Guidelines Fail?
00:08:30 - The C15 Benefits
00:12:03 - A Geroprotector?
00:15:17 - Testing Longevity Drugs
00:17:09 - Children's Health
00:19:20 - Dairy's Comeback
00:21:51 - Navy Dolphin Discovery
00:24:35 - Human Evidence Grows
00:26:15 - Optimizing C15
00:30:12 - Beyond Precision Nutrition
00:33:16 - Diseases And C15
00:36:11 - The Future Of C15
00:40:48 - Rapid Fire Insights]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079244Mon, 29 Jun 2026 07:49:20 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://fatty15.com/UNLOCKED

----------
Guests:

Stephanie Venn-Watson, DVM, MPH
Co-Founder, Chief Executive Officer, Fatty15
LinkedIn: https://www.linkedin.com/in/stephanievennwatson/
Website: https://fatty15.com/

Nicholas J. Schork, PhD, MA
Co-Founder, Senior Sciencist, Fatty15
Research: https://www.researchgate.net/profile/Nicholas-Schork
Website: https://fatty15.com/

----------
What if one of the most influential nutrition recommendations of the last 50 years overlooked a nutrient essential for long-term health?

Phil Newman and Dr. Nina Patrick sit down with Dr. Stephanie Venn-Watson, veterinary epidemiologist, public health scientist, inventor, and co-founder of Fatty15, alongside Dr. Nicholas Schork, distinguished professor and leading researcher in quantitative medicine and longevity science, to explore the emerging evidence behind C15 and the future of nutrition research.

Together they examine how dietary guidelines introduced in 1977 led to widespread reductions in saturated fat consumption, while rates of obesity, metabolic disease, fatty liver disease, and type 2 diabetes continued to climb. Drawing on evidence from population studies, molecular biology, and animal research, they discuss why not all saturated fats behave the same way and how advances in metabolomics are helping researchers identify specific nutrients that may play critical roles in health and aging.

The conversation traces the remarkable discovery of C15 from aging Navy dolphins, where researchers found that higher C15 levels were associated with healthier aging and lower rates of metabolic dysfunction. They explore why C15 is emerging as a candidate essential fatty acid, how it may support cell membrane stability, mitochondrial function, AMPK activation, inflammation regulation, and metabolic resilience, and why some researchers now view it as a promising geroprotector.

They also discuss childhood nutrition, dairy consumption trends, grass-fed dairy, personalized versus essential nutrition, anemia, metabolic disease, and the challenges of translating emerging science into public health recommendations.

In this episode, you’ll learn:

- Why researchers believe saturated fats should no longer be treated as a single category
- How Navy dolphin research led to the discovery of C15's potential health benefits
- Why every 0.1% increase in circulating C15 has been associated with a 32% lower risk of developing type 2 diabetes
- What makes C15 a potential geroprotector that may influence multiple hallmarks of aging
- How future dietary guidelines may evolve as evidence around C15 continues to grow

If you want to understand how advances in nutrition science, aging biology, and public health research are reshaping our understanding of dietary fat, this episode offers a thought-provoking look at one of the most debated topics in longevity today.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
Timestamps:

00:00:00 - Why C15 Matters
00:00:53 - Finding C15 In Food
00:04:04 - Did Guidelines Fail?
00:08:30 - The C15 Benefits
00:12:03 - A Geroprotector?
00:15:17 - Testing Longevity Drugs
00:17:09 - Children's...]]>3033falsefullhttps://www.spreaker.com/episode/are-forever-chemicals-in-your-longevity-stack-longevity-news-roundup-week-26-2026--74818040
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine CRISPR gene editing, national longevity strategies, AI-powered drug discovery, next-generation health imaging, metabolic therapies, and the impact of forever chemicals on aging.

- Intellia Therapeutics reported positive Phase 3 results for lonvo-z, a one-time in vivo CRISPR treatment for hereditary angioedema. Patients saw an 87% reduction in monthly attacks, marking the first successful pivotal Phase 3 trial of an in vivo CRISPR gene-editing therapy.
- Canada's "Shaping Canada's Longevity Advantage" initiative, backed by Manulife and the World Economic Forum, aims to improve health, financial resilience, and social connectedness for one million Canadians within three to five years.
- Insilico Medicine signed a collaboration with SK Biopharmaceuticals worth more than $2.5 billion in potential milestone payments. The partnership will use Insilico's Pharma.AI platform to develop therapies for neuroimmune and central nervous system disorders.
- Midjourney unveiled plans for Midjourney Medical, a full-body imaging platform designed to create detailed body maps in approximately 60 seconds. The company plans to launch its first scanning facility in San Francisco in 2027.
- Cambrian Bio presented Phase 1B data for ATX-304 in adults with obesity and prediabetes. After eight weeks, participants showed an 8% increase in resting metabolic rate alongside reductions in visceral fat, liver fat, and triglycerides.
- New research linked common PFAS "forever chemicals" to accelerated epigenetic aging. The findings highlight how environmental exposures may influence biological age and why longevity strategies may need to address toxic burden alongside lifestyle interventions.

----------
News & References:

- World’s first in vivo gene editing Phase 3 win → https://longevity.technology/news/worlds-first-in-vivo-gene-editing-phase-3-win/
- Building Canada’s longevity advantage → https://longevity.technology/news/building-canadas-longevity-advantage/
- Insilico’s $2.5b AI drug discovery deal targets neuroimmune failure → https://longevity.technology/news/insilicos-2-5b-ai-drug-discovery-deal-targets-neuroimmune-failure/
- New image? AI art giant Midjourney’s wildest leap into longevity → https://longevity.technology/news/new-image-ai-art-giant-midjourneys-wildest-leap-into-longevity/
- Human data validate Cambrian Bio’s aging target → https://longevity.technology/news/human-data-validate-cambrian-bios-aging-target/
- Forever chemicals may be aging you – longevity needs to wake up → https://longevity.technology/news/forever-chemicals-may-be-aging-you-longevity-needs-to-wake-up/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079241Fri, 26 Jun 2026 09:42:13 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable,...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine CRISPR gene editing, national longevity strategies, AI-powered drug discovery, next-generation health imaging, metabolic therapies, and the impact of forever chemicals on aging.

- Intellia Therapeutics reported positive Phase 3 results for lonvo-z, a one-time in vivo CRISPR treatment for hereditary angioedema. Patients saw an 87% reduction in monthly attacks, marking the first successful pivotal Phase 3 trial of an in vivo CRISPR gene-editing therapy.
- Canada's "Shaping Canada's Longevity Advantage" initiative, backed by Manulife and the World Economic Forum, aims to improve health, financial resilience, and social connectedness for one million Canadians within three to five years.
- Insilico Medicine signed a collaboration with SK Biopharmaceuticals worth more than $2.5 billion in potential milestone payments. The partnership will use Insilico's Pharma.AI platform to develop therapies for neuroimmune and central nervous system disorders.
- Midjourney unveiled plans for Midjourney Medical, a full-body imaging platform designed to create detailed body maps in approximately 60 seconds. The company plans to launch its first scanning facility in San Francisco in 2027.
- Cambrian Bio presented Phase 1B data for ATX-304 in adults with obesity and prediabetes. After eight weeks, participants showed an 8% increase in resting metabolic rate alongside reductions in visceral fat, liver fat, and triglycerides.
- New research linked common PFAS "forever chemicals" to accelerated epigenetic aging. The findings highlight how environmental exposures may influence biological age and why longevity strategies may need to address toxic burden alongside lifestyle interventions.

----------
News & References:

- World’s first in vivo gene editing Phase 3 win → https://longevity.technology/news/worlds-first-in-vivo-gene-editing-phase-3-win/
- Building Canada’s longevity advantage → https://longevity.technology/news/building-canadas-longevity-advantage/
- Insilico’s $2.5b AI drug discovery deal targets neuroimmune failure → https://longevity.technology/news/insilicos-2-5b-ai-drug-discovery-deal-targets-neuroimmune-failure/
- New image? AI art giant Midjourney’s wildest leap into longevity → https://longevity.technology/news/new-image-ai-art-giant-midjourneys-wildest-leap-into-longevity/
- Human data validate Cambrian Bio’s aging target → https://longevity.technology/news/human-data-validate-cambrian-bios-aging-target/
- Forever chemicals may be aging you – longevity needs to wake up → https://longevity.technology/news/forever-chemicals-may-be-aging-you-longevity-needs-to-wake-up/]]>1730falsefullhttps://www.spreaker.com/episode/the-rise-of-preventive-longevity-medicine-longevity-news-roundup-week-25-2026--74818050
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GLP-1 off-ramps, ovarian aging, combination longevity therapies, AI-driven aging models, Alzheimer’s prevention, and regenerative stem cell advances.

- Fractyl Health released one-year data from its REVEAL-1 study, showing patients maintained roughly 78% of their GLP-1-related weight loss after receiving the Revita procedure. The results raise the possibility of a long-term off-ramp for Ozempic and similar drugs, though controlled trials are still needed.
- The Longevity Science Foundation launched a campaign to accelerate ovarian aging research, an area many experts consider critically underfunded despite its relevance to female healthspan and aging biology.
- Immorta Bio published peer-reviewed preclinical findings showing more than a 70% lifespan increase when senescent cell clearance was combined with regenerative therapies, supporting the idea that multiple aging mechanisms may need to be addressed simultaneously.
- Gero secured $17 million in new funding and expanded its collaboration with Chugai Pharmaceutical, applying physics-based models and large-scale human datasets to identify aging-related therapeutic targets.
- Eli Lilly signed a deal potentially worth more than $1 billion with AlzeCure Pharma to develop a preventive Alzheimer's therapy aimed at stopping disease processes years before symptoms emerge.
- MuseCell Innovations continues advancing stress-resistant stem cell therapies designed to repair damaged tissue while potentially opening new pathways for regenerative longevity medicine.

----------
News & References:

- A new off-ramp from Ozempic and Wegovy? → https://longevity.technology/news/a-new-off-ramp-from-ozempic-and-wegovy/
- Can crowdfunding change ovarian aging research (and opinions)? → https://longevity.technology/news/can-crowdfunding-change-ovarian-aging-research-and-opinions/
- Dual stem cell and anti-aging therapy extends mouse lifespan by over 70% → https://longevity.technology/news/dual-stem-cell-and-anti-aging-therapy-extends-mouse-lifespan-by-over-70/
- Gero raises $17m to model the mathematics of aging → https://longevity.technology/news/gero-raises-17m-to-model-the-mathematics-of-aging/
- Lilly places $1b bet on AlzeCure’s Alzheimer’s project → https://longevity.technology/news/lilly-places-1b-bet-on-alzecures-alzheimers-project/
- Harnessing Muse cells in longevity medicine → https://longevity.technology/news/harnessing-muse-cells-in-longevity-medicine/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079368Fri, 19 Jun 2026 10:35:08 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable,...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GLP-1 off-ramps, ovarian aging, combination longevity therapies, AI-driven aging models, Alzheimer’s prevention, and regenerative stem cell advances.

- Fractyl Health released one-year data from its REVEAL-1 study, showing patients maintained roughly 78% of their GLP-1-related weight loss after receiving the Revita procedure. The results raise the possibility of a long-term off-ramp for Ozempic and similar drugs, though controlled trials are still needed.
- The Longevity Science Foundation launched a campaign to accelerate ovarian aging research, an area many experts consider critically underfunded despite its relevance to female healthspan and aging biology.
- Immorta Bio published peer-reviewed preclinical findings showing more than a 70% lifespan increase when senescent cell clearance was combined with regenerative therapies, supporting the idea that multiple aging mechanisms may need to be addressed simultaneously.
- Gero secured $17 million in new funding and expanded its collaboration with Chugai Pharmaceutical, applying physics-based models and large-scale human datasets to identify aging-related therapeutic targets.
- Eli Lilly signed a deal potentially worth more than $1 billion with AlzeCure Pharma to develop a preventive Alzheimer's therapy aimed at stopping disease processes years before symptoms emerge.
- MuseCell Innovations continues advancing stress-resistant stem cell therapies designed to repair damaged tissue while potentially opening new pathways for regenerative longevity medicine.

----------
News & References:

- A new off-ramp from Ozempic and Wegovy? → https://longevity.technology/news/a-new-off-ramp-from-ozempic-and-wegovy/
- Can crowdfunding change ovarian aging research (and opinions)? → https://longevity.technology/news/can-crowdfunding-change-ovarian-aging-research-and-opinions/
- Dual stem cell and anti-aging therapy extends mouse lifespan by over 70% → https://longevity.technology/news/dual-stem-cell-and-anti-aging-therapy-extends-mouse-lifespan-by-over-70/
- Gero raises $17m to model the mathematics of aging → https://longevity.technology/news/gero-raises-17m-to-model-the-mathematics-of-aging/
- Lilly places $1b bet on AlzeCure’s Alzheimer’s project → https://longevity.technology/news/lilly-places-1b-bet-on-alzecures-alzheimers-project/
- Harnessing Muse cells in longevity medicine → https://longevity.technology/news/harnessing-muse-cells-in-longevity-medicine/]]>1659falsefullhttps://www.spreaker.com/episode/the-drugs-that-could-slow-aging-are-already-here-dr-nir-barzilai--74818063
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
Guests: Nir Barzilai

Director of the Institute for Aging Research at the Albert Einstein College of Medicine
LinkedIn: https://www.linkedin.com/in/nir-barzilai-7a86a7212/
Link to Nir's works: https://einsteinmed.edu/faculty/484/nir-barzilai, https://www.sciencedirect.com/author/7005711408/nir-barzilai

----------
What if aging itself is the biggest medical opportunity of the 21st century?

Phil Newman and Dr. Nina Patrick sit down with Dr. Nir Barzilai, physician-scientist, professor of medicine and genetics, founding director of the Institute for Aging Research at Albert Einstein College of Medicine, and one of the pioneers of geroscience, to explore why targeting the biology of aging could delay multiple diseases at once.

Together they explain how decades of centenarian research revealed that healthy longevity is biologically achievable. From centenarians who remain healthy until their final year of life to real-world evidence showing GLP-1 therapies can reduce hospitalization and mortality, these insights are reshaping modern medicine. They also discuss metformin, SGLT2 inhibitors, biological age testing, longevity biomarkers, regulatory progress at the FDA, and the future of aging therapeutics.

Barzilai shares the scientific foundations behind the geroscience hypothesis, the idea that aging itself is the major driver of chronic disease. He explains why interventions that target aging biology may offer broader benefits than treating diseases one by one, and how decades of research have shifted the conversation from lifespan extension toward extending healthspan and compressing morbidity.

The discussion also explores the challenges facing the longevity field, from supplement overuse and biomarker validation to clinical trial design and regulatory pathways. Barzilai offers his perspective on emerging therapies, the promise of biological age measurement, and why the next generation of longevity medicine may look very different from today's healthcare model.

In this episode, you’ll learn:

- Why aging biology drives diseases like Alzheimer's, diabetes, and cardiovascular disease
- How centenarians compress morbidity and remain healthy into extreme old age
- Why GLP-1 therapies reduced hospitalization and death by roughly 60% in one study
- Why Barzilai tracks proteomics and believes biomarkers will transform longevity medicine
- Which longevity interventions he personally uses, including metformin and Rejuvant

If you want to understand how aging science is moving from theory to clinical reality, this episode connects cutting-edge research with practical insights for extending human healthspan.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
00:00:00 - The Geroscience Pioneer
00:02:01 - Nir's Longevity Stack
00:05:19 - What Is Geroscience?
00:10:14 - Why Healthspan Saves Money
00:14:27 - Lessons From Centenarians
00:16:58 - Which Drugs Extend Healthspan?
00:23:13 - Who Should Take Metformin?
00:25:48 - GLP-1s And Aging
00:35:44 - The Biomarker Revolution
00:40:03 - What Comes Next?
00:42:35 - Why Nir Takes Rejuvant
00:45:28 - Supplement Risks Explained
00:47:37 - FDA And Longevity Regulation
00:56:42 - Rapid Fire Insights
00:58:32 - The Next Decade Of Aging Biotech]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079250Mon, 15 Jun 2026 09:57:56 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable,...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------
Guests: Nir Barzilai

Director of the Institute for Aging Research at the Albert Einstein College of Medicine
LinkedIn: https://www.linkedin.com/in/nir-barzilai-7a86a7212/
Link to Nir's works: https://einsteinmed.edu/faculty/484/nir-barzilai, https://www.sciencedirect.com/author/7005711408/nir-barzilai

----------
What if aging itself is the biggest medical opportunity of the 21st century?

Phil Newman and Dr. Nina Patrick sit down with Dr. Nir Barzilai, physician-scientist, professor of medicine and genetics, founding director of the Institute for Aging Research at Albert Einstein College of Medicine, and one of the pioneers of geroscience, to explore why targeting the biology of aging could delay multiple diseases at once.

Together they explain how decades of centenarian research revealed that healthy longevity is biologically achievable. From centenarians who remain healthy until their final year of life to real-world evidence showing GLP-1 therapies can reduce hospitalization and mortality, these insights are reshaping modern medicine. They also discuss metformin, SGLT2 inhibitors, biological age testing, longevity biomarkers, regulatory progress at the FDA, and the future of aging therapeutics.

Barzilai shares the scientific foundations behind the geroscience hypothesis, the idea that aging itself is the major driver of chronic disease. He explains why interventions that target aging biology may offer broader benefits than treating diseases one by one, and how decades of research have shifted the conversation from lifespan extension toward extending healthspan and compressing morbidity.

The discussion also explores the challenges facing the longevity field, from supplement overuse and biomarker validation to clinical trial design and regulatory pathways. Barzilai offers his perspective on emerging therapies, the promise of biological age measurement, and why the next generation of longevity medicine may look very different from today's healthcare model.

In this episode, you’ll learn:

- Why aging biology drives diseases like Alzheimer's, diabetes, and cardiovascular disease
- How centenarians compress morbidity and remain healthy into extreme old age
- Why GLP-1 therapies reduced hospitalization and death by roughly 60% in one study
- Why Barzilai tracks proteomics and believes biomarkers will transform longevity medicine
- Which longevity interventions he personally uses, including metformin and Rejuvant

If you want to understand how aging science is moving from theory to clinical reality, this episode connects cutting-edge research with practical insights for extending human healthspan.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
00:00:00 - The Geroscience Pioneer
00:02:01 - Nir's Longevity Stack
00:05:19 - What Is Geroscience?
00:10:14 - Why Healthspan Saves Money
00:14:27 - Lessons From Centenarians
00:16:58 - Which Drugs Extend Healthspan?
00:23:13 - Who Should Take Metformin?
00:25:48 - GLP-1s And Aging
00:35:44 - The Biomarker Revolution
00:40:03 - What Comes Next?
00:42:35 - Why Nir...]]>3631falsefullhttps://www.spreaker.com/episode/can-wearables-become-clinical-tools-longevity-news-roundup-week-24-2026--74818099
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------
In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine clinical AI, cortisol wearables, blood pressure monitoring, animal longevity biotech, stem cell therapies and next-generation obesity treatments.

- Longevitix launched a clinical intelligence platform designed for longevity, preventive and functional medicine clinics. The system combines laboratory results, wearable data, clinical notes and patient histories into physician-ready summaries, prioritized insights and personalized intervention plans.
- Rejuvenate Bio secured $6 million in new financing alongside a strategic collaboration with Merck Animal Health. The partnership aims to advance gene therapies for chronic and age-related conditions in pets, highlighting growing interest in animal longevity as a pathway for translational research.
- Adaptyx Biosciences presented data on a wearable cortisol sensor capable of continuously tracking free cortisol over multiple days. The device successfully captured daily cortisol rhythms and showed strong agreement with paired blood measurements.
- Celularity partnered with Fountain Life to offer placental-derived cell therapies at Fountain Life’s Florida facility. The collaboration leverages Florida’s evolving framework for early-stage stem cell treatments and could provide valuable real-world clinical data.
- South Korea became the first country to include Skylabs’ Cart BP Pro in its national hypertension treatment guidelines. The ring-shaped device continuously monitors blood pressure without the need for a traditional arm cuff, helping detect risks that often go unnoticed during routine clinic visits.
- MitoRx presented preclinical data for MTRX31, a mitochondrial-targeted obesity therapy designed to improve metabolic health through a mechanism distinct from GLP-1 drugs. The approach could serve as either a standalone treatment or a complementary therapy, making it a potentially attractive target for future pharmaceutical partnerships.


----------
News & References:

- Longevitix launches AI platform to tackle longevity data overload → https://longevity.technology/news/longevitix-launches-ai-platform-to-tackle-longevity-data-overload/
- Rejuvenate Bio secures funding and Merck partnership → https://longevity.technology/news/rejuvenate-bio-secures-funding-and-merck-partnership/
- Adaptyx debuts first continuous cortisol tracking wearable → https://longevity.technology/news/adaptyx-debuts-first-continuous-cortisol-tracking-wearable/
- Celularity, Fountain Life to offer experimental cell therapy in Florida → https://longevity.technology/news/celularity-fountain-life-to-offer-experimental-cell-therapy-in-florida/
- Goodbye, arm cuffs? South Korea bets on ring-type BP monitor → https://longevity.technology/news/goodbye-arm-cuffs-south-korea-bets-on-ring-type-bp-monitor/
- MitoRX’s new obesity drug targets metabolism, not appetite → https://longevity.technology/news/mitorxs-new-obesity-drug-targets-metabolism-not-appetite/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079254Fri, 12 Jun 2026 11:17:52 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------
In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine clinical AI, cortisol wearables, blood pressure monitoring, animal longevity biotech, stem cell therapies and next-generation obesity treatments.

- Longevitix launched a clinical intelligence platform designed for longevity, preventive and functional medicine clinics. The system combines laboratory results, wearable data, clinical notes and patient histories into physician-ready summaries, prioritized insights and personalized intervention plans.
- Rejuvenate Bio secured $6 million in new financing alongside a strategic collaboration with Merck Animal Health. The partnership aims to advance gene therapies for chronic and age-related conditions in pets, highlighting growing interest in animal longevity as a pathway for translational research.
- Adaptyx Biosciences presented data on a wearable cortisol sensor capable of continuously tracking free cortisol over multiple days. The device successfully captured daily cortisol rhythms and showed strong agreement with paired blood measurements.
- Celularity partnered with Fountain Life to offer placental-derived cell therapies at Fountain Life’s Florida facility. The collaboration leverages Florida’s evolving framework for early-stage stem cell treatments and could provide valuable real-world clinical data.
- South Korea became the first country to include Skylabs’ Cart BP Pro in its national hypertension treatment guidelines. The ring-shaped device continuously monitors blood pressure without the need for a traditional arm cuff, helping detect risks that often go unnoticed during routine clinic visits.
- MitoRx presented preclinical data for MTRX31, a mitochondrial-targeted obesity therapy designed to improve metabolic health through a mechanism distinct from GLP-1 drugs. The approach could serve as either a standalone treatment or a complementary therapy, making it a potentially attractive target for future pharmaceutical partnerships.


----------
News & References:

- Longevitix launches AI platform to tackle longevity data overload → https://longevity.technology/news/longevitix-launches-ai-platform-to-tackle-longevity-data-overload/
- Rejuvenate Bio secures funding and Merck partnership → https://longevity.technology/news/rejuvenate-bio-secures-funding-and-merck-partnership/
- Adaptyx debuts first continuous cortisol tracking wearable → https://longevity.technology/news/adaptyx-debuts-first-continuous-cortisol-tracking-wearable/
- Celularity, Fountain Life to offer experimental cell therapy in Florida → https://longevity.technology/news/celularity-fountain-life-to-offer-experimental-cell-therapy-in-florida/
- Goodbye, arm cuffs? South Korea bets on ring-type BP monitor → https://longevity.technology/news/goodbye-arm-cuffs-south-korea-bets-on-ring-type-bp-monitor/
- MitoRX’s new obesity drug targets metabolism, not appetite → https://longevity.technology/news/mitorxs-new-obesity-drug-targets-metabolism-not-appetite/]]>1834falsefullhttps://www.spreaker.com/episode/could-banking-your-cells-today-add-healthy-years-tomorrow--74818043
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Acorn Biolabs

Acorn Biolabs is a science-driven regenerative medicine company that preserves your own hair follicle stem cells for future personalized treatments. Through a simple, non-invasive collection process, Acorn helps you bank your healthiest cells today, supporting regenerative skincare and hair therapies now while preparing for the future of longevity and cellular medicine.

Click the link below to learn more about Acorn's innovative approach to stem cell preservation.

Link: www.acorn.me

----------
Guests: Drew Taylor

CEO and co-founder of Acorn Biolabs
LinkedIn: https://www.linkedin.com/in/drew-taylor-65b6ab10/
Website: www.acorn.me

----------
What if the smartest longevity investment isn’t another supplement or infusion, but preserving your younger cells before aging changes them?

Phil Newman and Dr. Nina Patrick sit down with Drew Taylor, CEO and co-founder of Acorn Biolabs and biomedical engineer, to explore how regenerative medicine is shifting from reactive repair toward biological preservation and future optionality.

Together they explain why hair follicle stem cells may offer one of the most accessible entry points into autologous regenerative medicine. From collecting stem cells with simple hair plucking instead of invasive bone marrow extraction to cryopreserving younger biology for decades, Drew breaks down how Acorn’s platform aims to freeze cellular aging in time. The conversation also explores how these cells produce secretomes rich in growth factors, cytokines, collagen, extracellular vesicles, and exosomes that can later be used in skin rejuvenation, hair restoration, and orthopedic applications.

The discussion also dives into the darker side of the industry, including stem cell tourism, regulatory gaps, misinformation, and the risks patients face when traveling abroad for unverified treatments. Drew argues that ethical regenerative medicine must prioritize transparency, patient safety, and clinically validated protocols over hype.

They also explore the future of the field, including NK cells engineered from preserved hair follicle cells, cartilage regeneration research, AI-powered omics analysis, fertility applications, Parkinson’s research, and the possibility of one day growing replacement tissues and organs from your own preserved biology.

In this episode, you’ll learn:
- Why Acorn can generate up to 108 treatment vials from one collection
- How secretomes deliver growth factors, cytokines, collagen, and exosomes
- Why stem cell numbers decline faster than stem cell performance with age
- How NK cells derived from hair follicles suppressed cancer cell growth in lab studies
- Why Drew believes “cells will become the next currency in healthcare”

If you want to understand how regenerative medicine could shift from aesthetics to personalized disease prevention, this episode connects cutting-edge cell science with practical longevity strategies.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
00:00:03 - Longevity’s Missing Strategy
00:01:16 - Baseball Injury Lessons
00:04:09 - Why Hair Follicles?
00:07:01 - The Secretome Explained
00:09:07 - Best Age to Bank
00:10:50 - Autologous vs Donor Cells
00:14:47 - Treatment Timeline & Access
00:16:28 - Banking for the Future
00:19:21 - Acorn’s Clinic Network
00:22:01 - Stem Cell Industry Risks
00:26:18 - Beyond Aesthetics
00:30:48 - Future Medical Applications
00:32:35 - Making Prevention Mainstream
00:38:09 - Regenerative Medicine in 10 Years
00:43:13 - Rapid Fire Predictions]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079346Mon, 08 Jun 2026 09:41:51 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Acorn Biolabs Acorn Biolabs is a science-driven regenerative medicine company that preserves your own hair follicle stem cells for future...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Acorn Biolabs

Acorn Biolabs is a science-driven regenerative medicine company that preserves your own hair follicle stem cells for future personalized treatments. Through a simple, non-invasive collection process, Acorn helps you bank your healthiest cells today, supporting regenerative skincare and hair therapies now while preparing for the future of longevity and cellular medicine.

Click the link below to learn more about Acorn's innovative approach to stem cell preservation.

Link: www.acorn.me

----------
Guests: Drew Taylor

CEO and co-founder of Acorn Biolabs
LinkedIn: https://www.linkedin.com/in/drew-taylor-65b6ab10/
Website: www.acorn.me

----------
What if the smartest longevity investment isn’t another supplement or infusion, but preserving your younger cells before aging changes them?

Phil Newman and Dr. Nina Patrick sit down with Drew Taylor, CEO and co-founder of Acorn Biolabs and biomedical engineer, to explore how regenerative medicine is shifting from reactive repair toward biological preservation and future optionality.

Together they explain why hair follicle stem cells may offer one of the most accessible entry points into autologous regenerative medicine. From collecting stem cells with simple hair plucking instead of invasive bone marrow extraction to cryopreserving younger biology for decades, Drew breaks down how Acorn’s platform aims to freeze cellular aging in time. The conversation also explores how these cells produce secretomes rich in growth factors, cytokines, collagen, extracellular vesicles, and exosomes that can later be used in skin rejuvenation, hair restoration, and orthopedic applications.

The discussion also dives into the darker side of the industry, including stem cell tourism, regulatory gaps, misinformation, and the risks patients face when traveling abroad for unverified treatments. Drew argues that ethical regenerative medicine must prioritize transparency, patient safety, and clinically validated protocols over hype.

They also explore the future of the field, including NK cells engineered from preserved hair follicle cells, cartilage regeneration research, AI-powered omics analysis, fertility applications, Parkinson’s research, and the possibility of one day growing replacement tissues and organs from your own preserved biology.

In this episode, you’ll learn:
- Why Acorn can generate up to 108 treatment vials from one collection
- How secretomes deliver growth factors, cytokines, collagen, and exosomes
- Why stem cell numbers decline faster than stem cell performance with age
- How NK cells derived from hair follicles suppressed cancer cell growth in lab studies
- Why Drew believes “cells will become the next currency in healthcare”

If you want to understand how regenerative medicine could shift from aesthetics to personalized disease prevention, this episode connects cutting-edge cell science with practical longevity strategies.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
00:00:03 - Longevity’s Missing Strategy
00:01:16 - Baseball Injury Lessons
00:04:09 - Why Hair Follicles?
00:07:01 - The Secretome Explained
00:09:07 - Best Age to Bank
00:10:50 - Autologous vs Donor Cells
00:14:47 - Treatment Timeline & Access
00:16:28 - Banking for the Future
00:19:21 - Acorn’s Clinic Network
00:22:01 - Stem Cell Industry Risks
00:26:18 - Beyond Aesthetics
00:30:48 - Future Medical Applications
00:32:35 - Making Prevention Mainstream
00:38:09 - Regenerative Medicine in 10 Years2857falsefullhttps://www.spreaker.com/episode/are-brain-interfaces-finally-ready-for-daily-life-longevity-news-roundup-week-23-2026--74818029
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------
In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine wearable health innovation, brain-computer interfaces, physician-led longevity care, Alzheimer’s research, and the evolution of the longevity industry.

- ŌURA launched Ring 5, a redesigned device that is 40% smaller while maintaining week-long battery life. New features include blood pressure signals, breathing monitoring, GLP-1 insights, and integrated health data designed to make wearables a central health management platform.
- Ability Neurotech received approval in the Netherlands to begin long-term studies of its battery-free optical brain implant in ALS patients. The system is designed for everyday home use, highlighting the industry's shift from laboratory demonstrations toward real-world functionality.
- Elysium Health launched The Elysium Longevity Institute (TELI), combining physician oversight, advanced testing, supplements, prescriptions, and peptides. The move reflects a broader trend of established longevity brands expanding into comprehensive clinical care.
- A study of 69 women aged 65 and older linked poor sleep, increased Alzheimer’s genetic risk, greater tau accumulation, and weaker visual memory. Researchers suggest sleep and visual memory changes may offer valuable signals of early disease processes.
- From 95 startups across 32 countries entering the Longevity Show pitch competition to growing investment in diagnostics, prevention platforms, AI, and care delivery, the sector is increasingly focused on translating science into scalable healthspan solutions.
- The broader transition from sick care to prevention-led systems, where aging biology becomes a core risk factor and healthspan metrics replace disease counting. Insurance, pensions, and healthcare payment models need to adapt as longevity becomes embedded in economic infrastructure, not just products.


----------
News & References:

- What poor sleep may be telling women about Alzheimer’s? → https://longevity.technology/news/what-poor-sleep-may-be-telling-women-about-alzheimers/
- Five finalists advance in longevity pitch contest → https://longevity.technology/news/five-finalists-advance-in-longevity-pitch-contest/
- ŌURA’s smallest smart ring launched with expanded health monitoring → https://longevity.technology/news/ouras-smallest-smart-ring-launched-with-expanded-health-monitoring/
- Optical brain implant moves into real-world use → https://longevity.technology/news/optical-brain-implant-moves-into-real-world-use/
- Elysium expands into physician-led longevity care → https://longevity.technology/news/elysium-expands-into-physician-led-longevity-care/
- Public health faces longevity imperative → https://longevity.technology/news/public-health-faces-longevity-imperative/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079280Fri, 05 Jun 2026 10:17:13 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------
In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine wearable health innovation, brain-computer interfaces, physician-led longevity care, Alzheimer’s research, and the evolution of the longevity industry.

- ŌURA launched Ring 5, a redesigned device that is 40% smaller while maintaining week-long battery life. New features include blood pressure signals, breathing monitoring, GLP-1 insights, and integrated health data designed to make wearables a central health management platform.
- Ability Neurotech received approval in the Netherlands to begin long-term studies of its battery-free optical brain implant in ALS patients. The system is designed for everyday home use, highlighting the industry's shift from laboratory demonstrations toward real-world functionality.
- Elysium Health launched The Elysium Longevity Institute (TELI), combining physician oversight, advanced testing, supplements, prescriptions, and peptides. The move reflects a broader trend of established longevity brands expanding into comprehensive clinical care.
- A study of 69 women aged 65 and older linked poor sleep, increased Alzheimer’s genetic risk, greater tau accumulation, and weaker visual memory. Researchers suggest sleep and visual memory changes may offer valuable signals of early disease processes.
- From 95 startups across 32 countries entering the Longevity Show pitch competition to growing investment in diagnostics, prevention platforms, AI, and care delivery, the sector is increasingly focused on translating science into scalable healthspan solutions.
- The broader transition from sick care to prevention-led systems, where aging biology becomes a core risk factor and healthspan metrics replace disease counting. Insurance, pensions, and healthcare payment models need to adapt as longevity becomes embedded in economic infrastructure, not just products.


----------
News & References:

- What poor sleep may be telling women about Alzheimer’s? → https://longevity.technology/news/what-poor-sleep-may-be-telling-women-about-alzheimers/
- Five finalists advance in longevity pitch contest → https://longevity.technology/news/five-finalists-advance-in-longevity-pitch-contest/
- ŌURA’s smallest smart ring launched with expanded health monitoring → https://longevity.technology/news/ouras-smallest-smart-ring-launched-with-expanded-health-monitoring/
- Optical brain implant moves into real-world use → https://longevity.technology/news/optical-brain-implant-moves-into-real-world-use/
- Elysium expands into physician-led longevity care → https://longevity.technology/news/elysium-expands-into-physician-led-longevity-care/
- Public health faces longevity imperative → https://longevity.technology/news/public-health-faces-longevity-imperative/]]>1384falsefullhttps://www.spreaker.com/episode/dezawa-musecells-explained-the-next-generation-of-regenerative-medicine--74818032
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: MuseCell Innovations

MuseCell Innovations is a science-backed regenerative medicine company developing patented Dezawa MuseCells®, unique stem cells that support the body's natural repair and regeneration processes. Benefits include cellular renewal, tissue repair, healthy aging, improved resilience, and overall wellbeing.

Click the link below to explore the science, research, and technology behind this innovative approach to regenerative medicine.

Link: https://musecellinnovations.com/

----------
Guests:

Dominik Duscher MD PhD
President & Chief Executive Officer at MuseCell Innovations
Instagram: https://www.instagram.com/dr.dominikduscher/
Website: https://musecellinnovations.com/

Dr. Jeffrey J. Wiegers
Chief Medical Officer at MuseCell Innovations
Instagram: https://www.instagram.com/jeffwiegers/
Website: https://musecellinnovations.com/

----------
What if a naturally occurring stem cell subpopulation could home to sites of injury and support tissue repair across multiple indications?

Phil Newman and Dr. Nina Patrick sit down with Dr. Dominik Duscher, MD PhD, President and CEO of MuseCell Innovations, and Dr. Jeffrey Wiegers, MD, Chief Medical Officer, to explore the unique properties of Dezawa MuseCells®. In this session, they describe these cells as highly enriched in a purified product with pluripotent-like potential, signaling that enables targeted homing, and immune tolerance that supports allogeneic use without major immune activation, based on early human experience.

From first-in-human intravenous use in acute myocardial infarction showing safety and encouraging left ventricle performance signals, to randomized placebo-controlled subacute ischemic stroke data showing higher response rates than placebo, they walk through human trial experience without overstating effects. They also discuss repeated intravenous dosing in an amyotrophic lateral sclerosis study suggesting stabilizing signal with minimal adverse events, single-arm spinal cord injury data, and early work in neonatal hypoxic-ischemic encephalopathy showing recovery signals in some infants.

They also address broader practicalities around manufacturing rigor, quality control, and provider competency as determinants of safety in clinical settings, and they describe the need for clear documentation and oversight to avoid unlicensed or inferior products.

In this episode, you’ll learn:

- Why pluripotency, homing ability, and immune tolerance are considered key features of Dezawa MuseCells® and how these properties may relate to tissue repair.
- What early human studies in conditions like heart attack, stroke, ALS, spinal cord injury, and neonatal brain injury have shown in terms of safety and early clinical signals.
- Why manufacturing quality, purification, and standardization are critical for consistency and safety in cell-based therapies.
- Why clinician expertise and proper oversight matter when these therapies move from research into clinical use.
- How to think about verifying product authenticity and avoiding unregulated or non-standard cell therapies.

If you want to understand the biological features, emerging human data, and practical considerations around Dezawa MuseCells® as discussed by leaders in the field, this episode connects cellular biology with real-world context for regenerative medicine and longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
00:00:03 - Opening welcome
00:02:04 - Stem cell limits
00:05:40 - Manufacturing quality
00:07:05 - MuseCells explained
00:08:18 - Pluripotency power
00:11:09 - Homing to damage
00:14:03 - Immune tolerance edge
00:18:09 - Heart trial results
00:20:08 - Stroke recovery signals
00:21:31 - ALS dosing study
00:24:15 - Fragile patient success
00:28:39 - Stroke rehab pairing
00:29:07 - Safety and tumor risk
00:36:58 - Dual business model
00:45:20 - Future of Dezawa MuseCells®]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079233Mon, 01 Jun 2026 09:52:48 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: MuseCell Innovations MuseCell Innovations is a science-backed regenerative medicine company developing patented Dezawa MuseCells®, unique stem...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: MuseCell Innovations

MuseCell Innovations is a science-backed regenerative medicine company developing patented Dezawa MuseCells®, unique stem cells that support the body's natural repair and regeneration processes. Benefits include cellular renewal, tissue repair, healthy aging, improved resilience, and overall wellbeing.

Click the link below to explore the science, research, and technology behind this innovative approach to regenerative medicine.

Link: https://musecellinnovations.com/

----------
Guests:

Dominik Duscher MD PhD
President & Chief Executive Officer at MuseCell Innovations
Instagram: https://www.instagram.com/dr.dominikduscher/
Website: https://musecellinnovations.com/

Dr. Jeffrey J. Wiegers
Chief Medical Officer at MuseCell Innovations
Instagram: https://www.instagram.com/jeffwiegers/
Website: https://musecellinnovations.com/

----------
What if a naturally occurring stem cell subpopulation could home to sites of injury and support tissue repair across multiple indications?

Phil Newman and Dr. Nina Patrick sit down with Dr. Dominik Duscher, MD PhD, President and CEO of MuseCell Innovations, and Dr. Jeffrey Wiegers, MD, Chief Medical Officer, to explore the unique properties of Dezawa MuseCells®. In this session, they describe these cells as highly enriched in a purified product with pluripotent-like potential, signaling that enables targeted homing, and immune tolerance that supports allogeneic use without major immune activation, based on early human experience.

From first-in-human intravenous use in acute myocardial infarction showing safety and encouraging left ventricle performance signals, to randomized placebo-controlled subacute ischemic stroke data showing higher response rates than placebo, they walk through human trial experience without overstating effects. They also discuss repeated intravenous dosing in an amyotrophic lateral sclerosis study suggesting stabilizing signal with minimal adverse events, single-arm spinal cord injury data, and early work in neonatal hypoxic-ischemic encephalopathy showing recovery signals in some infants.

They also address broader practicalities around manufacturing rigor, quality control, and provider competency as determinants of safety in clinical settings, and they describe the need for clear documentation and oversight to avoid unlicensed or inferior products.

In this episode, you’ll learn:

- Why pluripotency, homing ability, and immune tolerance are considered key features of Dezawa MuseCells® and how these properties may relate to tissue repair.
- What early human studies in conditions like heart attack, stroke, ALS, spinal cord injury, and neonatal brain injury have shown in terms of safety and early clinical signals.
- Why manufacturing quality, purification, and standardization are critical for consistency and safety in cell-based therapies.
- Why clinician expertise and proper oversight matter when these therapies move from research into clinical use.
- How to think about verifying product authenticity and avoiding unregulated or non-standard cell therapies.

If you want to understand the biological features, emerging human data, and practical considerations around Dezawa MuseCells® as discussed by leaders in the field, this episode connects cellular biology with real-world context for regenerative medicine and longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
00:00:03 - Opening welcome
00:02:04 - Stem cell limits
00:05:40 - Manufacturing quality
00:07:05 - MuseCells...]]>3162falsefullhttps://www.spreaker.com/episode/sam-altman-s-1-8b-longevity-company-crispr-ai-health-longevity-news-roundup-week-22-2026--74818048
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------
In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine FDA-cleared sleep diagnostics, safer CRISPR therapies, longevity clinic accountability, Retro Biosciences’ valuation, and AI-driven preventative healthcare.

- Sunrise received FDA clearance for Sunrise Air, a rechargeable at-home sleep apnea diagnostic using a chin sensor for multi-night testing. The device tracks airflow, oxygen, pulse, and snoring while targeting underdiagnosis linked to cardiovascular and cognitive decline.
- Insilico and Human Longevity have announced a multimillion-dollar collaboration to build what they describe as the industry’s first large-scale AI foundation model dedicated to longevity science. 
- Daewoong Pharmaceutical acquired Turn Biotechnologies’ partial reprogramming assets, including its ERA mRNA platform. The deal gives longevity-focused age reversal IP a new clinical and regulatory pathway.
- Scribe Therapeutics presented preclinical ELXR CRISPR data showing 18-month cholesterol reduction in primates through epigenetic PCSK9 silencing. The platform reduced off-target activity by up to 100-fold without permanently altering DNA.
- At the Milan Longevity Summit 2026 they explored how longevity clinics are moving from wellness branding toward evidence-based preventative medicine. Clinics are increasingly being pressured to prove outcomes through validated biomarkers and longitudinal patient data.
- Retro Biosciences reached a $1.8 billion valuation while advancing an Alzheimer’s drug into human trials. Retro’s approach focuses on boosting a natural cellular process called autophagy, essentially the body’s built-in recycling program.

----------
News & References:

- Retro Bio’s $1.8b moment: Hopes up as Alzheimer’s trial advances → https://longevity.technology/news/retro-bios-1-8b-moment-hopes-up-as-alzheimers-trial-advances/
- Longevity clinics face their proving ground → https://longevity.technology/news/longevity-clinics-face-their-proving-ground/
- Sunrise receives FDA clearance for rechargeable at-home sleep test → https://longevity.technology/news/sunrise-receives-fda-clearance-for-rechargeable-at-home-sleep-test/
- Daewoong acquires Turn Bio age-reversal assets → https://longevity.technology/news/daewoong-acquires-turn-bio-age-reversal-assets/
- Scribe Therapeutics debuts CRISPR platforms for cholesterol treatment → https://longevity.technology/news/scribe-therapeutics-debuts-crispr-platforms-for-cholesterol-treatment/
- Insilico and Human Longevity eye to predict disease early with AI → https://longevity.technology/news/insilico-and-human-longevity-eye-to-predict-disease-early-with-ai/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987442970079248Fri, 29 May 2026 09:21:15 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------
In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine FDA-cleared sleep diagnostics, safer CRISPR therapies, longevity clinic accountability, Retro Biosciences’ valuation, and AI-driven preventative healthcare.

- Sunrise received FDA clearance for Sunrise Air, a rechargeable at-home sleep apnea diagnostic using a chin sensor for multi-night testing. The device tracks airflow, oxygen, pulse, and snoring while targeting underdiagnosis linked to cardiovascular and cognitive decline.
- Insilico and Human Longevity have announced a multimillion-dollar collaboration to build what they describe as the industry’s first large-scale AI foundation model dedicated to longevity science. 
- Daewoong Pharmaceutical acquired Turn Biotechnologies’ partial reprogramming assets, including its ERA mRNA platform. The deal gives longevity-focused age reversal IP a new clinical and regulatory pathway.
- Scribe Therapeutics presented preclinical ELXR CRISPR data showing 18-month cholesterol reduction in primates through epigenetic PCSK9 silencing. The platform reduced off-target activity by up to 100-fold without permanently altering DNA.
- At the Milan Longevity Summit 2026 they explored how longevity clinics are moving from wellness branding toward evidence-based preventative medicine. Clinics are increasingly being pressured to prove outcomes through validated biomarkers and longitudinal patient data.
- Retro Biosciences reached a $1.8 billion valuation while advancing an Alzheimer’s drug into human trials. Retro’s approach focuses on boosting a natural cellular process called autophagy, essentially the body’s built-in recycling program.

----------
News & References:

- Retro Bio’s $1.8b moment: Hopes up as Alzheimer’s trial advances → https://longevity.technology/news/retro-bios-1-8b-moment-hopes-up-as-alzheimers-trial-advances/
- Longevity clinics face their proving ground → https://longevity.technology/news/longevity-clinics-face-their-proving-ground/
- Sunrise receives FDA clearance for rechargeable at-home sleep test → https://longevity.technology/news/sunrise-receives-fda-clearance-for-rechargeable-at-home-sleep-test/
- Daewoong acquires Turn Bio age-reversal assets → https://longevity.technology/news/daewoong-acquires-turn-bio-age-reversal-assets/
- Scribe Therapeutics debuts CRISPR platforms for cholesterol treatment → https://longevity.technology/news/scribe-therapeutics-debuts-crispr-platforms-for-cholesterol-treatment/
- Insilico and Human Longevity eye to predict disease early with AI → https://longevity.technology/news/insilico-and-human-longevity-eye-to-predict-disease-early-with-ai/]]>1424falsefullhttps://www.spreaker.com/episode/this-wearable-tracks-the-female-cycle-in-real-time--74818054
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://fatty15.com/UNLOCKED

----------
Guests:

Jenny Duan
Co-Founder and CEO of Clair Health
LinkedIn: https://www.linkedin.com/in/jennysduan/
Website: https://wearclair.com/

Abhinav Agarwal
Co-Founder and CTO of Clair Health
LinkedIn: https://www.linkedin.com/in/agarwalaabhinav/
Website: https://wearclair.com/

----------
What if women’s hormones were tracked like heart rate, continuously and contextually, not through annual snapshots?

Phil Newman and Dr. Nina Patrick sit down with Jenny Duan, CEO of Clair, and Abhinav Argawal, CTO, to explore how a jewelry-inspired wrist wearable uses multi-sensor biosignals to infer estrogen and progesterone in real time across daily life.

They explain how signals such as skin temperature, HRV, sweat response, intracellular and extracellular current shifts, and more than 100 derived biomarkers are combined through sensor fusion to model hormone trajectories that update throughout the day. From forecasting an athlete’s rate of perceived exertion days before training to identifying progesterone patterns associated with PCOS and endometriosis risk, these examples show what continuous data reveals that snapshot testing cannot. The discussion also uncovers how this level of visibility allows the female cycle to be understood as nine distinct sub-phases rather than the traditional four.

They also discuss how lifestyle context, such as sleep, hydration, stress, and schedule, is integrated into the model to avoid contradictions between device feedback and lived experience. Early beta studies across PCOS, endometriosis, and perimenopause cohorts are already informing how this data can support fertility planning and symptom awareness.

In this episode, you’ll learn:

- Why the female cycle can be divided into nine hormone sub-phases
- How 230 biomarkers are refined into 100 inputs for hormone modeling
- How athletes can adjust hydration and nutrition before exertion spikes
- How progesterone trends may signal risk patterns for PCOS and endometriosis
- Why fertility and perimenopause represent 60% of early pre-orders

If you want to understand how continuous hormone visibility reshapes female health decisions across life stages, this episode connects biosensing, AI modeling, and practical insights for longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
Timestamps:

00:00:03 - Future of Hormones
00:01:03 - Why Claire Started
00:01:32 - Hormones As Operating System
00:02:24 - Beyond Snapshot Testing
00:03:24 - Fertility To Menopause
00:04:20 - Training Around Hormones
00:05:34 - Inside The App
00:06:28 - Designing For Women
00:08:20 - Sensors vs Elegance
00:10:02 - Softness As Power
00:12:03 - How Claire Predicts Hormones
00:14:40 - Lifestyle Context Matters
00:16:39 - Women Have 9 Phases
00:18:59 - Fertility Drives Demand
00:26:32 - Ending Hormone Confusion]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553766Mon, 25 May 2026 10:50:20 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://fatty15.com/UNLOCKED

----------
Guests:

Jenny Duan
Co-Founder and CEO of Clair Health
LinkedIn: https://www.linkedin.com/in/jennysduan/
Website: https://wearclair.com/

Abhinav Agarwal
Co-Founder and CTO of Clair Health
LinkedIn: https://www.linkedin.com/in/agarwalaabhinav/
Website: https://wearclair.com/

----------
What if women’s hormones were tracked like heart rate, continuously and contextually, not through annual snapshots?

Phil Newman and Dr. Nina Patrick sit down with Jenny Duan, CEO of Clair, and Abhinav Argawal, CTO, to explore how a jewelry-inspired wrist wearable uses multi-sensor biosignals to infer estrogen and progesterone in real time across daily life.

They explain how signals such as skin temperature, HRV, sweat response, intracellular and extracellular current shifts, and more than 100 derived biomarkers are combined through sensor fusion to model hormone trajectories that update throughout the day. From forecasting an athlete’s rate of perceived exertion days before training to identifying progesterone patterns associated with PCOS and endometriosis risk, these examples show what continuous data reveals that snapshot testing cannot. The discussion also uncovers how this level of visibility allows the female cycle to be understood as nine distinct sub-phases rather than the traditional four.

They also discuss how lifestyle context, such as sleep, hydration, stress, and schedule, is integrated into the model to avoid contradictions between device feedback and lived experience. Early beta studies across PCOS, endometriosis, and perimenopause cohorts are already informing how this data can support fertility planning and symptom awareness.

In this episode, you’ll learn:

- Why the female cycle can be divided into nine hormone sub-phases
- How 230 biomarkers are refined into 100 inputs for hormone modeling
- How athletes can adjust hydration and nutrition before exertion spikes
- How progesterone trends may signal risk patterns for PCOS and endometriosis
- Why fertility and perimenopause represent 60% of early pre-orders

If you want to understand how continuous hormone visibility reshapes female health decisions across life stages, this episode connects biosensing, AI modeling, and practical insights for longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
Timestamps:

00:00:03 - Future of Hormones
00:01:03 - Why Claire Started
00:01:32 - Hormones As Operating System
00:02:24 - Beyond Snapshot Testing
00:03:24 - Fertility To Menopause
00:04:20 - Training Around Hormones
00:05:34 - Inside The App
00:06:28 - Designing For Women
00:08:20 - Sensors vs Elegance
00:10:02 - Softness As Power
00:12:03 - How Claire Predicts Hormones
00:14:40 - Lifestyle Context Matters
00:16:39 - Women Have 9 Phases
00:18:59 - Fertility Drives Demand
00:26:32 - Ending Hormone Confusion]]>1844falsefullhttps://www.spreaker.com/episode/glp-1-gene-therapy-a-one-time-fix-for-obesity-diabetes-longevity-news-roundup-week-21-2026--74818110
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------
In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick examine pancreatic cancer immunotherapy, GLP-1 gene therapy, immune system rebuilding, cardiovascular plaque reversal and microbiome medicine.

-MatterBio filed its first IND application for Lm-LLO-TT, an engineered Listeria-based therapy targeting pancreatic ductal adenocarcinoma. Pending FDA clearance, the company plans a Phase 1/2a study evaluating safety, dosing and early efficacy in advanced pancreatic cancer patients resistant to conventional immunotherapy.
- Fractyl Health received European approval to begin a first-in-human Phase 1/2 trial of RJVA-001, GLP-1 gene therapy for obesity and type 2 diabetes. The therapy uses endoscopic ultrasound-guided pancreatic delivery to program beta cells to produce GLP-1 in response to meals rather than relying on repeated injections.
- Ossium Health presented clinical trial data showing successful engraftment using cryopreserved bone marrow collected from deceased organ donors. Researchers believe the banking platform could eventually simplify bone marrow transplantation logistics and expand future immune system renewal applications.
- Cyclarity shared new progress on therapies targeting 7-ketocholesterol, an oxidized cholesterol molecule linked to plaque instability and chronic arterial inflammation. Rather than slowing plaque growth, the company aims to physically remove toxic cholesterol deposits already embedded within blood vessel walls.
- Microbiotica reported positive Phase 1b MELODY-1 trial data for MB097, a microbiome therapy containing nine bacterial strains combined with KEYTRUDA in advanced melanoma patients. The therapy showed successful gut engraftment and encouraging signals that microbiome modulation may help overcome immunotherapy resistance.
- The episode also explored health equity in longevity medicine with Poonam Desai ahead of The Longevity Show. Discussions focused on sex-specific medicine, unequal access to longevity care and the risks of building precision health systems around biased clinical data.

----------
News & References:

- ‘Rebuilding the human immune system is possible’ → https://longevity.technology/news/rebuilding-the-human-immune-system-is-possible/
- Fractyl Health to begin EU trials for one-time weight loss gene therapy → https://longevity.technology/news/fractyl-health-to-begin-eu-trials-for-one-time-weight-loss-gene-therapy/
- Matter Bio takes pancreatic therapy to clinic → https://longevity.technology/news/matter-bio-takes-pancreatic-therapy-to-clinic/
- New data suggests plaque damage can be cleared → https://longevity.technology/news/new-data-suggests-plaque-damage-can-be-cleared/
- Microbiome medicine moves past wellness into clinics → https://longevity.technology/news/microbiome-medicine-moves-past-wellness-into-clinics/
- ‘Equity in longevity is the entire ballgame’ → https://longevity.technology/news/equity-in-longevity-is-the-entire-ballgame/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553731Fri, 22 May 2026 10:02:33 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------
In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick examine pancreatic cancer immunotherapy, GLP-1 gene therapy, immune system rebuilding, cardiovascular plaque reversal and microbiome medicine.

-MatterBio filed its first IND application for Lm-LLO-TT, an engineered Listeria-based therapy targeting pancreatic ductal adenocarcinoma. Pending FDA clearance, the company plans a Phase 1/2a study evaluating safety, dosing and early efficacy in advanced pancreatic cancer patients resistant to conventional immunotherapy.
- Fractyl Health received European approval to begin a first-in-human Phase 1/2 trial of RJVA-001, GLP-1 gene therapy for obesity and type 2 diabetes. The therapy uses endoscopic ultrasound-guided pancreatic delivery to program beta cells to produce GLP-1 in response to meals rather than relying on repeated injections.
- Ossium Health presented clinical trial data showing successful engraftment using cryopreserved bone marrow collected from deceased organ donors. Researchers believe the banking platform could eventually simplify bone marrow transplantation logistics and expand future immune system renewal applications.
- Cyclarity shared new progress on therapies targeting 7-ketocholesterol, an oxidized cholesterol molecule linked to plaque instability and chronic arterial inflammation. Rather than slowing plaque growth, the company aims to physically remove toxic cholesterol deposits already embedded within blood vessel walls.
- Microbiotica reported positive Phase 1b MELODY-1 trial data for MB097, a microbiome therapy containing nine bacterial strains combined with KEYTRUDA in advanced melanoma patients. The therapy showed successful gut engraftment and encouraging signals that microbiome modulation may help overcome immunotherapy resistance.
- The episode also explored health equity in longevity medicine with Poonam Desai ahead of The Longevity Show. Discussions focused on sex-specific medicine, unequal access to longevity care and the risks of building precision health systems around biased clinical data.

----------
News & References:

- ‘Rebuilding the human immune system is possible’ → https://longevity.technology/news/rebuilding-the-human-immune-system-is-possible/
- Fractyl Health to begin EU trials for one-time weight loss gene therapy → https://longevity.technology/news/fractyl-health-to-begin-eu-trials-for-one-time-weight-loss-gene-therapy/
- Matter Bio takes pancreatic therapy to clinic → https://longevity.technology/news/matter-bio-takes-pancreatic-therapy-to-clinic/
- New data suggests plaque damage can be cleared → https://longevity.technology/news/new-data-suggests-plaque-damage-can-be-cleared/
- Microbiome medicine moves past wellness into clinics → https://longevity.technology/news/microbiome-medicine-moves-past-wellness-into-clinics/
- ‘Equity in longevity is the entire ballgame’ → https://longevity.technology/news/equity-in-longevity-is-the-entire-ballgame/]]>1401falsefullhttps://www.spreaker.com/episode/valter-longo-can-short-fasting-cycles-regenerate-the-body--74818052
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: fatty15.com/UNLOCKED

----------
Guests: Valter Longo

Professor and Director at USC Longevity Institute
Instagram: https://www.instagram.com/prof_valterlongo/
Website: https://valterlongo.com/

----------
What if a five-day diet could reset metabolism, regenerate tissue, and challenge decades of nutrition dogma?

Phil Newman and Dr. Nina Patrick sit down with Valter Longo, USC Longevity Institute researcher and architect of the fasting mimicking diet, to explore how short, periodic fasting cycles may interact with aging biology, insulin signaling, and tissue regeneration.

Together they break down how the fasting mimicking diet differs from water fasting and simple calorie restriction, and why its plant based, low protein, low sugar, and high fat composition is designed to maintain protection while still triggering nutrient sensing pathways. Longo explains how in clinical and preclinical data, repeated cycles have shown improvements in insulin resistance, reductions in diabetes medication use by 60 to 70% in some cohorts, and measurable shifts in metabolic biomarkers compared to Mediterranean diet controls.

The conversation also explores mechanistic findings, including autophagy activation peaking around day five in human studies, stem cell associated regeneration signals, and embryonic like gene expression patterns observed in multiple organ systems. In animal models, these cycles have been associated with pancreatic regeneration, kidney repair after induced damage, and normalization of cholesterol and glucose regulation.

In this episode, you’ll learn:

- Autophagy activation and peak biological signaling observed around day five in human fasting mimicking protocols
- Clinical trials in diabetes showing 60 to 70% reduction in medication use within one year in some populations
- Animal studies showing reversal of severe metabolic dysfunction with monthly fasting mimicking cycles
- Protein restriction and mTOR IGF-1 signaling pathways repeatedly linked with lifespan extension across multiple species
- Risk discussion around prolonged fasting triggering energy conserving metabolic adaptation states

If you want to understand how structured fasting protocols may interact with aging pathways, metabolic disease, and regenerative biology, this episode connects clinical evidence with evolutionary and mechanistic frameworks shaping modern longevity science.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping human healthspan.

----------
Timestamps:

00:00:03 - Introduction
00:00:23 - Longevity Debate
00:00:38 - Valter Arrives
00:00:57 - First Personal Question
00:01:15 - Weight Control
00:02:05 - Muscle-Sparing Fat Loss
00:03:16 - Exercise During FMD
00:03:56 - Skip the Workout
00:05:11 - Five-Day Logic
00:07:19 - Autophagy Peak
00:09:23 - Don’t Fast Too Long
00:11:15 - What FMD Means
00:13:44 - Refeed Matters
00:17:14 - Evidence Stack
00:23:40 - FMD vs GLP-1]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553707Mon, 18 May 2026 08:43:15 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: fatty15.com/UNLOCKED

----------
Guests: Valter Longo

Professor and Director at USC Longevity Institute
Instagram: https://www.instagram.com/prof_valterlongo/
Website: https://valterlongo.com/

----------
What if a five-day diet could reset metabolism, regenerate tissue, and challenge decades of nutrition dogma?

Phil Newman and Dr. Nina Patrick sit down with Valter Longo, USC Longevity Institute researcher and architect of the fasting mimicking diet, to explore how short, periodic fasting cycles may interact with aging biology, insulin signaling, and tissue regeneration.

Together they break down how the fasting mimicking diet differs from water fasting and simple calorie restriction, and why its plant based, low protein, low sugar, and high fat composition is designed to maintain protection while still triggering nutrient sensing pathways. Longo explains how in clinical and preclinical data, repeated cycles have shown improvements in insulin resistance, reductions in diabetes medication use by 60 to 70% in some cohorts, and measurable shifts in metabolic biomarkers compared to Mediterranean diet controls.

The conversation also explores mechanistic findings, including autophagy activation peaking around day five in human studies, stem cell associated regeneration signals, and embryonic like gene expression patterns observed in multiple organ systems. In animal models, these cycles have been associated with pancreatic regeneration, kidney repair after induced damage, and normalization of cholesterol and glucose regulation.

In this episode, you’ll learn:

- Autophagy activation and peak biological signaling observed around day five in human fasting mimicking protocols
- Clinical trials in diabetes showing 60 to 70% reduction in medication use within one year in some populations
- Animal studies showing reversal of severe metabolic dysfunction with monthly fasting mimicking cycles
- Protein restriction and mTOR IGF-1 signaling pathways repeatedly linked with lifespan extension across multiple species
- Risk discussion around prolonged fasting triggering energy conserving metabolic adaptation states

If you want to understand how structured fasting protocols may interact with aging pathways, metabolic disease, and regenerative biology, this episode connects clinical evidence with evolutionary and mechanistic frameworks shaping modern longevity science.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping human healthspan.

----------
Timestamps:

00:00:03 - Introduction
00:00:23 - Longevity Debate
00:00:38 - Valter Arrives
00:00:57 - First Personal Question
00:01:15 - Weight Control
00:02:05 - Muscle-Sparing Fat Loss
00:03:16 - Exercise During FMD
00:03:56 - Skip the Workout
00:05:11 - Five-Day Logic
00:07:19 - Autophagy Peak
00:09:23 - Don’t Fast Too Long
00:11:15 - What FMD Means
00:13:44 - Refeed Matters
00:17:14 - Evidence Stack
00:23:40 - FMD vs GLP-1]]>3768falsefullhttps://www.spreaker.com/episode/can-longevity-disrupt-hospitals-from-within-longevity-news-roundup-week-20-2026--74818066
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------
In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GLP-1 drugs in progressive MS, Executive Health as a gateway to longevity care, AI-assisted skin regeneration, lab-grown red blood cells, and convergence in aging biomarkers.

- Neuraly’s NLY01 dosed its first Phase 2 patient with progressive MS in the 120-person, 96-week TAGMS trial. Instead of tracking relapse rates, researchers will use MRI-measured brain atrophy as the primary endpoint to determine whether the GLP-1 receptor agonist can slow neurodegeneration after inflammation is controlled.
- Biograph’s six-hour executive assessment compresses what they describe as three months of diagnostics into a single visit. Advanced imaging, biomarker panels, cardiac testing, biological age metrics, and cancer screening are bundled into one experience followed by a personalized action plan.
- ROKIT Healthcare presented one to two-year follow-up data showing sensory restoration, minimal scarring, functional recovery, and zero cancer recurrence after AI-assisted autologous skin reconstruction. The platform uses a patient’s own fat-derived cells combined with AI-guided bioprinting to recreate tissue that behaves like original skin.
- Hospitals are recognizing that prevention-focused longevity care could erode revenue from late-stage cardiometabolic and surgical interventions. At the same time, they already possess the imaging, labs, multidisciplinary teams, and care coordination required to deliver structured midlife risk assessment programs.
- Scarlet Therapeutics raised $4 million in seed funding after demonstrating that lab-grown red blood cells survive in circulation as long as donor-derived cells. The company is developing applications that include universal transfusion supply, therapeutic carrier cells, and engineered red blood cells designed for enhanced biological function.
- Steve Horvath argues that apparent biomarker chaos is narrowing toward a smaller set of aging measures that consistently predict mortality, disease risk, and functional decline. This convergence is critical for trials, clinics, and employer programs that need reliable endpoints to justify prevention strategies.

----------
News & References:

- GLP-1 drug enters trial for progressive multiple sclerosis → https://longevity.technology/news/glp-1-drug-enters-trial-for-progressive-multiple-sclerosis/
- Executive Health program condenses three months of testing into six hours → https://longevity.technology/news/executive-health-program-condenses-three-months-of-testing-into-six-hours/
- AI regenerative medicine targets skin recovery → https://longevity.technology/news/ai-regenerative-medicine-targets-skin-recovery/
- Hospitals confront longevity’s quiet disruption → https://longevity.technology/news/hospitals-confront-longevitys-quiet-disruption/
- Scarlet raises $4m as lab-grown blood matches donor cell survival → https://longevity.technology/news/scarlet-raises-4m-as-lab-grown-blood-matches-donor-cell-survival/
- ‘We are not at consensus but we are at convergence’ → https://longevity.technology/news/we-are-not-at-consensus-but-we-are-at-convergence/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553732Fri, 15 May 2026 09:36:05 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------
In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GLP-1 drugs in progressive MS, Executive Health as a gateway to longevity care, AI-assisted skin regeneration, lab-grown red blood cells, and convergence in aging biomarkers.

- Neuraly’s NLY01 dosed its first Phase 2 patient with progressive MS in the 120-person, 96-week TAGMS trial. Instead of tracking relapse rates, researchers will use MRI-measured brain atrophy as the primary endpoint to determine whether the GLP-1 receptor agonist can slow neurodegeneration after inflammation is controlled.
- Biograph’s six-hour executive assessment compresses what they describe as three months of diagnostics into a single visit. Advanced imaging, biomarker panels, cardiac testing, biological age metrics, and cancer screening are bundled into one experience followed by a personalized action plan.
- ROKIT Healthcare presented one to two-year follow-up data showing sensory restoration, minimal scarring, functional recovery, and zero cancer recurrence after AI-assisted autologous skin reconstruction. The platform uses a patient’s own fat-derived cells combined with AI-guided bioprinting to recreate tissue that behaves like original skin.
- Hospitals are recognizing that prevention-focused longevity care could erode revenue from late-stage cardiometabolic and surgical interventions. At the same time, they already possess the imaging, labs, multidisciplinary teams, and care coordination required to deliver structured midlife risk assessment programs.
- Scarlet Therapeutics raised $4 million in seed funding after demonstrating that lab-grown red blood cells survive in circulation as long as donor-derived cells. The company is developing applications that include universal transfusion supply, therapeutic carrier cells, and engineered red blood cells designed for enhanced biological function.
- Steve Horvath argues that apparent biomarker chaos is narrowing toward a smaller set of aging measures that consistently predict mortality, disease risk, and functional decline. This convergence is critical for trials, clinics, and employer programs that need reliable endpoints to justify prevention strategies.

----------
News & References:

- GLP-1 drug enters trial for progressive multiple sclerosis → https://longevity.technology/news/glp-1-drug-enters-trial-for-progressive-multiple-sclerosis/
- Executive Health program condenses three months of testing into six hours → https://longevity.technology/news/executive-health-program-condenses-three-months-of-testing-into-six-hours/
- AI regenerative medicine targets skin recovery → https://longevity.technology/news/ai-regenerative-medicine-targets-skin-recovery/
- Hospitals confront longevity’s quiet disruption → https://longevity.technology/news/hospitals-confront-longevitys-quiet-disruption/
- Scarlet raises $4m as lab-grown blood matches donor cell survival → https://longevity.technology/news/scarlet-raises-4m-as-lab-grown-blood-matches-donor-cell-survival/
- ‘We are not at consensus but we are at convergence’ → https://longevity.technology/news/we-are-not-at-consensus-but-we-are-at-convergence/]]>1293falsefullhttps://www.spreaker.com/episode/can-you-reverse-cognitive-decline--74818064
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: fatty15.com/UNLOCKED

----------
Guests:

Dr Henry Mahncke
CEO of BrainHQ from Posit Science
Instagram: https://www.instagram.com/brainhq_app/
Website: https://www.brainhq.com/

Dr Majid Fotuhi
Johns Hopkins Professor and Author of The Invincible Brain
Instagram: https://www.instagram.com/dr_fotuhi/
Website: https://drfotuhi.com/

----------
What if cognitive decline is not a fixed trajectory but a reversible biological state shaped by how we train the brain?

In this episode of Longevity Technology Unlocked, Dr. Nina Patrick and Phil Newman are joined by Dr. Henry Mahncke, CEO of Posit Science, and Dr. Majid Fotuhi, Johns Hopkins affiliated neurologist and author of The Invincible Brain. The discussion explores a shift in neuroscience thinking, from viewing cognitive aging as inevitable decline to seeing it as a modifiable process driven by neuroplasticity, attention, and lifestyle.

They break down why dementia and cognitive decline are increasingly being reframed as outcomes influenced by multiple modifiable systems. Dr. Mahncke explains how decades of brain plasticity research, including early cochlear implant studies, helped establish that the adult brain remains capable of change. Dr. Fotuhi adds a clinical framework built around five pillars of brain health, combining cognitive training with exercise, sleep, diet, and stress control as a unified intervention strategy for cognitive resilience.

Across both perspectives, the emphasis is on adaptive, challenging training that continuously engages attention and processing speed as a driver of broad brain plasticity rather than isolated cognitive skills.

In this episode, you’ll learn:

- How speed-based cognitive training is linked to long-term reductions in dementia risk
- Why attention and processing speed are central drivers of neuroplasticity
- How structured 12-week programs can improve memory and cognitive performance
- The role of lifestyle pillars like sleep, exercise, and diet in brain resilience
- Why mindset and perceived cognitive limits may influence brain adaptation

If you want to understand how neuroplasticity reshapes aging trajectories, this episode connects clinical neuroscience with real-world interventions for brain healthspan.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
Timestamps:

00:00:01 - Intro & Brain Pillars
00:02:29 - Guest Intros: Brain Experts
00:05:59 - Personal Brain Practices
00:06:09 - Majid's Miracle Story
00:13:33 - Neuroplasticity Revolution Unveiled
00:13:57 - Speed Training Explained
00:20:28 - Why Speed Beats Memory Games
00:23:55 - ADHD & Concussion Wins
00:31:33 - Five Pillars Deep Dive
00:42:22 - AI's Brain Impact Debated
00:48:50 - Busy Exec Minimum Routine
00:59:45 - Rapid Fire Myths Busted
01:03:49 - Closing]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553630Mon, 11 May 2026 09:28:49 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: fatty15.com/UNLOCKED

----------
Guests:

Dr Henry Mahncke
CEO of BrainHQ from Posit Science
Instagram: https://www.instagram.com/brainhq_app/
Website: https://www.brainhq.com/

Dr Majid Fotuhi
Johns Hopkins Professor and Author of The Invincible Brain
Instagram: https://www.instagram.com/dr_fotuhi/
Website: https://drfotuhi.com/

----------
What if cognitive decline is not a fixed trajectory but a reversible biological state shaped by how we train the brain?

In this episode of Longevity Technology Unlocked, Dr. Nina Patrick and Phil Newman are joined by Dr. Henry Mahncke, CEO of Posit Science, and Dr. Majid Fotuhi, Johns Hopkins affiliated neurologist and author of The Invincible Brain. The discussion explores a shift in neuroscience thinking, from viewing cognitive aging as inevitable decline to seeing it as a modifiable process driven by neuroplasticity, attention, and lifestyle.

They break down why dementia and cognitive decline are increasingly being reframed as outcomes influenced by multiple modifiable systems. Dr. Mahncke explains how decades of brain plasticity research, including early cochlear implant studies, helped establish that the adult brain remains capable of change. Dr. Fotuhi adds a clinical framework built around five pillars of brain health, combining cognitive training with exercise, sleep, diet, and stress control as a unified intervention strategy for cognitive resilience.

Across both perspectives, the emphasis is on adaptive, challenging training that continuously engages attention and processing speed as a driver of broad brain plasticity rather than isolated cognitive skills.

In this episode, you’ll learn:

- How speed-based cognitive training is linked to long-term reductions in dementia risk
- Why attention and processing speed are central drivers of neuroplasticity
- How structured 12-week programs can improve memory and cognitive performance
- The role of lifestyle pillars like sleep, exercise, and diet in brain resilience
- Why mindset and perceived cognitive limits may influence brain adaptation

If you want to understand how neuroplasticity reshapes aging trajectories, this episode connects clinical neuroscience with real-world interventions for brain healthspan.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
Timestamps:

00:00:01 - Intro & Brain Pillars
00:02:29 - Guest Intros: Brain Experts
00:05:59 - Personal Brain Practices
00:06:09 - Majid's Miracle Story
00:13:33 - Neuroplasticity Revolution Unveiled
00:13:57 - Speed Training Explained
00:20:28 - Why Speed Beats Memory Games
00:23:55 - ADHD & Concussion Wins
00:31:33 - Five Pillars Deep Dive
00:42:22 - AI's Brain Impact Debated
00:48:50 - Busy Exec Minimum Routine
00:59:45 - Rapid Fire Myths Busted
01:03:49 - Closing]]>4036falsefullhttps://www.spreaker.com/episode/the-future-of-longevity-medicine-longevity-news-roundup-week-19-2026--74818122
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine multi-target Alzheimer's therapy, sugar glycation in aging, personalized CRISPR for Parkinson's, Longevity.Technology partnerships, FDA real-time trials, and peptide platforms.

- Longevity.Technology partners with AND Capital Ventures to combine DLT intelligence platform with funding for healthspan startups. It maps hallmarks, biomarkers, and revenue trajectories to scale longevity firms from data to investment. This scaffolds the ecosystem like oncology, signaling maturation into an asset class.
- Annovis Bio's Buntanetap oral pill reduces production of multiple neurotoxic proteins like amyloid, tau, and alpha-synuclein by targeting mRNA translation machinery. This upstream approach outperforms single-target amyloid drugs, offering a practical pill over infusions.
- Estée Lauder research reveals sugar-induced glycation in skin cells triggers inflammation, senescence, and elasticity loss beyond collagen stiffening. Published in International Journal of Molecular Sciences, it links metabolic sugar exposure to systemic aging in vessels and organs.
- Scribe Therapeutics' CRISPR platform, with STX-1150 data, advances personalized gene editing for Parkinson's, repairing genetic defects in neurons for dopamine restoration. Precise delivery shows strong safety and efficiency signals.
- FDA pilots real-time cloud-based trials with AstraZeneca and Amgen, streaming data for faster safety signals and approvals. Aimed at accelerating development, it suits longevity's slow endpoints via validated biomarkers like frailty indices.
- LifespanningRX launches clinician-guided peptide programs for clinics, handling prescriptions, compounding, and shipping amid RFK Jr.-era FDA easing. With $500K funding, it taps recovery and longevity stacks demand via compliant platforms. Raises standards but risks hype without outcome tracking.

----------

News & References:

- Longevity.Technology and AND Capital Ventures launch partnership → https://longevity.technology/news/longevity-technology-and-and-capital-ventures-launch-partnership/
- Buntanetap gains ground in new Alzheimer’s trial results → https://longevity.technology/news/buntanetap-gains-ground-in-new-alzheimers-trial-results/
- Sugar’s hidden role in skin aging revealed → https://longevity.technology/news/sugars-hidden-role-in-skin-aging-revealed/
- LifespanningRx launches partner program for peptide therapy → https://longevity.technology/news/lifespanningrx-launches-partner-program-for-peptide-therapy/
- FDA’s real-time trial push could transform medicine – if they work → https://longevity.technology/news/fdas-real-time-trial-push-could-transform-medicine-if-they-work/
- Scribe highlights CRISPR advances and STX-1150 data at ASGCT, EAS → https://longevity.technology/news/scribe-highlights-crispr-advances-and-stx-1150-data-at-asgct-eas/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553795Fri, 08 May 2026 10:55:14 +0000saderHosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging...
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine multi-target Alzheimer's therapy, sugar glycation in aging, personalized CRISPR for Parkinson's, Longevity.Technology partnerships, FDA real-time trials, and peptide platforms.

- Longevity.Technology partners with AND Capital Ventures to combine DLT intelligence platform with funding for healthspan startups. It maps hallmarks, biomarkers, and revenue trajectories to scale longevity firms from data to investment. This scaffolds the ecosystem like oncology, signaling maturation into an asset class.
- Annovis Bio's Buntanetap oral pill reduces production of multiple neurotoxic proteins like amyloid, tau, and alpha-synuclein by targeting mRNA translation machinery. This upstream approach outperforms single-target amyloid drugs, offering a practical pill over infusions.
- Estée Lauder research reveals sugar-induced glycation in skin cells triggers inflammation, senescence, and elasticity loss beyond collagen stiffening. Published in International Journal of Molecular Sciences, it links metabolic sugar exposure to systemic aging in vessels and organs.
- Scribe Therapeutics' CRISPR platform, with STX-1150 data, advances personalized gene editing for Parkinson's, repairing genetic defects in neurons for dopamine restoration. Precise delivery shows strong safety and efficiency signals.
- FDA pilots real-time cloud-based trials with AstraZeneca and Amgen, streaming data for faster safety signals and approvals. Aimed at accelerating development, it suits longevity's slow endpoints via validated biomarkers like frailty indices.
- LifespanningRX launches clinician-guided peptide programs for clinics, handling prescriptions, compounding, and shipping amid RFK Jr.-era FDA easing. With $500K funding, it taps recovery and longevity stacks demand via compliant platforms. Raises standards but risks hype without outcome tracking.

----------

News & References:

- Longevity.Technology and AND Capital Ventures launch partnership → https://longevity.technology/news/longevity-technology-and-and-capital-ventures-launch-partnership/
- Buntanetap gains ground in new Alzheimer’s trial results → https://longevity.technology/news/buntanetap-gains-ground-in-new-alzheimers-trial-results/
- Sugar’s hidden role in skin aging revealed → https://longevity.technology/news/sugars-hidden-role-in-skin-aging-revealed/
- LifespanningRx launches partner program for peptide therapy → https://longevity.technology/news/lifespanningrx-launches-partner-program-for-peptide-therapy/
- FDA’s real-time trial push could transform medicine – if they work → https://longevity.technology/news/fdas-real-time-trial-push-could-transform-medicine-if-they-work/
- Scribe highlights CRISPR advances and STX-1150 data at ASGCT, EAS → https://longevity.technology/news/scribe-highlights-crispr-advances-and-stx-1150-data-at-asgct-eas/]]>1385falsefullhttps://www.spreaker.com/episode/glycans-inflammation-biological-age-a-new-lens-on-longevity--74818053----------
Sponsor: GlycanAge

Inflammaging drives CVD, metabolic disorders, and accelerated aging, but clinicians still lack reliable tools to measure, intervene, and track it in practice. GlycanAge brings together leading experts to close that gap with practical frameworks for assessing immune aging in real-world clinical settings.

Register via the link below and join the one-day event to learn how to measure immune aging and apply it to preventive and longevity care.

Date: June 20 2026 | Location: Hotel Dubrovnik Palace, Croatia

Link: https://glycanage.com/inflammaging-in-clinical-practice

----------
Guests: Nikolina Lauc
CEO & Co-Founder of GlycanAge
LinkedIn: https://www.linkedin.com/in/nikolinalauc/
Website: https://glycanage.com/

----------
What if glycans—the neglected sugars on immune proteins—reveal inflammation and biological age more accurately than DNA methylation or CRP?

Phil Newman and Dr. Nina Patrick sit down with Nikolina Lauc, CEO and co-founder of GlycanAge, to explore how these biomarkers integrate genetics, epigenetics, and environment for superior aging insights.

Together they explain glycan shifts predicting cardiovascular events better than standard markers, with 300,000+ samples showing changes up to 10 years before diabetes. From perimenopause accelerating biological age by nine years (or decades in months for some) to moderate exercise yielding 10 years younger profiles versus pros matching sedentary inflammation, these reveal immune-driven aging realities. Contrasting epigenetic clocks' 10% variability (five-year swings same-day), glycans stay stable within one year.

They also discuss hormone replacement reversing effects, fasting dropping profiles in days despite 21-day half-life, overtraining myths, and psychology like PTSD adding 15 years immune age—pushing immune resilience scores over raw age.

In this episode, you’ll learn:

- Glycans predict CV risk/mortality across 350+ papers, outperforming CRP
- Perimenopause doubles aging rate; estrogen reverses 9-year spike
- Over-exercisers match sedentary inflammation; moderates gain 10 years
- Fasting alters glycans in days vs 21-day half-life
- Stress/divorce adds decades; PTSD shortens expectancy 15-20 years
- Glycans enable modifiable risk scores for hospitals like Northwestern

If you want to understand why inflammation may be the true driver of aging, this episode connects large-scale glycan data with real-world clinical implications for prevention and longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
Hosts:

Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Timestamps:

00:00:05 - Intro
00:00:47 - Nikolina's Origin Story
00:04:36 - Glycans vs Epigenetics
00:08:20 - Clinical Applications
00:17:17 - Funding & Strategy Pivot
00:28:17 - Immune Resilience Score
00:43:28 - Intervention Surprises
01:02:08 - Women's Health Hormones
01:42:44 - Overtraining & Psychology
02:30:50 - Break & Inflammation Ad
02:55:23 - Nikolina's Personal Insights
03:28:20 - High Achiever Stress
04:13:00 - Failed Interventions
04:59:00 - Personalization Future
05:11:00 - Closing]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553618Mon, 04 May 2026 10:22:26 +0000saderFind Nina Patrick here: https://qrco.de/bgXpKn ---------- Sponsor: GlycanAge Inflammaging drives CVD, metabolic disorders, and accelerated aging, but clinicians still lack reliable tools to measure, intervene, and track it in practice. GlycanAge...----------
Sponsor: GlycanAge

Inflammaging drives CVD, metabolic disorders, and accelerated aging, but clinicians still lack reliable tools to measure, intervene, and track it in practice. GlycanAge brings together leading experts to close that gap with practical frameworks for assessing immune aging in real-world clinical settings.

Register via the link below and join the one-day event to learn how to measure immune aging and apply it to preventive and longevity care.

Date: June 20 2026 | Location: Hotel Dubrovnik Palace, Croatia

Link: https://glycanage.com/inflammaging-in-clinical-practice

----------
Guests: Nikolina Lauc
CEO & Co-Founder of GlycanAge
LinkedIn: https://www.linkedin.com/in/nikolinalauc/
Website: https://glycanage.com/

----------
What if glycans—the neglected sugars on immune proteins—reveal inflammation and biological age more accurately than DNA methylation or CRP?

Phil Newman and Dr. Nina Patrick sit down with Nikolina Lauc, CEO and co-founder of GlycanAge, to explore how these biomarkers integrate genetics, epigenetics, and environment for superior aging insights.

Together they explain glycan shifts predicting cardiovascular events better than standard markers, with 300,000+ samples showing changes up to 10 years before diabetes. From perimenopause accelerating biological age by nine years (or decades in months for some) to moderate exercise yielding 10 years younger profiles versus pros matching sedentary inflammation, these reveal immune-driven aging realities. Contrasting epigenetic clocks' 10% variability (five-year swings same-day), glycans stay stable within one year.

They also discuss hormone replacement reversing effects, fasting dropping profiles in days despite 21-day half-life, overtraining myths, and psychology like PTSD adding 15 years immune age—pushing immune resilience scores over raw age.

In this episode, you’ll learn:

- Glycans predict CV risk/mortality across 350+ papers, outperforming CRP
- Perimenopause doubles aging rate; estrogen reverses 9-year spike
- Over-exercisers match sedentary inflammation; moderates gain 10 years
- Fasting alters glycans in days vs 21-day half-life
- Stress/divorce adds decades; PTSD shortens expectancy 15-20 years
- Glycans enable modifiable risk scores for hospitals like Northwestern

If you want to understand why inflammation may be the true driver of aging, this episode connects large-scale glycan data with real-world clinical implications for prevention and longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
Hosts:

Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Timestamps:

00:00:05 - Intro
00:00:47 - Nikolina's Origin Story
00:04:36 - Glycans vs Epigenetics
00:08:20 - Clinical Applications
00:17:17 - Funding & Strategy Pivot
00:28:17 - Immune Resilience Score
00:43:28 - Intervention Surprises
01:02:08 - Women's Health Hormones
01:42:44 - Overtraining & Psychology
02:30:50 - Break & Inflammation Ad
02:55:23 - Nikolina's Personal Insights
03:28:20 - High Achiever Stress
04:13:00 - Failed Interventions
04:59:00 - Personalization Future
05:11:00 - Closing]]>3183falsefullhttps://www.spreaker.com/episode/world-s-first-longevity-fitness-games-longevity-news-roundup-week-18-2026--74818124----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine epigenetic consolidation, SuperAge Games, Endless funding, Genflow gene therapy partnership, knee implants, and longevity business models.

-Infinite Epigenetics acquired Tally Health, gaining its cheek swab biological age test and supplement recommendations. Largest epigenetic datasets could edge personalized medicine.
- SuperAge announced the SuperAge Games in New York this November, a healthspan-focused competition like CrossFit testing endurance, strength, balance, cognition, and social capacity via biomarkers. It reframes athleticism for durability over intensity, celebrating competitors at 50-70. Contrasts enhanced games by prioritizing sustained resilience.
- Endlyz closed Seed 2 funding for root-cause neurodegeneration targeting beyond plaques or inflammation. Aims for early causal interventions differing from symptom treatments. Needs specific mechanisms and biomarkers for credibility amid neuro translation challenges.
- Genflow Biosciences partnered with Acuitas Therapeutics on SIRT6 mRNA from centenarians for DNA repair, using proven lipid nanoparticles fully funded by Acuitas. De-risks delivery for preclinical tests in dogs and beyond and signals promise in aging gene therapy.
- Smith+Nephew's FDA-approved AGILI-C knee implant showed superior 5-year pain reduction and mobility in mild-moderate osteoarthritis. Targets treatment gap patients, with CPT reimbursement in 2027.
- Companies race longevity-ready models profiting from healthspan in healthcare to workplaces via screenings and benefits. Hard metrics on absenteeism excite employers at Longevity Show, and flips sickcare threats to assets.

----------
Hosts:

Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------

News & References:

- Infinite Epigenetics acquires Tally Health → https://longevity.technology/news/infinite-epigenetics-acquires-tally-health/
- Super Age debuts world’s first longevity fitness games → https://longevity.technology/news/super-age-debuts-worlds-first-longevity-fitness-games/
- Endlyz raises Seed 2 financing, leans into root-cause neuroscience → https://longevity.technology/news/endlyz-raises-seed-2-financing-leans-into-root-cause-neuroscience/
- Genflow teams with Acuitas on gene delivery in fully-funded deal → https://longevity.technology/news/genflow-teams-with-acuitas-on-gene-delivery-in-fully-funded-deal/
- Knee implant outperforms standard care at 5 years → https://longevity.technology/news/knee-implant-outperforms-standard-care-at-5-years/
- Inside the race to build longevity-ready business models → https://longevity.technology/news/inside-the-race-to-build-longevity-ready-business-models/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553658Fri, 01 May 2026 10:03:52 +0000saderFind Nina Patrick here: https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits...----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine epigenetic consolidation, SuperAge Games, Endless funding, Genflow gene therapy partnership, knee implants, and longevity business models.

-Infinite Epigenetics acquired Tally Health, gaining its cheek swab biological age test and supplement recommendations. Largest epigenetic datasets could edge personalized medicine.
- SuperAge announced the SuperAge Games in New York this November, a healthspan-focused competition like CrossFit testing endurance, strength, balance, cognition, and social capacity via biomarkers. It reframes athleticism for durability over intensity, celebrating competitors at 50-70. Contrasts enhanced games by prioritizing sustained resilience.
- Endlyz closed Seed 2 funding for root-cause neurodegeneration targeting beyond plaques or inflammation. Aims for early causal interventions differing from symptom treatments. Needs specific mechanisms and biomarkers for credibility amid neuro translation challenges.
- Genflow Biosciences partnered with Acuitas Therapeutics on SIRT6 mRNA from centenarians for DNA repair, using proven lipid nanoparticles fully funded by Acuitas. De-risks delivery for preclinical tests in dogs and beyond and signals promise in aging gene therapy.
- Smith+Nephew's FDA-approved AGILI-C knee implant showed superior 5-year pain reduction and mobility in mild-moderate osteoarthritis. Targets treatment gap patients, with CPT reimbursement in 2027.
- Companies race longevity-ready models profiting from healthspan in healthcare to workplaces via screenings and benefits. Hard metrics on absenteeism excite employers at Longevity Show, and flips sickcare threats to assets.

----------
Hosts:

Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------

News & References:

- Infinite Epigenetics acquires Tally Health → https://longevity.technology/news/infinite-epigenetics-acquires-tally-health/
- Super Age debuts world’s first longevity fitness games → https://longevity.technology/news/super-age-debuts-worlds-first-longevity-fitness-games/
- Endlyz raises Seed 2 financing, leans into root-cause neuroscience → https://longevity.technology/news/endlyz-raises-seed-2-financing-leans-into-root-cause-neuroscience/
- Genflow teams with Acuitas on gene delivery in fully-funded deal → https://longevity.technology/news/genflow-teams-with-acuitas-on-gene-delivery-in-fully-funded-deal/
- Knee implant outperforms standard care at 5 years → https://longevity.technology/news/knee-implant-outperforms-standard-care-at-5-years/
- Inside the race to build longevity-ready business models → https://longevity.technology/news/inside-the-race-to-build-longevity-ready-business-models/]]>1454falsefullhttps://www.spreaker.com/episode/how-muscle-mass-regulates-aging-metabolism-longevity--74818070----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------
Guests: JJ Virgin
Founder of Health Business Growth Collective and Well Beyond 40
Instagram: https://www.instagram.com/jj.virgin/
Website: https://jjvirgin.com/

----------
What if the key to living longer wasn’t a pill, but making your body stronger?

Phil Newman and Dr. Nina Patrick sit down with JJ Virgin, triple board-certified nutrition expert, fitness hall of famer, and founder of the Health Business Growth Collective, to explore how muscle drives strength, resilience, and decades of high performance.

According to JJ, muscle quietly slips away after 30. Protein synthesis drops 30% per decade, hitting women earliest and hardest as perimenopause estrogen fades against their lower starting mass. Grip strength reveals the truth first, signaling all-cause mortality risk—the weakest quartile faces the steepest odds—even as 50% of normal-weight adults harbor sarcopenic obesity, blending frailty with hidden fat that rushes aging.

JJ cuts through the noise. Grip dynamometer tests deliver the simplest proxy: squeeze for "great" versus your age group, with under 10% hand asymmetry. She flips GLP-1s on their head—build muscle first with protein matched to ideal weight and fat-free mass tracking, then cut calories. Beginners start her 2x2x2: two days weekly, two moves per body part, two sets to near-failure. Neural gains arrive before the mirror notices.

In this episode, you’ll learn:

- Grip strength predicts mortality. Test 3x per side; track gains as neural adaptations lead hypertrophy by 6-8 weeks.
- Build muscle first. GLP-1s expose weak diets, risking 40% muscle loss on calorie cuts without resistance training.
- Women lose fast-twitch fibers quickest. Challenge with 6-12 reps near failure to rebuild power.
- Resting metabolic rate climbs 7-10 calories per pound of muscle; protein-first meals spike thermic effect 25%.
- Start simple: pushups (wall to toes), squats to chair (30-sec power test), rows. Progress from bodyweight to loads.
- 40 years of clinical insights deliver actionable tests and programming against gravity's pull.

If you want to understand how muscle powers healthspan against gravity-fueled decline, this episode connects 40 years of clinical insights with actionable tests and programming for powerful aging.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
Hosts:

Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Timestamps:

00:00 Managing Energy And Recovery
02:01 Energy Management From Tony Robbins Events
06:07 Why Women Must Build More Muscle
07:14 Stop Using The Scale Measure Muscle Quality
23:06 Muscle First Before Calorie Restriction
24:09 Track Where Your Weight Loss Comes From
26:44 Protein Thermic Effect And Eating Protein First
33:03 Why Squats Matter For Daily Life
33:35 How To Know You Are Lifting Heavy Enough
34:47 You Can Build Muscle At Any Age
54:02 Muscle Contraction As Powerful Medicine
57:54 Jump Training For Bone Density
59:10 Grip Strength As Longevity Metric
59:28 PEMF Mat Recovery Routine
01:00 Sauna Red Light And Recovery Stack]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553752Mon, 27 Apr 2026 10:24:03 +0000saderFind Nina Patrick here: https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits...----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------
Guests: JJ Virgin
Founder of Health Business Growth Collective and Well Beyond 40
Instagram: https://www.instagram.com/jj.virgin/
Website: https://jjvirgin.com/

----------
What if the key to living longer wasn’t a pill, but making your body stronger?

Phil Newman and Dr. Nina Patrick sit down with JJ Virgin, triple board-certified nutrition expert, fitness hall of famer, and founder of the Health Business Growth Collective, to explore how muscle drives strength, resilience, and decades of high performance.

According to JJ, muscle quietly slips away after 30. Protein synthesis drops 30% per decade, hitting women earliest and hardest as perimenopause estrogen fades against their lower starting mass. Grip strength reveals the truth first, signaling all-cause mortality risk—the weakest quartile faces the steepest odds—even as 50% of normal-weight adults harbor sarcopenic obesity, blending frailty with hidden fat that rushes aging.

JJ cuts through the noise. Grip dynamometer tests deliver the simplest proxy: squeeze for "great" versus your age group, with under 10% hand asymmetry. She flips GLP-1s on their head—build muscle first with protein matched to ideal weight and fat-free mass tracking, then cut calories. Beginners start her 2x2x2: two days weekly, two moves per body part, two sets to near-failure. Neural gains arrive before the mirror notices.

In this episode, you’ll learn:

- Grip strength predicts mortality. Test 3x per side; track gains as neural adaptations lead hypertrophy by 6-8 weeks.
- Build muscle first. GLP-1s expose weak diets, risking 40% muscle loss on calorie cuts without resistance training.
- Women lose fast-twitch fibers quickest. Challenge with 6-12 reps near failure to rebuild power.
- Resting metabolic rate climbs 7-10 calories per pound of muscle; protein-first meals spike thermic effect 25%.
- Start simple: pushups (wall to toes), squats to chair (30-sec power test), rows. Progress from bodyweight to loads.
- 40 years of clinical insights deliver actionable tests and programming against gravity's pull.

If you want to understand how muscle powers healthspan against gravity-fueled decline, this episode connects 40 years of clinical insights with actionable tests and programming for powerful aging.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------
Hosts:

Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------
Timestamps:

00:00 Managing Energy And Recovery
02:01 Energy Management From Tony Robbins Events
06:07 Why Women Must Build More Muscle
07:14 Stop Using The Scale Measure Muscle Quality
23:06 Muscle First Before Calorie Restriction
24:09 Track Where Your Weight Loss Comes From
26:44 Protein Thermic Effect And Eating Protein First
33:03 Why Squats Matter For Daily Life
33:35 How To Know You Are Lifting Heavy Enough
34:47 You Can Build Muscle At Any Age
54:02 Muscle Contraction As Powerful Medicine
57:54 Jump Training For Bone Density
59:10 Grip Strength As Longevity Metric
59:28 PEMF Mat Recovery Routine
01:00 Sauna Red Light And Recovery Stack]]>4157falsefullhttps://www.spreaker.com/episode/the-biggest-longevity-breakthroughs-this-week-week-17-2026--74818141----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine energy span as a fatigue biomarker, GSK's $950M 35 Pharma acquisition, January AI's Medicare app entry, OsteoBoost's $8M funding, Seragon's SRN-901 33% mouse lifespan boost, and skin longevity advances.

- Energy span proposes viewing fatigue as an early mitochondrial decline signal before chronic disease. Advances in wearable technology and continuous monitoring are making it possible to track proxies of energy regulation – heart rate variability as a marker of autonomic balance, glucose dynamics as a reflection of metabolic stability, sleep architecture as a proxy for recovery.
- GSK acquired 35Pharma for $950M, gaining a pulmonary hypertension candidate affecting lung arteries. Proof-of-concept trials are expected to begin soon in two forms of the disease: pulmonary arterial hypertension (PAH) and PH linked to heart failure with preserved ejection fraction (PH-HFpEF).
- January AI joined Medicare's app library for 69M users, using food photos and AI to predict glucose responses. It lowers barriers for metabolic coaching but needs integration and targeting for adoption.
- OsteoBoost raised $8M for a vibration wearable mimicking bone-loading to combat osteoporosis in 200M worldwide. It offers non-drug options amid bisphosphonate trade-offs, with mixed prior studies on dose.
- Seragon's oral SRN-901 extended late-life mouse lifespan 33%, cut frailty 70%, tumors 30% via mitophagy and NAD support, outperforming rapamycin.
- Epicutis' TCP serum improved skin appearance 77% in 8-week trial versus placebo, signaling cellular modulation in aesthetics.

----------
Hosts:

Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------

News & References:

- GSK acquires 35Pharma in $950m deal, advancing PH drug → https://longevity.technology/news/gsk-acquires-35pharma-in-950m-deal-advancing-ph-drug/
- Energy Span reframes fatigue as early warning → https://longevity.technology/news/energy-span-reframes-fatigue-as-early-warning/
- Osteoboost raises $8m to scale bone wearable → https://longevity.technology/news/osteoboost-raises-8m-to-scale-bone-wearable/
- January AI enters Medicare App Library, reaches 69m+ patients → https://longevity.technology/news/january-ai-enters-medicare-app-library-reaches-69m-patients/
- Seragon study shows SRN-901 extends median lifespan in mice → https://longevity.technology/news/seragon-study-shows-srn-901-extends-median-lifespan-in-mice/
- Epicutis clinical study shows 77% improvement in skin appearance → https://longevity.technology/news/epicutis-clinical-study-shows-77-improvement-in-skin-appearance/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553736Fri, 24 Apr 2026 10:28:44 +0000saderFind Nina Patrick here: https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits...----------
Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine energy span as a fatigue biomarker, GSK's $950M 35 Pharma acquisition, January AI's Medicare app entry, OsteoBoost's $8M funding, Seragon's SRN-901 33% mouse lifespan boost, and skin longevity advances.

- Energy span proposes viewing fatigue as an early mitochondrial decline signal before chronic disease. Advances in wearable technology and continuous monitoring are making it possible to track proxies of energy regulation – heart rate variability as a marker of autonomic balance, glucose dynamics as a reflection of metabolic stability, sleep architecture as a proxy for recovery.
- GSK acquired 35Pharma for $950M, gaining a pulmonary hypertension candidate affecting lung arteries. Proof-of-concept trials are expected to begin soon in two forms of the disease: pulmonary arterial hypertension (PAH) and PH linked to heart failure with preserved ejection fraction (PH-HFpEF).
- January AI joined Medicare's app library for 69M users, using food photos and AI to predict glucose responses. It lowers barriers for metabolic coaching but needs integration and targeting for adoption.
- OsteoBoost raised $8M for a vibration wearable mimicking bone-loading to combat osteoporosis in 200M worldwide. It offers non-drug options amid bisphosphonate trade-offs, with mixed prior studies on dose.
- Seragon's oral SRN-901 extended late-life mouse lifespan 33%, cut frailty 70%, tumors 30% via mitophagy and NAD support, outperforming rapamycin.
- Epicutis' TCP serum improved skin appearance 77% in 8-week trial versus placebo, signaling cellular modulation in aesthetics.

----------
Hosts:

Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
----------

News & References:

- GSK acquires 35Pharma in $950m deal, advancing PH drug → https://longevity.technology/news/gsk-acquires-35pharma-in-950m-deal-advancing-ph-drug/
- Energy Span reframes fatigue as early warning → https://longevity.technology/news/energy-span-reframes-fatigue-as-early-warning/
- Osteoboost raises $8m to scale bone wearable → https://longevity.technology/news/osteoboost-raises-8m-to-scale-bone-wearable/
- January AI enters Medicare App Library, reaches 69m+ patients → https://longevity.technology/news/january-ai-enters-medicare-app-library-reaches-69m-patients/
- Seragon study shows SRN-901 extends median lifespan in mice → https://longevity.technology/news/seragon-study-shows-srn-901-extends-median-lifespan-in-mice/
- Epicutis clinical study shows 77% improvement in skin appearance → https://longevity.technology/news/epicutis-clinical-study-shows-77-improvement-in-skin-appearance/]]>1516falsefullhttps://www.spreaker.com/episode/biohacking-is-dead-with-tim-gray--74818057Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.
Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: ⁠https://partners.fatty15.com/UNLOCKED⁠
-----
Guests:
Tim Gray
Founder, Health Optimization Summit
Website: ⁠https://healthoptimization.com/⁠
Instagram: ⁠https://www.instagram.com/timbiohacker/⁠
-----
What if biohacking is not about doing more, but about doing less, better?

Phil Newman and Dr. Nina Patrick sit down with Tim Gray, founder of the Health Optimization Summit and one of the most influential figures in the biohacking movement, to explore how the space has evolved from niche experimentation to mainstream health optimization. From supplements and wearables to nervous system regulation and community-driven health, Tim shares what actually moves the needle and what does not.

They discuss the shift from complex protocols to foundational health principles, why oversupplementation and excessive data can backfire, and how environment and lifestyle often outperform expensive technologies. The conversation also explores emerging trends including peptides, stem cells, microplastics, and the growing importance of nervous system regulation.

The episode examines how large-scale personal data is shaping health insights, the balance between personal experimentation and clinical evidence, and why loneliness may be one of the most overlooked risks to longevity.

In this episode, you will learn:

- How biohacking has evolved into health optimization
- Why simplifying your health routine often leads to better results
- The risks of oversupplementation and over-reliance on data
- How environment influences the need for health technologies
- The role of peptides and stem cells in the future of medicine
- Why nervous system regulation is becoming a central pillar of health
- The impact of community and relationships on longevity

How to think about personalization versus foundational health principles
If you want to understand where the longevity and biohacking space is heading and how to focus on what actually works, this episode offers a grounded, experience-led perspective on optimizing health in a complex world.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping how we live longer and better.
-----
Hosts:

Phil Newman: ⁠⁠⁠https://qrco.de/bgXpNY⁠
Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠

____

00:00:02 - Epic Longevity Kickoff
00:01:23 - Corfu Retreat Secrets
00:02:43 - Simplify to Thrive
00:04:38 - Ditched Biohacks Revealed
00:08:35 - Must-Keep Essentials
00:10:51 - Sleep Supremacy Rules
00:11:39 - Anecdotes Trump Studies?
00:16:56 - Founder Obsession Hunt
00:22:48 - Peptides Power Surge
00:25:21 - Stem Cells Miracle
00:29:36 - Loneliness Kills Fast
00:34:47 - Wearables Data Clash
00:39:51 - Biohacking's Dying Gasp
00:43:05 - Nervous System Hacks
00:46:56 - Personalization Trap]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553659Mon, 20 Apr 2026 10:45:34 +0000saderSponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall...Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.
Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: ⁠https://partners.fatty15.com/UNLOCKED⁠
-----
Guests:
Tim Gray
Founder, Health Optimization Summit
Website: ⁠https://healthoptimization.com/⁠
Instagram: ⁠https://www.instagram.com/timbiohacker/⁠
-----
What if biohacking is not about doing more, but about doing less, better?

Phil Newman and Dr. Nina Patrick sit down with Tim Gray, founder of the Health Optimization Summit and one of the most influential figures in the biohacking movement, to explore how the space has evolved from niche experimentation to mainstream health optimization. From supplements and wearables to nervous system regulation and community-driven health, Tim shares what actually moves the needle and what does not.

They discuss the shift from complex protocols to foundational health principles, why oversupplementation and excessive data can backfire, and how environment and lifestyle often outperform expensive technologies. The conversation also explores emerging trends including peptides, stem cells, microplastics, and the growing importance of nervous system regulation.

The episode examines how large-scale personal data is shaping health insights, the balance between personal experimentation and clinical evidence, and why loneliness may be one of the most overlooked risks to longevity.

In this episode, you will learn:

- How biohacking has evolved into health optimization
- Why simplifying your health routine often leads to better results
- The risks of oversupplementation and over-reliance on data
- How environment influences the need for health technologies
- The role of peptides and stem cells in the future of medicine
- Why nervous system regulation is becoming a central pillar of health
- The impact of community and relationships on longevity

How to think about personalization versus foundational health principles
If you want to understand where the longevity and biohacking space is heading and how to focus on what actually works, this episode offers a grounded, experience-led perspective on optimizing health in a complex world.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping how we live longer and better.
-----
Hosts:

Phil Newman: ⁠⁠⁠https://qrco.de/bgXpNY⁠
Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠

____

00:00:02 - Epic Longevity Kickoff
00:01:23 - Corfu Retreat Secrets
00:02:43 - Simplify to Thrive
00:04:38 - Ditched Biohacks Revealed
00:08:35 - Must-Keep Essentials
00:10:51 - Sleep Supremacy Rules
00:11:39 - Anecdotes Trump Studies?
00:16:56 - Founder Obsession Hunt
00:22:48 - Peptides Power Surge
00:25:21 - Stem Cells Miracle
00:29:36 - Loneliness Kills Fast
00:34:47 - Wearables Data Clash
00:39:51 - Biohacking's Dying Gasp
00:43:05 - Nervous System Hacks
00:46:56 - Personalization Trap]]>3462falsefullhttps://www.spreaker.com/episode/67b-longevity-boom-big-tech-health-partnerships-longevity-news-roundup-week-16-2026--74818062
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore the $67B longevity market projection, Technogym’s Google partnership, Function Health’s acquisition, mitochondrial transplants, clinical education, and the rise of workforce healthspan.

A new report projects the longevity and healthy aging market will reach $67B by 2035, spanning therapeutics, diagnostics, supplements, and lifestyle interventions. Growth signals mainstream adoption, but raises concerns around “longevity washing” and the need for stronger scientific validation.
Technogym expands its partnership with Google Cloud to build AI-powered, personalized fitness and health coaching. Alongside moves from L’Oréal and wearables players, big tech and legacy brands are embedding longevity into everyday consumer platforms.

Function Health acquires GetLabs to enable at-home blood draws, removing friction in biomarker testing. The move strengthens longitudinal health tracking, though success depends on pairing access with meaningful clinical guidance.

Mitrix Bio reports early safety data on mitochondrial transplants, injecting lab-grown mitochondria to restore cellular energy. With only two participants and clinics already launching under “Right to Try,” the approach highlights tensions between innovation speed and clinical evidence.

Longevity.Technology launches a clinical education marketplace, curating vetted training programs for clinicians, founders, and consumers. The platform aims to address fragmentation and raise standards across the rapidly evolving sector.

Employers are shifting toward healthspan-focused benefits, prioritizing diagnostics, mental health, and preventative care over traditional perks. Workforce longevity strategies are emerging as a key lever for productivity, retention, and cost control.

----------

Hosts:

Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

News & References:

Technogym & Google Cloud partnership → https://longevity.technology/news/technogym-and-google-cloud-expand-ai-fitness/
Function Health acquires GetLabs → https://longevity.technology/news/function-acquires-getlabs-to-scale-at-home-testing/
Mitrix Bio mitochondrial transplant trials → https://longevity.technology/news/mitrix-moves-mitochondria-into-the-clinic/
Longevity.Technology education marketplace launch → https://longevity.technology/news/education-platform-targets-longevity-knowledge-gap/
Workforce healthspan trends → https://longevity.technology/news/workers-rethink-benefits-healthspan-comes-first/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553751Fri, 17 Apr 2026 11:37:16 +0000saderSponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and...
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore the $67B longevity market projection, Technogym’s Google partnership, Function Health’s acquisition, mitochondrial transplants, clinical education, and the rise of workforce healthspan.

A new report projects the longevity and healthy aging market will reach $67B by 2035, spanning therapeutics, diagnostics, supplements, and lifestyle interventions. Growth signals mainstream adoption, but raises concerns around “longevity washing” and the need for stronger scientific validation.
Technogym expands its partnership with Google Cloud to build AI-powered, personalized fitness and health coaching. Alongside moves from L’Oréal and wearables players, big tech and legacy brands are embedding longevity into everyday consumer platforms.

Function Health acquires GetLabs to enable at-home blood draws, removing friction in biomarker testing. The move strengthens longitudinal health tracking, though success depends on pairing access with meaningful clinical guidance.

Mitrix Bio reports early safety data on mitochondrial transplants, injecting lab-grown mitochondria to restore cellular energy. With only two participants and clinics already launching under “Right to Try,” the approach highlights tensions between innovation speed and clinical evidence.

Longevity.Technology launches a clinical education marketplace, curating vetted training programs for clinicians, founders, and consumers. The platform aims to address fragmentation and raise standards across the rapidly evolving sector.

Employers are shifting toward healthspan-focused benefits, prioritizing diagnostics, mental health, and preventative care over traditional perks. Workforce longevity strategies are emerging as a key lever for productivity, retention, and cost control.

----------

Hosts:

Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

News & References:

Technogym & Google Cloud partnership → https://longevity.technology/news/technogym-and-google-cloud-expand-ai-fitness/
Function Health acquires GetLabs → https://longevity.technology/news/function-acquires-getlabs-to-scale-at-home-testing/
Mitrix Bio mitochondrial transplant trials → https://longevity.technology/news/mitrix-moves-mitochondria-into-the-clinic/
Longevity.Technology education marketplace launch → https://longevity.technology/news/education-platform-targets-longevity-knowledge-gap/
Workforce healthspan trends → https://longevity.technology/news/workers-rethink-benefits-healthspan-comes-first/]]>2060falsefullhttps://www.spreaker.com/episode/she-was-told-ms-was-irreversible-then-she-walked-again--74818079
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://partners.fatty15.com/UNLOCKED
______________________

Guests:

Dr Terry Wahls
Physician and Author of The Wahls Protocol
Website: https://terrywahls.com/

______________________

What if autoimmune disease isn’t irreversible, but a reflection of deeper dysfunction at the cellular level?

Phil Newman and Dr. Nina Patrick sit down with Dr. Terry Wahls, clinician, researcher, and author of The Wahls Protocol, to explore how diet, lifestyle, and cellular health can reshape outcomes in chronic disease. Diagnosed with progressive multiple sclerosis and confined to a wheelchair, Dr. Wahls applied a science-led, systems-based approach to restore her function, challenging conventional assumptions about what is possible in autoimmune conditions.

They explore how mitochondria, the microbiome, and immune function interact to drive disease, and how targeted interventions across nutrition, movement, and lifestyle can improve resilience, energy, and overall health.

The conversation covers nutrient density, gut health, fasting, fats, and behavioural change, connecting clinical science with practical application. It also examines the resistance faced by non-traditional approaches in medicine, the difficulty of funding complex lifestyle research, and why personalised, systems-level thinking may shape the future of healthcare.

In this episode, you will learn:

How Dr. Wahls went from wheelchair-bound to walking and cycling again
The role of mitochondria and cellular function in autoimmune disease
How diet, gut health, and the microbiome influence immunity and brain health
Why ultra-processed foods drive inflammation and chronic disease
The importance of personalised nutrition and lifestyle interventions
How to use “biosensors” to track what works for your body
The limitations of current microbiome testing and one-size-fits-all diets

If you want to understand how science-backed lifestyle interventions can influence chronic disease, performance, and long-term health, this episode offers a clear and evidence-informed perspective on what is possible.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping how we live longer and better.

______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

______________________

Timestamps:

00:00:00 Introduction to longevity and healthspan
00:02:30 Dr. Wahls’ MS diagnosis and decline
00:05:00 Turning point from drugs to cellular health
00:08:30 The Wahls Protocol and dietary strategy
00:12:00 Mitochondria and energy production
00:15:30 Microbiome, gut health, and immunity
00:19:00 Fiber, fermented foods, and inflammation
00:23:00 Fats, omega balance, and brain health
00:27:00 Fasting, muscle loss, and aging
00:31:00 Lifestyle pillars including sleep, stress, and movement
00:35:00 Resistance from the medical community
00:39:00 Research challenges and funding barriers
00:43:00 Personalisation and biosensor tracking
00:47:00 The future of autoimmune treatment]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553665Mon, 13 Apr 2026 10:54:53 +0000saderSponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and...
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://partners.fatty15.com/UNLOCKED
______________________

Guests:

Dr Terry Wahls
Physician and Author of The Wahls Protocol
Website: https://terrywahls.com/

______________________

What if autoimmune disease isn’t irreversible, but a reflection of deeper dysfunction at the cellular level?

Phil Newman and Dr. Nina Patrick sit down with Dr. Terry Wahls, clinician, researcher, and author of The Wahls Protocol, to explore how diet, lifestyle, and cellular health can reshape outcomes in chronic disease. Diagnosed with progressive multiple sclerosis and confined to a wheelchair, Dr. Wahls applied a science-led, systems-based approach to restore her function, challenging conventional assumptions about what is possible in autoimmune conditions.

They explore how mitochondria, the microbiome, and immune function interact to drive disease, and how targeted interventions across nutrition, movement, and lifestyle can improve resilience, energy, and overall health.

The conversation covers nutrient density, gut health, fasting, fats, and behavioural change, connecting clinical science with practical application. It also examines the resistance faced by non-traditional approaches in medicine, the difficulty of funding complex lifestyle research, and why personalised, systems-level thinking may shape the future of healthcare.

In this episode, you will learn:

How Dr. Wahls went from wheelchair-bound to walking and cycling again
The role of mitochondria and cellular function in autoimmune disease
How diet, gut health, and the microbiome influence immunity and brain health
Why ultra-processed foods drive inflammation and chronic disease
The importance of personalised nutrition and lifestyle interventions
How to use “biosensors” to track what works for your body
The limitations of current microbiome testing and one-size-fits-all diets

If you want to understand how science-backed lifestyle interventions can influence chronic disease, performance, and long-term health, this episode offers a clear and evidence-informed perspective on what is possible.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping how we live longer and better.

______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

______________________

Timestamps:

00:00:00 Introduction to longevity and healthspan
00:02:30 Dr. Wahls’ MS diagnosis and decline
00:05:00 Turning point from drugs to cellular health
00:08:30 The Wahls Protocol and dietary strategy
00:12:00 Mitochondria and energy production
00:15:30 Microbiome, gut health, and immunity
00:19:00 Fiber, fermented foods, and inflammation
00:23:00 Fats, omega balance, and brain health
00:27:00 Fasting, muscle loss, and aging
00:31:00 Lifestyle pillars including sleep, stress, and movement
00:35:00 Resistance from the medical community
00:39:00 Research challenges and funding barriers
00:43:00 Personalisation and biosensor tracking
00:47:00 The future of autoimmune treatment]]>3267falsefullhttps://www.spreaker.com/episode/how-longevity-is-converging-with-drugs-data-and-movement-longevity-news-roundup-week-15-2026--74818051
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://partners.fatty15.com/UNLOCKED
______________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GeneRare funding, Noom's pharmacy buy, Anovis neuro combos, Life Biosciences reprogramming, wearable partnerships, and Peloton at Longevity Show.

- Generare raised $21.6M (€20M) Series A to scale microbial genome scanning for novel natural product molecules, identifying 200+ hits in 2025. Funds expand libraries from plants, fungi, marine sources and team to 50 for bioactive drug leads. AI optimizes hits despite supply/IP challenges, eyeing geroprotectors like rapamycin analogs.
- Noom acquired a 503A compounding pharmacy to dispense GLP-1s, peptides like sermorelin, NAD+ with behavioral coaching for healthy aging. Vertical integration pairs app data with pharma access to scale longevity interventions. Success needs strong clinical governance over revenue incentives.
- Annovis advances buntanetap, oral molecule from Calabar bean "execution poison," reducing amyloid beta, tau, alpha-synuclein translation in phase 3 Alzheimer's and Parkinson's trials. Combos with sildenafil boost cerebral blood flow, NO-cGMP as vascular support.
- Life Biosciences landed $80M Series D to push ER-100 partial epigenetic "cell reset" therapy into phase 1 for optic neuropathies like glaucoma. Targets retinal ganglion cell rejuvenation as beachhead for organ-specific proofs toward systemic aging reversal. Measurable vision outcomes validate reprogramming.
- Agentis partners Ultrahuman integrating CGM/HRV into Longevity Quotient platforms; Well Health ties AliveCor for AI-ECG AFib detection in Canada. Wearables enable dynamic monitoring beyond snapshots for arrhythmias, metabolic drift. Demand proven clinical outcomes over data noise.
- Peloton named official movement partner for Longevity Show 2026 (June 26-27, London) with rooftop workouts, 5K runs, rave featuring Leanne Hainesby. Anchors exercise as healthspan core alongside biomarkers, bridging fitness-longevity audiences. Preview April 19 Covent Garden.
______________________

News & References:

- Generare bags $21.6m for nature-derived drug leads → https://longevity.technology/news/generare-bags-21-6m-for-nature-derived-drug-leads/
- Noom buys pharmacy to push into healthy aging → https://longevity.technology/news/noom-buys-pharmacy-to-push-into-healthy-aging/
- Annovis traces buntanetap’s road to Alzheimer’s → https://longevity.technology/news/annovis-traces-buntanetaps-road-to-alzheimers/
- Life Biosciences lands $80m to push cell reset therapy → https://longevity.technology/news/life-biosciences-lands-80m-to-push-cell-reset-therapy/
- Agentis, Ultrahuman tie wearables to longevity care → https://longevity.technology/news/agentis-ultrahuman-tie-wearables-to-longevity-care/
- Peloton named Movement Partner for The Longevity Show 2026 → https://longevity.technology/news/peloton-named-movement-partner-for-the-longevity-show-2026/
______________________

Hosts:
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553693Fri, 10 Apr 2026 10:54:55 +0000saderSponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and...
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://partners.fatty15.com/UNLOCKED
______________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GeneRare funding, Noom's pharmacy buy, Anovis neuro combos, Life Biosciences reprogramming, wearable partnerships, and Peloton at Longevity Show.

- Generare raised $21.6M (€20M) Series A to scale microbial genome scanning for novel natural product molecules, identifying 200+ hits in 2025. Funds expand libraries from plants, fungi, marine sources and team to 50 for bioactive drug leads. AI optimizes hits despite supply/IP challenges, eyeing geroprotectors like rapamycin analogs.
- Noom acquired a 503A compounding pharmacy to dispense GLP-1s, peptides like sermorelin, NAD+ with behavioral coaching for healthy aging. Vertical integration pairs app data with pharma access to scale longevity interventions. Success needs strong clinical governance over revenue incentives.
- Annovis advances buntanetap, oral molecule from Calabar bean "execution poison," reducing amyloid beta, tau, alpha-synuclein translation in phase 3 Alzheimer's and Parkinson's trials. Combos with sildenafil boost cerebral blood flow, NO-cGMP as vascular support.
- Life Biosciences landed $80M Series D to push ER-100 partial epigenetic "cell reset" therapy into phase 1 for optic neuropathies like glaucoma. Targets retinal ganglion cell rejuvenation as beachhead for organ-specific proofs toward systemic aging reversal. Measurable vision outcomes validate reprogramming.
- Agentis partners Ultrahuman integrating CGM/HRV into Longevity Quotient platforms; Well Health ties AliveCor for AI-ECG AFib detection in Canada. Wearables enable dynamic monitoring beyond snapshots for arrhythmias, metabolic drift. Demand proven clinical outcomes over data noise.
- Peloton named official movement partner for Longevity Show 2026 (June 26-27, London) with rooftop workouts, 5K runs, rave featuring Leanne Hainesby. Anchors exercise as healthspan core alongside biomarkers, bridging fitness-longevity audiences. Preview April 19 Covent Garden.
______________________

News & References:

- Generare bags $21.6m for nature-derived drug leads → https://longevity.technology/news/generare-bags-21-6m-for-nature-derived-drug-leads/
- Noom buys pharmacy to push into healthy aging → https://longevity.technology/news/noom-buys-pharmacy-to-push-into-healthy-aging/
- Annovis traces buntanetap’s road to Alzheimer’s → https://longevity.technology/news/annovis-traces-buntanetaps-road-to-alzheimers/
- Life Biosciences lands $80m to push cell reset therapy → https://longevity.technology/news/life-biosciences-lands-80m-to-push-cell-reset-therapy/
- Agentis, Ultrahuman tie wearables to longevity care → https://longevity.technology/news/agentis-ultrahuman-tie-wearables-to-longevity-care/
- Peloton named Movement Partner for The Longevity Show 2026 → https://longevity.technology/news/peloton-named-movement-partner-for-the-longevity-show-2026/
______________________

Hosts:
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn]]>1556falsefullhttps://www.spreaker.com/episode/how-animal-biology-is-shaping-the-future-of-medicine--74818059
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://partners.fatty15.com/UNLOCKED
______________________

Guests:

Ashley Zehnder
CEO, Fauna Bio
Linkedin: https://www.linkedin.com/in/ashley-zehnder-31950827/
Website: https://www.faunabio.com/

Daniel Oliver
Co-Founder & CEO, Rejuvenate Bio
Linkedin: https://www.linkedin.com/in/danielcoliver/
Website: https://rejuvenatebio.com/
______________________

What if the animal kingdom holds the key to improving human healthspan and performance?

Phil Newman and Dr. Nina Patrick sit down with Ashley Zehnder, CEO of Fauna Bio, and Daniel Oliver, CEO of Rejuvenate Bio, to explore how insights from hibernating animals, long-lived species, and regenerative models are shaping next-generation longevity therapies. From metabolic adaptations and ketone utilization to epigenetic reprogramming, they reveal how studying other species can guide interventions for human health, recovery, and overall wellness.

Together they explain how species that naturally resist disease, survive extreme conditions, or regenerate tissues provide a roadmap for interventions in humans. From hibernating mammals that switch to ketone-based metabolism to long-lived rodents showing epigenetic resilience, these insights are shaping therapies that target recovery, metabolism, and overall wellness.

They also discuss how these discoveries could inform practical strategies for human health, from personalized nutrition and exercise to novel drug targets that mimic nature’s resilience.

In this episode, you’ll learn:

- How gene therapies in animals improve endurance, recovery, frailty, and lifespan
- What hibernating animals and high-performance species teach about metabolism and resilience
- How AI and comparative genomics accelerate drug discovery and improve translational success
- Common misconceptions about translating animal biology to human health
- Future priorities in longevity research, including regenerative biology and disease resistance

If you want to understand how comparative biology and cutting-edge therapies are unlocking new pathways to enhance human healthspan, this episode connects science from the animal kingdom with actionable insights for human longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
______________________

Timestamps:

00:00:00 Why animals matter in aging research
00:02:18 Limits of traditional mouse models
00:04:52 Cancer resistance in large mammals
00:07:31 Hibernation and metabolic shutdown
00:10:06 Extreme physiology as a longevity map
00:12:44 Disease model vs wellness model
00:15:28 Reversible damage in nature
00:18:10 Translating animal traits to humans
00:21:37 Genomics and comparative mapping
00:24:12 Early medical proof points
00:28:03 AI and aging pathway discovery
00:32:22 Hypoxia and cardiometabolic recovery
00:37:12 FGF21 and metabolic crossover
00:42:25 Reversing vs preventing aging damage
00:49:05 Biologics and gene therapy future]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553785Mon, 06 Apr 2026 10:38:37 +0000saderSponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and...
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://partners.fatty15.com/UNLOCKED
______________________

Guests:

Ashley Zehnder
CEO, Fauna Bio
Linkedin: https://www.linkedin.com/in/ashley-zehnder-31950827/
Website: https://www.faunabio.com/

Daniel Oliver
Co-Founder & CEO, Rejuvenate Bio
Linkedin: https://www.linkedin.com/in/danielcoliver/
Website: https://rejuvenatebio.com/
______________________

What if the animal kingdom holds the key to improving human healthspan and performance?

Phil Newman and Dr. Nina Patrick sit down with Ashley Zehnder, CEO of Fauna Bio, and Daniel Oliver, CEO of Rejuvenate Bio, to explore how insights from hibernating animals, long-lived species, and regenerative models are shaping next-generation longevity therapies. From metabolic adaptations and ketone utilization to epigenetic reprogramming, they reveal how studying other species can guide interventions for human health, recovery, and overall wellness.

Together they explain how species that naturally resist disease, survive extreme conditions, or regenerate tissues provide a roadmap for interventions in humans. From hibernating mammals that switch to ketone-based metabolism to long-lived rodents showing epigenetic resilience, these insights are shaping therapies that target recovery, metabolism, and overall wellness.

They also discuss how these discoveries could inform practical strategies for human health, from personalized nutrition and exercise to novel drug targets that mimic nature’s resilience.

In this episode, you’ll learn:

- How gene therapies in animals improve endurance, recovery, frailty, and lifespan
- What hibernating animals and high-performance species teach about metabolism and resilience
- How AI and comparative genomics accelerate drug discovery and improve translational success
- Common misconceptions about translating animal biology to human health
- Future priorities in longevity research, including regenerative biology and disease resistance

If you want to understand how comparative biology and cutting-edge therapies are unlocking new pathways to enhance human healthspan, this episode connects science from the animal kingdom with actionable insights for human longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn
______________________

Timestamps:

00:00:00 Why animals matter in aging research
00:02:18 Limits of traditional mouse models
00:04:52 Cancer resistance in large mammals
00:07:31 Hibernation and metabolic shutdown
00:10:06 Extreme physiology as a longevity map
00:12:44 Disease model vs wellness model
00:15:28 Reversible damage in nature
00:18:10 Translating animal traits to humans
00:21:37 Genomics and comparative mapping
00:24:12 Early medical proof points
00:28:03 AI and aging pathway discovery
00:32:22 Hypoxia and cardiometabolic recovery
00:37:12 FGF21 and metabolic crossover
00:42:25 Reversing vs preventing aging damage
00:49:05 Biologics and gene therapy future]]>3179falsefullhttps://www.spreaker.com/episode/can-aging-be-treated-like-a-disease-longevity-news-roundup-week-14-2026--74818161
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://partners.fatty15.com/UNLOCKED
______________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine how early neurodegeneration screening, bioprinted tissues, senolytic therapies, pharma strategy shifts, and private clinic evolution are reshaping how longevity medicine is practiced and regulated.

- PREMAZ partnered with Health is One to expand access to early brain screening designed to detect neurodegenerative risk before symptoms appear. While full biomarker validation data has not yet been published, the initiative highlights the growing race to identify preclinical Alzheimer’s and dementia signals at a stage where lifestyle and therapeutic interventions may still alter trajectory.
- Eli Lilly continues assembling what increasingly resembles a longevity-aligned portfolio. Through AI drug discovery alliances, cardiometabolic dominance via GLP-1s, and deep investments across fibrosis, neurodegeneration, muscle, immune, and vascular aging, the company is building a multi-pathway prevention strategy even without using the term longevity publicly.
- Berlin-based startup Cellbricks secured €10 million to advance its vascularized 3D bioprinted tissue implants toward preclinical development. Solving the vascularization bottleneck in functional tissue printing could eventually transform how age-related organ failure is treated, reducing reliance on donor transplantation.
- Global advocacy efforts are intensifying to push regulators to classify aging itself as a modifiable condition rather than a background risk factor. Campaigns call for changes to disease classification systems, funding pathways, and regulatory trial frameworks that allow therapies to target aging mechanisms directly rather than single disease endpoints.
- Rubedo Life Sciences reported first human trial results for a topical senolytic therapy targeting senescent cells in patients with psoriasis and eczema. The treatment showed reduced senescent cell burden, lower inflammatory markers, and increased skin collagen thickness after four weeks, offering an early human proof of concept for targeted senotherapeutics.
- Private hospitals and premium clinics are increasingly repositioning themselves as longevity centers. With existing diagnostics, labs, imaging, and clinical teams, these facilities are well placed to transition from reactive sick care to proactive health span management. The challenge now is standardization, clinician training, shared biomarkers, and evidence-based protocols to prevent longevity medicine from becoming personality driven rather than data driven.
______________________

News & References:

- PREMAZ expands early brain screening through Health is One → https://longevity.technology/news/premaz-expands-early-brain-screening-through-health-is-one/
- Lilly races to become first longevity Big Pharma → https://longevity.technology/news/lilly-races-to-become-first-longevity-big-pharma/
- Cellbricks Therapeutics secures €10 million to advance tissue implants → https://longevity.technology/news/cellbricks-therapeutics-secures-e10-million-to-advance-tissue-implants/
- Global rallies call for aging to be treated → https://longevity.technology/news/global-rallies-call-for-aging-to-be-treated/
- Rubedo reports early clinical signal for senotherapeutic drug → https://longevity.technology/news/rubedo-reports-early-clinical-signal-for-senotherapeutic-drug/
- Private clinics face longevity learning curve → https://longevity.technology/news/private-clinics-face-longevity-learning-curve/
______________________

Hosts:
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553737Fri, 03 Apr 2026 10:05:33 +0000saderSponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and...
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://partners.fatty15.com/UNLOCKED
______________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine how early neurodegeneration screening, bioprinted tissues, senolytic therapies, pharma strategy shifts, and private clinic evolution are reshaping how longevity medicine is practiced and regulated.

- PREMAZ partnered with Health is One to expand access to early brain screening designed to detect neurodegenerative risk before symptoms appear. While full biomarker validation data has not yet been published, the initiative highlights the growing race to identify preclinical Alzheimer’s and dementia signals at a stage where lifestyle and therapeutic interventions may still alter trajectory.
- Eli Lilly continues assembling what increasingly resembles a longevity-aligned portfolio. Through AI drug discovery alliances, cardiometabolic dominance via GLP-1s, and deep investments across fibrosis, neurodegeneration, muscle, immune, and vascular aging, the company is building a multi-pathway prevention strategy even without using the term longevity publicly.
- Berlin-based startup Cellbricks secured €10 million to advance its vascularized 3D bioprinted tissue implants toward preclinical development. Solving the vascularization bottleneck in functional tissue printing could eventually transform how age-related organ failure is treated, reducing reliance on donor transplantation.
- Global advocacy efforts are intensifying to push regulators to classify aging itself as a modifiable condition rather than a background risk factor. Campaigns call for changes to disease classification systems, funding pathways, and regulatory trial frameworks that allow therapies to target aging mechanisms directly rather than single disease endpoints.
- Rubedo Life Sciences reported first human trial results for a topical senolytic therapy targeting senescent cells in patients with psoriasis and eczema. The treatment showed reduced senescent cell burden, lower inflammatory markers, and increased skin collagen thickness after four weeks, offering an early human proof of concept for targeted senotherapeutics.
- Private hospitals and premium clinics are increasingly repositioning themselves as longevity centers. With existing diagnostics, labs, imaging, and clinical teams, these facilities are well placed to transition from reactive sick care to proactive health span management. The challenge now is standardization, clinician training, shared biomarkers, and evidence-based protocols to prevent longevity medicine from becoming personality driven rather than data driven.
______________________

News & References:

- PREMAZ expands early brain screening through Health is One → https://longevity.technology/news/premaz-expands-early-brain-screening-through-health-is-one/
- Lilly races to become first longevity Big Pharma → https://longevity.technology/news/lilly-races-to-become-first-longevity-big-pharma/
- Cellbricks Therapeutics secures €10 million to advance tissue implants → https://longevity.technology/news/cellbricks-therapeutics-secures-e10-million-to-advance-tissue-implants/
- Global rallies call for aging to be treated → https://longevity.technology/news/global-rallies-call-for-aging-to-be-treated/
- Rubedo reports early clinical signal for senotherapeutic drug → https://longevity.technology/news/rubedo-reports-early-clinical-signal-for-senotherapeutic-drug/
- Private clinics face longevity learning curve →...]]>1574falsefullhttps://www.spreaker.com/episode/aubrey-de-grey-on-why-everything-you-think-about-aging-is-wrong--74818170
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://partners.fatty15.com/UNLOCKED
______________________

Guests: Dr. Aubrey de Grey

President and CSO at LEV Foundation
Linkedin: https://www.linkedin.com/in/aubrey-de-grey-24260b/
Website: https://www.levf.org/
______________________

What if aging is not inevitable… but something we can actively manage?

Phil Newman and Dr. Nina Patrick sit down with Aubrey de Grey, Chief Science Officer at the LEV Foundation, to explore how preventative medicine, intrinsic capacity, and early longevity therapeutics are reshaping the way we think about healthspan and lifespan. From drug development bottlenecks to off-label therapies and ethical access, they explain why progress depends less on luck and more on aligning science, policy, and society.

Aubrey explains how concepts like intrinsic capacity and resilience offer measurable ways to track functional health, allowing interventions earlier in the aging process. He highlights the promise and limitations of ARPA-H funding, the potential of GLP-1 drugs and other preventative medicines, and how longevity clinics and early adopters help normalize medical control of aging.

Together, they show that making longevity medicine accessible is not just a scientific challenge, it is an economic, societal, and regulatory one.

In this episode, you’ll learn:

- How intrinsic capacity and resilience can measure functional aging earlier than traditional methods
- Why preventative medicines face societal and regulatory barriers
- How high-profile advocates and clinics are shaping public acceptance of longevity therapies
- Ethical and practical considerations for equitable access worldwide
- Where Aubrey would prioritize additional funding in aging research and what the healthcare landscape could look like by 2040

If you want to understand how preventative medicine and early longevity therapeutics could extend healthspan and lifespan, this episode connects cutting-edge aging research with actionable insights on access, equity, and real-world application.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

______________________

Timestamps:
0:00 – Repairing damage vs slowing aging
4:32 – Rejuvenation cycles and buying 20 years of time
5:31 – Timeframes, probabilities, and “make aging the new Covid”
10:43 – Mouse lifespan extension as the field’s proof point
12:59 – Why repair is the most practical framework
27:48 – What result would convince the scientific community
29:23 – Why lifespan is the acid test, not healthspan claims
30:27 – AI, AlphaFold, and In Silico Medicine accelerating biotech
37:49 – Aging vs disease, intrinsic capacity, and resilience metrics
40:00 – GLP-1 drugs and the barrier to preventive medicine
43:06 – Longevity clinics, off label use, and “nibbling around the edges”
48:19 – The economic imperative and why every country must invest
49:55 – Overpopulation, pollution, and why the concern is overstated
52:37 – How Aubrey’s predictions shifted over 20 years
58:53 – What aging medicine might look like by 2040 and close]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553667Mon, 30 Mar 2026 14:21:31 +0000saderSponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and...
Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.
Link: https://partners.fatty15.com/UNLOCKED
______________________

Guests: Dr. Aubrey de Grey

President and CSO at LEV Foundation
Linkedin: https://www.linkedin.com/in/aubrey-de-grey-24260b/
Website: https://www.levf.org/
______________________

What if aging is not inevitable… but something we can actively manage?

Phil Newman and Dr. Nina Patrick sit down with Aubrey de Grey, Chief Science Officer at the LEV Foundation, to explore how preventative medicine, intrinsic capacity, and early longevity therapeutics are reshaping the way we think about healthspan and lifespan. From drug development bottlenecks to off-label therapies and ethical access, they explain why progress depends less on luck and more on aligning science, policy, and society.

Aubrey explains how concepts like intrinsic capacity and resilience offer measurable ways to track functional health, allowing interventions earlier in the aging process. He highlights the promise and limitations of ARPA-H funding, the potential of GLP-1 drugs and other preventative medicines, and how longevity clinics and early adopters help normalize medical control of aging.

Together, they show that making longevity medicine accessible is not just a scientific challenge, it is an economic, societal, and regulatory one.

In this episode, you’ll learn:

- How intrinsic capacity and resilience can measure functional aging earlier than traditional methods
- Why preventative medicines face societal and regulatory barriers
- How high-profile advocates and clinics are shaping public acceptance of longevity therapies
- Ethical and practical considerations for equitable access worldwide
- Where Aubrey would prioritize additional funding in aging research and what the healthcare landscape could look like by 2040

If you want to understand how preventative medicine and early longevity therapeutics could extend healthspan and lifespan, this episode connects cutting-edge aging research with actionable insights on access, equity, and real-world application.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

______________________

Timestamps:
0:00 – Repairing damage vs slowing aging
4:32 – Rejuvenation cycles and buying 20 years of time
5:31 – Timeframes, probabilities, and “make aging the new Covid”
10:43 – Mouse lifespan extension as the field’s proof point
12:59 – Why repair is the most practical framework
27:48 – What result would convince the scientific community
29:23 – Why lifespan is the acid test, not healthspan claims
30:27 – AI, AlphaFold, and In Silico Medicine accelerating biotech
37:49 – Aging vs disease, intrinsic capacity, and resilience metrics
40:00 – GLP-1 drugs and the barrier to preventive medicine
43:06 – Longevity clinics, off label use, and “nibbling around the edges”
48:19 – The economic imperative and why every country must invest
49:55 – Overpopulation, pollution, and why the concern is overstated
52:37 – How Aubrey’s predictions shifted over 20 years
58:53 – What aging medicine might look like by 2040 and close]]>3614falsefullhttps://www.spreaker.com/episode/hibernating-animals-ai-longevity-mortality-risks-longevity-news-roundup-week-13-2026--74818166
Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Affiliate link: https://www.getstride.com/unlocked/
____________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore cutting-edge developments in longevity, from hibernating animals inspiring obesity treatments to AI-driven industry insights and the world’s first Parkinson’s test kit.

- FaunaBio identified a metabolic target from hibernating mammals that could preserve muscle during weight loss. The California-based company said the achievement triggers an undisclosed milestone payment as part of a multi-year agreement signed with Lilly in 2023, which could be worth up to $494 million. This will advance this first-in-class approach, signaling serious pharma conviction in extreme-animal-inspired drug discovery.
- Longevity.Technology developed DLT (Decoding Longevity Trends), a three-stage AI system to gather, fact-check, and synthesize complex longevity data. DLT tracks over 700 longevity and age-related disease biotechs in paid-beta; the broader datasets (800+ wider ecosystem companies and 300+ longevity clinics) will be released in 2H26.
- The MODAG's PD Detect kit measures alpha-synuclein aggregates in cerebrospinal fluid with 97.8% sensitivity and 100% specificity, moving Parkinson’s diagnosis from observation to evidence. Early detection can help enroll patients at stages where disease-modifying drugs have the best chance of success.
- The Senotherapeutics Biomarker Consortium (SBC) aims to standardize cellular senescence measurement in humans to support regulators, clinicians, and drug development. Framed as a precompetitive collaboration, it brings together academia, industry and regulators to do something less glamorous than drug discovery, but arguably more necessary – to agree on how senescence should be measured, validated and ultimately trusted in the clinic.
- The experimental pill Enlicitide lowered LDL cholesterol by 57% in a phase three trial of 2,909 patients with cardiovascular risk. Daily oral dosing could finally improve compliance compared with injectable PCSK9 inhibitors, potentially reducing cardiovascular events at a population level.
- Cardiovascular disease and cancer (particularly colon cancer) and “external causes” remain top mortality risks. These conditions are leading causes of death for Gen X and Millennials, highlighting the urgent need for early detection and preventive health strategies.
____________________

News & References:

- Fauna Bio hits key milestone in Lilly obesity drug collab → https://longevity.technology/news/fauna-bio-hits-key-milestone-in-lilly-obesity-drug-collab/
- Longevity.Technology has quietly become an AI company → https://longevity.technology/news/longevity-technology-has-quietly-become-an-ai-company/
- MODAG brings world’s first Parkinson’s test to market → https://longevity.technology/news/modag-brings-worlds-first-parkinsons-test-to-market/
- Senescence consortium targets biomarker gap → https://longevity.technology/news/senescence-consortium-targets-biomarker-gap/
- Experimental pill cuts ‘bad cholesterol’ by up to 60% → https://longevity.technology/news/experimental-pill-cuts-bad-cholesterol-by-up-to-60/
- Longevity wake-up call for younger generations → https://longevity.technology/news/longevity-wake-up-call-for-younger-generations/

____________________
Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553777Fri, 27 Mar 2026 12:19:40 +0000saderSponsor: Stride Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science....
Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Affiliate link: https://www.getstride.com/unlocked/
____________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore cutting-edge developments in longevity, from hibernating animals inspiring obesity treatments to AI-driven industry insights and the world’s first Parkinson’s test kit.

- FaunaBio identified a metabolic target from hibernating mammals that could preserve muscle during weight loss. The California-based company said the achievement triggers an undisclosed milestone payment as part of a multi-year agreement signed with Lilly in 2023, which could be worth up to $494 million. This will advance this first-in-class approach, signaling serious pharma conviction in extreme-animal-inspired drug discovery.
- Longevity.Technology developed DLT (Decoding Longevity Trends), a three-stage AI system to gather, fact-check, and synthesize complex longevity data. DLT tracks over 700 longevity and age-related disease biotechs in paid-beta; the broader datasets (800+ wider ecosystem companies and 300+ longevity clinics) will be released in 2H26.
- The MODAG's PD Detect kit measures alpha-synuclein aggregates in cerebrospinal fluid with 97.8% sensitivity and 100% specificity, moving Parkinson’s diagnosis from observation to evidence. Early detection can help enroll patients at stages where disease-modifying drugs have the best chance of success.
- The Senotherapeutics Biomarker Consortium (SBC) aims to standardize cellular senescence measurement in humans to support regulators, clinicians, and drug development. Framed as a precompetitive collaboration, it brings together academia, industry and regulators to do something less glamorous than drug discovery, but arguably more necessary – to agree on how senescence should be measured, validated and ultimately trusted in the clinic.
- The experimental pill Enlicitide lowered LDL cholesterol by 57% in a phase three trial of 2,909 patients with cardiovascular risk. Daily oral dosing could finally improve compliance compared with injectable PCSK9 inhibitors, potentially reducing cardiovascular events at a population level.
- Cardiovascular disease and cancer (particularly colon cancer) and “external causes” remain top mortality risks. These conditions are leading causes of death for Gen X and Millennials, highlighting the urgent need for early detection and preventive health strategies.
____________________

News & References:

- Fauna Bio hits key milestone in Lilly obesity drug collab → https://longevity.technology/news/fauna-bio-hits-key-milestone-in-lilly-obesity-drug-collab/
- Longevity.Technology has quietly become an AI company → https://longevity.technology/news/longevity-technology-has-quietly-become-an-ai-company/
- MODAG brings world’s first Parkinson’s test to market → https://longevity.technology/news/modag-brings-worlds-first-parkinsons-test-to-market/
- Senescence consortium targets biomarker gap → https://longevity.technology/news/senescence-consortium-targets-biomarker-gap/
- Experimental pill cuts ‘bad cholesterol’ by up to 60% → https://longevity.technology/news/experimental-pill-cuts-bad-cholesterol-by-up-to-60/
- Longevity wake-up call for younger generations → https://longevity.technology/news/longevity-wake-up-call-for-younger-generations/

____________________
Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn]]>2053falsefullhttps://www.spreaker.com/episode/are-we-managing-women-s-health-all-wrong--74818077
Dr Lara Briden
Naturopathic doctor and Bestselling Author
Instagram: www.instagram.com/larabriden/
Website: www.larabriden.com/

Dr Molly Maloof
Educator, Author, and Founder of Adamo
Instagram: www.instagram.com/drmolly.co/?hl=en
Website: https://drmolly.co/
______________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Link: www.getstride.com/unlocked/
______________________

What if the key to female longevity has been hiding in plain sight?

In this episode, Phil Newman and Dr Nina Patrick sits down with Dr Lara Briden, evolutionary biologist and hormone expert, and Dr Molly Maloof, functional medicine practitioner, to explore the metabolic, hormonal, and evolutionary factors that shape female longevity.

They dive into the often-overlooked role of iron in perimenopause and post-menopause, the hidden epidemic of insulin resistance, and the nuanced balance of fatty acids for cellular health. Lara reframes menopause as an adaptive stage that supports the survival of the next generation, while Molly explains why metabolic flexibility is one of the most powerful tools for long-term health.

Together, they discuss practical strategies women can use across their lifespan—from iron management and blood markers to gut health, nutrition, and exercise—as well as exciting breakthroughs in biotechnology, peptides, and regenerative medicine that could extend female healthspan in the next decade.

In this episode, you’ll learn:

- Why managing iron levels is crucial for longevity, especially in perimenopause and post-menopause.
- How regular ovulatory cycles and pregnancy shape long-term metabolic and reproductive health.
- The hidden role of insulin resistance and simple blood markers that can flag early metabolic dysfunction.
- The importance of omega-6, omega-3, and saturated fats balance for cell membrane and neurological health.
- How evolutionary biology explains menopause as a “superpower” for human survival.
- Practical steps for women to optimize metabolism, exercise, and nutrient intake across their lifespan.
- The emerging role of biotechnology, regenerative medicine, and peptides in extending female healthspan.

If you want to take control of your metabolic health, understand menopause as a stage of strength, and learn strategies to optimize female longevity across the lifespan, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging strategies and interventions shaping the future of female health.
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

______________________

00:35:47 – Iron Deficiency Drives Perimenopause Fatigue
00:36:29 – Symptoms & Treatments for Low Ferritin
00:37:42 – Ferritin: Europe vs US Standards
00:38:14 – Fertility & Longevity: Optimal Ferritin
00:39:37 – Managing High Iron After Menopause
00:41:24 – Stride DNA & Biome Test Overview
00:42:59 – Menopause as a Superpower
00:46:04 – Matriarch Roles in Human & Orca Longevity
00:47:31 – Insulin Resistance & Metabolic Health Basics
00:50:48 – Hormones, Toxins & Insulin Sensitivity
00:53:44 – Easy Blood Markers for Insulin Resistance
00:55:19 – Omega Fatty Acids & Cell Health
01:01:32 – Start Longevity Young: Reproductive Health
01:04:17 – Lifestyle Limits & Lifespan Potential
01:05:36 – Biotechnology: Delaying Ovarian Aging]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553773Mon, 23 Mar 2026 12:25:55 +0000saderGuests: Dr Lara Briden Naturopathic doctor and Bestselling Author Instagram: www.instagram.com/larabriden/ Website: www.larabriden.com/ Dr Molly Maloof Educator, Author, and Founder of Adamo Instagram: www.instagram.com/drmolly.co/?hl=en Website:...
Dr Lara Briden
Naturopathic doctor and Bestselling Author
Instagram: www.instagram.com/larabriden/
Website: www.larabriden.com/

Dr Molly Maloof
Educator, Author, and Founder of Adamo
Instagram: www.instagram.com/drmolly.co/?hl=en
Website: https://drmolly.co/
______________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Link: www.getstride.com/unlocked/
______________________

What if the key to female longevity has been hiding in plain sight?

In this episode, Phil Newman and Dr Nina Patrick sits down with Dr Lara Briden, evolutionary biologist and hormone expert, and Dr Molly Maloof, functional medicine practitioner, to explore the metabolic, hormonal, and evolutionary factors that shape female longevity.

They dive into the often-overlooked role of iron in perimenopause and post-menopause, the hidden epidemic of insulin resistance, and the nuanced balance of fatty acids for cellular health. Lara reframes menopause as an adaptive stage that supports the survival of the next generation, while Molly explains why metabolic flexibility is one of the most powerful tools for long-term health.

Together, they discuss practical strategies women can use across their lifespan—from iron management and blood markers to gut health, nutrition, and exercise—as well as exciting breakthroughs in biotechnology, peptides, and regenerative medicine that could extend female healthspan in the next decade.

In this episode, you’ll learn:

- Why managing iron levels is crucial for longevity, especially in perimenopause and post-menopause.
- How regular ovulatory cycles and pregnancy shape long-term metabolic and reproductive health.
- The hidden role of insulin resistance and simple blood markers that can flag early metabolic dysfunction.
- The importance of omega-6, omega-3, and saturated fats balance for cell membrane and neurological health.
- How evolutionary biology explains menopause as a “superpower” for human survival.
- Practical steps for women to optimize metabolism, exercise, and nutrient intake across their lifespan.
- The emerging role of biotechnology, regenerative medicine, and peptides in extending female healthspan.

If you want to take control of your metabolic health, understand menopause as a stage of strength, and learn strategies to optimize female longevity across the lifespan, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging strategies and interventions shaping the future of female health.
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠

______________________

00:35:47 – Iron Deficiency Drives Perimenopause Fatigue
00:36:29 – Symptoms & Treatments for Low Ferritin
00:37:42 – Ferritin: Europe vs US Standards
00:38:14 – Fertility & Longevity: Optimal Ferritin
00:39:37 – Managing High Iron After Menopause
00:41:24 – Stride DNA & Biome Test Overview
00:42:59 – Menopause as a Superpower
00:46:04 – Matriarch Roles in Human & Orca Longevity
00:47:31 – Insulin Resistance & Metabolic Health Basics
00:50:48 – Hormones, Toxins & Insulin Sensitivity
00:53:44 – Easy Blood Markers for Insulin Resistance
00:55:19 – Omega Fatty Acids & Cell Health
01:01:32 – Start Longevity Young: Reproductive Health
01:04:17 – Lifestyle Limits...]]>4241falsefullhttps://www.spreaker.com/episode/macrocyclic-peptides-hbot-south-korea-s-longevity-boom-longevity-news-roundup-week-12-2026--74818065
Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Link: https://www.getstride.com/unlocked/
______________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from macrocyclic peptides targeting previously undruggable diseases to hyperbaric oxygen therapy in performance and longevity, and South Korea emerging as a global biotech hub.

- Santa Cruz-based Unnatural Products raised $45 million in Series B funding and secured a potential $1.7 billion collaboration with Novartis. The company develops macrocyclic peptide therapeutics, molecules that combine the selectivity of biologics with the cell permeability of small molecules, targeting age-related cardiometabolic, inflammatory, and immunological diseases.
- Hyperbaric oxygen therapy (HBOT) is moving into the longevity and biohacking space, with companies like HPO.TECH’s launching chambers for performance and wellness settings. Early anecdotal reports suggest improvements in sleep and cognition, but long-term, large-scale clinical evidence is still limited.
- South Korea is quietly becoming a major longevity hub. Eli Lilly and Roche have invested nearly $1 billion in local biotech infrastructure, including incubation programs and advanced hospitals. By providing funding, regulatory support, and access to clinical trials, South Korea is positioning itself as a strategic global node for aging research and biotech innovation.
- Serotonin Centers launches a partner program bringing medically supervised longevity services directly into gyms across the US. By integrating diagnostics, therapies, and biomarker-driven programs into existing fitness spaces, this model increases accessibility and scalability for preventive health, bridging the gap between clinical longevity interventions and everyday fitness routines.
- The Aging Research & Drug Discovery (ARDD) conference is relocating to Boston in 2026, placing one of the world’s leading longevity science meetings directly in the heart of a dense biotech, pharma, and academic corridor. This move strengthens connections between research, startups, and decision-makers, accelerating deal flow and industry engagement while highlighting the mainstreaming of aging biology into drug development pipelines.
- Evolve Science has launched a US-based longevity peptide platform designed around medically supervised protocols targeting core aging pathways, including tissue repair, mitochondrial function, and metabolic regulation. By combining proper manufacturing, analytics, and clinical follow-up, the platform aims to separate validated therapeutic peptides from gray-market hype, addressing the growing demand for safe, evidence-based interventions in the longevity space.

News & References:

- Engineering longevity with the ZEUGMA hyperbaric chamber → https://longevity.technology/news/engineering-longevity-with-the-zeugma-hyperbaric-chamber/
- Biotech lands $45m to drug the undruggable → https://longevity.technology/news/biotech-lands-45m-to-drug-the-undruggable/
- Gyms tap medical longevity with Serotonin Centers’ model → https://longevity.technology/news/gyms-tap-medical-longevity-with-serotonin-centers-model/
- Lilly commits $500m in South Korea’s rise as longevity hub → https://longevity.technology/news/lilly-commits-500m-in-south-koreas-rise-as-longevity-hub/
- ARDD 2026 to relocate to Boston → https://longevity.technology/news/ardd-2026-to-relocate-to-boston/
- Evolve Science launches longevity peptide platform → https://longevity.technology/news/evolve-science-launches-longevity-peptide-platform/
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553790Fri, 20 Mar 2026 12:21:05 +0000saderSponsor: Stride Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science....
Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Link: https://www.getstride.com/unlocked/
______________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from macrocyclic peptides targeting previously undruggable diseases to hyperbaric oxygen therapy in performance and longevity, and South Korea emerging as a global biotech hub.

- Santa Cruz-based Unnatural Products raised $45 million in Series B funding and secured a potential $1.7 billion collaboration with Novartis. The company develops macrocyclic peptide therapeutics, molecules that combine the selectivity of biologics with the cell permeability of small molecules, targeting age-related cardiometabolic, inflammatory, and immunological diseases.
- Hyperbaric oxygen therapy (HBOT) is moving into the longevity and biohacking space, with companies like HPO.TECH’s launching chambers for performance and wellness settings. Early anecdotal reports suggest improvements in sleep and cognition, but long-term, large-scale clinical evidence is still limited.
- South Korea is quietly becoming a major longevity hub. Eli Lilly and Roche have invested nearly $1 billion in local biotech infrastructure, including incubation programs and advanced hospitals. By providing funding, regulatory support, and access to clinical trials, South Korea is positioning itself as a strategic global node for aging research and biotech innovation.
- Serotonin Centers launches a partner program bringing medically supervised longevity services directly into gyms across the US. By integrating diagnostics, therapies, and biomarker-driven programs into existing fitness spaces, this model increases accessibility and scalability for preventive health, bridging the gap between clinical longevity interventions and everyday fitness routines.
- The Aging Research & Drug Discovery (ARDD) conference is relocating to Boston in 2026, placing one of the world’s leading longevity science meetings directly in the heart of a dense biotech, pharma, and academic corridor. This move strengthens connections between research, startups, and decision-makers, accelerating deal flow and industry engagement while highlighting the mainstreaming of aging biology into drug development pipelines.
- Evolve Science has launched a US-based longevity peptide platform designed around medically supervised protocols targeting core aging pathways, including tissue repair, mitochondrial function, and metabolic regulation. By combining proper manufacturing, analytics, and clinical follow-up, the platform aims to separate validated therapeutic peptides from gray-market hype, addressing the growing demand for safe, evidence-based interventions in the longevity space.

News & References:

- Engineering longevity with the ZEUGMA hyperbaric chamber → https://longevity.technology/news/engineering-longevity-with-the-zeugma-hyperbaric-chamber/
- Biotech lands $45m to drug the undruggable → https://longevity.technology/news/biotech-lands-45m-to-drug-the-undruggable/
- Gyms tap medical longevity with Serotonin Centers’ model → https://longevity.technology/news/gyms-tap-medical-longevity-with-serotonin-centers-model/
- Lilly commits $500m in South Korea’s rise as longevity hub → https://longevity.technology/news/lilly-commits-500m-in-south-koreas-rise-as-longevity-hub/
- ARDD 2026 to relocate to Boston → https://longevity.technology/news/ardd-2026-to-relocate-to-boston/
- Evolve Science launches longevity peptide platform →...]]>1647falsefullhttps://www.spreaker.com/episode/how-can-you-turn-your-stress-into-advantage--74818092Dr. Dave Rabin MD, PhD
Founder of Apollo Neuro
Linkedin: https://www.linkedin.com/in/drdavemdphd/
Website: https://apolloneuro.com/

Dr Pedram Shojai
Founder of The Urban Monk
Instagram:https://www.instagram.com/drpedramshojai/
Website: https://theurbanmonk.com/
___________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: https://www.getstride.com/unlocked/
___________________

What if stress isn’t something to eliminate… but something to train?

Phil Newman and Dr. Nina Patrick sit down with neuroscientist and psychiatrist Dr. Dave Rabin and physician and Qigong teacher Dr. Pedram Shojai to explore how resilience is built through the nervous system. From circadian rhythms and recovery to breathwork, movement, and biofeedback, they explain why longevity depends less on constant performance and more on structured restoration.

Dave explains how chronic uncertainty activates threat responses in the brain, disrupting sleep, focus, immunity, and emotional regulation. Predictability, safety signals, and vagus nerve activation help restore recovery pathways that support cognition and long term health.

Pedram shares how attention, perception, and daily pacing influence vitality. Practices like mindfulness, Qigong, and intentional routines help shift the body out of survival mode, while technology can support awareness but cannot replace foundational habits.

Together, they show that resilience is not a hack. It is a rhythm between effort and recovery that trains the brain to adapt, learn, and age well.

In this episode, you’ll learn:

- How chronic stress alters brain function, sleep, and long-term health
- Why recovery should be scheduled like performance
- How breathwork and somatic practices activate safety pathways
- The role of circadian rhythm in resilience and cognition
- Where wearable technology helps and where it doesn’t

If you want to understand how stress regulation shapes cognitive performance, sleep quality, and healthy aging, this episode connects neuroscience with practical daily habits you can actually apply.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the systems shaping how we live longer and better.
___________________

Hosts:
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: https://qrco.de/bgXpKn
___________________

0:00 Introduction to Stress, Resilience, and Longevity
1:24 Meet the Guests: Pedram Shojai and Dr Dave Rabin
2:03 Daily Habits That Improve Health and Longevity
4:17 Pedram’s Morning Practice and Inner Awareness
5:27 Time Compression and Managing Stress in Modern Life
8:00 Why Peak Recovery Matters as Much as Performance
12:16 How Stress Affects the Brain and Nervous System
14:08 The Vagus Nerve, Safety Signals, and Recovery
18:19 Sleep, Safety, and the Neuroscience of Rest
23:23 Dave Rabin’s Pre-Bed Routine for Better Sleep
25:19 Pedram’s Family Wind-Down and Night Rituals
29:14 Neuroplasticity, Movement, and Mind-Body Practices
32:57 Wearables, Biofeedback, and Nervous System Technology
38:49 Personal Agency and Taking Control of Health
42:00 One Simple Daily Habit to Improve Long-Term Vitality]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553608Mon, 16 Mar 2026 13:40:26 +0000saderGuests: Dr. Dave Rabin MD, PhD Founder of Apollo Neuro Linkedin: https://www.linkedin.com/in/drdavemdphd/ Website: https://apolloneuro.com/ Dr Pedram Shojai Founder of The Urban Monk Instagram:https://www.instagram.com/drpedramshojai/ Website:...Dr. Dave Rabin MD, PhD
Founder of Apollo Neuro
Linkedin: https://www.linkedin.com/in/drdavemdphd/
Website: https://apolloneuro.com/

Dr Pedram Shojai
Founder of The Urban Monk
Instagram:https://www.instagram.com/drpedramshojai/
Website: https://theurbanmonk.com/
___________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Link: https://www.getstride.com/unlocked/
___________________

What if stress isn’t something to eliminate… but something to train?

Phil Newman and Dr. Nina Patrick sit down with neuroscientist and psychiatrist Dr. Dave Rabin and physician and Qigong teacher Dr. Pedram Shojai to explore how resilience is built through the nervous system. From circadian rhythms and recovery to breathwork, movement, and biofeedback, they explain why longevity depends less on constant performance and more on structured restoration.

Dave explains how chronic uncertainty activates threat responses in the brain, disrupting sleep, focus, immunity, and emotional regulation. Predictability, safety signals, and vagus nerve activation help restore recovery pathways that support cognition and long term health.

Pedram shares how attention, perception, and daily pacing influence vitality. Practices like mindfulness, Qigong, and intentional routines help shift the body out of survival mode, while technology can support awareness but cannot replace foundational habits.

Together, they show that resilience is not a hack. It is a rhythm between effort and recovery that trains the brain to adapt, learn, and age well.

In this episode, you’ll learn:

- How chronic stress alters brain function, sleep, and long-term health
- Why recovery should be scheduled like performance
- How breathwork and somatic practices activate safety pathways
- The role of circadian rhythm in resilience and cognition
- Where wearable technology helps and where it doesn’t

If you want to understand how stress regulation shapes cognitive performance, sleep quality, and healthy aging, this episode connects neuroscience with practical daily habits you can actually apply.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the systems shaping how we live longer and better.
___________________

Hosts:
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: https://qrco.de/bgXpKn
___________________

0:00 Introduction to Stress, Resilience, and Longevity
1:24 Meet the Guests: Pedram Shojai and Dr Dave Rabin
2:03 Daily Habits That Improve Health and Longevity
4:17 Pedram’s Morning Practice and Inner Awareness
5:27 Time Compression and Managing Stress in Modern Life
8:00 Why Peak Recovery Matters as Much as Performance
12:16 How Stress Affects the Brain and Nervous System
14:08 The Vagus Nerve, Safety Signals, and Recovery
18:19 Sleep, Safety, and the Neuroscience of Rest
23:23 Dave Rabin’s Pre-Bed Routine for Better Sleep
25:19 Pedram’s Family Wind-Down and Night Rituals
29:14 Neuroplasticity, Movement, and Mind-Body Practices
32:57 Wearables, Biofeedback, and Nervous System Technology
38:49 Personal Agency and Taking Control of Health
42:00 One Simple Daily Habit to Improve Long-Term Vitality]]>2987falsefullhttps://www.spreaker.com/episode/glp-1-brain-effects-als-eye-test-bionic-vision-longevity-news-roundup-week-11-2026--74818045
- A growing body of research suggests that GLP-1 receptor agonists may influence brain aging. A recent review in the Journal of Clinical Investigation highlights how these drugs could support neuronal energy production, stimulate autophagy, reduce chronic inflammation, and improve synaptic resilience. Early human studies show signals of preserved brain metabolism in Alzheimer’s patients, though larger clinical trials are still underway.
- New diagnostic tools for neurodegeneration are also emerging. Startup Amydis received funding from the National Institute on Aging to develop an eye-based molecular imaging test for Amyotrophic Lateral Sclerosis (ALS). Their approach uses fluorescent tracers that bind to TDP-43, allowing early disease signatures to be detected through routine retinal imaging.
- In metabolic health, Mimio Health reported results from a randomized controlled trial testing a fasting-mimetic supplement. The formulation includes Spermidine and Nicotinamide, compounds that rise during prolonged fasting. Over eight weeks, participants showed improvements in fasting glucose and lipid markers, suggesting the possibility of replicating certain fasting signals without caloric restriction.
- Hardware innovation is also advancing longevity care. Science Corporation raised $230 million to scale its PRIMA retinal implant, a tiny photovoltaic chip placed beneath the retina. Working with specialized glasses that project infrared patterns, the implant converts light signals into electrical stimulation, restoring basic visual perception for patients with advanced geographic atrophy.
- In sports longevity, Capriroso launched a new training intelligence system designed for endurance athletes. By combining sleep metrics, heart rate variability, training load, and recovery data, the platform aims to optimize performance across decades rather than short-term race cycles.
- Finally, emerging research into sleep and circadian biology continues to reshape dementia prevention strategies. Studies show that disrupting circadian rhythms can trigger inflammatory changes in brain immune cells known as microglia, which may contribute to neurodegenerative disease. Researchers are also studying hibernating animals to understand how certain species tolerate extreme metabolic stress and reverse neurological damage, offering potential new targets for human therapies.

_____________________
News and References:

- GLP-1 drugs hint at protection against neurodegeneration → https://longevity.technology/news/glp-1-drugs-hint-at-protection-against-neurodegeneration/
- Amydis lands NIA funding to detect ALS in the eye → https://longevity.technology/news/amydis-lands-nia-funding-to-detect-als-in-the-eye/
- Fasting mimetic shows metabolic effects in trial → https://longevity.technology/news/fasting-mimetic-shows-metabolic-effects-in-trial/
- Science Corp lands $230m to commercialize vision restoration chip → https://longevity.technology/news/science-corp-lands-230m-to-commercialize-vision-restoration-chip/
- Capriroso launches platform for athlete longevity → https://longevity.technology/news/capriroso-launches-platform-for-athlete-longevity/
- Sleep rhythms and dementia risk link emerges → https://longevity.technology/news/sleep-rhythms-and-dementia-risk-link-emerges/

_____________________
Hosts:
Phil Newman: ⁠⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠⁠
Nina Patrick: ⁠⁠⁠⁠https://qrco.de/bgXpKn⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553674Fri, 13 Mar 2026 12:11:53 +0000saderIn this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from neuroprotective obesity drugs and fasting-mimicking supplements to bionic vision implants and AI-driven athletic...
- A growing body of research suggests that GLP-1 receptor agonists may influence brain aging. A recent review in the Journal of Clinical Investigation highlights how these drugs could support neuronal energy production, stimulate autophagy, reduce chronic inflammation, and improve synaptic resilience. Early human studies show signals of preserved brain metabolism in Alzheimer’s patients, though larger clinical trials are still underway.
- New diagnostic tools for neurodegeneration are also emerging. Startup Amydis received funding from the National Institute on Aging to develop an eye-based molecular imaging test for Amyotrophic Lateral Sclerosis (ALS). Their approach uses fluorescent tracers that bind to TDP-43, allowing early disease signatures to be detected through routine retinal imaging.
- In metabolic health, Mimio Health reported results from a randomized controlled trial testing a fasting-mimetic supplement. The formulation includes Spermidine and Nicotinamide, compounds that rise during prolonged fasting. Over eight weeks, participants showed improvements in fasting glucose and lipid markers, suggesting the possibility of replicating certain fasting signals without caloric restriction.
- Hardware innovation is also advancing longevity care. Science Corporation raised $230 million to scale its PRIMA retinal implant, a tiny photovoltaic chip placed beneath the retina. Working with specialized glasses that project infrared patterns, the implant converts light signals into electrical stimulation, restoring basic visual perception for patients with advanced geographic atrophy.
- In sports longevity, Capriroso launched a new training intelligence system designed for endurance athletes. By combining sleep metrics, heart rate variability, training load, and recovery data, the platform aims to optimize performance across decades rather than short-term race cycles.
- Finally, emerging research into sleep and circadian biology continues to reshape dementia prevention strategies. Studies show that disrupting circadian rhythms can trigger inflammatory changes in brain immune cells known as microglia, which may contribute to neurodegenerative disease. Researchers are also studying hibernating animals to understand how certain species tolerate extreme metabolic stress and reverse neurological damage, offering potential new targets for human therapies.

_____________________
News and References:

- GLP-1 drugs hint at protection against neurodegeneration → https://longevity.technology/news/glp-1-drugs-hint-at-protection-against-neurodegeneration/
- Amydis lands NIA funding to detect ALS in the eye → https://longevity.technology/news/amydis-lands-nia-funding-to-detect-als-in-the-eye/
- Fasting mimetic shows metabolic effects in trial → https://longevity.technology/news/fasting-mimetic-shows-metabolic-effects-in-trial/
- Science Corp lands $230m to commercialize vision restoration chip → https://longevity.technology/news/science-corp-lands-230m-to-commercialize-vision-restoration-chip/
- Capriroso launches platform for athlete longevity → https://longevity.technology/news/capriroso-launches-platform-for-athlete-longevity/
- Sleep rhythms and dementia risk link emerges → https://longevity.technology/news/sleep-rhythms-and-dementia-risk-link-emerges/

_____________________
Hosts:
Phil Newman: ⁠⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠⁠
Nina Patrick: ⁠⁠⁠⁠https://qrco.de/bgXpKn⁠]]>1291falsefullhttps://www.spreaker.com/episode/how-your-mouth-shapes-your-longevity--74818058Dr James Goolnik
Founder of Optimal Dental Health
Instagram: www.instagram.com/jamesgoolnik/?hl=en
Website: www.optimaldentalhealth.co.uk/

Dr Aoife Stack
Co-founder of Airway School
Instagram: www.instagram.com/doctor_aoife/?hl=en
Website: www.airwayschool.co.uk
______________________

What if your mouth was more than just teeth and gums? What if it silently shaped your sleep, metabolism, immunity, and brain health?

Phil Newman and Dr. Nina Patrick sit down with Dr. Aoife Stack and Dr. James Goolnik, two clinicians taking a systems-level approach to oral health. They explore how the mouth and airway influence sleep, metabolism, inflammation, and brain function, and why dental care isn’t just about teeth.

Aoife explains the importance of nasal breathing, tongue posture, and myofunctional therapy for optimal sleep and overall health. James highlights practical strategies around sugar reduction, saliva balance, and oral hygiene that protect against decay and inflammation. Together, they unpack the science connecting oral health with the microbiome, nitric oxide production, and systemic resilience.

The conversation dives into childhood and adult interventions—from simple nasal tape and tongue exercises to orthodontics and myofunctional therapy—showing how small adjustments can create meaningful improvements in energy, cognitive function, and long-term health. They also discuss how lifestyle factors, dietary habits, and awareness of daily routines can prevent cascading health issues before they start.

This episode emphasizes that longevity is more than exercise and diet. Supporting oral and airway health, understanding systemic connections, and applying practical, sustainable habits are essential pillars for extending healthspan, optimizing sleep, and improving quality of life.

In this episode, you’ll learn:

- Why nasal breathing, tongue posture, and oral function are foundational to sleep, energy, and brain health
- How simple practices like tongue scraping, nasal tape, and myofunctional exercises can improve airway and posture
- The role of saliva, oral microbiome, and diet in preventing decay, gum disease, and systemic inflammation
- How small childhood and adult interventions can create long-term benefits for airway function, sleep quality, and resilience
- Strategies for sustainable sugar reduction and habit stacking to protect oral and systemic health

If you care about improving long-term health, sleep, and energy, and want actionable advice grounded in evidence-based science, this conversation is a must-listen.

Subscribe for weekly episodes that explore longevity science, preventative strategies, and the emerging tools and interventions that help us understand and optimize the body’s natural systems for lasting healthspan.
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553730Mon, 09 Mar 2026 11:13:02 +0000saderGuests: Dr James Goolnik Founder of Optimal Dental Health Instagram: www.instagram.com/jamesgoolnik/?hl=en Website: www.optimaldentalhealth.co.uk/ Dr Aoife Stack Co-founder of Airway School Instagram: www.instagram.com/doctor_aoife/?hl=en Website:...Dr James Goolnik
Founder of Optimal Dental Health
Instagram: www.instagram.com/jamesgoolnik/?hl=en
Website: www.optimaldentalhealth.co.uk/

Dr Aoife Stack
Co-founder of Airway School
Instagram: www.instagram.com/doctor_aoife/?hl=en
Website: www.airwayschool.co.uk
______________________

What if your mouth was more than just teeth and gums? What if it silently shaped your sleep, metabolism, immunity, and brain health?

Phil Newman and Dr. Nina Patrick sit down with Dr. Aoife Stack and Dr. James Goolnik, two clinicians taking a systems-level approach to oral health. They explore how the mouth and airway influence sleep, metabolism, inflammation, and brain function, and why dental care isn’t just about teeth.

Aoife explains the importance of nasal breathing, tongue posture, and myofunctional therapy for optimal sleep and overall health. James highlights practical strategies around sugar reduction, saliva balance, and oral hygiene that protect against decay and inflammation. Together, they unpack the science connecting oral health with the microbiome, nitric oxide production, and systemic resilience.

The conversation dives into childhood and adult interventions—from simple nasal tape and tongue exercises to orthodontics and myofunctional therapy—showing how small adjustments can create meaningful improvements in energy, cognitive function, and long-term health. They also discuss how lifestyle factors, dietary habits, and awareness of daily routines can prevent cascading health issues before they start.

This episode emphasizes that longevity is more than exercise and diet. Supporting oral and airway health, understanding systemic connections, and applying practical, sustainable habits are essential pillars for extending healthspan, optimizing sleep, and improving quality of life.

In this episode, you’ll learn:

- Why nasal breathing, tongue posture, and oral function are foundational to sleep, energy, and brain health
- How simple practices like tongue scraping, nasal tape, and myofunctional exercises can improve airway and posture
- The role of saliva, oral microbiome, and diet in preventing decay, gum disease, and systemic inflammation
- How small childhood and adult interventions can create long-term benefits for airway function, sleep quality, and resilience
- Strategies for sustainable sugar reduction and habit stacking to protect oral and systemic health

If you care about improving long-term health, sleep, and energy, and want actionable advice grounded in evidence-based science, this conversation is a must-listen.

Subscribe for weekly episodes that explore longevity science, preventative strategies, and the emerging tools and interventions that help us understand and optimize the body’s natural systems for lasting healthspan.
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>3298falsefullhttps://www.spreaker.com/episode/arpa-h-funding-brain-wearables-nanotech-biosensing-longevity-news-roundup-week-10-2026--74818105
- The US government committed $144 million through ARPA-H’s PROSPR program to fund research proving that aging can be treated in humans. Cambrian BioPharma received $30.8 million for trials of a next-generation rapamycin analog, while Linnaeus Therapeutics received $22 million to explore oncology-derived drugs showing age-related benefits. PROSPR also funds biomarker development and trial infrastructure to enable rapid, large-scale healthspan studies.
- Temple is developing a head-worn wearable that continuously monitors cerebral blood flow and brain activity. This next-generation device moves beyond wrist-worn fitness trackers, providing real-time insight into cognitive function, fatigue, and brain health for both elite athletes and general populations.
- Berlin-based YOU(th) closed a $4.5 million round for its smartphone-based health screening platform. Using AI and photoplethysmography, the platform analyzes face videos, voice recordings, and other sensors to assess 50 digital biomarkers in under two minutes, offering a scalable, longitudinal view of health outside the clinic.Mainstream pharma is also advancing longevity research.
- Richter acquired Celmatix’ ovarian biology assets to expand therapies targeting ovarian aging. Slowing ovarian decline could impact fertility, bone health, cardiovascular risk, and cognitive resilience, reinforcing women’s health as a central longevity focus.
- Data on billionaire longevity shows wealth alone offers minimal lifespan extension. Male billionaires live about four years longer than peers, while female billionaires have life expectancy below long-lived populations. The analysis highlights the importance of investing in scientific research over relying solely on lifestyle or capital.
- Finally, Swiss startup Xsensio is developing a nanotech-enabled continuous biosensing platform. This minimally invasive skin sensor tracks metabolites, electrolytes, and inflammatory markers in real time, offering a path toward proactive, biomarker-driven healthcare and continuous monitoring of intrinsic capacity.

_____________________
News & References:

- ARPA-H pours millions into healthspan-focused human trials → ⁠https://longevity.technology/news/arpa-h-pours-millions-into-healthspan-focused-human-trials⁠
- Wearable startup Temple secures $54m for brain monitoring → ⁠https://longevity.technology/news/wearable-startup-temple-secures-54m-for-brain-monitoring/⁠
- YOU(th) lands funding for smartphone-based preventive health screening → ⁠https://longevity.technology/news/youth-lands-funding-for-smartphone-based-preventive-health-screening/⁠
- Richter sharpens ovarian aging focus following Celmatix asset deal → ⁠https://longevity.technology/news/richter-sharpens-ovarian-aging-focus-following-celmatix-asset-deal/⁠
- How billionaires die → ⁠https://longevity.technology/news/how-billionaires-die/⁠
- Nanotech startup lands funding for continuous biosensing platform → ⁠https://longevity.technology/news/nanotech-startup-lands-funding-for-continuous-biosensing-platform/⁠

_____________________
Hosts:
Phil Newman: ⁠⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠⁠
Nina Patrick: ⁠⁠⁠⁠https://qrco.de/bgXpKn⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553778Fri, 06 Mar 2026 12:14:41 +0000saderIn this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping longevity and proactive healthcare. From government-backed healthspan trials to next-generation brain wearables, smartphone-based health...
- The US government committed $144 million through ARPA-H’s PROSPR program to fund research proving that aging can be treated in humans. Cambrian BioPharma received $30.8 million for trials of a next-generation rapamycin analog, while Linnaeus Therapeutics received $22 million to explore oncology-derived drugs showing age-related benefits. PROSPR also funds biomarker development and trial infrastructure to enable rapid, large-scale healthspan studies.
- Temple is developing a head-worn wearable that continuously monitors cerebral blood flow and brain activity. This next-generation device moves beyond wrist-worn fitness trackers, providing real-time insight into cognitive function, fatigue, and brain health for both elite athletes and general populations.
- Berlin-based YOU(th) closed a $4.5 million round for its smartphone-based health screening platform. Using AI and photoplethysmography, the platform analyzes face videos, voice recordings, and other sensors to assess 50 digital biomarkers in under two minutes, offering a scalable, longitudinal view of health outside the clinic.Mainstream pharma is also advancing longevity research.
- Richter acquired Celmatix’ ovarian biology assets to expand therapies targeting ovarian aging. Slowing ovarian decline could impact fertility, bone health, cardiovascular risk, and cognitive resilience, reinforcing women’s health as a central longevity focus.
- Data on billionaire longevity shows wealth alone offers minimal lifespan extension. Male billionaires live about four years longer than peers, while female billionaires have life expectancy below long-lived populations. The analysis highlights the importance of investing in scientific research over relying solely on lifestyle or capital.
- Finally, Swiss startup Xsensio is developing a nanotech-enabled continuous biosensing platform. This minimally invasive skin sensor tracks metabolites, electrolytes, and inflammatory markers in real time, offering a path toward proactive, biomarker-driven healthcare and continuous monitoring of intrinsic capacity.

_____________________
News & References:

- ARPA-H pours millions into healthspan-focused human trials → ⁠https://longevity.technology/news/arpa-h-pours-millions-into-healthspan-focused-human-trials⁠
- Wearable startup Temple secures $54m for brain monitoring → ⁠https://longevity.technology/news/wearable-startup-temple-secures-54m-for-brain-monitoring/⁠
- YOU(th) lands funding for smartphone-based preventive health screening → ⁠https://longevity.technology/news/youth-lands-funding-for-smartphone-based-preventive-health-screening/⁠
- Richter sharpens ovarian aging focus following Celmatix asset deal → ⁠https://longevity.technology/news/richter-sharpens-ovarian-aging-focus-following-celmatix-asset-deal/⁠
- How billionaires die → ⁠https://longevity.technology/news/how-billionaires-die/⁠
- Nanotech startup lands funding for continuous biosensing platform → ⁠https://longevity.technology/news/nanotech-startup-lands-funding-for-continuous-biosensing-platform/⁠

_____________________
Hosts:
Phil Newman: ⁠⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠⁠
Nina Patrick: ⁠⁠⁠⁠https://qrco.de/bgXpKn⁠]]>1764falsefullhttps://www.spreaker.com/episode/designing-healthspan-inside-the-morrow-model--74818078Allen Law
Founder and CEO of MORROW
Linkedin: https://www.linkedin.com/in/allenlawphg/
Website:https://morrow.health/

Dr William Tan
Clinical Governance Officer of MORROW
Linkedin: https://www.linkedin.com/in/dr-william-tan-05438649/
Website: https://morrow.health/
______________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Link: https://www.getstride.com/unlocked/
______________________

What if longevity wasn’t a treatment… but a system you live inside every day?

In this episode, Phil Newman sits down with Allen Law, founder and CEO of Morrow, and Dr William Tan, physician-neuroscientist and Chief Governance Officer of Morrow, to explore a new model of preventive healthcare designed around daily behavior, measurable biology, and community support.

They discuss why modern medicine often reacts to disease rather than preventing it, how lifestyle medicine can be structured into actionable programs, and why most people fail to act on their health data even after testing. Allen explains how Morrow combines diagnostics, coaching, and artificial intelligence to translate biomarkers into habits, while William shares how his personal journey through disability and elite sport shaped his philosophy of proactive health.

Together, they examine accessibility in longevity care, the economics of preventive medicine, and why community engagement may be as important as any clinical intervention. The conversation also looks at Singapore’s evolving health ecosystem and how technology could scale personalized care beyond elite clinics.

In this episode, you’ll learn:

- Why preventive healthcare often fails despite widespread testing
- How Morrow connects diagnostics directly to daily lifestyle interventions
- The role of AI in turning health data into consistent habit change
- Why community and purpose influence long term health outcomes
- How accessibility could reshape the longevity clinic industry
- What Singapore’s healthcare model reveals about future global systems
- Why small consistent habits outperform short term health resolutions

If you want to understand how healthcare may shift from treating illness to designing wellbeing, and what real world longevity infrastructure could look like, this conversation offers a practical view of the future of healthspan.

Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠
______________________

00:00 Dr William Tan on retirement, fatigue, and losing energy
03:45 Why comfort can reduce vitality
06:10 The decision to return to wheelchair marathon racing
08:30 Preparing for the London Marathon comeback
10:50 Purpose, identity, and performance at 69

13:40 Why modern medicine reacts instead of prevents
16:05 The six pillars of lifestyle medicine explained
19:20 Why community is essential for long term health
22:00 Healthspan vs lifespan

25:10 Why most people fail to act on their health data
28:00 Turning diagnostics into daily habit change
31:30 How AI supports personalized preventive care

35:20 The economics of longevity clinics
39:10 Singapore’s healthcare model and scaling prevention
44:30 Small consistent habits that extend healthspan]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553664Mon, 02 Mar 2026 14:28:08 +0000saderGuests: Allen Law Founder and CEO of MORROW Linkedin: https://www.linkedin.com/in/allenlawphg/ Website:https://morrow.health/ Dr William Tan Clinical Governance Officer of MORROW Linkedin: https://www.linkedin.com/in/dr-william-tan-05438649/...Allen Law
Founder and CEO of MORROW
Linkedin: https://www.linkedin.com/in/allenlawphg/
Website:https://morrow.health/

Dr William Tan
Clinical Governance Officer of MORROW
Linkedin: https://www.linkedin.com/in/dr-william-tan-05438649/
Website: https://morrow.health/
______________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Link: https://www.getstride.com/unlocked/
______________________

What if longevity wasn’t a treatment… but a system you live inside every day?

In this episode, Phil Newman sits down with Allen Law, founder and CEO of Morrow, and Dr William Tan, physician-neuroscientist and Chief Governance Officer of Morrow, to explore a new model of preventive healthcare designed around daily behavior, measurable biology, and community support.

They discuss why modern medicine often reacts to disease rather than preventing it, how lifestyle medicine can be structured into actionable programs, and why most people fail to act on their health data even after testing. Allen explains how Morrow combines diagnostics, coaching, and artificial intelligence to translate biomarkers into habits, while William shares how his personal journey through disability and elite sport shaped his philosophy of proactive health.

Together, they examine accessibility in longevity care, the economics of preventive medicine, and why community engagement may be as important as any clinical intervention. The conversation also looks at Singapore’s evolving health ecosystem and how technology could scale personalized care beyond elite clinics.

In this episode, you’ll learn:

- Why preventive healthcare often fails despite widespread testing
- How Morrow connects diagnostics directly to daily lifestyle interventions
- The role of AI in turning health data into consistent habit change
- Why community and purpose influence long term health outcomes
- How accessibility could reshape the longevity clinic industry
- What Singapore’s healthcare model reveals about future global systems
- Why small consistent habits outperform short term health resolutions

If you want to understand how healthcare may shift from treating illness to designing wellbeing, and what real world longevity infrastructure could look like, this conversation offers a practical view of the future of healthspan.

Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠
______________________

00:00 Dr William Tan on retirement, fatigue, and losing energy
03:45 Why comfort can reduce vitality
06:10 The decision to return to wheelchair marathon racing
08:30 Preparing for the London Marathon comeback
10:50 Purpose, identity, and performance at 69

13:40 Why modern medicine reacts instead of prevents
16:05 The six pillars of lifestyle medicine explained
19:20 Why community is essential for long term health
22:00 Healthspan vs lifespan

25:10 Why most people fail to act on their health data
28:00 Turning diagnostics into daily habit change
31:30 How AI supports personalized preventive care

35:20 The economics of longevity clinics
39:10 Singapore’s healthcare model and scaling prevention
44:30 Small consistent habits that extend healthspan]]>2959falsefullhttps://www.spreaker.com/episode/nanoplastics-mrna-therapy-drug-approvals-longevity-news-roundup-week-9-2026--74818175
- Recent research shows that nanoplastics, ultra-small fragments of degraded plastic closer in size to viruses than visible debris, are accumulating in human brain tissue. Age does not predict accumulation, and higher concentrations appear in tissues affected by Alzheimer’s and vascular dementia.
- Klothea has launched a phase 1b human trial for their AKL003 mRNA therapy, aiming to boost levels of the longevity-associated protein alpha-Klotho. Conducted in Prospera, Honduras, the study measures epigenetic clocks, inflammatory and metabolic markers, mitochondrial function, sleep, and patient-reported quality of life. This represents one of the first human longevity trials designed around lifespan as the primary endpoint rather than disease.
- In sports and metabolic monitoring, PointFit is developing a wearable sweat patch that continuously tracks lactate, cortisol, creatine, and glucose. Lactate serves as a real-time biomarker for exercise intensity and fatigue, bridging elite athlete optimization and general population healthspan. Early adoption is expected in high-performance sports, but applications in rehab and clinical aging are promising.
- Regulatory innovation continues with the FDA officially ending the “two trial dogma.” One pivotal, rigorously designed trial may now suffice for drug approval, lowering barriers for therapies targeting aging processes and biomarker-driven endpoints. This shift could shave three to five years off development timelines and reduce costs by tens of millions, accelerating the path for human longevity drugs.
- Finally, AI is moving from broad discovery to targeted intervention. Scienta Lab unveiled EVA, a multimodal AI platform mapping inflammatory networks tied to aging, aiming to design precision anti-inflammatory therapies. Rather than simply accelerating existing pharma pipelines, platforms like EVA could guide the development of highly personalized interventions tailored to an individual’s inflammatory signature, tissue context, and age.
- The Longevity Show has confirmed Hertility as Strategic Content and Scientific Lead Partner for the Women’s Health Summit at its inaugural 2026 event in London. Hertility will co-lead the scientific framing and programme development of the Summit. The partnership positions female biology not as a thematic sidebar, but as a structural lens through which longevity science and infrastructure must increasingly be designed.

______________________
News & References:

- Nanoplastics found in the brain raise new aging questions → https://longevity.technology/news/nanoplastics-found-in-the-brain-raise-new-aging-questions/
- Klothea initiates longevity-focused human trial of klotho therapy → https://longevity.technology/news/klothea-initiates-longevity-focused-human-trial-of-klotho-therapy/
- Seveno backs PointFit wearable patch → https://longevity.technology/news/seveno-backs-pointfit-wearable-patch/
- FDA rewrites drug approval rules and longevity stands to gain → https://longevity.technology/news/fda-rewrites-drug-approval-rules-and-longevity-stands-to-gain/
- Scienta’s new AI model targets aging-linked inflammation → https://longevity.technology/news/scientas-new-ai-model-targets-aging-linked-inflammation/
- Hertility announced as Women’s Health Partner for Longevity Show → https://longevity.technology/news/hertility-announced-as-womens-health-partner-for-longevity-show/

______________________
Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553697Fri, 27 Feb 2026 10:58:42 +0000saderIn this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest discoveries transforming longevity science. From invisible nanoplastics crossing the blood-brain barrier to first-of-its-kind Klothea mRNA human trials,...
- Recent research shows that nanoplastics, ultra-small fragments of degraded plastic closer in size to viruses than visible debris, are accumulating in human brain tissue. Age does not predict accumulation, and higher concentrations appear in tissues affected by Alzheimer’s and vascular dementia.
- Klothea has launched a phase 1b human trial for their AKL003 mRNA therapy, aiming to boost levels of the longevity-associated protein alpha-Klotho. Conducted in Prospera, Honduras, the study measures epigenetic clocks, inflammatory and metabolic markers, mitochondrial function, sleep, and patient-reported quality of life. This represents one of the first human longevity trials designed around lifespan as the primary endpoint rather than disease.
- In sports and metabolic monitoring, PointFit is developing a wearable sweat patch that continuously tracks lactate, cortisol, creatine, and glucose. Lactate serves as a real-time biomarker for exercise intensity and fatigue, bridging elite athlete optimization and general population healthspan. Early adoption is expected in high-performance sports, but applications in rehab and clinical aging are promising.
- Regulatory innovation continues with the FDA officially ending the “two trial dogma.” One pivotal, rigorously designed trial may now suffice for drug approval, lowering barriers for therapies targeting aging processes and biomarker-driven endpoints. This shift could shave three to five years off development timelines and reduce costs by tens of millions, accelerating the path for human longevity drugs.
- Finally, AI is moving from broad discovery to targeted intervention. Scienta Lab unveiled EVA, a multimodal AI platform mapping inflammatory networks tied to aging, aiming to design precision anti-inflammatory therapies. Rather than simply accelerating existing pharma pipelines, platforms like EVA could guide the development of highly personalized interventions tailored to an individual’s inflammatory signature, tissue context, and age.
- The Longevity Show has confirmed Hertility as Strategic Content and Scientific Lead Partner for the Women’s Health Summit at its inaugural 2026 event in London. Hertility will co-lead the scientific framing and programme development of the Summit. The partnership positions female biology not as a thematic sidebar, but as a structural lens through which longevity science and infrastructure must increasingly be designed.

______________________
News & References:

- Nanoplastics found in the brain raise new aging questions → https://longevity.technology/news/nanoplastics-found-in-the-brain-raise-new-aging-questions/
- Klothea initiates longevity-focused human trial of klotho therapy → https://longevity.technology/news/klothea-initiates-longevity-focused-human-trial-of-klotho-therapy/
- Seveno backs PointFit wearable patch → https://longevity.technology/news/seveno-backs-pointfit-wearable-patch/
- FDA rewrites drug approval rules and longevity stands to gain → https://longevity.technology/news/fda-rewrites-drug-approval-rules-and-longevity-stands-to-gain/
- Scienta’s new AI model targets aging-linked inflammation → https://longevity.technology/news/scientas-new-ai-model-targets-aging-linked-inflammation/
- Hertility announced as Women’s Health Partner for Longevity Show → https://longevity.technology/news/hertility-announced-as-womens-health-partner-for-longevity-show/

______________________
Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick:...]]>1963falsefullhttps://www.spreaker.com/episode/the-future-beyond-aging-metrics--74818068Founder, CEO and CBO at Insilico Medicine
Linkedin: www.linkedin.com/in/zhavoronkov/
Website: https://insilico.com/
______________________

What if the biggest breakthrough in longevity wasn’t a single drug… but a faster way to discover them?

In this episode, Phil Newman and Dr Nina Patrick sit down with Alex Zhavoronkov, founder and CEO of Insilico Medicine, to explore how artificial intelligence is reshaping biotechnology, from target discovery to clinical trials.

They discuss why advanced diagnostics may currently outperform most longevity interventions, how AI platforms design entirely new molecules, and why no longevity drug has yet proven efficacy in humans despite promising animal data. Alex explains how modern biotech companies balance aging research with traditional disease treatment, and why the first real longevity therapeutics will likely emerge as side benefits of drugs built for specific conditions.

Together, they examine the reality behind GLP-1 drugs, long term safety testing, and the limits of predictive algorithms. The conversation also looks ahead to brain computer interfaces, multimodal biological models, and the possibility of pharmaceutical superintelligence accelerating medical progress within the next decade.

In this episode, you’ll learn:
- Why early diagnostics may currently be the most reliable longevity strategy.
- How AI can design drug candidates in months instead of years.
- Why most longevity drugs succeed in animals but fail to prove benefits in humans.
- How disease focused therapeutics could become future aging interventions.
- What GLP-1 drugs reveal about the future of longevity medicine.
- The real role of clinical trials in validating AI generated therapies.
- How next generation technologies like brain computer interfaces could extend healthy lifespan.

If you want to understand how artificial intelligence is changing medicine, what real longevity therapeutics may look like, and why the future of healthspan depends on both biology and computation, this is a conversation you don’t want to miss.

Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987449542553698Mon, 23 Feb 2026 15:23:32 +0000saderGuest: Alexander Zhavoronkov Founder, CEO and CBO at Insilico Medicine Linkedin: www.linkedin.com/in/zhavoronkov/ Website: https://insilico.com/ ______________________ What if the biggest breakthrough in longevity wasn’t a single drug… but a faster...Founder, CEO and CBO at Insilico Medicine
Linkedin: www.linkedin.com/in/zhavoronkov/
Website: https://insilico.com/
______________________

What if the biggest breakthrough in longevity wasn’t a single drug… but a faster way to discover them?

In this episode, Phil Newman and Dr Nina Patrick sit down with Alex Zhavoronkov, founder and CEO of Insilico Medicine, to explore how artificial intelligence is reshaping biotechnology, from target discovery to clinical trials.

They discuss why advanced diagnostics may currently outperform most longevity interventions, how AI platforms design entirely new molecules, and why no longevity drug has yet proven efficacy in humans despite promising animal data. Alex explains how modern biotech companies balance aging research with traditional disease treatment, and why the first real longevity therapeutics will likely emerge as side benefits of drugs built for specific conditions.

Together, they examine the reality behind GLP-1 drugs, long term safety testing, and the limits of predictive algorithms. The conversation also looks ahead to brain computer interfaces, multimodal biological models, and the possibility of pharmaceutical superintelligence accelerating medical progress within the next decade.

In this episode, you’ll learn:
- Why early diagnostics may currently be the most reliable longevity strategy.
- How AI can design drug candidates in months instead of years.
- Why most longevity drugs succeed in animals but fail to prove benefits in humans.
- How disease focused therapeutics could become future aging interventions.
- What GLP-1 drugs reveal about the future of longevity medicine.
- The real role of clinical trials in validating AI generated therapies.
- How next generation technologies like brain computer interfaces could extend healthy lifespan.

If you want to understand how artificial intelligence is changing medicine, what real longevity therapeutics may look like, and why the future of healthspan depends on both biology and computation, this is a conversation you don’t want to miss.

Subscribe for weekly episodes exploring longevity science, emerging biotech, and the innovations shaping the future of human health.
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>3338falsefullhttps://www.spreaker.com/episode/glp-1-pills-longevity-generation-amazon-health-insights-longevity-news-roundup-week-8-2026--74818073
Stride helps people understand and improve their wellbeing and longevity through personalized DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Link: https://www.getstride.com/unlocked/
______________________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping healthspan and longevity. From oral GLP-1 pills transforming obesity and metabolic care, to early gene therapy results in aging dogs, and Amazon integrating biomarker-driven longevity insights into primary care, this episode covers innovation, risk, and opportunity across human and animal longevity.

- Novo Nordisk and Eli Lilly are moving forward with oral versions of their GLP-1 drugs, potentially bringing millions more patients onto treatment. Pills are easier to access than injections, but counterfeiting risks are rising. GLP-1 therapies are evolving beyond weight loss into long-term metabolic health interventions, targeting cardiovascular, joint, and chronic pain outcomes.
- London-based GenFlow Biosciences released preliminary data from its SIRT6 gene therapy in aged dogs. All treatment groups showed improved survival, muscle mass, and frailty scores. This dual approach addresses companion animal health while acting as a translational model for human aging interventions.
- In digital health, Amazon One Medical is rolling out biomarker-driven insights powered by LifeForce’s longevity platform. Members can receive personalized wellness scores and domain-specific biomarker breakdowns, bridging AI, telehealth, and preventative care. This signals a growing shift in how consumer and clinical longevity data will influence behavior, outcomes, and healthcare delivery.
- In consumer trends, global PR firm Edelman highlights the rise of the longevity generation. Their Longevity Lab initiative shows that people 55 and older control more than half of global consumer spending, yet receive only a fraction of marketing budgets. Brands are beginning to rethink products, campaigns, and services for older, active, high-spending consumers, a growing business opportunity in the health, finance, hospitality, and lifestyle sectors.
- Israeli neurotech company QuantalX launched the Delphi MD system in the US, a non-invasive brain function assessment combining transcranial magnetic stimulation, EEG, and AI analytics. The system can detect subtle functional network changes before structural damage appears, enabling early tracking of cognitive aging. Already deploying at Penn, Mass General, UCSF, and UT Dallas, the test has a reimbursement code, potentially shifting brain health monitoring from reactive to preventative care.
- Gimv, a European investment firm, signaled a pullback from early-stage aging biotech, citing long timelines and unpredictable ROI. Capital is now shifting toward technology-enabled services, diagnostics, and digital longevity platforms where returns are faster and more measurable. Phil and Nina frame this as a healthy evolution, removing less patient investors and making room for long-term, patient capital, strengthening the overall longevity ecosystem.

______________________
News & References:

What Gimv’s biotech pullback says about aging markets → https://longevity.technology/news/what-gimvs-biotech-pullback-says-about-aging-markets/
- Are global brands ready for longevity? → https://longevity.technology/news/are-global-brands-ready-for-longevity/
- New functional brain assessment system rolls out in the US → https://longevity.technology/news/new-functional-brain-assessment-system-rolls-out-in-the-us/
- As obesity drugs go oral and access grows, so do fakes → https://longevity.technology/news/as-obesity-drugs-go-oral-and-access-grows-so-do-fakes/
- Genflow reveals early data from SIRT6 gene therapy trial in dogs → https://longevity.technology/news/genflow-reveals-early-data-from-sirt6-gene-therapy-trial-in-dogs/
- Amazon makes longevity move with Lifeforce collab → https://longevity.technology/news/amazon-makes-longevity-move-with-lifeforce-collab/

______________________
Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379945Fri, 20 Feb 2026 12:09:03 +0000saderSponsor: Stride Stride helps people understand and improve their wellbeing and longevity through personalized DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science....
Stride helps people understand and improve their wellbeing and longevity through personalized DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Link: https://www.getstride.com/unlocked/
______________________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping healthspan and longevity. From oral GLP-1 pills transforming obesity and metabolic care, to early gene therapy results in aging dogs, and Amazon integrating biomarker-driven longevity insights into primary care, this episode covers innovation, risk, and opportunity across human and animal longevity.

- Novo Nordisk and Eli Lilly are moving forward with oral versions of their GLP-1 drugs, potentially bringing millions more patients onto treatment. Pills are easier to access than injections, but counterfeiting risks are rising. GLP-1 therapies are evolving beyond weight loss into long-term metabolic health interventions, targeting cardiovascular, joint, and chronic pain outcomes.
- London-based GenFlow Biosciences released preliminary data from its SIRT6 gene therapy in aged dogs. All treatment groups showed improved survival, muscle mass, and frailty scores. This dual approach addresses companion animal health while acting as a translational model for human aging interventions.
- In digital health, Amazon One Medical is rolling out biomarker-driven insights powered by LifeForce’s longevity platform. Members can receive personalized wellness scores and domain-specific biomarker breakdowns, bridging AI, telehealth, and preventative care. This signals a growing shift in how consumer and clinical longevity data will influence behavior, outcomes, and healthcare delivery.
- In consumer trends, global PR firm Edelman highlights the rise of the longevity generation. Their Longevity Lab initiative shows that people 55 and older control more than half of global consumer spending, yet receive only a fraction of marketing budgets. Brands are beginning to rethink products, campaigns, and services for older, active, high-spending consumers, a growing business opportunity in the health, finance, hospitality, and lifestyle sectors.
- Israeli neurotech company QuantalX launched the Delphi MD system in the US, a non-invasive brain function assessment combining transcranial magnetic stimulation, EEG, and AI analytics. The system can detect subtle functional network changes before structural damage appears, enabling early tracking of cognitive aging. Already deploying at Penn, Mass General, UCSF, and UT Dallas, the test has a reimbursement code, potentially shifting brain health monitoring from reactive to preventative care.
- Gimv, a European investment firm, signaled a pullback from early-stage aging biotech, citing long timelines and unpredictable ROI. Capital is now shifting toward technology-enabled services, diagnostics, and digital longevity platforms where returns are faster and more measurable. Phil and Nina frame this as a healthy evolution, removing less patient investors and making room for long-term, patient capital, strengthening the overall longevity ecosystem.

______________________
News & References:

What Gimv’s biotech pullback says about aging markets → https://longevity.technology/news/what-gimvs-biotech-pullback-says-about-aging-markets/
- Are global brands ready for longevity? → https://longevity.technology/news/are-global-brands-ready-for-longevity/
- New functional brain assessment system rolls out in the US → https://longevity.technology/news/new-functional-brain-assessment-system-rolls-out-in-the-us/
- As obesity drugs go oral and access grows, so do fakes →...]]>1627falsefullhttps://www.spreaker.com/episode/how-stem-cells-unlock-your-body-s-repair-potential--74818086Founder + Chief Science Officer of STEMREGEN
Instagram: www.instagram.com/stemcellchristian
Website: www.stemregen.co
______________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Link: https://www.getstride.com/unlocked/
______________________

What if your body had a repair system that could predict and prevent age-related disease?

Phil Newman and Dr. Nina Patrick sit down with Christian Drapeau, a researcher and expert in stem cells and regenerative biology. Christian explains how stem cells act as the body’s natural repair system, why measuring them could become a key biomarker for health, and how lifestyle factors, diet, and specific plant compounds can optimize their activity.

They explore the science behind stem cell release, how exercise, fasting, meditation, sauna, and cold exposure support regeneration, and the emerging technologies helping stem cells reach their full potential. Christian also discusses targeted applications for heart repair, joint health, and other tissues, as well as the future of accessible stem cell measurement.

This conversation highlights that supporting longevity goes beyond lifestyle hacks or clinical treatments. Christian’s research shows that understanding stem cell biology, preparing the body’s “terrain” for repair, and aligning interventions with evidence-based science are all critical for extending healthspan and improving long-term quality of life.

In this episode, you’ll learn:
- Why stem cells are the cornerstone of the body’s repair system
- How measuring stem cells could predict age-related disease and track health
- Lifestyle and diet strategies to naturally boost stem cell release
- How technology like PMF, sauna, and cold exposure work with stem cells
- Targeted stem cell applications for heart, joints, and tissue repair care

If you care about protecting your long-term health and want to understand how science, technology, and clinical strategies intersect to shape the future of healthspan, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging strategies, interventions, and technologies helping us understand and harness the body’s natural repair systems.
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561380024Mon, 16 Feb 2026 10:48:26 +0000saderGuest: Christian Drapeau Founder + Chief Science Officer of STEMREGEN Instagram: www.instagram.com/stemcellchristian Website: www.stemregen.co ______________________ Sponsor: Stride Stride helps people understand and improve their wellbeing and...Founder + Chief Science Officer of STEMREGEN
Instagram: www.instagram.com/stemcellchristian
Website: www.stemregen.co
______________________

Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Link: https://www.getstride.com/unlocked/
______________________

What if your body had a repair system that could predict and prevent age-related disease?

Phil Newman and Dr. Nina Patrick sit down with Christian Drapeau, a researcher and expert in stem cells and regenerative biology. Christian explains how stem cells act as the body’s natural repair system, why measuring them could become a key biomarker for health, and how lifestyle factors, diet, and specific plant compounds can optimize their activity.

They explore the science behind stem cell release, how exercise, fasting, meditation, sauna, and cold exposure support regeneration, and the emerging technologies helping stem cells reach their full potential. Christian also discusses targeted applications for heart repair, joint health, and other tissues, as well as the future of accessible stem cell measurement.

This conversation highlights that supporting longevity goes beyond lifestyle hacks or clinical treatments. Christian’s research shows that understanding stem cell biology, preparing the body’s “terrain” for repair, and aligning interventions with evidence-based science are all critical for extending healthspan and improving long-term quality of life.

In this episode, you’ll learn:
- Why stem cells are the cornerstone of the body’s repair system
- How measuring stem cells could predict age-related disease and track health
- Lifestyle and diet strategies to naturally boost stem cell release
- How technology like PMF, sauna, and cold exposure work with stem cells
- Targeted stem cell applications for heart, joints, and tissue repair care

If you care about protecting your long-term health and want to understand how science, technology, and clinical strategies intersect to shape the future of healthspan, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging strategies, interventions, and technologies helping us understand and harness the body’s natural repair systems.
______________________

Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>2884falsefullhttps://www.spreaker.com/episode/longevity-drugs-for-dogs-pfas-detox-and-gene-therapies-longevity-news-roundup-week-7-2026--74818061
Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Link: https://www.getstride.com/unlocked/
______________________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore breakthroughs shaping healthspan and longevity, from pioneering longevity drugs for dogs to one-shot gene therapies for ALS, AI-driven longevity data platforms, and innovations in environmental detox.

- Loyal, backed by Laura Deming’s Age1 Fund and other investors, raised $100 million Series C to advance LOY002, a daily pill aimed at extending the healthy lifespan of senior dogs. The drug has cleared two of three FDA hurdles, and its STAY trial will enroll 1,300 dogs across 70 clinics, potentially setting a regulatory precedent for aging as an approvable indication.
- Decoding Longevity Trends, a new AI-native platform tracking over 600 longevity-focused companies, including pipelines, mechanisms of action, and clinical stages. The system features a chatbot for complex queries and aims to accelerate insights for investors, pharma, and operators in the longevity ecosystem.
- Cambiotics, a Copenhagen-based startup, raised $4 million to develop 46and, a probiotic supplement designed to help the body eliminate PFAS (“forever chemicals”). Early research shows specific gut bacteria can bind PFAS, with human trials expected in the US this year, marking a step forward in exposome-based longevity interventions.
- In neurodegeneration news, Vector Y dosed its first patient in a Phase 1 trial for VTX002, a one-time gene therapy targeting TDP43 pathology in ALS. This vectorized antibody approach installs a long-term antibody factory in the CNS, potentially transforming treatment from repeated dosing to durable, one-shot interventions and extending to other neurodegenerative conditions.
- The biohacking and self-managed health sector is projected to hit $216 billion by 2035, led by North America. Wearables, diagnostics, genetics, and personalized health platforms are driving adoption, while longevity and neuroscience increasingly intersect with consumer-driven biohacking practices.
- Backed by a five-year, $3.3 million federal award, a new research initiative at Oregon Health & Science University (OHSU) aims to develop a retinal screening tool that could flag the earliest biological signals of Alzheimer’s using nothing more than an eye drop and a quick scan.

______________________
News & References:

- Loyal raises $100m as canine longevity drug nears approval → https://longevity.technology/news/loyal-raises-100m-as-canine-longevity-drug-nears-approval/
- VectorY doses first patient in ALS gene therapy trial → https://longevity.technology/news/vectory-doses-first-patient-in-als-gene-therapy-trial/
- Longevity.Technology unveils DLT – the intelligence platform for longevity → https://longevity.technology/news/longevity-technology-unveils-dlt-the-intelligence-platform-for-longevity
- Danish startup aims to remove ‘forever chemicals’ from the body → https://longevity.technology/news/danish-startup-aims-to-remove-forever-chemicals-from-the-body/
- Biohacking market projected to top US$216 billion by 2035 → https://longevity.technology/news/biohacking-market-projected-to-top-us216-billion-by-2035/
- New retinal screening targets Alzheimer’s before memory loss → https://longevity.technology/news/new-retinal-screening-targets-alzheimers-before-memory-loss/

______________________
Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379925Fri, 13 Feb 2026 12:46:13 +0000saderSponsor: Stride Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science....
Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.
Link: https://www.getstride.com/unlocked/
______________________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore breakthroughs shaping healthspan and longevity, from pioneering longevity drugs for dogs to one-shot gene therapies for ALS, AI-driven longevity data platforms, and innovations in environmental detox.

- Loyal, backed by Laura Deming’s Age1 Fund and other investors, raised $100 million Series C to advance LOY002, a daily pill aimed at extending the healthy lifespan of senior dogs. The drug has cleared two of three FDA hurdles, and its STAY trial will enroll 1,300 dogs across 70 clinics, potentially setting a regulatory precedent for aging as an approvable indication.
- Decoding Longevity Trends, a new AI-native platform tracking over 600 longevity-focused companies, including pipelines, mechanisms of action, and clinical stages. The system features a chatbot for complex queries and aims to accelerate insights for investors, pharma, and operators in the longevity ecosystem.
- Cambiotics, a Copenhagen-based startup, raised $4 million to develop 46and, a probiotic supplement designed to help the body eliminate PFAS (“forever chemicals”). Early research shows specific gut bacteria can bind PFAS, with human trials expected in the US this year, marking a step forward in exposome-based longevity interventions.
- In neurodegeneration news, Vector Y dosed its first patient in a Phase 1 trial for VTX002, a one-time gene therapy targeting TDP43 pathology in ALS. This vectorized antibody approach installs a long-term antibody factory in the CNS, potentially transforming treatment from repeated dosing to durable, one-shot interventions and extending to other neurodegenerative conditions.
- The biohacking and self-managed health sector is projected to hit $216 billion by 2035, led by North America. Wearables, diagnostics, genetics, and personalized health platforms are driving adoption, while longevity and neuroscience increasingly intersect with consumer-driven biohacking practices.
- Backed by a five-year, $3.3 million federal award, a new research initiative at Oregon Health & Science University (OHSU) aims to develop a retinal screening tool that could flag the earliest biological signals of Alzheimer’s using nothing more than an eye drop and a quick scan.

______________________
News & References:

- Loyal raises $100m as canine longevity drug nears approval → https://longevity.technology/news/loyal-raises-100m-as-canine-longevity-drug-nears-approval/
- VectorY doses first patient in ALS gene therapy trial → https://longevity.technology/news/vectory-doses-first-patient-in-als-gene-therapy-trial/
- Longevity.Technology unveils DLT – the intelligence platform for longevity → https://longevity.technology/news/longevity-technology-unveils-dlt-the-intelligence-platform-for-longevity
- Danish startup aims to remove ‘forever chemicals’ from the body → https://longevity.technology/news/danish-startup-aims-to-remove-forever-chemicals-from-the-body/
- Biohacking market projected to top US$216 billion by 2035 → https://longevity.technology/news/biohacking-market-projected-to-top-us216-billion-by-2035/
- New retinal screening targets Alzheimer’s before memory loss → https://longevity.technology/news/new-retinal-screening-targets-alzheimers-before-memory-loss/

______________________
Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>1799falsefullhttps://www.spreaker.com/episode/bridging-ethics-science-and-practical-longevity--74818125Carolyn Ringel, JD, MBE
Consultant and Instructor for Harvard Medical School Center for Bioethics
LinkedIn: ⁠https://www.linkedin.com/in/carolyn-baker-ringel-35378431/⁠

David Barzilai, MD, PhD, MBA, MS, DipABLM
Founder and CEO of Barzilai Longevity Consulting
LinkedIn: ⁠https://www.linkedin.com/in/agingdoc/⁠
Website: ⁠https://www.barzilaiconsulting.com/david⁠
________________

Longevity ethics? What if extending healthspan required rethinking not just medicine, but society itself?

Phil Newman and Dr. Nina Patrick sit down with Carolyn Ringel, a bioethicist at Harvard Medical School, and Dr. David Barzilai, a longevity medicine physician. They explore how aging research and geroscience can address urgent health issues like heart disease, diabetes, cancer, and dementia, while highlighting the ethical responsibilities of science and medicine.

Carolyn emphasizes that studying aging is not an either-or with addressing current health crises; by understanding aging, we can better prevent and treat age-related diseases. She also explores how healthcare funding, housing, and social infrastructure can be designed to support longer, healthier lives, creating a society where longevity benefits everyone.

David explains the importance of trusted patient-doctor relationships, scientific literacy, and emerging interventions like aging biomarkers, cellular reprogramming, and regenerative medicine. He highlights the potential of integrated, systems-based approaches and AI-driven research to accelerate the development of safe, effective longevity strategies.

This conversation highlights that longevity is not just about supplements, exercise, or clinical interventions. Ethical frameworks, societal design, and evidence-based medicine all play a crucial role in extending healthspan and improving quality of life.

In this episode, you’ll learn:
- How geroscience can prevent multiple age-related diseases simultaneously
- The ethical considerations of patient empowerment and longevity interventions
- How societal infrastructure and healthcare funding can support longer, healthier lives
- The role of biomarkers and AI in safe, effective longevity strategies
- The future of integrated, evidence-based, and ethical longevity care

If you care about protecting your long-term health and want to understand how ethics, policy, and science intersect to shape the future of healthspan, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging technologies, policies, and strategies
________________
Connect with our hosts:
Phil Newman: ⁠⁠⁠https://qrco.de/bgXpNY⁠⁠
Dr. Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379931Mon, 09 Feb 2026 12:14:42 +0000saderGuests: Carolyn Ringel, JD, MBE Consultant and Instructor for Harvard Medical School Center for Bioethics LinkedIn: ⁠https://www.linkedin.com/in/carolyn-baker-ringel-35378431/⁠ David Barzilai, MD, PhD, MBA, MS, DipABLM Founder and CEO of Barzilai...Carolyn Ringel, JD, MBE
Consultant and Instructor for Harvard Medical School Center for Bioethics
LinkedIn: ⁠https://www.linkedin.com/in/carolyn-baker-ringel-35378431/⁠

David Barzilai, MD, PhD, MBA, MS, DipABLM
Founder and CEO of Barzilai Longevity Consulting
LinkedIn: ⁠https://www.linkedin.com/in/agingdoc/⁠
Website: ⁠https://www.barzilaiconsulting.com/david⁠
________________

Longevity ethics? What if extending healthspan required rethinking not just medicine, but society itself?

Phil Newman and Dr. Nina Patrick sit down with Carolyn Ringel, a bioethicist at Harvard Medical School, and Dr. David Barzilai, a longevity medicine physician. They explore how aging research and geroscience can address urgent health issues like heart disease, diabetes, cancer, and dementia, while highlighting the ethical responsibilities of science and medicine.

Carolyn emphasizes that studying aging is not an either-or with addressing current health crises; by understanding aging, we can better prevent and treat age-related diseases. She also explores how healthcare funding, housing, and social infrastructure can be designed to support longer, healthier lives, creating a society where longevity benefits everyone.

David explains the importance of trusted patient-doctor relationships, scientific literacy, and emerging interventions like aging biomarkers, cellular reprogramming, and regenerative medicine. He highlights the potential of integrated, systems-based approaches and AI-driven research to accelerate the development of safe, effective longevity strategies.

This conversation highlights that longevity is not just about supplements, exercise, or clinical interventions. Ethical frameworks, societal design, and evidence-based medicine all play a crucial role in extending healthspan and improving quality of life.

In this episode, you’ll learn:
- How geroscience can prevent multiple age-related diseases simultaneously
- The ethical considerations of patient empowerment and longevity interventions
- How societal infrastructure and healthcare funding can support longer, healthier lives
- The role of biomarkers and AI in safe, effective longevity strategies
- The future of integrated, evidence-based, and ethical longevity care

If you care about protecting your long-term health and want to understand how ethics, policy, and science intersect to shape the future of healthspan, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging technologies, policies, and strategies
________________
Connect with our hosts:
Phil Newman: ⁠⁠⁠https://qrco.de/bgXpNY⁠⁠
Dr. Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠]]>3265falsefullhttps://www.spreaker.com/episode/genetics-psychedelics-epigenetic-reprogramming-longevity-news-roundup-week-6-2026--74818084
- New research challenges long-standing estimates of genetic contribution to lifespan. When deaths caused by environmental factors are separated from intrinsic aging, heritability for intrinsic lifespan rises to around 50–55%, doubling previous assumptions and reshaping how we think about early interventions.
- Gameto licenses meiosis induction technology from Harvard to create ovarian organoids in a dish, opening a platform for women’s reproductive longevity, drug testing during pregnancy, and potentially improved menopause therapeutics.
- Houston-based Prana X Corp raises $17 million to develop exosome-based regenerative biologics, applying techniques initially developed for oncology toward healthy aging, inflammation reduction, and tissue repair.
- Digital health is evolving with AI concierge platforms like Death Clock and family-focused monitoring systems like Lufu, which track health data across households to drive actionable behavior change and support intergenerational wellbeing.
- Life Biosciences receives FDA approval for the first human trial of partial epigenetic reprogramming therapy ER100, targeting retinal cells in serious age-related eye disease. This milestone moves longevity science from theory to first-in-human application with the potential to expand to other organs and systemic age reversal.
- Psychedelics are re-emerging as potential tools for cognitive resilience and emotional health in older adults, with early studies showing unexpected benefits in Parkinson’s patients and implications for preventative approaches to mental health and neuroplasticity.

______________________
News & References:

- Genes reclaim center stage in longevity debate → https://longevity.technology/news/genes-reclaim-center-stage-in-longevity-debate/
- The regulatory path for rescheduling psychedelics for healthspan → https://longevity.technology/news/the-regulatory-path-for-rescheduling-psychedelics-for-healthspan/
- FDA clears first human trial of epigenetic reprogramming therapy → https://longevity.technology/news/fda-clears-first-human-trial-of-epigenetic-reprogramming-therapy/
- Death prediction app launches ‘AI health concierge’ → https://longevity.technology/news/death-prediction-app-launches-ai-health-concierge/
- Gameto licenses Harvard meiosis IP to advance human ovary‑in‑a‑dish platform → https://longevity.technology/news/gameto-licenses-harvard-meiosis-ip-to-advance-human-ovary-in-a-dish-platform/
- PranaX lands $17m to harness exosomes in regenerative biologics → https://longevity.technology/news/pranax-lands-17m-to-harness-exosomes-in-regenerative-biologics/

______________________
Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379872Fri, 06 Feb 2026 13:17:47 +0000saderIn this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping healthspan and longevity, from new insights into genetic influence on lifespan to reproductive longevity, exosome therapeutics, AI health...
- New research challenges long-standing estimates of genetic contribution to lifespan. When deaths caused by environmental factors are separated from intrinsic aging, heritability for intrinsic lifespan rises to around 50–55%, doubling previous assumptions and reshaping how we think about early interventions.
- Gameto licenses meiosis induction technology from Harvard to create ovarian organoids in a dish, opening a platform for women’s reproductive longevity, drug testing during pregnancy, and potentially improved menopause therapeutics.
- Houston-based Prana X Corp raises $17 million to develop exosome-based regenerative biologics, applying techniques initially developed for oncology toward healthy aging, inflammation reduction, and tissue repair.
- Digital health is evolving with AI concierge platforms like Death Clock and family-focused monitoring systems like Lufu, which track health data across households to drive actionable behavior change and support intergenerational wellbeing.
- Life Biosciences receives FDA approval for the first human trial of partial epigenetic reprogramming therapy ER100, targeting retinal cells in serious age-related eye disease. This milestone moves longevity science from theory to first-in-human application with the potential to expand to other organs and systemic age reversal.
- Psychedelics are re-emerging as potential tools for cognitive resilience and emotional health in older adults, with early studies showing unexpected benefits in Parkinson’s patients and implications for preventative approaches to mental health and neuroplasticity.

______________________
News & References:

- Genes reclaim center stage in longevity debate → https://longevity.technology/news/genes-reclaim-center-stage-in-longevity-debate/
- The regulatory path for rescheduling psychedelics for healthspan → https://longevity.technology/news/the-regulatory-path-for-rescheduling-psychedelics-for-healthspan/
- FDA clears first human trial of epigenetic reprogramming therapy → https://longevity.technology/news/fda-clears-first-human-trial-of-epigenetic-reprogramming-therapy/
- Death prediction app launches ‘AI health concierge’ → https://longevity.technology/news/death-prediction-app-launches-ai-health-concierge/
- Gameto licenses Harvard meiosis IP to advance human ovary‑in‑a‑dish platform → https://longevity.technology/news/gameto-licenses-harvard-meiosis-ip-to-advance-human-ovary-in-a-dish-platform/
- PranaX lands $17m to harness exosomes in regenerative biologics → https://longevity.technology/news/pranax-lands-17m-to-harness-exosomes-in-regenerative-biologics/

______________________
Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>2013falsefullhttps://www.spreaker.com/episode/regenerative-health-ai-longevity--74818083Dr Hany Demian
CEO, Praesentia Healthcare
Website: ⁠https://drdemian.com/
LinkedIn: ⁠https://www.linkedin.com/in/hany-demian-md-5b79b659/
________________
What if chronic pain wasn’t just something to manage, but a key signal of deeper biological stress? And what if regenerative medicine could play a role in protecting long-term health and function?

In conversation with Phil Newman and Dr. Nina Patrick, Dr. Hany Demian explores how regenerative medicine and peptide-based therapies are being used to support recovery, mobility, and healthy aging. He explains how chronic pain is often linked to inflammation, metabolic dysfunction, and impaired tissue repair rather than isolated injury.

Dr. Demian highlights how tools such as PRP, peptides, cell-based therapies, and AI-assisted diagnostics can optimize repair, monitor progress, and guide personalized treatment plans, all while maintaining ethical, patient-centered care. The conversation shows how individualized protocols, informed by AI and clinical oversight, can improve outcomes without relying on one-size-fits-all solutions.

This discussion reinforces that longevity is not only about supplements or exercise. Addressing pain, inflammation, and tissue health with precision medicine is a critical but often overlooked component of healthspan.

In this episode, you’ll learn:
How chronic pain affects long-term healthWhy regenerative approaches focus on repair, not symptom maskingThe role of AI and personalized treatment planningHow ethical oversight matters in regenerative careWhat the future of regenerative medicine may hold

If you care about protecting mobility, reducing chronic pain, and supporting long-term healthspan, this is a conversation you won’t want to miss.

Subscribe for weekly episodes exploring longevity science, healthspan optimization, and emerging regenerative therapies.

________________
Connect with our hosts:
Phil Newman: ⁠https://qrco.de/bgXpNY
Dr. Nina Patrick: ⁠https://qrco.de/bgXpKn]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379887Mon, 02 Feb 2026 12:01:45 +0000saderGuest: Dr Hany Demian CEO, Praesentia Healthcare Website: ⁠https://drdemian.com/ LinkedIn: ⁠https://www.linkedin.com/in/hany-demian-md-5b79b659/ ________________ What if chronic pain wasn’t just something to manage, but a key signal of deeper...Dr Hany Demian
CEO, Praesentia Healthcare
Website: ⁠https://drdemian.com/
LinkedIn: ⁠https://www.linkedin.com/in/hany-demian-md-5b79b659/
________________
What if chronic pain wasn’t just something to manage, but a key signal of deeper biological stress? And what if regenerative medicine could play a role in protecting long-term health and function?

In conversation with Phil Newman and Dr. Nina Patrick, Dr. Hany Demian explores how regenerative medicine and peptide-based therapies are being used to support recovery, mobility, and healthy aging. He explains how chronic pain is often linked to inflammation, metabolic dysfunction, and impaired tissue repair rather than isolated injury.

Dr. Demian highlights how tools such as PRP, peptides, cell-based therapies, and AI-assisted diagnostics can optimize repair, monitor progress, and guide personalized treatment plans, all while maintaining ethical, patient-centered care. The conversation shows how individualized protocols, informed by AI and clinical oversight, can improve outcomes without relying on one-size-fits-all solutions.

This discussion reinforces that longevity is not only about supplements or exercise. Addressing pain, inflammation, and tissue health with precision medicine is a critical but often overlooked component of healthspan.

In this episode, you’ll learn:
How chronic pain affects long-term healthWhy regenerative approaches focus on repair, not symptom maskingThe role of AI and personalized treatment planningHow ethical oversight matters in regenerative careWhat the future of regenerative medicine may hold

If you care about protecting mobility, reducing chronic pain, and supporting long-term healthspan, this is a conversation you won’t want to miss.

Subscribe for weekly episodes exploring longevity science, healthspan optimization, and emerging regenerative therapies.

________________
Connect with our hosts:
Phil Newman: ⁠https://qrco.de/bgXpNY
Dr. Nina Patrick: ⁠https://qrco.de/bgXpKn]]>2323falsefullhttps://www.spreaker.com/episode/sound-neurotech-ai-enabled-scans-longevity-news-roundup-week-5-2026--74818080Website: https://longevityshow.com/
The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.

____________________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping longevity science and technology, from epigenetic reprogramming and non-invasive brain therapies to AI-driven diagnostics.

- Elon Musk, speaking at Davos, suggested that aging is “very solvable,” framing it as an engineering challenge and emphasizing the growing mainstream awareness that biology can be engineered to extend healthspan.
- New research shows that sound stimulation at 40 Hz may help the brain clear toxic proteins linked to Alzheimer’s disease, offering a non-invasive, scalable approach to cognitive health if validated in humans.
- SimonMed launches longevity-focused MRI programs across the US, combining AI-enabled whole-body scans with lab testing and biomarkers to identify risks before symptoms arise.
- Researchers develop tiny wireless brain implants that can cross the blood-brain barrier without surgery, potentially transforming interventions for neurological aging and disease.
- Longevity has moved from lab benches to beauty counters, but as the category scales, experts warn that science-lite marketing could hollow it out.
- India’s Sun Pharma readies to launch generic semaglutide for weight management after patent expiry in 2026.

____________________

News & References:

- Elon Musk suggests aging is ‘very solvable’ → https://longevity.technology/news/elon-musk-suggests-aging-is-very-solvable/
- Non‑invasive sound therapy shows promise for Alzheimer’s → https://longevity.technology/news/non-invasive-sound-therapy-shows-promise-for-alzheimers/
- SimonMed launches longevity‑focused MRI program → https://longevity.technology/news/simonmed-launches-longevity-focused-mri-program/
- Sun Pharma gets approval for Wegovy-style weight loss shot → https://longevity.technology/news/sun-pharma-gets-approval-for-wegovy-style-weight-loss-shot/
- Brain implants may soon work without surgery → https://longevity.technology/news/brain-implants-may-soon-work-without-surgery/
- As longevity beauty grows, fears of ‘longevity washing’ rise → https://longevity.technology/news/as-longevity-beauty-grows-fears-of-longevity-washing-rise/

____________________

Connect with our hosts:
Phil Newman: ⁠https://qrco.de/bgXpNY⁠
Dr. Nina Patrick: ⁠https://qrco.de/bgXpKn⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561380001Fri, 30 Jan 2026 12:39:22 +0000saderThe Longevity Show Website: https://longevityshow.com/ The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo....Website: https://longevityshow.com/
The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.

____________________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping longevity science and technology, from epigenetic reprogramming and non-invasive brain therapies to AI-driven diagnostics.

- Elon Musk, speaking at Davos, suggested that aging is “very solvable,” framing it as an engineering challenge and emphasizing the growing mainstream awareness that biology can be engineered to extend healthspan.
- New research shows that sound stimulation at 40 Hz may help the brain clear toxic proteins linked to Alzheimer’s disease, offering a non-invasive, scalable approach to cognitive health if validated in humans.
- SimonMed launches longevity-focused MRI programs across the US, combining AI-enabled whole-body scans with lab testing and biomarkers to identify risks before symptoms arise.
- Researchers develop tiny wireless brain implants that can cross the blood-brain barrier without surgery, potentially transforming interventions for neurological aging and disease.
- Longevity has moved from lab benches to beauty counters, but as the category scales, experts warn that science-lite marketing could hollow it out.
- India’s Sun Pharma readies to launch generic semaglutide for weight management after patent expiry in 2026.

____________________

News & References:

- Elon Musk suggests aging is ‘very solvable’ → https://longevity.technology/news/elon-musk-suggests-aging-is-very-solvable/
- Non‑invasive sound therapy shows promise for Alzheimer’s → https://longevity.technology/news/non-invasive-sound-therapy-shows-promise-for-alzheimers/
- SimonMed launches longevity‑focused MRI program → https://longevity.technology/news/simonmed-launches-longevity-focused-mri-program/
- Sun Pharma gets approval for Wegovy-style weight loss shot → https://longevity.technology/news/sun-pharma-gets-approval-for-wegovy-style-weight-loss-shot/
- Brain implants may soon work without surgery → https://longevity.technology/news/brain-implants-may-soon-work-without-surgery/
- As longevity beauty grows, fears of ‘longevity washing’ rise → https://longevity.technology/news/as-longevity-beauty-grows-fears-of-longevity-washing-rise/

____________________

Connect with our hosts:
Phil Newman: ⁠https://qrco.de/bgXpNY⁠
Dr. Nina Patrick: ⁠https://qrco.de/bgXpKn⁠]]>1982falsefullhttps://www.spreaker.com/episode/how-dentistry-can-extend-your-healthspan--74818075Founder and clinical director of White Clinic
Website: https://miguelstanley.com/
Instagram: https://www.instagram.com/drmiguelstanley/?hl=en

Sponsor: The Longevity Show
Website: https://longevityshow.com/
The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.

____________________

What if your dentist could do more than just fix teeth? What if oral health became a key driver of long-term wellness and longevity?

Phil Newman and Dr. Nina Patrick sit down with Miguel Stanley, a pioneer in longevity-focused dentistry. He explains how outdated dental work can create subclinical infections that contribute to systemic inflammation, impacting over 22 chronic diseases. Using CBCT imaging, strategic sequencing, and AI-assisted diagnostics, Miguel shows how modern dentistry can protect both healthspan and quality of life.

He introduces revision dentistry; removing or updating old dental work that no longer supports health, and emphasizes ethical, patient-centered care. Patients who are informed and supported by AI can make smarter choices, while dentists can deliver more precise, preventive, and personalized care.

This conversation highlights that longevity is not just about diet, supplements, or exercise. Oral health is a hidden lever for systemic wellness. With advanced diagnostics, treatment planning, and patient empowerment, dentistry can play a vital role in extending healthspan.

In this episode, you’ll learn:

- How subclinical oral inflammation affects systemic health
- Why revision dentistry is critical for longevity
- The role of AI in accurate diagnostics and patient empowerment
- How sequencing dental treatments can optimize outcomes
- The future of preventive, longevity-focused dentistry

If you care about protecting your long-term health and want to understand how oral care impacts your entire body, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging technologies and strategies shaping the future of preventive, longevity-focused dentistry.

____________________

Connect with our hosts:
Phil Newman: https://qrco.de/bgXpNY
Dr. Nina Patrick: https://qrco.de/bgXpKn]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379877Mon, 26 Jan 2026 12:37:36 +0000saderGuest: Dr Miguel Stanley Founder and clinical director of White Clinic Website: https://miguelstanley.com/ Instagram: https://www.instagram.com/drmiguelstanley/?hl=en Sponsor: The Longevity Show Website: https://longevityshow.com/ The Longevity...Founder and clinical director of White Clinic
Website: https://miguelstanley.com/
Instagram: https://www.instagram.com/drmiguelstanley/?hl=en

Sponsor: The Longevity Show
Website: https://longevityshow.com/
The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.

____________________

What if your dentist could do more than just fix teeth? What if oral health became a key driver of long-term wellness and longevity?

Phil Newman and Dr. Nina Patrick sit down with Miguel Stanley, a pioneer in longevity-focused dentistry. He explains how outdated dental work can create subclinical infections that contribute to systemic inflammation, impacting over 22 chronic diseases. Using CBCT imaging, strategic sequencing, and AI-assisted diagnostics, Miguel shows how modern dentistry can protect both healthspan and quality of life.

He introduces revision dentistry; removing or updating old dental work that no longer supports health, and emphasizes ethical, patient-centered care. Patients who are informed and supported by AI can make smarter choices, while dentists can deliver more precise, preventive, and personalized care.

This conversation highlights that longevity is not just about diet, supplements, or exercise. Oral health is a hidden lever for systemic wellness. With advanced diagnostics, treatment planning, and patient empowerment, dentistry can play a vital role in extending healthspan.

In this episode, you’ll learn:

- How subclinical oral inflammation affects systemic health
- Why revision dentistry is critical for longevity
- The role of AI in accurate diagnostics and patient empowerment
- How sequencing dental treatments can optimize outcomes
- The future of preventive, longevity-focused dentistry

If you care about protecting your long-term health and want to understand how oral care impacts your entire body, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan optimization, and the emerging technologies and strategies shaping the future of preventive, longevity-focused dentistry.

____________________

Connect with our hosts:
Phil Newman: https://qrco.de/bgXpNY
Dr. Nina Patrick: https://qrco.de/bgXpKn]]>3719falsefullhttps://www.spreaker.com/episode/bcis-microplastics-space-aging-longevity-news-roundup-week-4-2026--74818186Website: https://longevityshow.com/
The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.

__________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping longevity science and technology, from brain-computer interfaces and AI-driven diagnostics to spaceflight epigenetics and longevity event updates.

- Merge Labs, Sam Altman’s BCI startup, launches with funding from OpenAI, exploring next-generation neural interfaces that could merge human cognition with AI.
- Lumati introduces an at-home saliva microplastics test, giving individuals a practical way to track environmental exposure and its potential health impacts.
- Spaceflight research reveals dynamic DNA methylation changes in astronauts on the Axiom 2 mission, offering fast insights into biological aging and epigenetic plasticity.
- The Houstonian Hotel, Club & Spa has appointed Fountain Life as its exclusive partner for longevity and preventive health services.
- The Longevity Show 2026 gears up with NAD Clinic as an official Innovator Partner, plus new speakers announced, highlighting the convergence of longevity clinics, wellness, and technology.
- Investment momentum continues to accelerate across longevity ventures, reflecting growing interest in diagnostics, neurotech, and preventive health innovations.

__________

News & References:

- Sam Altman’s BCI startup Merge Labs launches with funding from OpenAI → https://longevity.technology/news/sam-altmans-bci-startup-merge-labs-launches-with-funding-from-openai/
- Lumati launches at-home saliva microplastics test → https://longevity.technology/news/lumati-launches-at-home-saliva-microplastics-test/
- NADclinic named Innovator Partner for The Longevity Show 2026 → https://longevity.technology/news/nadclinic-named-innovator-partner-for-the-longevity-show-2026/
- Longevity Show reveals second wave of speakers → https://longevity.technology/news/longevity-show-reveals-second-wave-of-speakers/
- SciNeuro and Novartis ink $1.7b deal for new Alzheimer’s treatment →https://longevity.technology/news/scineuro-and-novartis-ink-1-7b-deal-for-new-alzheimers-treatment/
- Fountain Life named exclusive longevity partner of Houstonian hotel and spa → https://longevity.technology/news/fountain-life-named-exclusive-longevity-partner-of-houstonian-hotel-and-spa/

__________
Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379987Fri, 23 Jan 2026 12:27:25 +0000saderThe Longevity Show Website: https://longevityshow.com/ The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo....Website: https://longevityshow.com/
The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.

__________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping longevity science and technology, from brain-computer interfaces and AI-driven diagnostics to spaceflight epigenetics and longevity event updates.

- Merge Labs, Sam Altman’s BCI startup, launches with funding from OpenAI, exploring next-generation neural interfaces that could merge human cognition with AI.
- Lumati introduces an at-home saliva microplastics test, giving individuals a practical way to track environmental exposure and its potential health impacts.
- Spaceflight research reveals dynamic DNA methylation changes in astronauts on the Axiom 2 mission, offering fast insights into biological aging and epigenetic plasticity.
- The Houstonian Hotel, Club & Spa has appointed Fountain Life as its exclusive partner for longevity and preventive health services.
- The Longevity Show 2026 gears up with NAD Clinic as an official Innovator Partner, plus new speakers announced, highlighting the convergence of longevity clinics, wellness, and technology.
- Investment momentum continues to accelerate across longevity ventures, reflecting growing interest in diagnostics, neurotech, and preventive health innovations.

__________

News & References:

- Sam Altman’s BCI startup Merge Labs launches with funding from OpenAI → https://longevity.technology/news/sam-altmans-bci-startup-merge-labs-launches-with-funding-from-openai/
- Lumati launches at-home saliva microplastics test → https://longevity.technology/news/lumati-launches-at-home-saliva-microplastics-test/
- NADclinic named Innovator Partner for The Longevity Show 2026 → https://longevity.technology/news/nadclinic-named-innovator-partner-for-the-longevity-show-2026/
- Longevity Show reveals second wave of speakers → https://longevity.technology/news/longevity-show-reveals-second-wave-of-speakers/
- SciNeuro and Novartis ink $1.7b deal for new Alzheimer’s treatment →https://longevity.technology/news/scineuro-and-novartis-ink-1-7b-deal-for-new-alzheimers-treatment/
- Fountain Life named exclusive longevity partner of Houstonian hotel and spa → https://longevity.technology/news/fountain-life-named-exclusive-longevity-partner-of-houstonian-hotel-and-spa/

__________
Hosts:
Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠
Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠]]>1806falsefullhttps://www.spreaker.com/episode/the-cell-tech-that-could-transform-aging--74818150
Nabiha Saklayen
CEO and Co-Founder of Cellino
LinkedIn: ⁠https://www.linkedin.com/in/nabihasaklayen/
Cellino: ⁠https://cellinobio.com/

Vladik Krupalnik
CEO and Co-Founder of RenewalBio
LinkedIn: https://www.linkedin.com/in/vladik-krupalnik-0669b729/
RenewalBio: ⁠https://www.renewal.bio/
__________

What can regenerative medicine teach us about health, longevity, and personalized medicine?

Phil Newman and Dr. Nina Patrick sit down with biotech pioneers Nabiha Saklayen and Vladik Krupalnik to explore how cutting-edge stem cell technologies are transforming medicine. They discuss how induced pluripotent stem cells (iPSCs) can be scaled for various applications, from rare blood disorders to organ-specific cells, and how these approaches could redefine healthspan and lifespan.

Beyond individual treatments, Nabiha and Vladik share their visions for decentralized, on-demand cell manufacturing, regulatory strategies, and AI-driven platforms that could make personalized regenerative medicine accessible globally. They also highlight how infrastructure, standardization, and investor alignment are shaping the trajectory of longevity-focused biotech.

This conversation combines the science of regenerative medicine with practical insights for anyone interested in extending healthspan, optimizing personalized therapies, and leveraging technology to transform medicine. Subscribe for weekly episodes on longevity science, regenerative medicine, and the innovations shaping our future.

In this episode, you’ll learn:
- How iPSCs are being used to generate blood, liver, heart, and pancreatic cells
- Stepwise strategies for moving from preclinical work to first-in-human trials
- The distinction between science fiction and realistic regenerative therapies
- How decentralized manufacturing can safely bring therapies closer to patients
- Investor perspectives on longevity and regenerative medicine
- How personalized cell therapies may eventually extend human healthspan

If you care about living longer and healthier, and you’re curious about how regenerative medicine could redefine personalized healthcare, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan extension, and the breakthrough technologies shaping the future of regenerative and personalized medicine.

__________

Connect with our Hosts:
Phil Newman⁠: https://qrco.de/bgXpNY ⁠
Dr. Nina Patrick⁠: https://qrco.de/bgXpKn]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379896Mon, 19 Jan 2026 12:21:01 +0000saderGuests: Nabiha Saklayen CEO and Co-Founder of Cellino LinkedIn: ⁠https://www.linkedin.com/in/nabihasaklayen/ Cellino: ⁠https://cellinobio.com/ Vladik Krupalnik CEO and Co-Founder of RenewalBio LinkedIn:...
Nabiha Saklayen
CEO and Co-Founder of Cellino
LinkedIn: ⁠https://www.linkedin.com/in/nabihasaklayen/
Cellino: ⁠https://cellinobio.com/

Vladik Krupalnik
CEO and Co-Founder of RenewalBio
LinkedIn: https://www.linkedin.com/in/vladik-krupalnik-0669b729/
RenewalBio: ⁠https://www.renewal.bio/
__________

What can regenerative medicine teach us about health, longevity, and personalized medicine?

Phil Newman and Dr. Nina Patrick sit down with biotech pioneers Nabiha Saklayen and Vladik Krupalnik to explore how cutting-edge stem cell technologies are transforming medicine. They discuss how induced pluripotent stem cells (iPSCs) can be scaled for various applications, from rare blood disorders to organ-specific cells, and how these approaches could redefine healthspan and lifespan.

Beyond individual treatments, Nabiha and Vladik share their visions for decentralized, on-demand cell manufacturing, regulatory strategies, and AI-driven platforms that could make personalized regenerative medicine accessible globally. They also highlight how infrastructure, standardization, and investor alignment are shaping the trajectory of longevity-focused biotech.

This conversation combines the science of regenerative medicine with practical insights for anyone interested in extending healthspan, optimizing personalized therapies, and leveraging technology to transform medicine. Subscribe for weekly episodes on longevity science, regenerative medicine, and the innovations shaping our future.

In this episode, you’ll learn:
- How iPSCs are being used to generate blood, liver, heart, and pancreatic cells
- Stepwise strategies for moving from preclinical work to first-in-human trials
- The distinction between science fiction and realistic regenerative therapies
- How decentralized manufacturing can safely bring therapies closer to patients
- Investor perspectives on longevity and regenerative medicine
- How personalized cell therapies may eventually extend human healthspan

If you care about living longer and healthier, and you’re curious about how regenerative medicine could redefine personalized healthcare, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that explore longevity science, healthspan extension, and the breakthrough technologies shaping the future of regenerative and personalized medicine.

__________

Connect with our Hosts:
Phil Newman⁠: https://qrco.de/bgXpNY ⁠
Dr. Nina Patrick⁠: https://qrco.de/bgXpKn]]>3967falsefullhttps://www.spreaker.com/episode/als-treatments-neuroplasticity-biotech-longevity-news-roundup-week-3-2026--74818191Website: ⁠https://longevityshow.com/⁠
The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.

__________________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping the longevity ecosystem, from breakthrough neurological therapeutics and pet longevity innovations to advances in neuroplasticity, wearable tech, and early-stage cardiovascular interventions.

- Vector Y’s ALS drug, VTX002, received Fast Track designation, targeting the TDP43 protein and marking a potential shift from symptom management to disease modification in ALS.

- Loyal’s senior dog longevity drug, LOY002, clears FDA safety hurdles, aiming to extend lifespan in large mammals while providing insights for human longevity applications.

- Cumulus introduces a scalable neuroplasticity measurement platform with wireless dry EEG sensors, allowing researchers to monitor brain adaptation and recovery in clinical settings efficiently.

- Significant investment activity continues in longevity-focused startups, including multi-million-dollar raises for cardiovascular disease prevention, extracellular matrix-targeted therapies, and regenerative biologics.

__________________

News & References:

- Vector Y wins FDA Fast Track for ALS therapy → ⁠https://longevity.technology/news/vectory-wins-fda-fast-track-for-als-therapy/
- ⁠FDA clears safety step for Loyal’s senior dog longevity drug → ⁠https://longevity.technology/news/fda-clears-safety-step-for-loyals-senior-dog-longevity-drug/
- ⁠Cumulus proves brain plasticity can be measured at scale → ⁠https://longevity.technology/news/cumulus-proves-brain-plasticity-can-be-measured-at-scale/⁠
- Nvidia and Eli Lilly bet $1 billion on AI-powered drug discovery → ⁠https://longevity.technology/news/nvidia-and-eli-lilly-bet-1-billion-on-ai-powered-drug-discovery/⁠
- 50M boost secured for BioBeat’s wearable blood pressure tech → ⁠https://longevity.technology/news/50m-boost-secured-for-biobeats-wearable-blood-pressure-tech/⁠
- Engitix raises $25M to target tissue aging at its source → ⁠https://longevity.technology/news/engitix-raises-25m-to-target-tissue-aging-at-its-source/⁠
- Corsera lands $80M to predict and prevent cardiovascular disease → ⁠https://longevity.technology/news/corsera-lands-80m-to-predict-and-prevent-cardiovascular-disease/⁠
- Proxima lands $80M to make protein interactions programmable → ⁠https://longevity.technology/news/proxima-lands-80m-to-make-protein-interactions-programmable/⁠

__________________
Hosts:
Phil Newman: ⁠https://qrco.de/bgXpNY⁠
Nina Patrick: ⁠https://qrco.de/bgXpKn⁠]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379988Fri, 16 Jan 2026 12:37:03 +0000saderSponsor: The Longevity Show Website: ⁠https://longevityshow.com/⁠ The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an...Website: ⁠https://longevityshow.com/⁠
The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.

__________________

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping the longevity ecosystem, from breakthrough neurological therapeutics and pet longevity innovations to advances in neuroplasticity, wearable tech, and early-stage cardiovascular interventions.

- Vector Y’s ALS drug, VTX002, received Fast Track designation, targeting the TDP43 protein and marking a potential shift from symptom management to disease modification in ALS.

- Loyal’s senior dog longevity drug, LOY002, clears FDA safety hurdles, aiming to extend lifespan in large mammals while providing insights for human longevity applications.

- Cumulus introduces a scalable neuroplasticity measurement platform with wireless dry EEG sensors, allowing researchers to monitor brain adaptation and recovery in clinical settings efficiently.

- Significant investment activity continues in longevity-focused startups, including multi-million-dollar raises for cardiovascular disease prevention, extracellular matrix-targeted therapies, and regenerative biologics.

__________________

News & References:

- Vector Y wins FDA Fast Track for ALS therapy → ⁠https://longevity.technology/news/vectory-wins-fda-fast-track-for-als-therapy/
- ⁠FDA clears safety step for Loyal’s senior dog longevity drug → ⁠https://longevity.technology/news/fda-clears-safety-step-for-loyals-senior-dog-longevity-drug/
- ⁠Cumulus proves brain plasticity can be measured at scale → ⁠https://longevity.technology/news/cumulus-proves-brain-plasticity-can-be-measured-at-scale/⁠
- Nvidia and Eli Lilly bet $1 billion on AI-powered drug discovery → ⁠https://longevity.technology/news/nvidia-and-eli-lilly-bet-1-billion-on-ai-powered-drug-discovery/⁠
- 50M boost secured for BioBeat’s wearable blood pressure tech → ⁠https://longevity.technology/news/50m-boost-secured-for-biobeats-wearable-blood-pressure-tech/⁠
- Engitix raises $25M to target tissue aging at its source → ⁠https://longevity.technology/news/engitix-raises-25m-to-target-tissue-aging-at-its-source/⁠
- Corsera lands $80M to predict and prevent cardiovascular disease → ⁠https://longevity.technology/news/corsera-lands-80m-to-predict-and-prevent-cardiovascular-disease/⁠
- Proxima lands $80M to make protein interactions programmable → ⁠https://longevity.technology/news/proxima-lands-80m-to-make-protein-interactions-programmable/⁠

__________________
Hosts:
Phil Newman: ⁠https://qrco.de/bgXpNY⁠
Nina Patrick: ⁠https://qrco.de/bgXpKn⁠]]>1948falsefullhttps://www.spreaker.com/episode/the-longevity-secret-of-formula-e-champion--74818089Website: https://digrassi.com/
Instagram: https://www.instagram.com/lucasdigrassi/

Sponsor: The Longevity Show
Website: https://longevityshow.com/
The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.

__________________

What can professional racing teach us about health, longevity, and peak human performance?

Phil Newman and Dr. Nina Patrick sit down with Formula E and endurance racing champion Lucas di Grassi to explore how elite athletes optimize metabolism, nutrition, hydration, and supplementation to maintain health under extreme stress. Lucas shares his personal strategies, from microbiome-focused supplements and metabolic flexibility to controlling stress and tracking biological age.

Beyond personal optimization, Lucas discusses emerging technologies that could revolutionize human healthspan, including AI-driven digital twins, protein design with AlphaFold 2, and continuous biometric monitoring. He also shares his insights on how lessons from motorsport telemetry, environmental awareness, and data-driven decision-making can translate to everyday life and longevity.

This conversation combines the science of performance with practical insights for anyone seeking to improve healthspan, optimize lifestyle, and leverage technology to extend both lifespan and quality of life. Subscribe for weekly episodes on longevity science, health optimization, and the innovations shaping our future.

Key Topics:

- Lessons from professional racing for metabolism, nutrition, and hydration
- Stress management and biological age tracking
- AI-driven digital twins and protein design with AlphaFold 2
- Continuous biometric monitoring and data-driven health insights
- Translating elite performance strategies to everyday longevity

If you care about living longer and healthier while optimizing your performance and lifestyle, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that dig into longevity science, healthspan optimization, and the technologies shaping our future health.

__________
Connect with our hosts:
Phil Newman: https://qrco.de/bgXpNY
Dr. Nina Patrick: https://qrco.de/bgXpKn]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379977Mon, 12 Jan 2026 12:34:16 +0000saderGuest: Lucas di Grassi Website: https://digrassi.com/ Instagram: https://www.instagram.com/lucasdigrassi/ Sponsor: The Longevity Show Website: https://longevityshow.com/ The Longevity Show is a science and wellness festival in London focused on...Website: https://digrassi.com/
Instagram: https://www.instagram.com/lucasdigrassi/

Sponsor: The Longevity Show
Website: https://longevityshow.com/
The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.

__________________

What can professional racing teach us about health, longevity, and peak human performance?

Phil Newman and Dr. Nina Patrick sit down with Formula E and endurance racing champion Lucas di Grassi to explore how elite athletes optimize metabolism, nutrition, hydration, and supplementation to maintain health under extreme stress. Lucas shares his personal strategies, from microbiome-focused supplements and metabolic flexibility to controlling stress and tracking biological age.

Beyond personal optimization, Lucas discusses emerging technologies that could revolutionize human healthspan, including AI-driven digital twins, protein design with AlphaFold 2, and continuous biometric monitoring. He also shares his insights on how lessons from motorsport telemetry, environmental awareness, and data-driven decision-making can translate to everyday life and longevity.

This conversation combines the science of performance with practical insights for anyone seeking to improve healthspan, optimize lifestyle, and leverage technology to extend both lifespan and quality of life. Subscribe for weekly episodes on longevity science, health optimization, and the innovations shaping our future.

Key Topics:

- Lessons from professional racing for metabolism, nutrition, and hydration
- Stress management and biological age tracking
- AI-driven digital twins and protein design with AlphaFold 2
- Continuous biometric monitoring and data-driven health insights
- Translating elite performance strategies to everyday longevity

If you care about living longer and healthier while optimizing your performance and lifestyle, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that dig into longevity science, healthspan optimization, and the technologies shaping our future health.

__________
Connect with our hosts:
Phil Newman: https://qrco.de/bgXpNY
Dr. Nina Patrick: https://qrco.de/bgXpKn]]>3995falsefullhttps://www.spreaker.com/episode/ai-drugs-autophagy-blue-zones-return-longevity-news-roundup-week-2-2026--74818081
- A new study in the International Journal of Epidemiology confirms that Blue Zone populations still enjoy statistically significant longevity advantages, highlighting the role of community, movement, and diet in healthy aging.

- Insilico Medicine made headlines with its Hong Kong IPO, raising $293M and signaling strong investor confidence in AI-driven longevity biotech. The company also secured an $888M oncology collaboration with Servier, marking a major step for AI-powered drug discovery.

- At CES, Withings unveiled its at-home Longevity Station, a device that measures 60 biomarkers in just 90 seconds. It tracks cardiovascular function, vascular health, cellular composition, and early cardiometabolic risk, bringing advanced health monitoring into the home.

- Retro Biosciences dosed the first patient in a phase one trial of its autophagy-targeting drug, RTR242, a key milestone for clinical-stage longevity therapeutics.

- Human clinical evidence from El Nutra’s ProLon fasting-mimicking diet demonstrates measurable activation of autophagy, supporting cellular renewal, improved insulin sensitivity, and metabolic health.

----------
News & References:

• Insilico debuts on HK stock exchange, locking in more than $290M → https://longevity.technology/news/insilico-debuts-on-hk-stock-exchange-locking-in-more-than-290m/
• Insilico Medicine and Servier agree up to US$888M oncology collaboration → https://longevity.technology/news/insilico-medicine-and-servier-agree-up-to-us888-m-oncology-drug-discovery-collaboration/
• Retro Bio commences first-in-human trial for RIP242 → https://longevity.technology/news/retro-bio-commences-first-in-human-trial/
• Why long-bio is poised for a breakout at JPM 2026 → https://longevity.technology/news/why-longbio-is-poised-for-a-breakout-at-jpm-2026/
• Withings launches at-home Longevity Station at CES → https://longevity.technology/news/withings-launches-at-home-longevity-station-at-ces/
• First human trial links fasting-mimicking diet to cellular renewal → https://longevity.technology/news/first-human-trial-links-fasting-mimicking-diet-to-cellular-renewal/
• New study reaffirms Blue Zones longevity claims → https://longevity.technology/news/new-study-reaffirms-blue-zones-longevity-claims/
----------
Connect with our hosts:
Phil Newman: https://qrco.de/bgXpNY
Dr. Nina Patrick: https://qrco.de/bgXpKn]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379869Fri, 09 Jan 2026 11:54:13 +0000saderIn this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping the longevity ecosystem from validated lifestyle science and AI-driven drug discovery to breakthrough clinical trials, CES health tech, and the...
- A new study in the International Journal of Epidemiology confirms that Blue Zone populations still enjoy statistically significant longevity advantages, highlighting the role of community, movement, and diet in healthy aging.

- Insilico Medicine made headlines with its Hong Kong IPO, raising $293M and signaling strong investor confidence in AI-driven longevity biotech. The company also secured an $888M oncology collaboration with Servier, marking a major step for AI-powered drug discovery.

- At CES, Withings unveiled its at-home Longevity Station, a device that measures 60 biomarkers in just 90 seconds. It tracks cardiovascular function, vascular health, cellular composition, and early cardiometabolic risk, bringing advanced health monitoring into the home.

- Retro Biosciences dosed the first patient in a phase one trial of its autophagy-targeting drug, RTR242, a key milestone for clinical-stage longevity therapeutics.

- Human clinical evidence from El Nutra’s ProLon fasting-mimicking diet demonstrates measurable activation of autophagy, supporting cellular renewal, improved insulin sensitivity, and metabolic health.

----------
News & References:

• Insilico debuts on HK stock exchange, locking in more than $290M → https://longevity.technology/news/insilico-debuts-on-hk-stock-exchange-locking-in-more-than-290m/
• Insilico Medicine and Servier agree up to US$888M oncology collaboration → https://longevity.technology/news/insilico-medicine-and-servier-agree-up-to-us888-m-oncology-drug-discovery-collaboration/
• Retro Bio commences first-in-human trial for RIP242 → https://longevity.technology/news/retro-bio-commences-first-in-human-trial/
• Why long-bio is poised for a breakout at JPM 2026 → https://longevity.technology/news/why-longbio-is-poised-for-a-breakout-at-jpm-2026/
• Withings launches at-home Longevity Station at CES → https://longevity.technology/news/withings-launches-at-home-longevity-station-at-ces/
• First human trial links fasting-mimicking diet to cellular renewal → https://longevity.technology/news/first-human-trial-links-fasting-mimicking-diet-to-cellular-renewal/
• New study reaffirms Blue Zones longevity claims → https://longevity.technology/news/new-study-reaffirms-blue-zones-longevity-claims/
----------
Connect with our hosts:
Phil Newman: https://qrco.de/bgXpNY
Dr. Nina Patrick: https://qrco.de/bgXpKn]]>1895falsefullhttps://www.spreaker.com/episode/glp-1s-should-we-all-be-taking-them--74818094
In the first episode Longevity.Technology UNLOCKED, hosts Phil Newman and Dr. Nina Patrick sit down with two of the world’s leading authorities to unpack one of the most important health debates of our time: Should we all be taking GLP-1 agonists?

Joining the conversation are Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging, and Professor Jens Juul Holst, the scientist who first discovered the GLP-1 hormone. Together, they explore the science, hype, risks, and real-world implications of drugs like Ozempic, Wegovy, and tirzepatide going far beyond weight loss headlines.

From insulin resistance and inflammation to cardiovascular protection, brain health, and the future of preventive medicine, this wide-ranging discussion examines whether GLP-1s could redefine how we think about aging itself. The episode also tackles difficult questions around microdosing, off-label use, muscle loss, access, regulation, and the ethics of medicating lifestyle versus disease.

Key Topics:
- What GLP-1 agonists actually do in the body
- Obesity, metabolic syndrome, and lifespan
- Weight-independent longevity effects
- Inflammation, cardiovascular and renal protection
- Brain health and Alzheimer’s disease
- Microdosing, personalization, and patient-led experimentation
- Risks, side effects, and media exaggeration
- Are GLP-1s the first true preventive longevity drugs?

If you care about living longer and healthier and understanding the trade-offs along the way, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that dig into longevity science, healthspan optimization, and the technologies shaping our future health.

----------

Connect with our hosts:
Phil Newman: https://qrco.de/bgXpNY
Dr. Nina Patrick: https://qrco.de/bgXpKn]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561380028Mon, 05 Jan 2026 17:33:33 +0000saderGLP-1 drugs have exploded into the mainstream, but are they truly longevity medicines, or simply powerful tools for treating obesity and metabolic disease? In the first episode Longevity.Technology UNLOCKED, hosts Phil Newman and Dr. Nina Patrick sit...
In the first episode Longevity.Technology UNLOCKED, hosts Phil Newman and Dr. Nina Patrick sit down with two of the world’s leading authorities to unpack one of the most important health debates of our time: Should we all be taking GLP-1 agonists?

Joining the conversation are Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging, and Professor Jens Juul Holst, the scientist who first discovered the GLP-1 hormone. Together, they explore the science, hype, risks, and real-world implications of drugs like Ozempic, Wegovy, and tirzepatide going far beyond weight loss headlines.

From insulin resistance and inflammation to cardiovascular protection, brain health, and the future of preventive medicine, this wide-ranging discussion examines whether GLP-1s could redefine how we think about aging itself. The episode also tackles difficult questions around microdosing, off-label use, muscle loss, access, regulation, and the ethics of medicating lifestyle versus disease.

Key Topics:
- What GLP-1 agonists actually do in the body
- Obesity, metabolic syndrome, and lifespan
- Weight-independent longevity effects
- Inflammation, cardiovascular and renal protection
- Brain health and Alzheimer’s disease
- Microdosing, personalization, and patient-led experimentation
- Risks, side effects, and media exaggeration
- Are GLP-1s the first true preventive longevity drugs?

If you care about living longer and healthier and understanding the trade-offs along the way, this is a conversation you don’t want to miss.

Subscribe for weekly episodes that dig into longevity science, healthspan optimization, and the technologies shaping our future health.

----------

Connect with our hosts:
Phil Newman: https://qrco.de/bgXpNY
Dr. Nina Patrick: https://qrco.de/bgXpKn]]>3828falsefullhttps://www.spreaker.com/episode/hearing-loss-brain-health-and-the-hidden-longevity-risk-brent-lucas-and-caroline-arnedt--74818088
Phil Newman is joined by Dr. Caroline Arnedt of Envoy Medical and Brent Lucas, CEO of Envoy Medical, to unpack the science behind a major longitudinal study linking untreated hearing loss with increased cognitive load, brain atrophy, and social isolation. Together, they discuss why hearing loss changes the brain, how stigma delays treatment, and why hearing should be part of any serious longevity strategy.

The conversation also dives into the future of hearing technology, from discreet fully implanted devices to evolving treatment pathways, and why addressing hearing earlier rather than later may help protect cognition, independence, and connection as we age.

------------------------------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y
Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561380041Fri, 19 Dec 2025 12:29:23 +0000saderHearing loss is often dismissed as an inevitable part of aging, but emerging research suggests it may be one of the most overlooked and modifiable risk factors for cognitive decline and dementia. In this episode of Longevity.Technology Unlocked, we...
Phil Newman is joined by Dr. Caroline Arnedt of Envoy Medical and Brent Lucas, CEO of Envoy Medical, to unpack the science behind a major longitudinal study linking untreated hearing loss with increased cognitive load, brain atrophy, and social isolation. Together, they discuss why hearing loss changes the brain, how stigma delays treatment, and why hearing should be part of any serious longevity strategy.

The conversation also dives into the future of hearing technology, from discreet fully implanted devices to evolving treatment pathways, and why addressing hearing earlier rather than later may help protect cognition, independence, and connection as we age.

------------------------------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y
Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1004falsefullhttps://www.spreaker.com/episode/we-need-to-intervene-in-the-young-population-now--74818087
The publication of Hevolution’s second Global Healthspan Report earlier this month added fresh momentum to a field that has long argued for better data, clearer policy signals and more sustained investment. The report’s analysis – spanning trial activity, demographic risk, capital flows and shifting public attitudes – sets out a landscape in which healthspan is no longer a niche concern but an economic and societal imperative. It is also a landscape in which Hevolution has become, by sheer scale, one of the most influential actors.

Founded only five years ago and already the largest non-governmental funder of aging biology, Hevolution now sits at a strategic crossroads. With more than 250 research grants, multiple translational partnerships and four early biotech investments already in the clinic, the organization is preparing its “2.0” phase: a shift from open-call grantmaking to more directed, mission-led programmes. In the wake of the Global Healthspan Report, Longevity.Technology spoke to CEO Dr Mehmood Khan about funding gaps, global scientific geography and how public appetite for prevention may shape the next decade.

The Global Healthspan Report, which was authored by our team, arrives at a time when governments are grappling with aging populations, strained healthcare budgets and rising consumer expectations; evidence-led analysis that connects prevention with economic reality is therefore timely. Reports of this breadth matter because they translate a sprawling, sometimes fragmented field into something that policymakers, investors and public health leaders can actually use; they also remind us that healthspan is a systems challenge – scientific, demographic and financial – rather than a single-pill solution. If the longevity sector is to mature, it will require precisely this kind of synthesis: sober, data-rich and unafraid to highlight both opportunity and shortfall.

Read The Global Healthspan Report – https://bit.ly/493XfaD
---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379890Wed, 10 Dec 2025 16:51:00 +0000saderHevolution CEO Mehmood Khan on mapping the next five years of healthspan science and shifting from passive funding to strategic direction. The publication of Hevolution’s second Global Healthspan Report earlier this month added fresh momentum to a...
The publication of Hevolution’s second Global Healthspan Report earlier this month added fresh momentum to a field that has long argued for better data, clearer policy signals and more sustained investment. The report’s analysis – spanning trial activity, demographic risk, capital flows and shifting public attitudes – sets out a landscape in which healthspan is no longer a niche concern but an economic and societal imperative. It is also a landscape in which Hevolution has become, by sheer scale, one of the most influential actors.

Founded only five years ago and already the largest non-governmental funder of aging biology, Hevolution now sits at a strategic crossroads. With more than 250 research grants, multiple translational partnerships and four early biotech investments already in the clinic, the organization is preparing its “2.0” phase: a shift from open-call grantmaking to more directed, mission-led programmes. In the wake of the Global Healthspan Report, Longevity.Technology spoke to CEO Dr Mehmood Khan about funding gaps, global scientific geography and how public appetite for prevention may shape the next decade.

The Global Healthspan Report, which was authored by our team, arrives at a time when governments are grappling with aging populations, strained healthcare budgets and rising consumer expectations; evidence-led analysis that connects prevention with economic reality is therefore timely. Reports of this breadth matter because they translate a sprawling, sometimes fragmented field into something that policymakers, investors and public health leaders can actually use; they also remind us that healthspan is a systems challenge – scientific, demographic and financial – rather than a single-pill solution. If the longevity sector is to mature, it will require precisely this kind of synthesis: sober, data-rich and unafraid to highlight both opportunity and shortfall.

Read The Global Healthspan Report – https://bit.ly/493XfaD
---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>1951falsefullhttps://www.spreaker.com/episode/age-is-not-your-cage--74818204
The Global Longevity Summit 2025 in Geneva is fast approaching – three days of science, strategy and spirited debate beneath the banner Mastering the Ageing Clock: Transform Your Practice and Patient Care. Gathering some of the most respected voices in geroscience, preventive health and longevity innovation, it promises to connect the lab bench to the bedside – and, in some cases, to the hiking trail.

Among the experts taking to the stage is Dr Melissa Sundermann, double board-certified in Internal and Lifestyle Medicine and known to many as Doctor Outdoors. She’s the founding chair of the Nature as Medicine Committee at the American College of Lifestyle Medicine, where she champions evidence-based engagement with the natural world. Her message is both simple and subversive: sustainable health begins with sustainable habits – nutrition, movement, sleep and a daily dose of fresh air – because, as she reminds her patients, “age is not your cage”.

It’s refreshing, in a field sometimes dazzled by peptides, exosomes and algorithmic biomarkers, to hear a physician place such confident emphasis on the basics – not as nostalgic simplicity, but as biological bedrock. Sundermann’s prescription of food, fasting and forests may sound almost quaint beside plasma exchange and gene reprogramming, yet the data – and her patients – suggest otherwise. Her practice, grounded in lifestyle medicine and animated by her osteopathic training – that whole-person connection between body, mind and environment – bridges the clinical and the elemental. In her view, our future selves may be shaped not only by what’s in our bloodstream, but by the view from our window – preferably one that contains a tree.

Dr Melissa Sundermann will speak on Nutrition, Fasting & Metabolism at the Global Longevity Summit 2025 in Geneva (28–30 October). Her session will explore how nutrition and fasting protocols influence metabolic pathways linked to aging – and how clinicians can apply dietary interventions to promote metabolic flexibility and extend healthspan.

Find out more: https://www.a4m.com/global-longevity-summit-2025.html
---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379940Tue, 21 Oct 2025 16:30:15 +0000saderCorewell Health's Melissa Sundermann on nutrition, fasting and finding lasting longevity in the great outdoors. The Global Longevity Summit 2025 in Geneva is fast approaching – three days of science, strategy and spirited debate beneath the banner...
The Global Longevity Summit 2025 in Geneva is fast approaching – three days of science, strategy and spirited debate beneath the banner Mastering the Ageing Clock: Transform Your Practice and Patient Care. Gathering some of the most respected voices in geroscience, preventive health and longevity innovation, it promises to connect the lab bench to the bedside – and, in some cases, to the hiking trail.

Among the experts taking to the stage is Dr Melissa Sundermann, double board-certified in Internal and Lifestyle Medicine and known to many as Doctor Outdoors. She’s the founding chair of the Nature as Medicine Committee at the American College of Lifestyle Medicine, where she champions evidence-based engagement with the natural world. Her message is both simple and subversive: sustainable health begins with sustainable habits – nutrition, movement, sleep and a daily dose of fresh air – because, as she reminds her patients, “age is not your cage”.

It’s refreshing, in a field sometimes dazzled by peptides, exosomes and algorithmic biomarkers, to hear a physician place such confident emphasis on the basics – not as nostalgic simplicity, but as biological bedrock. Sundermann’s prescription of food, fasting and forests may sound almost quaint beside plasma exchange and gene reprogramming, yet the data – and her patients – suggest otherwise. Her practice, grounded in lifestyle medicine and animated by her osteopathic training – that whole-person connection between body, mind and environment – bridges the clinical and the elemental. In her view, our future selves may be shaped not only by what’s in our bloodstream, but by the view from our window – preferably one that contains a tree.

Dr Melissa Sundermann will speak on Nutrition, Fasting & Metabolism at the Global Longevity Summit 2025 in Geneva (28–30 October). Her session will explore how nutrition and fasting protocols influence metabolic pathways linked to aging – and how clinicians can apply dietary interventions to promote metabolic flexibility and extend healthspan.

Find out more: https://www.a4m.com/global-longevity-summit-2025.html
---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>1139falsefullhttps://www.spreaker.com/episode/we-can-map-brain-health-before-decline-begins--74818093
As our bodies age, so do our brains – but the pace and pattern are far from predetermined. At this year’s Global Longevity Summit (28–30 October 2025, Geneva), leading experts will gather under the banner Mastering the Aging Clock: The Science of Longevity to explore how breakthroughs in biology, technology and policy are reshaping healthspan.

Among them is Dr Evelyne Bischof, an internationally recognized longevity physician, Harvard- and Columbia-trained with clinical experience spanning Switzerland, the US and China. Known for her pioneering work in personalized longevity medicine and advanced AI monitoring, Bischof will take to the stage on Wednesday to ask how we can anticipate, personalize and optimize brain health – and whether it is possible to intervene before cognitive decline begins.

For Dr Evelyne Bischof, anticipation is everything; if cognitive health can be charted before decline begins, interventions can be both timelier and more tailored. New biomarkers, advanced imaging and functional assessments are giving clinicians the means to detect subtle shifts long before impairment is visible – an approach that could reframe how we think about brain aging and neurodegeneration.

Yet diagnostics are only the first step; Bischof is equally concerned with interventions, from lifestyle and behavioral strategies through to pharmacological innovations and AI-driven therapies now moving through trials. Crucially, she places brain health not in isolation but within the broader landscape of biological aging – integrating omics, functional testing and mental health to create evidence-based, personalized trajectories. This is longevity medicine with a cognitive focus; it is about preventing decline rather than managing it, extending not simply life but the quality of thought, memory and resilience that underpin it. Ahead of the Summit, we sat down with Bischof to explore why mapping brain health matters, how new tools are reshaping prevention, and what it means for the future of cognitive longevity.

The Global Longevity Summit runs 28–30 October 2025 in Geneva, Switzerland.
Find out more: https://www.a4m.com/global-longevity-summit-2025.html

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379852Fri, 03 Oct 2025 16:10:55 +0000saderEvelyne Bischof on cognition, biomarkers and the evolving science of keeping our brains younger for longer. As our bodies age, so do our brains – but the pace and pattern are far from predetermined. At this year’s Global Longevity Summit (28–30...
As our bodies age, so do our brains – but the pace and pattern are far from predetermined. At this year’s Global Longevity Summit (28–30 October 2025, Geneva), leading experts will gather under the banner Mastering the Aging Clock: The Science of Longevity to explore how breakthroughs in biology, technology and policy are reshaping healthspan.

Among them is Dr Evelyne Bischof, an internationally recognized longevity physician, Harvard- and Columbia-trained with clinical experience spanning Switzerland, the US and China. Known for her pioneering work in personalized longevity medicine and advanced AI monitoring, Bischof will take to the stage on Wednesday to ask how we can anticipate, personalize and optimize brain health – and whether it is possible to intervene before cognitive decline begins.

For Dr Evelyne Bischof, anticipation is everything; if cognitive health can be charted before decline begins, interventions can be both timelier and more tailored. New biomarkers, advanced imaging and functional assessments are giving clinicians the means to detect subtle shifts long before impairment is visible – an approach that could reframe how we think about brain aging and neurodegeneration.

Yet diagnostics are only the first step; Bischof is equally concerned with interventions, from lifestyle and behavioral strategies through to pharmacological innovations and AI-driven therapies now moving through trials. Crucially, she places brain health not in isolation but within the broader landscape of biological aging – integrating omics, functional testing and mental health to create evidence-based, personalized trajectories. This is longevity medicine with a cognitive focus; it is about preventing decline rather than managing it, extending not simply life but the quality of thought, memory and resilience that underpin it. Ahead of the Summit, we sat down with Bischof to explore why mapping brain health matters, how new tools are reshaping prevention, and what it means for the future of cognitive longevity.

The Global Longevity Summit runs 28–30 October 2025 in Geneva, Switzerland.
Find out more: https://www.a4m.com/global-longevity-summit-2025.html

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>928falsefullhttps://www.spreaker.com/episode/there-will-never-be-a-single-test-for-aging--74818098
The Global Longevity Summit 2025, hosted by A4M, will bring together researchers, clinicians and entrepreneurs in Geneva next month to debate how emerging science can be applied in practice. Central to the agenda are questions of measurement – how we assess biological aging, how we translate these tools into clinics and how individual variation can guide more effective interventions. The meeting also reflects a wider shift in healthcare, as policy makers and practitioners begin to confront the societal and economic challenges of an aging population.

Among the speakers is Gordan Lauc, co-founder of GlycanAge and Professor of Biochemistry and Molecular Biology at the University of Zagreb. His pioneering work in glycobiology has helped to show how glycan signatures can reveal biological age and illuminate the hidden variation between individuals – a perspective that challenges medicine’s reliance on averages and emphasizes the need for personalized approaches.

At the Summit he will deliver a presentation, Mastering the Aging Clock – The Science of Longevity, charting the development of epigenetic clocks from early iterations to contemporary AI-driven models. The session will highlight their utility in tracking biological aging, assessing disease risk and evaluating the impact of interventions aimed at rejuvenation. This will be followed by a moderated fireside exchange before Lauc joins Jennifer Pearlman MD, Joseph Raffaele MD and Steven Horvath PhD for a panel on epigenetics and biological clocks – a discussion that will consider both scientific consensus and the practical realities of applying biological age measures in clinics and research settings.

The debate on biological clocks reveals medicine’s preference for universals colliding with biology’s refusal to conform. We may long for a single test, a single score, a single pill, but human variability will not oblige – the opportunity lies in embracing precision rather than perfection, allowing interventions to be judged by how well they suit the individual rather than the average. Longevity science, if it is to succeed, must learn to balance aspiration, evidence and individuality. In this spirit, Gordan Lauc argues against the search for a single definitive measure of aging, urging instead that tools such as glycan profiles and epigenetic clocks be developed to diagnostic standards so they can guide physicians in practice. His emphasis on diversity is less a counsel of despair than a reminder that personalization is not optional – it is the only realistic route forward.

The Global Longevity Summit runs 28–30 October 2025 in Geneva, Switzerland.
Find out more: https://www.a4m.com/global-longevity-summit-2025.html

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379916Fri, 26 Sep 2025 16:56:45 +0000saderGlycanAge’s Gordan Lauc on individuality, biology’s hidden signatures, and why epigenetic clocks may redefine how we measure aging. The Global Longevity Summit 2025, hosted by A4M, will bring together researchers, clinicians and entrepreneurs in...
The Global Longevity Summit 2025, hosted by A4M, will bring together researchers, clinicians and entrepreneurs in Geneva next month to debate how emerging science can be applied in practice. Central to the agenda are questions of measurement – how we assess biological aging, how we translate these tools into clinics and how individual variation can guide more effective interventions. The meeting also reflects a wider shift in healthcare, as policy makers and practitioners begin to confront the societal and economic challenges of an aging population.

Among the speakers is Gordan Lauc, co-founder of GlycanAge and Professor of Biochemistry and Molecular Biology at the University of Zagreb. His pioneering work in glycobiology has helped to show how glycan signatures can reveal biological age and illuminate the hidden variation between individuals – a perspective that challenges medicine’s reliance on averages and emphasizes the need for personalized approaches.

At the Summit he will deliver a presentation, Mastering the Aging Clock – The Science of Longevity, charting the development of epigenetic clocks from early iterations to contemporary AI-driven models. The session will highlight their utility in tracking biological aging, assessing disease risk and evaluating the impact of interventions aimed at rejuvenation. This will be followed by a moderated fireside exchange before Lauc joins Jennifer Pearlman MD, Joseph Raffaele MD and Steven Horvath PhD for a panel on epigenetics and biological clocks – a discussion that will consider both scientific consensus and the practical realities of applying biological age measures in clinics and research settings.

The debate on biological clocks reveals medicine’s preference for universals colliding with biology’s refusal to conform. We may long for a single test, a single score, a single pill, but human variability will not oblige – the opportunity lies in embracing precision rather than perfection, allowing interventions to be judged by how well they suit the individual rather than the average. Longevity science, if it is to succeed, must learn to balance aspiration, evidence and individuality. In this spirit, Gordan Lauc argues against the search for a single definitive measure of aging, urging instead that tools such as glycan profiles and epigenetic clocks be developed to diagnostic standards so they can guide physicians in practice. His emphasis on diversity is less a counsel of despair than a reminder that personalization is not optional – it is the only realistic route forward.

The Global Longevity Summit runs 28–30 October 2025 in Geneva, Switzerland.
Find out more: https://www.a4m.com/global-longevity-summit-2025.html

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>1086falsefullhttps://www.spreaker.com/episode/it-s-time-to-bring-innovations-from-bench-to-bedside--74818126
The Global Longevity Summit, entitled Mastering the Aging Clock: The Science of Longevity, will convene in Geneva this October, bringing together international leaders in science, medicine and innovation under the banner Transform Your Practice and Patient Care. With education and clinical adoption at its core, the event reflects a broader shift towards embedding longevity science into mainstream healthcare practice.

Professor Dominik Thor, President of the Geneva College of Longevity Science (GCLS), will be among the keynote speakers. His focus: how cutting-edge innovation can be responsibly moved from research labs into clinical settings – and how to equip practitioners across disciplines with the knowledge and tools needed to manage the evolving science of aging.

Innovation is an alluring concept – but longevity has learned the hard way that not all shiny new interventions stand the test of time, let alone the scrutiny of clinical validation. Thor’s approach is refreshingly pragmatic; sift through the hype, cut through the noise and focus on evidence that physicians can actually use. It’s not that he dismisses experimental science – far from it – but he recognizes the risks of premature adoption in a field where hope can easily outpace proof.

Equally striking is his insistence that education cannot be the preserve of physicians alone. Longevity is seeping into beauty, wellness and hospitality; physiotherapists, nutritionists and even hotel executives are now part of the conversation. To keep the field from fragmenting into jargon and quick fixes, Thor is expanding GCLS’s reach: executive masters, continuing medical education, even a forthcoming PhD track. The curriculum, he admits, requires constant updating – a weekly battle between novelty and robustness – but the wider goal is clear: create a lingua franca for longevity before misinformation claims the territory.

The Global Longevity Summit runs 28–30 October 2025 in Geneva, Switzerland.
Find out more: https://www.a4m.com/global-longevity-summit-2025.html

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379974Thu, 18 Sep 2025 15:47:16 +0000saderGeneva College of Longevity Science President Dominik Thor on education, evidence and the adoption of longevity technologies. The Global Longevity Summit, entitled Mastering the Aging Clock: The Science of Longevity, will convene in Geneva this...
The Global Longevity Summit, entitled Mastering the Aging Clock: The Science of Longevity, will convene in Geneva this October, bringing together international leaders in science, medicine and innovation under the banner Transform Your Practice and Patient Care. With education and clinical adoption at its core, the event reflects a broader shift towards embedding longevity science into mainstream healthcare practice.

Professor Dominik Thor, President of the Geneva College of Longevity Science (GCLS), will be among the keynote speakers. His focus: how cutting-edge innovation can be responsibly moved from research labs into clinical settings – and how to equip practitioners across disciplines with the knowledge and tools needed to manage the evolving science of aging.

Innovation is an alluring concept – but longevity has learned the hard way that not all shiny new interventions stand the test of time, let alone the scrutiny of clinical validation. Thor’s approach is refreshingly pragmatic; sift through the hype, cut through the noise and focus on evidence that physicians can actually use. It’s not that he dismisses experimental science – far from it – but he recognizes the risks of premature adoption in a field where hope can easily outpace proof.

Equally striking is his insistence that education cannot be the preserve of physicians alone. Longevity is seeping into beauty, wellness and hospitality; physiotherapists, nutritionists and even hotel executives are now part of the conversation. To keep the field from fragmenting into jargon and quick fixes, Thor is expanding GCLS’s reach: executive masters, continuing medical education, even a forthcoming PhD track. The curriculum, he admits, requires constant updating – a weekly battle between novelty and robustness – but the wider goal is clear: create a lingua franca for longevity before misinformation claims the territory.

The Global Longevity Summit runs 28–30 October 2025 in Geneva, Switzerland.
Find out more: https://www.a4m.com/global-longevity-summit-2025.html

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>914falsefullhttps://www.spreaker.com/episode/to-treat-aging-you-need-a-way-of-measuring-aging--74818095
As the Global Longevity Summit in Geneva draws closer (28–30 October 2025), excitement is building around its line-up of heavyweight speakers. With a theme of Mastering the Aging Clock: The Science of Longevity, the Summit will bring together leading researchers and clinicians to explore how translational science is reshaping patient care. A particular highlight will be the panel on epigenetics and biological clocks, featuring Dr Joseph Raffaele, longevity clinician and CEO of PhysioAge Health Analytics, Dr Steve Horvath, pioneer of epigenetic clocks, glycobiology leader Professor Gordan Lauc, and Dr Jennifer Pearlman, physician and founder of PearlMD Rejuvenation – a session set to unpack both the promise and the pitfalls of applying aging clocks in practice.

Dr Raffaele brings deep clinical experience to that stage. Having practiced longevity medicine for 25 years, he has published studies in telomere biology, epigenetics, hormone therapy and glycobiology. As co-founder, CEO and CMO of longevity medicine platform PhysioAge Health Analytics, he has developed tools that enable physicians worldwide to implement n-of-1 precision longevity medicine, tracking multiple biomarkers across organ systems. His insights, grounded in thousands of patient datasets, make him a compelling voice on how to interpret – and integrate – the many different measures of biological age.

Measuring and mapping the aging process is not a luxury – it’s the foundation for effective interventions. As Dr Raffaele emphasizes, you cannot treat aging without first finding reliable ways to track it. From epigenetic clocks and telomere dynamics to multi-omics panels and functional biomarkers, the field is moving beyond single metrics toward richer mosaics of patient biology. Embedding these tools into clinical practice, as the Summit will showcase, is critical for advancing safe, effective, and personalized longevity medicine. We sat down with Dr Raffaele to explore why multi-omics, telomere biology, and an n-of-1 approach are central to making longevity medicine both rigorous and real-world.

The Global Longevity Summit runs 28–30 October 2025 in Geneva, Switzerland.
Find out more: https://informaconnect.com/global-longevity-summit/

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379846Tue, 09 Sep 2025 15:32:25 +0000saderPhysioAge Health Analytics CEO on using biomarkers and multi-omics to reveal each patient’s unique aging journey. As the Global Longevity Summit in Geneva draws closer (28–30 October 2025), excitement is building around its line-up of heavyweight...
As the Global Longevity Summit in Geneva draws closer (28–30 October 2025), excitement is building around its line-up of heavyweight speakers. With a theme of Mastering the Aging Clock: The Science of Longevity, the Summit will bring together leading researchers and clinicians to explore how translational science is reshaping patient care. A particular highlight will be the panel on epigenetics and biological clocks, featuring Dr Joseph Raffaele, longevity clinician and CEO of PhysioAge Health Analytics, Dr Steve Horvath, pioneer of epigenetic clocks, glycobiology leader Professor Gordan Lauc, and Dr Jennifer Pearlman, physician and founder of PearlMD Rejuvenation – a session set to unpack both the promise and the pitfalls of applying aging clocks in practice.

Dr Raffaele brings deep clinical experience to that stage. Having practiced longevity medicine for 25 years, he has published studies in telomere biology, epigenetics, hormone therapy and glycobiology. As co-founder, CEO and CMO of longevity medicine platform PhysioAge Health Analytics, he has developed tools that enable physicians worldwide to implement n-of-1 precision longevity medicine, tracking multiple biomarkers across organ systems. His insights, grounded in thousands of patient datasets, make him a compelling voice on how to interpret – and integrate – the many different measures of biological age.

Measuring and mapping the aging process is not a luxury – it’s the foundation for effective interventions. As Dr Raffaele emphasizes, you cannot treat aging without first finding reliable ways to track it. From epigenetic clocks and telomere dynamics to multi-omics panels and functional biomarkers, the field is moving beyond single metrics toward richer mosaics of patient biology. Embedding these tools into clinical practice, as the Summit will showcase, is critical for advancing safe, effective, and personalized longevity medicine. We sat down with Dr Raffaele to explore why multi-omics, telomere biology, and an n-of-1 approach are central to making longevity medicine both rigorous and real-world.

The Global Longevity Summit runs 28–30 October 2025 in Geneva, Switzerland.
Find out more: https://informaconnect.com/global-longevity-summit/

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>1169falsefullhttps://www.spreaker.com/episode/biomarkers-of-aging-are-moving-closer-and-closer-to-the-clinic--74818103
The Biomarkers of Aging Conference 2025 takes place between the 20th and 21st of October at Harvard Medical School in Boston. Hosted by the Biomarkers of Aging Consortium, the two-day meeting will bring together world-leading academics, clinicians and industry experts to advance the development and validation of aging biomarkers – the tools that will allow longevity science to move closer to the clinic and to translational application.

Now in its third year, the Conference has expanded from a one-day kickoff event into a major international fixture; the 2025 edition builds on that growth, reflecting both the momentum in biomarker science and the urgency of establishing standards that can be applied in trials, in practice and eventually in regulatory pathways.

This year’s program will feature a keynote from Professor Andrea Maier, president of the Healthy Longevity Medicine Society, as well as sessions on immune aging developed in collaboration with XPRIZE. Attendees can also expect updates from the Consortium’s challenge series, a dedicated focus on biomarkers of brain aging, and more than 100 posters and flash talks showcasing early-career investigators – an agenda that reflects both scientific depth and the field’s growing diversity.

The Biomarkers of Aging Conference is more than just another entry in the crowded scientific calendar; it represents a serious attempt to draw together disparate efforts in academia, biotech and clinical practice and to forge consensus on what constitutes a valid measure of biological age. The validation of biomarkers is no mere academic exercise – it is central to regulatory approval, investment confidence and the clinical adoption of therapies. And this year’s emphasis on clinical integration is significant: biomarkers will not remain research curiosities for long, they must be explained to patients, deployed by doctors and trusted in practice. Bringing open science, global collaboration and the healthy longevity community under one roof in Boston reflects both ambition and necessity, and to find out more, we sat down with Executive Committee members Drs Jesse Poganik and Andrea Cipriano.

The Biomarkers of Aging Conference runs 20th & 21st October The Joseph B Martin Conference Center, Harvard Medical School, Boston, Massachusetts.
Find out more: https://www.agingconsortium.org/conference-home

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379918Fri, 05 Sep 2025 16:36:47 +0000saderBiomarkers of Aging Conference 2025 convenes leading researchers, clinicians and industry in Boston to advance consensus on measuring aging. The Biomarkers of Aging Conference 2025 takes place between the 20th and 21st of October at Harvard Medical...
The Biomarkers of Aging Conference 2025 takes place between the 20th and 21st of October at Harvard Medical School in Boston. Hosted by the Biomarkers of Aging Consortium, the two-day meeting will bring together world-leading academics, clinicians and industry experts to advance the development and validation of aging biomarkers – the tools that will allow longevity science to move closer to the clinic and to translational application.

Now in its third year, the Conference has expanded from a one-day kickoff event into a major international fixture; the 2025 edition builds on that growth, reflecting both the momentum in biomarker science and the urgency of establishing standards that can be applied in trials, in practice and eventually in regulatory pathways.

This year’s program will feature a keynote from Professor Andrea Maier, president of the Healthy Longevity Medicine Society, as well as sessions on immune aging developed in collaboration with XPRIZE. Attendees can also expect updates from the Consortium’s challenge series, a dedicated focus on biomarkers of brain aging, and more than 100 posters and flash talks showcasing early-career investigators – an agenda that reflects both scientific depth and the field’s growing diversity.

The Biomarkers of Aging Conference is more than just another entry in the crowded scientific calendar; it represents a serious attempt to draw together disparate efforts in academia, biotech and clinical practice and to forge consensus on what constitutes a valid measure of biological age. The validation of biomarkers is no mere academic exercise – it is central to regulatory approval, investment confidence and the clinical adoption of therapies. And this year’s emphasis on clinical integration is significant: biomarkers will not remain research curiosities for long, they must be explained to patients, deployed by doctors and trusted in practice. Bringing open science, global collaboration and the healthy longevity community under one roof in Boston reflects both ambition and necessity, and to find out more, we sat down with Executive Committee members Drs Jesse Poganik and Andrea Cipriano.

The Biomarkers of Aging Conference runs 20th & 21st October The Joseph B Martin Conference Center, Harvard Medical School, Boston, Massachusetts.
Find out more: https://www.agingconsortium.org/conference-home

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>1355falsefullhttps://www.spreaker.com/episode/reframe-mental-health-mindset-and-longevity-dr-caroline-leaf--74818142
We dig into the difference between the brain and the mind, how to interrupt toxic thought patterns, and why labeling mental health as a disease is making things worse, not better. Dr. Leaf offers practical tools for managing overwhelm, rewiring habits, and supporting brain health, all grounded in cutting-edge science and timeless wisdom.

Explore the science of the mind-body connection and discover how to turn chaos into clarity, one moment at a time.

📌 Connect with Dr. Caroline Leaf:
https://www.instagram.com/drcarolineleaf/

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

Read more about Help in a Hurry here: https://helpinahurrybook.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379971Wed, 27 Aug 2025 11:43:58 +0000saderWhat if we can apply mind principles to our mental health? In this episode, renowned neuroscientist Dr. Caroline Leaf joins us to explore how the mind, not just the brain, is central to our well-being. With four decades of clinical research and...
We dig into the difference between the brain and the mind, how to interrupt toxic thought patterns, and why labeling mental health as a disease is making things worse, not better. Dr. Leaf offers practical tools for managing overwhelm, rewiring habits, and supporting brain health, all grounded in cutting-edge science and timeless wisdom.

Explore the science of the mind-body connection and discover how to turn chaos into clarity, one moment at a time.

📌 Connect with Dr. Caroline Leaf:
https://www.instagram.com/drcarolineleaf/

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

Read more about Help in a Hurry here: https://helpinahurrybook.com/]]>2068falsefullhttps://www.spreaker.com/episode/how-the-gut-brain-connection-is-changing-the-way-we-age-dr-steven-gundry--74818121
In this compelling conversation, Dr. Steven Gundry, founder of Gundry MD and the author of The Plant Paradox, joins Longevity.Technology to explore the gut-brain paradox. Drawing from decades of clinical experience and new insights from his upcoming book, Dr. Gundry reveals how your microbiome influences cognition, mood, and long-term brain health. We dive into the science that’s reframing the gut-brain connection and shifting how we think about aging.

We also unpack the practical side:

- What you can do to rebuild your gut ecosystem
- How long it really takes to reverse leaky gut
- Why dietary shifts, not prescriptions, could be the real secret to resilience.

Whether you’re looking to sharpen your focus, reduce brain fog, or optimize for longevity, this episode is a must-watch.

📌 Connect with Dr. Steven Gundry:
https://www.instagram.com/drstevengundry/

------------------------------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

Read more about Dr. Gundry here: https://drgundry.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561380016Wed, 20 Aug 2025 10:21:49 +0000saderWhat if your brain fog, low energy, or even depression wasn’t “all in your head”… but started in your gut? In this compelling conversation, Dr. Steven Gundry, founder of Gundry MD and the author of The Plant Paradox, joins Longevity.Technology to...
In this compelling conversation, Dr. Steven Gundry, founder of Gundry MD and the author of The Plant Paradox, joins Longevity.Technology to explore the gut-brain paradox. Drawing from decades of clinical experience and new insights from his upcoming book, Dr. Gundry reveals how your microbiome influences cognition, mood, and long-term brain health. We dive into the science that’s reframing the gut-brain connection and shifting how we think about aging.

We also unpack the practical side:

- What you can do to rebuild your gut ecosystem
- How long it really takes to reverse leaky gut
- Why dietary shifts, not prescriptions, could be the real secret to resilience.

Whether you’re looking to sharpen your focus, reduce brain fog, or optimize for longevity, this episode is a must-watch.

📌 Connect with Dr. Steven Gundry:
https://www.instagram.com/drstevengundry/

------------------------------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

Read more about Dr. Gundry here: https://drgundry.com/]]>1411falsefullhttps://www.spreaker.com/episode/functional-medicine-and-aging-dr-stephen-cabral--74818148
We unpack the biological burden of stress, toxins, and nutrient deficiencies, and how small, daily interventions can shift your trajectory. Dr Cabral also shares insights from his own healing journey, offering a practical, empowering lens on how to extend healthspan through detoxification, rebalancing, and evidence-based lifestyle change.

Whether you’re navigating chronic symptoms or just looking to optimize how you age, this conversation is packed with accessible takeaways for reclaiming your health, one root cause at a time.

📌 Connect with Dr. Stephen Cabral:

https://www.instagram.com/stephencabral/

------------------------------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

Read more about EquiLife here: https://equi.life/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379984Tue, 12 Aug 2025 19:00:31 +0000saderWhat if the biggest drivers of aging weren’t your genetics or even your habits, but something deeper, like nutritional deficiencies and hidden toxicities? In this episode, Dr Stephen Cabral, board-certified naturopathic doctor and founder of EquiLife,...
We unpack the biological burden of stress, toxins, and nutrient deficiencies, and how small, daily interventions can shift your trajectory. Dr Cabral also shares insights from his own healing journey, offering a practical, empowering lens on how to extend healthspan through detoxification, rebalancing, and evidence-based lifestyle change.

Whether you’re navigating chronic symptoms or just looking to optimize how you age, this conversation is packed with accessible takeaways for reclaiming your health, one root cause at a time.

📌 Connect with Dr. Stephen Cabral:

https://www.instagram.com/stephencabral/

------------------------------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

Read more about EquiLife here: https://equi.life/]]>1760falsefullhttps://www.spreaker.com/episode/rethinking-aging-with-stem-cells-christian-drapeau-msc--74818090
Christian walks us through the journey that led him from researching blue-green algae to reshaping how we think about aging. With over 30 years of pioneering work in stem cell science, he shares compelling evidence that links age-related disease and stem cell decline, and why lifestyle interventions, plant-based ingredients, and targeted supplementation could be the new frontier in longevity.

From fasting to medicinal plants to pulse electromagnetic fields, this conversation unpacks what’s clinically promising and what’s already possible.

If you’re curious about how your body heals, and what that means for living better for longer, this one’s essential viewing.

📌 Connect with Christian Drapeau: https://www.instagram.com/stemcellchristian/

------------------------------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y
Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

Read more about STEMREGEN: https://www.stemregen.co/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379895Thu, 07 Aug 2025 13:10:21 +0000saderWhat if the secret to regeneration has been inside us all along? In this episode, we sit down with Christian Drapeau, stem cell scientist, author, and founder and CSO of STEMREGEN, to explore the groundbreaking science behind the regenerative...
Christian walks us through the journey that led him from researching blue-green algae to reshaping how we think about aging. With over 30 years of pioneering work in stem cell science, he shares compelling evidence that links age-related disease and stem cell decline, and why lifestyle interventions, plant-based ingredients, and targeted supplementation could be the new frontier in longevity.

From fasting to medicinal plants to pulse electromagnetic fields, this conversation unpacks what’s clinically promising and what’s already possible.

If you’re curious about how your body heals, and what that means for living better for longer, this one’s essential viewing.

📌 Connect with Christian Drapeau: https://www.instagram.com/stemcellchristian/

------------------------------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y
Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

Read more about STEMREGEN: https://www.stemregen.co/]]>1842falsefullhttps://www.spreaker.com/episode/we-re-all-part-of-something-remarkable--74818101
In May this year, the Vitalist Bay Longevity Investors Summit convened a cross-disciplinary cohort of scientists, entrepreneurs, clinicians and investors on the shores of the San Francisco Bay in Berkeley – a gathering that positioned itself not only as a forum for thought leadership but as a locus of commercial and translational momentum within the longevity space. Held within the context of the newly launched Vitalist Bay initiative – an ecosystem designed to accelerate geroscience innovation through collaboration, capital and community – the event featured a number of data-rich presentations, including a presentation by Phil Newman, the founder and CEO of Longevity.Technology. The session offered a candid assessment of the industry’s current state and mapped its possible futures – from the maturing scaffolds of Longevity 2.0 to the speculative architecture of Longevity 3.0.

More about Vitalist Bay: https://www.vitalistbay.com/

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561380011Tue, 05 Aug 2025 16:08:58 +0000saderLongevity.Technology CEO Phil Newman on the longevity industry's evolution and why Longevity 3.0 might not be as far off as it sounds. In May this year, the Vitalist Bay Longevity Investors Summit convened a cross-disciplinary cohort of scientists,...
In May this year, the Vitalist Bay Longevity Investors Summit convened a cross-disciplinary cohort of scientists, entrepreneurs, clinicians and investors on the shores of the San Francisco Bay in Berkeley – a gathering that positioned itself not only as a forum for thought leadership but as a locus of commercial and translational momentum within the longevity space. Held within the context of the newly launched Vitalist Bay initiative – an ecosystem designed to accelerate geroscience innovation through collaboration, capital and community – the event featured a number of data-rich presentations, including a presentation by Phil Newman, the founder and CEO of Longevity.Technology. The session offered a candid assessment of the industry’s current state and mapped its possible futures – from the maturing scaffolds of Longevity 2.0 to the speculative architecture of Longevity 3.0.

More about Vitalist Bay: https://www.vitalistbay.com/

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>1132falsefullhttps://www.spreaker.com/episode/female-physiology-s-impact-on-longevity-dr-lara-briden--74818082
In this episode, we sit down with Lara Briden, naturopathic doctor and bestselling author of The Period Repair Manual, Hormone Repair Manual, and Metabolism Repair for Women. With decades of experience and a deep understanding of women’s health, Lara offers a fresh, science-based perspective on women’s hormones, aging, and the misunderstood transition of perimenopause.

What you’ll learn in this episode:

✔ How metabolic flexibility directly supports aging well
✔ What interventions support healthy aging in women
✔ How to work with your hormones, not against them
✔ How hormonal shifts in perimenopause and menopause impact women's ability to age healthily


📌 Connect with Dr. Lara Briden:
https://www.instagram.com/larabriden/

------------------------------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y
Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

Read more about Dr. Lara here: https://www.larabriden.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379980Wed, 30 Jul 2025 14:39:28 +0000saderHow does female physiology impact longevity, and why are we only just beginning to understand its role? In this episode, we sit down with Lara Briden, naturopathic doctor and bestselling author of The Period Repair Manual, Hormone Repair Manual, and...
In this episode, we sit down with Lara Briden, naturopathic doctor and bestselling author of The Period Repair Manual, Hormone Repair Manual, and Metabolism Repair for Women. With decades of experience and a deep understanding of women’s health, Lara offers a fresh, science-based perspective on women’s hormones, aging, and the misunderstood transition of perimenopause.

What you’ll learn in this episode:

✔ How metabolic flexibility directly supports aging well
✔ What interventions support healthy aging in women
✔ How to work with your hormones, not against them
✔ How hormonal shifts in perimenopause and menopause impact women's ability to age healthily


📌 Connect with Dr. Lara Briden:
https://www.instagram.com/larabriden/

------------------------------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y
Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

Read more about Dr. Lara here: https://www.larabriden.com/]]>1618falsefullhttps://www.spreaker.com/episode/build-health-before-hacking-it-dr-darshan-shah--74818113
In this powerful conversation, Dr. Darshan Shah, founder of Next Health and a leading voice in health optimization, reveals why most people are approaching longevity backwards. From the Wellness Wheel to metabolic health, supplements, and muscle preservation, Dr. Shah breaks down exactly what needs to be fixed before you start thinking about anti-aging protocols or biohacks.

✅ Learn why chronic disease is mostly preventable
✅ Discover the core pillars of true healthspan
✅ Understand why lifestyle needs to be prioritized before longevity tech (at first!)
✅ Get insights on CGMs, muscle mass, supplements, and more

📌 Connect with Dr. Darshan Shah:
https://drshah.com
https://next-health.com

------------------------------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

Read more about Next|Health: https://www.next-health.com/about]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561380017Wed, 16 Jul 2025 16:00:46 +0000saderWhat if you're skipping the most important step in your longevity journey? In this powerful conversation, Dr. Darshan Shah, founder of Next Health and a leading voice in health optimization, reveals why most people are approaching longevity...
In this powerful conversation, Dr. Darshan Shah, founder of Next Health and a leading voice in health optimization, reveals why most people are approaching longevity backwards. From the Wellness Wheel to metabolic health, supplements, and muscle preservation, Dr. Shah breaks down exactly what needs to be fixed before you start thinking about anti-aging protocols or biohacks.

✅ Learn why chronic disease is mostly preventable
✅ Discover the core pillars of true healthspan
✅ Understand why lifestyle needs to be prioritized before longevity tech (at first!)
✅ Get insights on CGMs, muscle mass, supplements, and more

📌 Connect with Dr. Darshan Shah:
https://drshah.com
https://next-health.com

------------------------------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

Read more about Next|Health: https://www.next-health.com/about]]>1549falsefullhttps://www.spreaker.com/episode/technology-isn-t-the-enemy-we-just-need-to-know-how-to-embrace-it--74818117
Part investigation, part personal journey, the book is a measured yet accessible tour of the technologies shaping the future of medicine; one that doesn’t so much chase immortality as question how we might better inhabit the years we already have – and those that might soon be on offer.

Lewington’s Hacking Humanity adeptly navigates the intricate terrain of emerging health technologies, distilling complex scientific advancements into narratives that resonate beyond the confines of the laboratory. By intertwining personal experimentation with expert insights, she bridges the often daunting gap between cutting-edge research and everyday understanding. In doing so, Lewington doesn't merely inform; she invites readers to engage critically with the ethical, societal and personal implications of our accelerating quest for extended healthspan.

It's a timely contribution that challenges us to consider not just the possibilities of living longer, but the responsibilities that come with it. We sat down with her to find out more about her experiences and the book that came out of them.

Hacking Humanity by Lara Lewington is published today and is available from all good booksellers or online here:
https://lnk.to/HackingHumanityBook

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379907Thu, 10 Jul 2025 09:48:34 +0000saderLara Lewington has long been a trusted translator of tech – taking innovations that risk becoming opaque to all but the initiated and rendering them not only comprehensible but compelling. In Hacking Humanity, which is published today, Lewington turns...
Part investigation, part personal journey, the book is a measured yet accessible tour of the technologies shaping the future of medicine; one that doesn’t so much chase immortality as question how we might better inhabit the years we already have – and those that might soon be on offer.

Lewington’s Hacking Humanity adeptly navigates the intricate terrain of emerging health technologies, distilling complex scientific advancements into narratives that resonate beyond the confines of the laboratory. By intertwining personal experimentation with expert insights, she bridges the often daunting gap between cutting-edge research and everyday understanding. In doing so, Lewington doesn't merely inform; she invites readers to engage critically with the ethical, societal and personal implications of our accelerating quest for extended healthspan.

It's a timely contribution that challenges us to consider not just the possibilities of living longer, but the responsibilities that come with it. We sat down with her to find out more about her experiences and the book that came out of them.

Hacking Humanity by Lara Lewington is published today and is available from all good booksellers or online here:
https://lnk.to/HackingHumanityBook

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>1311falsefullhttps://www.spreaker.com/episode/community-is-the-most-underrated-hack-for-longevity--74818196
When a pediatric cardiac surgeon pivots from congenital heart defects to digital biomarkers, it is worth paying attention. Dr David Luu, founder of Longevity Docs, is bringing clinical precision to a deceptively simple problem – how to shift medicine’s focus from reactive to preventive. His solution is less about disruption and more about coordination: equip physicians, connect them and support their practice with evidence, tools and ongoing discourse. The result is Longevity Docs – now 400-strong across 50 countries – a physician-led platform for education, certification and the practical application of longevity medicine.

This June, that vision finds form in Cannes, where the inaugural Longevity Docs Summit will bring together doctors, policymakers, investors and technologists. The goal is both pragmatic and ambitious – to shape infrastructure, clarify standards and test the boundaries of what longevity medicine could become. Cannes may be best known for auteurs and allegories, but for two days in June, the script will focus on senescence, systems and solutions – and yes, there will be a red carpet, though this time it leads not to premieres, but to panels and practicalities.

What began as a WhatsApp group has grown – organically and globally – into a structured but open-ended community of clinicians united by a common interest in healthspan. Its appeal lies in balance: between innovation and rigor, optimism and regulation, experimentation and practice. In a field often driven by hype or heavy-handed protocol, Longevity Docs is cultivating something more interesting – a space for evidence, disagreement and shared learning. If longevity medicine is to become a medical specialty in its own right, it will need frameworks – but also forums. We sat down with David Luu to find out more.

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf

More about Longevity Docs: https://www.longevitydocs.org/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379938Tue, 03 Jun 2025 16:27:54 +0000saderLongevity Docs' David Luu on building a global doctor network, scaling innovation and realizing the power of prevention. When a pediatric cardiac surgeon pivots from congenital heart defects to digital biomarkers, it is worth paying attention. Dr...
When a pediatric cardiac surgeon pivots from congenital heart defects to digital biomarkers, it is worth paying attention. Dr David Luu, founder of Longevity Docs, is bringing clinical precision to a deceptively simple problem – how to shift medicine’s focus from reactive to preventive. His solution is less about disruption and more about coordination: equip physicians, connect them and support their practice with evidence, tools and ongoing discourse. The result is Longevity Docs – now 400-strong across 50 countries – a physician-led platform for education, certification and the practical application of longevity medicine.

This June, that vision finds form in Cannes, where the inaugural Longevity Docs Summit will bring together doctors, policymakers, investors and technologists. The goal is both pragmatic and ambitious – to shape infrastructure, clarify standards and test the boundaries of what longevity medicine could become. Cannes may be best known for auteurs and allegories, but for two days in June, the script will focus on senescence, systems and solutions – and yes, there will be a red carpet, though this time it leads not to premieres, but to panels and practicalities.

What began as a WhatsApp group has grown – organically and globally – into a structured but open-ended community of clinicians united by a common interest in healthspan. Its appeal lies in balance: between innovation and rigor, optimism and regulation, experimentation and practice. In a field often driven by hype or heavy-handed protocol, Longevity Docs is cultivating something more interesting – a space for evidence, disagreement and shared learning. If longevity medicine is to become a medical specialty in its own right, it will need frameworks – but also forums. We sat down with David Luu to find out more.

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf

More about Longevity Docs: https://www.longevitydocs.org/]]>1189falsefullhttps://www.spreaker.com/episode/longevity-is-the-lens-through-which-we-can-reshape-healthcare--74818140
The Founders Longevity Forum returns to London this June, drawing a curated group of entrepreneurs, investors and longevity leaders to discuss the evolving contours of the healthy human lifespan. Among the speakers is Dr William Kapp, co-founder and CEO of Fountain Life, a trailblazer in the design and deployment of data-driven longevity clinics. As the market matures, physical and digital clinical models are converging – offering individuals not only early disease detection but also personalized therapeutic pathways to slow or even reverse aging trajectories.

Fountain Life has positioned itself at the intersection of proactive healthcare and AI, with clinical sites already serving thousands of members and capturing one of the world’s largest datasets on asymptomatic individuals. Under Kapp’s leadership, the company has embraced an ecosystem model – layering genomics, imaging, metabolomics and AI analytics into a continuous loop of feedback between patient and physician. The vision is to embed longevity into mainstream care pathways; first via precision clinics, then through digital tools capable of scaling best practices across health systems globally.

As part of the London Forum’s session on Longevity Clinics, Kapp will speak on building a digital and AI-enabled clinical network – one that empowers clinicians to synthesize torrents of biomarker data, and patients to engage meaningfully with their own healthspan trajectories. Plus, in conversation with Founders Health Cofounder and CEO Stephen Watson, Kapp will explore the opportunities around physical and digital clinics for the professional diagnosis of health and aging biomarkers and engage in an audience Q&A moderated by Joanna Bensz, Founder & CEO, Longevity Centre Europe.

We have long tracked the shift from reactive healthcare to a preventative, personalized and data-intensive future – Fountain Life exemplifies this transition. From AI co-pilots that translate clinical complexity into patient action, to advanced diagnostics that reveal hidden pathology long before symptoms arise, Bill Kapp and his team are charting new territory in functional medicine. Ahead of the Forum, we sat down with him to discuss capturing the train of thought between patient and doctor, why functional medicine defies a cookie-cutter approach, and cellular therapeutics that address immunosenescence.

Find out more about Founders Longevity Forum London:
https://founderslongevity.co/founders-longevity-forum-london/

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Fountain Life: https://www.fountainlife.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379865Fri, 02 May 2025 15:16:03 +0000saderFountain Life Cofounder and CEO Bill Kapp on why longevity's next evolution will be adoption into mainstream healthcare. The Founders Longevity Forum returns to London this June, drawing a curated group of entrepreneurs, investors and longevity...
The Founders Longevity Forum returns to London this June, drawing a curated group of entrepreneurs, investors and longevity leaders to discuss the evolving contours of the healthy human lifespan. Among the speakers is Dr William Kapp, co-founder and CEO of Fountain Life, a trailblazer in the design and deployment of data-driven longevity clinics. As the market matures, physical and digital clinical models are converging – offering individuals not only early disease detection but also personalized therapeutic pathways to slow or even reverse aging trajectories.

Fountain Life has positioned itself at the intersection of proactive healthcare and AI, with clinical sites already serving thousands of members and capturing one of the world’s largest datasets on asymptomatic individuals. Under Kapp’s leadership, the company has embraced an ecosystem model – layering genomics, imaging, metabolomics and AI analytics into a continuous loop of feedback between patient and physician. The vision is to embed longevity into mainstream care pathways; first via precision clinics, then through digital tools capable of scaling best practices across health systems globally.

As part of the London Forum’s session on Longevity Clinics, Kapp will speak on building a digital and AI-enabled clinical network – one that empowers clinicians to synthesize torrents of biomarker data, and patients to engage meaningfully with their own healthspan trajectories. Plus, in conversation with Founders Health Cofounder and CEO Stephen Watson, Kapp will explore the opportunities around physical and digital clinics for the professional diagnosis of health and aging biomarkers and engage in an audience Q&A moderated by Joanna Bensz, Founder & CEO, Longevity Centre Europe.

We have long tracked the shift from reactive healthcare to a preventative, personalized and data-intensive future – Fountain Life exemplifies this transition. From AI co-pilots that translate clinical complexity into patient action, to advanced diagnostics that reveal hidden pathology long before symptoms arise, Bill Kapp and his team are charting new territory in functional medicine. Ahead of the Forum, we sat down with him to discuss capturing the train of thought between patient and doctor, why functional medicine defies a cookie-cutter approach, and cellular therapeutics that address immunosenescence.

Find out more about Founders Longevity Forum London:
https://founderslongevity.co/founders-longevity-forum-london/

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Fountain Life: https://www.fountainlife.com/]]>1172falsefullhttps://www.spreaker.com/episode/the-more-unashamedly-we-talk-about-radical-life-extension-the-better--74818109
RAADfest is the world’s largest and most immersive gathering dedicated to super longevity and radical life extension. Celebrating its 10th anniversary this year, RAADfest 2025 will take place from 10th to 13th July at the Red Rock Casino Resort and Spa in Las Vegas. More than just a conference, RAADfest is a dynamic fusion of cutting-edge scientific breakthroughs, clinical innovations and community-driven celebration – all designed to empower individuals to take control of their healthspan and lifespan. With its unique emphasis on accessibility, inspiration and integrity, RAADfest continues to set the global benchmark for longevity events.

This year’s event promises a bold new chapter – one that brings together the emotional momentum of grassroots activism with the scientific firepower of the Longevity Escape Velocity Foundation. From on-site therapeutic experiences at the new RAD Clinic to a renewed focus on aging as a disease and the launch of major public initiatives, including a planned longevity rights rally in Washington DC, RAADfest 2025 is not just about extending life – it’s about accelerating a movement.

We sat down with two visionary leaders in the field of life extension – James Strole, Executive Director of the Coalition for Radical Life Extension, and Dr Aubrey de Grey, President and CSO of the Longevity Escape Velocity Foundation – to discuss public advocacy for super longevity, the vision for radical life extension and the future of RAADfest as a science-powered movement.

Find out more about RAADfest: https://www.raadfest.com/

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379867Wed, 16 Apr 2025 16:57:53 +0000saderAubrey de Grey and James Strole look ahead to RAADfest 2025, discussing longevity rights, scientific synergy and rallying public support. RAADfest is the world’s largest and most immersive gathering dedicated to super longevity and radical life...
RAADfest is the world’s largest and most immersive gathering dedicated to super longevity and radical life extension. Celebrating its 10th anniversary this year, RAADfest 2025 will take place from 10th to 13th July at the Red Rock Casino Resort and Spa in Las Vegas. More than just a conference, RAADfest is a dynamic fusion of cutting-edge scientific breakthroughs, clinical innovations and community-driven celebration – all designed to empower individuals to take control of their healthspan and lifespan. With its unique emphasis on accessibility, inspiration and integrity, RAADfest continues to set the global benchmark for longevity events.

This year’s event promises a bold new chapter – one that brings together the emotional momentum of grassroots activism with the scientific firepower of the Longevity Escape Velocity Foundation. From on-site therapeutic experiences at the new RAD Clinic to a renewed focus on aging as a disease and the launch of major public initiatives, including a planned longevity rights rally in Washington DC, RAADfest 2025 is not just about extending life – it’s about accelerating a movement.

We sat down with two visionary leaders in the field of life extension – James Strole, Executive Director of the Coalition for Radical Life Extension, and Dr Aubrey de Grey, President and CSO of the Longevity Escape Velocity Foundation – to discuss public advocacy for super longevity, the vision for radical life extension and the future of RAADfest as a science-powered movement.

Find out more about RAADfest: https://www.raadfest.com/

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>1466falsefullhttps://www.spreaker.com/episode/we-want-to-completely-change-interaction-with-the-digital-world--74818085
The company recently emerged from stealth mode, announcing a $17 million seed funding round and unveiling its ambitious roadmap. Subsense’s platform is being developed with leading academic collaborators and incorporates advanced AI to design next-gen nanostructures – opening doors to medical applications and far-reaching implications for cognitive enhancement. The startup plans to begin preclinical demonstrations in mice, with a target to show closed-loop neural stimulation and symptom modulation for neurodegenerative conditions by 2026.

We’ve been tracking the convergence of neurotech, biotech and AI closely – and Subsense sits right at this cutting edge. CEO and cofounder Tetiana Alekandrova is a pioneer building at the edge of possibility, and we sat down with her to find out just how the technology works and the clinical pathways being explored, discussing nanoparticle delivery via the olfactory nerve and the ethics and regulation of future brain augmentation. Plus, we discuss the company’s ultimate vision: a direct neural interface with AI that could change how humans interact with knowledge itself.

More about Subsense: https://www.subsense-bci.com/

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379933Fri, 11 Apr 2025 14:10:17 +0000saderSubsense is developing a groundbreaking, non-surgical brain-computer interface (BCI) that leverages nanoparticle technology to read from and write to the brain. With a dual-system approach using plasmonic and magnetoelectric nanoparticles, Subsense...
The company recently emerged from stealth mode, announcing a $17 million seed funding round and unveiling its ambitious roadmap. Subsense’s platform is being developed with leading academic collaborators and incorporates advanced AI to design next-gen nanostructures – opening doors to medical applications and far-reaching implications for cognitive enhancement. The startup plans to begin preclinical demonstrations in mice, with a target to show closed-loop neural stimulation and symptom modulation for neurodegenerative conditions by 2026.

We’ve been tracking the convergence of neurotech, biotech and AI closely – and Subsense sits right at this cutting edge. CEO and cofounder Tetiana Alekandrova is a pioneer building at the edge of possibility, and we sat down with her to find out just how the technology works and the clinical pathways being explored, discussing nanoparticle delivery via the olfactory nerve and the ethics and regulation of future brain augmentation. Plus, we discuss the company’s ultimate vision: a direct neural interface with AI that could change how humans interact with knowledge itself.

More about Subsense: https://www.subsense-bci.com/

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>1328falsefullhttps://www.spreaker.com/episode/epigenetic-testing-puts-control-back-into-our-hands--74818119
Longevity Technology recently launched FLT, our new line of supplements focused on longevity, cognition and muscle health. Being able to measure and track your biological progress goes hand-in-hand with effective supplementation – after all, you can’t improve what you don’t measure. Therefore, we are delighted to be partnering with TruDiagnostic to bring their epigenetic test kits to our customers. These state-of-the-art tests, developed in concert with scientists at Cornell, Yale and Harvard, can track how fast you’re aging and how your nutritional and biological systems are performing, allowing you to make targeted improvements over time.

Our range of epigenetic tests includes:
* TruAge, which determines your biological age by analyzing over 75 biomarkers to assess cellular health and aging speed.
* TruHealth, offering insights into nutritional status by evaluating more than 110 epigenetic biomarker proxies (EBPs) for vitamins, minerals, amino acids and antioxidants.
* TruAge + TruHealth Bundle, combining both assessments for a comprehensive view of your biological age and nutritional health.

Measuring epigenetic change can play a key role in helping to shape health journeys. At Longevity Technology, our mission really is to equip people with the tools and knowledge they need to optimize their healthspan; we want to help people explore their biological age – and take personalized, actionable steps to improve it – and our partnership with TruDiagnostic is a significant step in that direction. We sat down with Ryan Smith, Founder and Global Head of Research at TruDiagnostic to find out how TruDiagnostic is empowering people to measure and understand their biological age and the broader impact of their lifestyle choices on their health.

Check out FLT's range of self-testing kits: https://flt.life/shop/self-testing/

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about TruDiagnostic: https://www.trudiagnostic.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379926Fri, 21 Mar 2025 17:53:00 +0000saderTruDiagnostic Founder Ryan Smith on personalized testing, disease risk prediction and how lifestyle choices can rewrite your health future. Longevity Technology recently launched FLT, our new line of supplements focused on longevity, cognition and...
Longevity Technology recently launched FLT, our new line of supplements focused on longevity, cognition and muscle health. Being able to measure and track your biological progress goes hand-in-hand with effective supplementation – after all, you can’t improve what you don’t measure. Therefore, we are delighted to be partnering with TruDiagnostic to bring their epigenetic test kits to our customers. These state-of-the-art tests, developed in concert with scientists at Cornell, Yale and Harvard, can track how fast you’re aging and how your nutritional and biological systems are performing, allowing you to make targeted improvements over time.

Our range of epigenetic tests includes:
* TruAge, which determines your biological age by analyzing over 75 biomarkers to assess cellular health and aging speed.
* TruHealth, offering insights into nutritional status by evaluating more than 110 epigenetic biomarker proxies (EBPs) for vitamins, minerals, amino acids and antioxidants.
* TruAge + TruHealth Bundle, combining both assessments for a comprehensive view of your biological age and nutritional health.

Measuring epigenetic change can play a key role in helping to shape health journeys. At Longevity Technology, our mission really is to equip people with the tools and knowledge they need to optimize their healthspan; we want to help people explore their biological age – and take personalized, actionable steps to improve it – and our partnership with TruDiagnostic is a significant step in that direction. We sat down with Ryan Smith, Founder and Global Head of Research at TruDiagnostic to find out how TruDiagnostic is empowering people to measure and understand their biological age and the broader impact of their lifestyle choices on their health.

Check out FLT's range of self-testing kits: https://flt.life/shop/self-testing/

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about TruDiagnostic: https://www.trudiagnostic.com/]]>753falsefullhttps://www.spreaker.com/episode/very-early-detection-of-cognitive-decline-is-our-purpose--74818120
​In an era where cognitive enhancement and mental well-being are paramount, Sens.ai emerges as a trailblazer with its innovative at-home brain training system. This pioneering technology seamlessly integrates neurofeedback, heart coherence training and transcranial photobiomodulation to offer users a comprehensive approach to enhancing cognitive performance and overall wellness. By personalizing each training session, Sens.ai empowers individuals to unlock their brain's full potential from the comfort of their homes, democratizing access to advanced neurotechnology and paving the way for improved healthspan.

By harnessing the power of neurofeedback and other cutting-edge technologies, Sens.ai is redefining cognitive enhancement, offering both at-home users and clinicians an innovative approach to brain training. We sat down with CEO Paola Telfer to explore how Sens.ai is pioneering personalized neurotechnology, its role in optimizing brain performance across different life stages and why a proactive approach to cognitive longevity is more crucial than ever – especially in an era where mental sharpness directly impacts quality of life. Plus she shares her thoughts on why the brain needs its own version of Ozempic...

More about Sens.ai: https://sens.ai/
---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379920Tue, 18 Mar 2025 18:29:08 +0000saderSens.ai Founder Paola Telfer on staving off cognitive decline and extending peak performance with transformative neurotechnology. ​In an era where cognitive enhancement and mental well-being are paramount, Sens.ai emerges as a trailblazer with its...
​In an era where cognitive enhancement and mental well-being are paramount, Sens.ai emerges as a trailblazer with its innovative at-home brain training system. This pioneering technology seamlessly integrates neurofeedback, heart coherence training and transcranial photobiomodulation to offer users a comprehensive approach to enhancing cognitive performance and overall wellness. By personalizing each training session, Sens.ai empowers individuals to unlock their brain's full potential from the comfort of their homes, democratizing access to advanced neurotechnology and paving the way for improved healthspan.

By harnessing the power of neurofeedback and other cutting-edge technologies, Sens.ai is redefining cognitive enhancement, offering both at-home users and clinicians an innovative approach to brain training. We sat down with CEO Paola Telfer to explore how Sens.ai is pioneering personalized neurotechnology, its role in optimizing brain performance across different life stages and why a proactive approach to cognitive longevity is more crucial than ever – especially in an era where mental sharpness directly impacts quality of life. Plus she shares her thoughts on why the brain needs its own version of Ozempic...

More about Sens.ai: https://sens.ai/
---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>1367falsefullhttps://www.spreaker.com/episode/niagen-biosciences-ceo-rob-fried-on-nad-longevity-and-the-next-frontier-in-cellular-health--74818152
#livehealthierlonger #NADplus #longevitylifestyle #healthyaging #longevitytip #boostNAD #NR]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561380009Fri, 28 Feb 2025 04:15:24 +0000saderJoin Phil Newman and Rob Fried, CEO of Niagen Biosciences (formerly ChromaDex), as they discuss the power of NAD+, groundbreaking research on Niagen, and the future of longevity science. Learn how NAD+ supplementation impacts aging, cellular health,...
#livehealthierlonger #NADplus #longevitylifestyle #healthyaging #longevitytip #boostNAD #NR]]>927falsefullhttps://www.spreaker.com/episode/dr-robert-kiltz-on-the-power-of-animal-based-nutrition-and-longevity--74818159
He challenges common nutrition myths, shares his personal journey, and explains why plant-based foods might be doing more harm than good.

Watch to learn how diet can transform your energy, mental clarity, and overall well-being!

#carnivorediet #animalbaseddiet #healthyaging #longevitytips #livehealthierlonger #drkiltz]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379914Wed, 26 Feb 2025 20:00:16 +0000saderDr. Robert Kiltz breaks down why an animal-based diet may be the key to better health, longevity, and fertility. He challenges common nutrition myths, shares his personal journey, and explains why plant-based foods might be doing more harm than...
He challenges common nutrition myths, shares his personal journey, and explains why plant-based foods might be doing more harm than good.

Watch to learn how diet can transform your energy, mental clarity, and overall well-being!

#carnivorediet #animalbaseddiet #healthyaging #longevitytips #livehealthierlonger #drkiltz]]>1582falsefullhttps://www.spreaker.com/episode/scanning-the-diagnostic-horizon-100-000-and-counting--74818158
Market leader Prenuvo has set a new standard in preventative healthcare, completing over 100,000 whole-body MRI scans – a major milestone for both the company and the broader imaging field. Its advanced technology enables full-body MRI scans in under an hour, capturing over one billion data points and generating significantly more clinical-grade images than conventional MRI systems. In 2024, Prenuvo raised $120 million in Series B funding to further its mission of transforming early disease detection. The company also secured FDA clearance for its Prenuvo Body Composition report, an AI-driven tool that provides a detailed analysis of visceral fat, liver fat, muscle volume and key organ measurements – insights that could be crucial for metabolic and cardiovascular health.

Beyond imaging, Prenuvo is expanding its preventative health capabilities with a new brain health scan, designed to detect early signs of cognitive decline and neurodegenerative diseases. The company has also developed a customized blood biomarker assessment, offering a functional and conventional panel that evaluates metabolic, cardiovascular, hormonal and immune health. This integration of imaging and blood analysis enhances early detection, giving patients a comprehensive view of their overall health.

As Prenuvo continues to innovate, it is redefining how we approach disease prevention – offering a proactive alternative to traditional reactive healthcare. However, as we know from our longevity clinics survey, only just over 30% of clinics offer whole body scanning as part of their imaging and diagnostics, something that demonstrates the emerging stratification in the market between diagnostics and interventions. Hot on the heels of their milestone 100,000 whole body MRIs, we sat down with Prenuvo Founder and CEO Andrew Lacy to discuss advancements in preventive health scanning, the importance of early detection in healthcare and the role of insurance in making these services accessible.

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

Find out more about Prenuvo: https://prenuvo.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379917Fri, 21 Feb 2025 18:10:45 +0000saderPrenuvo CEO Andrew Lacy on the role of whole body MRI tech and how AI is reducing costs and improving efficiency in diagnostics. Market leader Prenuvo has set a new standard in preventative healthcare, completing over 100,000 whole-body MRI scans – a...
Market leader Prenuvo has set a new standard in preventative healthcare, completing over 100,000 whole-body MRI scans – a major milestone for both the company and the broader imaging field. Its advanced technology enables full-body MRI scans in under an hour, capturing over one billion data points and generating significantly more clinical-grade images than conventional MRI systems. In 2024, Prenuvo raised $120 million in Series B funding to further its mission of transforming early disease detection. The company also secured FDA clearance for its Prenuvo Body Composition report, an AI-driven tool that provides a detailed analysis of visceral fat, liver fat, muscle volume and key organ measurements – insights that could be crucial for metabolic and cardiovascular health.

Beyond imaging, Prenuvo is expanding its preventative health capabilities with a new brain health scan, designed to detect early signs of cognitive decline and neurodegenerative diseases. The company has also developed a customized blood biomarker assessment, offering a functional and conventional panel that evaluates metabolic, cardiovascular, hormonal and immune health. This integration of imaging and blood analysis enhances early detection, giving patients a comprehensive view of their overall health.

As Prenuvo continues to innovate, it is redefining how we approach disease prevention – offering a proactive alternative to traditional reactive healthcare. However, as we know from our longevity clinics survey, only just over 30% of clinics offer whole body scanning as part of their imaging and diagnostics, something that demonstrates the emerging stratification in the market between diagnostics and interventions. Hot on the heels of their milestone 100,000 whole body MRIs, we sat down with Prenuvo Founder and CEO Andrew Lacy to discuss advancements in preventive health scanning, the importance of early detection in healthcare and the role of insurance in making these services accessible.

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

Find out more about Prenuvo: https://prenuvo.com/]]>894falsefullhttps://www.spreaker.com/episode/ai-peptides-the-ultimate-performance-hack--74818139
Featuring PeptiStrong – an innovative ingredient developed by Nuritas – this product aims to support muscle strength, recovery, and endurance.

Learn more about FLT MUSCLE - https://bit.ly/417ngAC

Traditional methods of peptide discovery would have taken centuries to identify combinations with the desired attributes; thanks to AI and rigorous biological testing, Nuritas pinpoints peptides with unparalleled precision, ensuring they are absorbable, effective and safe.
---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y
Shop for FLT MUSCLE – https://bit.ly/417ngAC

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379967Wed, 19 Feb 2025 16:36:55 +0000saderLongevity.Technology brand, FLT's latest supplement leverages advanced science to redefine muscle health and recovery. Featuring PeptiStrong – an innovative ingredient developed by Nuritas – this product aims to support muscle strength, recovery, and...
Featuring PeptiStrong – an innovative ingredient developed by Nuritas – this product aims to support muscle strength, recovery, and endurance.

Learn more about FLT MUSCLE - https://bit.ly/417ngAC

Traditional methods of peptide discovery would have taken centuries to identify combinations with the desired attributes; thanks to AI and rigorous biological testing, Nuritas pinpoints peptides with unparalleled precision, ensuring they are absorbable, effective and safe.
---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y
Shop for FLT MUSCLE – https://bit.ly/417ngAC

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>936falsefullhttps://www.spreaker.com/episode/ergothioneine-great-potential-for-cognitive-health-and-beyond--74818102
This precision-formulated blend combines antioxidants, adaptogens and natural nootropics to support the key pillars of cognitive health: focus, memory, and overall cognitive function.

Learn more about FLT COGNITION: https://bit.ly/3X5Etta

We wanted to take things a step further, developing a formula that targets both mental clarity and focus, as well as long-term brain health – these are obviously key areas for anyone looking to optimize their cognitive performance as well as obviously supporting healthy aging.

As lifespans continue to extend, maintaining cognitive sharpness is becoming a critical focus. People are realizing that living longer only matters if those additional years are spent with a clear mind and the ability to fully engage with life. Cognitive health directly impacts decision-making, creativity and emotional well-being, making it essential for achieving a fulfilling, productive life at any age. This shift reflects a broader understanding that brain health is foundational not just for aging well, but for living well.

What makes FLT COGNITION so special is a powerful blend of ingredients which includes Blue California's ErgoActive® L-Ergothioneine as one of its hero components. A naturally occurring amino acid, ergothioneine is a potent antioxidant that combats oxidative stress and cellular imbalance that contribute to cell damage.

Research also shows ergothioneine improves cognitive function by ameliorating mitochondrial damage and decreasing neuroinflammation. Conversely, low levels of ergothioneine in the body may increase the risk of cognitive impairment, dementia and Parkinson's disease, and in people with dementia, including Alzheimer's disease, cognitive decline is correlated with declining ET levels.

And to take a deeper dive into the science behind this incredible ingredient, we sat down with Dr Linda May Zhang, VP of Science and Innovation at Blue California.

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y
Shop for FLT COGNITION – https://bit.ly/3X5Etta

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf

More about Blue California: https://bluecal-ingredients.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379944Tue, 18 Feb 2025 12:16:35 +0000saderLongevity Technology’s supplement brand, FLT, has launched a brand-new supplement product: COGNITION. This precision-formulated blend combines antioxidants, adaptogens and natural nootropics to support the key pillars of cognitive health: focus,...
This precision-formulated blend combines antioxidants, adaptogens and natural nootropics to support the key pillars of cognitive health: focus, memory, and overall cognitive function.

Learn more about FLT COGNITION: https://bit.ly/3X5Etta

We wanted to take things a step further, developing a formula that targets both mental clarity and focus, as well as long-term brain health – these are obviously key areas for anyone looking to optimize their cognitive performance as well as obviously supporting healthy aging.

As lifespans continue to extend, maintaining cognitive sharpness is becoming a critical focus. People are realizing that living longer only matters if those additional years are spent with a clear mind and the ability to fully engage with life. Cognitive health directly impacts decision-making, creativity and emotional well-being, making it essential for achieving a fulfilling, productive life at any age. This shift reflects a broader understanding that brain health is foundational not just for aging well, but for living well.

What makes FLT COGNITION so special is a powerful blend of ingredients which includes Blue California's ErgoActive® L-Ergothioneine as one of its hero components. A naturally occurring amino acid, ergothioneine is a potent antioxidant that combats oxidative stress and cellular imbalance that contribute to cell damage.

Research also shows ergothioneine improves cognitive function by ameliorating mitochondrial damage and decreasing neuroinflammation. Conversely, low levels of ergothioneine in the body may increase the risk of cognitive impairment, dementia and Parkinson's disease, and in people with dementia, including Alzheimer's disease, cognitive decline is correlated with declining ET levels.

And to take a deeper dive into the science behind this incredible ingredient, we sat down with Dr Linda May Zhang, VP of Science and Innovation at Blue California.

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y
Shop for FLT COGNITION – https://bit.ly/3X5Etta

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf

More about Blue California: https://bluecal-ingredients.com/]]>1522falsefullhttps://www.spreaker.com/episode/oral-health-and-longevity-how-your-teeth-could-be-shortening-your-lifespan--74818172
From AI diagnostics to biohacking strategies, discover how your dental health impacts your well-being.

Watch now to learn why outdated dental work could be harming your health!

#oralhealth #longevitytip #biohackingteeth #dentalhealth #livehealthierlonger #healthyaging]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379870Fri, 14 Feb 2025 20:15:02 +0000saderDr. Miguel Stanley joins Phil Newman of Longevity.Technology to explore the crucial link between oral health and longevity. From AI diagnostics to biohacking strategies, discover how your dental health impacts your well-being. Watch now to learn...
From AI diagnostics to biohacking strategies, discover how your dental health impacts your well-being.

Watch now to learn why outdated dental work could be harming your health!

#oralhealth #longevitytip #biohackingteeth #dentalhealth #livehealthierlonger #healthyaging]]>1585falsefullhttps://www.spreaker.com/episode/front-facing-longevity-in-your-back-pocket--74818097
Just two weeks away, Founders Longevity Forum Singapore will serve as a key platform for driving discussions on how science, policy and investment can converge to accelerate progress in longevity. With the global population aging, the need to transition healthcare from reactive treatment to proactive prevention has never been more urgent. This shift relies on cutting-edge diagnostics and therapeutics that extend healthspan and reduce the burden of age-related diseases – an area FLF:SG will explore in depth.

Bringing together leading experts, researchers and industry pioneers, FLF:SG will highlight advancements in epigenetics, biomarker testing and precision diagnostics that enable earlier interventions and improve clinical adoption. By fostering collaboration, the forum aims to make longevity-focused healthcare more accessible, bridging the gap between scientific innovation and real-world impact.

TruDiagnostic is at the forefront of longevity science, specializing in DNA methylation-based diagnostics that provide deeper insights into biological aging. With over 75,000 patients tested and more than 30 approved clinical trials, the company is helping to define the role of epigenetics in preventive healthcare. By equipping clinicians and consumers with precision aging biomarkers, TruDiagnostic is bridging the gap between research and real-world applications in longevity and health optimization.

At FLF:SG, TruDiagnostic Cofounder and Director of Operations Hannah Went will be driving the conversation on the clinical and consumer adoption of biological age testing. In her session on the Use of Biological Gerodiagnostics in Clinical Settings, she'll be exploring how epigenetic data can enhance personalized medicine and longevity-focused interventions. In Consumer Diagnostics for Longevity and Healthspan, she will be discussing the growing accessibility of biological aging tests and their role in empowering individuals to take control of their long-term health. Through TruDiagnostic’s research and innovation, Went is helping shape the future of longevity-focused diagnostics, and ahead of the Forum, we sat down with her to discuss the integration of AI in diagnostics, the role of epigenetics as a promising biomarker and advancements in longevity diagnostics.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about TruDiagnostic: https://www.trudiagnostic.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379891Wed, 12 Feb 2025 18:10:03 +0000saderHannah Went on the future of health diagnostics and a brand-new app that could prove to be a healthspan gamechanger. Just two weeks away, Founders Longevity Forum Singapore will serve as a key platform for driving discussions on how science, policy...
Just two weeks away, Founders Longevity Forum Singapore will serve as a key platform for driving discussions on how science, policy and investment can converge to accelerate progress in longevity. With the global population aging, the need to transition healthcare from reactive treatment to proactive prevention has never been more urgent. This shift relies on cutting-edge diagnostics and therapeutics that extend healthspan and reduce the burden of age-related diseases – an area FLF:SG will explore in depth.

Bringing together leading experts, researchers and industry pioneers, FLF:SG will highlight advancements in epigenetics, biomarker testing and precision diagnostics that enable earlier interventions and improve clinical adoption. By fostering collaboration, the forum aims to make longevity-focused healthcare more accessible, bridging the gap between scientific innovation and real-world impact.

TruDiagnostic is at the forefront of longevity science, specializing in DNA methylation-based diagnostics that provide deeper insights into biological aging. With over 75,000 patients tested and more than 30 approved clinical trials, the company is helping to define the role of epigenetics in preventive healthcare. By equipping clinicians and consumers with precision aging biomarkers, TruDiagnostic is bridging the gap between research and real-world applications in longevity and health optimization.

At FLF:SG, TruDiagnostic Cofounder and Director of Operations Hannah Went will be driving the conversation on the clinical and consumer adoption of biological age testing. In her session on the Use of Biological Gerodiagnostics in Clinical Settings, she'll be exploring how epigenetic data can enhance personalized medicine and longevity-focused interventions. In Consumer Diagnostics for Longevity and Healthspan, she will be discussing the growing accessibility of biological aging tests and their role in empowering individuals to take control of their long-term health. Through TruDiagnostic’s research and innovation, Went is helping shape the future of longevity-focused diagnostics, and ahead of the Forum, we sat down with her to discuss the integration of AI in diagnostics, the role of epigenetics as a promising biomarker and advancements in longevity diagnostics.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about TruDiagnostic: https://www.trudiagnostic.com/]]>776falsefullhttps://www.spreaker.com/episode/longevity-biotech-is-the-apotheosis-of-medicine--74818104
In recent years, the field of longevity biotechnology has gained significant momentum, with myriad startups striving to develop therapies aimed at extending healthy human lifespan. Aiming to be at the forefront of this movement is Healthspan Capital, a VC firm dedicated to investing in early-stage longevity biotech – LongBio – and regenerative medicine startups.

Focused on its mission to support companies that are developing therapeutics targeting aging and extending healthy human lifespan, Healthspan Capital has been one of the most active investors in the LongBio field with a whopping 32 investments in three years. The VC was founded in 2021 by a triumvirate of longevity experience – Sebastian Brunemeier (former principal at Apollo Health Ventures, the largest longevity fund in the world and cofounder at Cambrian Bio, one of the larger companies in the space), Nathan Cheng (co-Founder of the Longevity Biotech Fellowship (LBF), the largest network in the world for LongBio) and Dr Michael Chinen (an AI researcher from Google who leads the firm’s computational diligence); it distinguishes itself through a diversified investment approach, deep expertise in longevity biotech and an extensive network of collaborators, advisors and founders in the field.

By investing in a broad portfolio of companies employing various approaches and modalities, the firm aims to catalyze advancements in rejuvenation biotechnology, which it believes is the future of healthspan medicine. Moreover, Healthspan Capital's rolling fund structure offers investors a flexible and straightforward way to engage in the longevity sector, making it more accessible to a wider range of stakeholders.

Healthspan Capital’s impact on the longevity sector extends beyond just funding. The firm plays a pivotal role in shaping the future of longevity biotech by not only providing capital but also by leveraging its network of scientific advisors, industry leaders and entrepreneurs to drive innovation. By supporting startups that tackle the biological mechanisms of aging, Healthspan Capital is accelerating the development of therapies that could redefine healthcare – shifting the focus from treating age-related diseases to fundamentally preventing them. This proactive investment strategy not only benefits the companies within its portfolio but also helps build a robust ecosystem where scientific breakthroughs translate into real-world medical solutions.

As mentioned above, one of the key figures behind Healthspan Capital is General Partner Sebastian Brunemeier, a biotech venture capitalist and company builder with a focus on longevity and regenerative medicine. Over the past five years, he has co-founded multiple longevity biotech companies, including Cambrian and Samsara Therapeutics, and we sat down with him to find out more about how Healthspan Capital and its vision is set to serve the need for more capital in the field.

Find out more about Healthspan Capital:
https://www.healthspancapital.vc/

Read The LongBio Report 2025:
https://www.healthspancapital.vc/longbio-report-2025

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379969Tue, 11 Feb 2025 16:54:30 +0000saderHealthspan Capital’s Sebastian Brunemeier on emerging trends, technological innovations and the investment landscape in LongBio. In recent years, the field of longevity biotechnology has gained significant momentum, with myriad startups striving to...
In recent years, the field of longevity biotechnology has gained significant momentum, with myriad startups striving to develop therapies aimed at extending healthy human lifespan. Aiming to be at the forefront of this movement is Healthspan Capital, a VC firm dedicated to investing in early-stage longevity biotech – LongBio – and regenerative medicine startups.

Focused on its mission to support companies that are developing therapeutics targeting aging and extending healthy human lifespan, Healthspan Capital has been one of the most active investors in the LongBio field with a whopping 32 investments in three years. The VC was founded in 2021 by a triumvirate of longevity experience – Sebastian Brunemeier (former principal at Apollo Health Ventures, the largest longevity fund in the world and cofounder at Cambrian Bio, one of the larger companies in the space), Nathan Cheng (co-Founder of the Longevity Biotech Fellowship (LBF), the largest network in the world for LongBio) and Dr Michael Chinen (an AI researcher from Google who leads the firm’s computational diligence); it distinguishes itself through a diversified investment approach, deep expertise in longevity biotech and an extensive network of collaborators, advisors and founders in the field.

By investing in a broad portfolio of companies employing various approaches and modalities, the firm aims to catalyze advancements in rejuvenation biotechnology, which it believes is the future of healthspan medicine. Moreover, Healthspan Capital's rolling fund structure offers investors a flexible and straightforward way to engage in the longevity sector, making it more accessible to a wider range of stakeholders.

Healthspan Capital’s impact on the longevity sector extends beyond just funding. The firm plays a pivotal role in shaping the future of longevity biotech by not only providing capital but also by leveraging its network of scientific advisors, industry leaders and entrepreneurs to drive innovation. By supporting startups that tackle the biological mechanisms of aging, Healthspan Capital is accelerating the development of therapies that could redefine healthcare – shifting the focus from treating age-related diseases to fundamentally preventing them. This proactive investment strategy not only benefits the companies within its portfolio but also helps build a robust ecosystem where scientific breakthroughs translate into real-world medical solutions.

As mentioned above, one of the key figures behind Healthspan Capital is General Partner Sebastian Brunemeier, a biotech venture capitalist and company builder with a focus on longevity and regenerative medicine. Over the past five years, he has co-founded multiple longevity biotech companies, including Cambrian and Samsara Therapeutics, and we sat down with him to find out more about how Healthspan Capital and its vision is set to serve the need for more capital in the field.

Find out more about Healthspan Capital:
https://www.healthspancapital.vc/

Read The LongBio Report 2025:
https://www.healthspancapital.vc/longbio-report-2025

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf]]>1161falsefullhttps://www.spreaker.com/episode/rewire-your-brain-for-resilience-and-longevity--74818108
Watch now to learn how small changes can make a big impact on your cognitive health!

#brainhealth #stressrelief #neuroplasticity #longevitytips #healthyaging #livehealthierlonger]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379961Thu, 06 Feb 2025 22:00:23 +0000saderFeeling stressed or struggling with focus? Lisa Wimberger shares practical tools like shaking, breathwork, and Neurosculpting to rewire your brain for resilience and longevity. Watch now to learn how small changes can make a big impact on your...
Watch now to learn how small changes can make a big impact on your cognitive health!

#brainhealth #stressrelief #neuroplasticity #longevitytips #healthyaging #livehealthierlonger]]>1123falsefullhttps://www.spreaker.com/episode/longevity-is-an-imperative-from-a-public-health-perspective--74818129
The Founders Longevity Forum Singapore is poised to convene global leaders, clinicians, academics and investors to advance knowledge and drive growth in the longevity sector. With a significant focus on longevity investment, the conference aims to explore innovative strategies to promote healthy aging – Singapore, recognized for its dynamic startup ecosystem, serves as an ideal backdrop for these discussions.

Vishal Harnal, Global Managing Partner at 500 Global, will be a distinguished speaker at the event. Under his leadership, 500 Global – a venture capital firm managing over $2.5 billion in assets – has backed over 5,000 founders representing more than 2,900 companies operating in 80+ countries, and including notable successes like Grab and Bukalapak.

Harnal's extensive experience in fostering innovation, capitalizing on emerging markets and navigating regulation positions him to offer valuable insights into the convergence of technology and longevity, highlighting investment opportunities that can drive advancements in healthy aging. Ahead of February's event, we sat down with Vishal Harnal to discuss growth of longevity investment in the APAC region and opportunities for startups in the longevity space. We also cover how his legal background influences his investment strategies and the importance of government involvement in healthcare.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about 500 Global: https://500.co/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561380022Wed, 29 Jan 2025 17:19:14 +0000saderVishal Harnal on consumer health trends, innovations in healthspan and the evaluation of early-stage startups. The Founders Longevity Forum Singapore is poised to convene global leaders, clinicians, academics and investors to advance knowledge and...
The Founders Longevity Forum Singapore is poised to convene global leaders, clinicians, academics and investors to advance knowledge and drive growth in the longevity sector. With a significant focus on longevity investment, the conference aims to explore innovative strategies to promote healthy aging – Singapore, recognized for its dynamic startup ecosystem, serves as an ideal backdrop for these discussions.

Vishal Harnal, Global Managing Partner at 500 Global, will be a distinguished speaker at the event. Under his leadership, 500 Global – a venture capital firm managing over $2.5 billion in assets – has backed over 5,000 founders representing more than 2,900 companies operating in 80+ countries, and including notable successes like Grab and Bukalapak.

Harnal's extensive experience in fostering innovation, capitalizing on emerging markets and navigating regulation positions him to offer valuable insights into the convergence of technology and longevity, highlighting investment opportunities that can drive advancements in healthy aging. Ahead of February's event, we sat down with Vishal Harnal to discuss growth of longevity investment in the APAC region and opportunities for startups in the longevity space. We also cover how his legal background influences his investment strategies and the importance of government involvement in healthcare.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about 500 Global: https://500.co/]]>1145falsefullhttps://www.spreaker.com/episode/dr-william-li-longevity-is-a-lifelong-journey--74818176
From the Holy Trinity of Beverages to immune-boosting foods like blueberries and broccoli sprouts, learn how simple dietary changes can transform your well-being.

Don't miss this fascinating conversation packed with practical tips and groundbreaking insights. Watch now and start your journey to a healthier, longer life!]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379958Fri, 24 Jan 2025 20:00:13 +0000saderDiscover how everyday foods can boost your health and extend your life! Join Dr. William Li and Phil Newman as they explore the science behind longevity. From the Holy Trinity of Beverages to immune-boosting foods like blueberries and broccoli...
From the Holy Trinity of Beverages to immune-boosting foods like blueberries and broccoli sprouts, learn how simple dietary changes can transform your well-being.

Don't miss this fascinating conversation packed with practical tips and groundbreaking insights. Watch now and start your journey to a healthier, longer life!]]>2660falsefullhttps://www.spreaker.com/episode/preventive-healthcare-is-an-unstoppable-force--74818100
The Founders Longevity Forum Singapore is gearing up to be a landmark event next month, uniting leading minds from science, medicine and investment to explore transformative solutions for healthy aging. Organized by Founders Forum, the Academy for Healthy Longevity at the National University of Singapore, and Longevity.Technology, this two-day gathering aims to accelerate progress in longevity research, foster collaborations and highlight innovation in the Asia-Pacific region – positioning Singapore as a global hub for aging science and healthspan advancements.

Dr David Dodick, Chief Science and Medical Officer at Atria, is among the distinguished speakers set to take the stage. With a career dedicated to advancing preventive neurology, Dr Dodick has championed a proactive approach to healthcare, emphasizing the integration of data-driven precision medicine to optimize cognitive and overall health. Under his leadership, Atria’s multidisciplinary team is pioneering strategies that promise to reshape how aging and brain health are managed.

As well as presenting an Introduction to the Longevity Universe, Dodick will be discussing viewpoints around The Use of Gerodiagnostics with Jeremy Lim (CEO, Ameli) and Vishal Harnal (Managing Partner, 500 Global). In anticipation of next month's forum, we spoke with Dr. Dodick about the shift from reactive to proactive care, the importance of data sharing and collaboration in longevity science, and why cognitive health should be prioritized from an early age.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#regi...

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Atria: https://www.atria.org/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379857Fri, 17 Jan 2025 16:48:18 +0000saderDavid Dodick on the evolving landscape of preventive healthcare and growing investment opportunities in proactive healthcare. The Founders Longevity Forum Singapore is gearing up to be a landmark event next month, uniting leading minds from science,...
The Founders Longevity Forum Singapore is gearing up to be a landmark event next month, uniting leading minds from science, medicine and investment to explore transformative solutions for healthy aging. Organized by Founders Forum, the Academy for Healthy Longevity at the National University of Singapore, and Longevity.Technology, this two-day gathering aims to accelerate progress in longevity research, foster collaborations and highlight innovation in the Asia-Pacific region – positioning Singapore as a global hub for aging science and healthspan advancements.

Dr David Dodick, Chief Science and Medical Officer at Atria, is among the distinguished speakers set to take the stage. With a career dedicated to advancing preventive neurology, Dr Dodick has championed a proactive approach to healthcare, emphasizing the integration of data-driven precision medicine to optimize cognitive and overall health. Under his leadership, Atria’s multidisciplinary team is pioneering strategies that promise to reshape how aging and brain health are managed.

As well as presenting an Introduction to the Longevity Universe, Dodick will be discussing viewpoints around The Use of Gerodiagnostics with Jeremy Lim (CEO, Ameli) and Vishal Harnal (Managing Partner, 500 Global). In anticipation of next month's forum, we spoke with Dr. Dodick about the shift from reactive to proactive care, the importance of data sharing and collaboration in longevity science, and why cognitive health should be prioritized from an early age.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#regi...

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Atria: https://www.atria.org/]]>1809falsefullhttps://www.spreaker.com/episode/walking-8-000-steps-is-the-ultimate-pill--74818242
From the simplicity of walking 8,000 steps to the power of sitting on the floor, his advice makes staying active and healthy accessible for everyone.

Key takeaways:
✅ Mobility = freedom to move pain-free
✅ Pain is your body’s “check-engine light”
✅ The Eights: Sleep, protein, veggies, and steps

Ready to take control of your health? Check out his conversation with Phil about his practical framework and start your journey to better living today.

#longevitysecrets #longevitytechnology #longevitylifestyle #longevitytips #mobilityimprovement #mobilitycoach #movementpractice #agingwell #agingwithgrace #agingprevention]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379975Wed, 15 Jan 2025 20:15:01 +0000saderDr Kelly Starrett, co-founder of The Ready State, shares game-changing tips on improving mobility, managing pain, and building lifelong resilience. From the simplicity of walking 8,000 steps to the power of sitting on the floor, his advice makes...
From the simplicity of walking 8,000 steps to the power of sitting on the floor, his advice makes staying active and healthy accessible for everyone.

Key takeaways:
✅ Mobility = freedom to move pain-free
✅ Pain is your body’s “check-engine light”
✅ The Eights: Sleep, protein, veggies, and steps

Ready to take control of your health? Check out his conversation with Phil about his practical framework and start your journey to better living today.

#longevitysecrets #longevitytechnology #longevitylifestyle #longevitytips #mobilityimprovement #mobilitycoach #movementpractice #agingwell #agingwithgrace #agingprevention]]>2105falsefullhttps://www.spreaker.com/episode/i-see-huge-scope-in-longevity-medicine--74818163
The Gulf Cooperation Council (GCC) region is currently experiencing significant economic growth and demographic shifts. The population across these nations has surged to nearly 60 million, and this growth is accompanied by a youthful demographic profile; in 2021, over 50% of the local population in GCC countries was under 25, while the proportion of older citizens remained low, with some countries having less than 6% of locals over the age of 65. But young people get old, and the GCC countries countries are making significant strides in addressing longevity and healthy aging, and Dubai, in particular, is demonstrating a forward-looking approach to longevity and healthspan. 

Dubai continues to attract global attention for its rapid development and investment opportunities. In line with this growth, BioAro Group, a Canadian biotech company specializing in genomics and precision medicine, has expanded its operations to the region, and under the leadership of cardiologist Dr Anmol Kapoor, BioAro has established a new Precision Health and Longevity Clinic in Dubai, which opened last year.

BioAro's expansion into Dubai is part of a broader strategy to establish the UAE as a global hub for precision medicine, genomics and personalized care. By investing in genome labs, clinics, and training for medical professionals, BioAro seeks to revolutionize healthcare delivery in the region, extending health spans and improving the quality of life for the population.

It's an initiative that aligns with the UAE's commitment to advancing healthcare services and embracing innovative technologies to meet the needs of its dynamic and growing population. The integration of precision medicine into the healthcare system could well address the unique demographic challenges of the GCC region, promoting proactive health management and disease prevention. To find out more about the burgeoning landscape of longevity practices in the GCC, we sat down with Anmol Kapoor, CEO of BioAro.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about BioAro: https://www.bioaro.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561380020Tue, 14 Jan 2025 17:10:29 +0000saderBioAro's Anmol Kapoor on Dubai as a centre for longevity and how blockchain can enhance delivery and control of personalized healthcare. The Gulf Cooperation Council (GCC) region is currently experiencing significant economic growth and demographic...
The Gulf Cooperation Council (GCC) region is currently experiencing significant economic growth and demographic shifts. The population across these nations has surged to nearly 60 million, and this growth is accompanied by a youthful demographic profile; in 2021, over 50% of the local population in GCC countries was under 25, while the proportion of older citizens remained low, with some countries having less than 6% of locals over the age of 65. But young people get old, and the GCC countries countries are making significant strides in addressing longevity and healthy aging, and Dubai, in particular, is demonstrating a forward-looking approach to longevity and healthspan. 

Dubai continues to attract global attention for its rapid development and investment opportunities. In line with this growth, BioAro Group, a Canadian biotech company specializing in genomics and precision medicine, has expanded its operations to the region, and under the leadership of cardiologist Dr Anmol Kapoor, BioAro has established a new Precision Health and Longevity Clinic in Dubai, which opened last year.

BioAro's expansion into Dubai is part of a broader strategy to establish the UAE as a global hub for precision medicine, genomics and personalized care. By investing in genome labs, clinics, and training for medical professionals, BioAro seeks to revolutionize healthcare delivery in the region, extending health spans and improving the quality of life for the population.

It's an initiative that aligns with the UAE's commitment to advancing healthcare services and embracing innovative technologies to meet the needs of its dynamic and growing population. The integration of precision medicine into the healthcare system could well address the unique demographic challenges of the GCC region, promoting proactive health management and disease prevention. To find out more about the burgeoning landscape of longevity practices in the GCC, we sat down with Anmol Kapoor, CEO of BioAro.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about BioAro: https://www.bioaro.com/]]>1288falsefullhttps://www.spreaker.com/episode/longevity-really-resides-in-prevention--74818136
The Founders Longevity Forum Singapore is just around the corner! This highly anticipated two-day event will bring together leading experts from science, healthcare, and investment to explore innovative breakthroughs and actionable strategies for promoting healthy aging. As global interest in longevity continues to soar, the forum will spotlight cutting-edge advancements in healthspan and vitality, foster impactful collaborations, and ignite critical discussions. With a spotlight on the Asia-Pacific region, the event will also highlight Singapore’s growing role as a pioneering hub for addressing the complexities of aging through innovation.

Yuta Lee, Founder and Chief Executive Officer of Accelerated Biosciences is a highly-anticipated speaker at the event. Under his leadership, Accelerated Biosciences has advanced the commercialization of human trophoblast stem cells (hTSCs), a pluripotent and immune-privileged stem cell platform with significant potential in regenerative medicine. Lee's strategic direction has been key in securing a robust patent portfolio, with over 49 patents granted worldwide, providing freedom-to-operate for partners seeking clear pathways to commercialization.

Lee's commitment to accelerating cell and gene therapies aims to address critical challenges associated with an aging population and escalating healthcare costs, positioning him as a leading figure in the field of regenerative medicine. Stem cells are a growing topic in longevity in both the biotech and the clinical spheres and Lee will be discussing Stem Cell Therapies at the Forum along with Mattias Bernow (CEO, Cellcolabs) and Jordan Schlain (Founder & Chairman, Private Medical). Ahead of next month's event, we sat down with Lee to discuss advancements in stem cell therapies, the scalability of human trophoblast stem cells, and the potential of exosomes in combating aging and chronic diseases.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Accelerated Biosciences: https://www.acceleratedbio.com/ https://www.longevitytech.fund/en/home]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987455561379871Mon, 13 Jan 2025 13:09:16 +0000saderYuta Lee on the future of stem cell therapies in enhancing healthspan and the challenges faced in regulatory approval for aging therapies. The Founders Longevity Forum Singapore is just around the corner! This highly anticipated two-day event will...
The Founders Longevity Forum Singapore is just around the corner! This highly anticipated two-day event will bring together leading experts from science, healthcare, and investment to explore innovative breakthroughs and actionable strategies for promoting healthy aging. As global interest in longevity continues to soar, the forum will spotlight cutting-edge advancements in healthspan and vitality, foster impactful collaborations, and ignite critical discussions. With a spotlight on the Asia-Pacific region, the event will also highlight Singapore’s growing role as a pioneering hub for addressing the complexities of aging through innovation.

Yuta Lee, Founder and Chief Executive Officer of Accelerated Biosciences is a highly-anticipated speaker at the event. Under his leadership, Accelerated Biosciences has advanced the commercialization of human trophoblast stem cells (hTSCs), a pluripotent and immune-privileged stem cell platform with significant potential in regenerative medicine. Lee's strategic direction has been key in securing a robust patent portfolio, with over 49 patents granted worldwide, providing freedom-to-operate for partners seeking clear pathways to commercialization.

Lee's commitment to accelerating cell and gene therapies aims to address critical challenges associated with an aging population and escalating healthcare costs, positioning him as a leading figure in the field of regenerative medicine. Stem cells are a growing topic in longevity in both the biotech and the clinical spheres and Lee will be discussing Stem Cell Therapies at the Forum along with Mattias Bernow (CEO, Cellcolabs) and Jordan Schlain (Founder & Chairman, Private Medical). Ahead of next month's event, we sat down with Lee to discuss advancements in stem cell therapies, the scalability of human trophoblast stem cells, and the potential of exosomes in combating aging and chronic diseases.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Accelerated Biosciences: https://www.acceleratedbio.com/ https://www.longevitytech.fund/en/home]]>737falsefullhttps://www.spreaker.com/episode/time-is-ticking-and-we-need-to-do-more-than-just-lifestyle-changes--74818123
The countdown to the Founders Longevity Forum Singapore has begun! Set to gather top minds from the worlds of science, healthcare and investment, this two-day event next month will delve into groundbreaking research and practical solutions for healthy aging. As interest in longevity accelerates worldwide, the forum aims to drive meaningful discussions, foster partnerships and showcase cutting-edge advancements in healthspan and vitality. With a strong focus on the Asia-Pacific region, it will also focus on Singapore’s emergence as a leading hub for innovation in addressing the challenges of aging.

Petr Šrámek, Cofounder, Chairman and Managing/General Partner at LongevityTech.Fund, will be a prominent attendee at the event. Renowned for his expertise in longevity-focused investments, Šrámek has played a pivotal role in identifying and funding innovative pre-clinical therapies with the potential to transform aging science. His leadership at LongevityTech.Fund has fostered groundbreaking advancements in the field, making him a prominent voice in longevity investment strategies.

Šrámek’s presentation on Investing in Pre-clinical Longevity Therapies will shed light on the financial and strategic considerations involved in accelerating early-stage therapies. This session promises to offer valuable insights into bridging the gap between cutting-edge research and real-world applications. Ahead of February’s Forum, we spoke with Šrámek to explore his vision for longevity investments, the role of venture capital in this field, and his thoughts on the future of pre-clinical therapies.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about LongevityTech.fund: https://www.longevitytech.fund/en/home]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686557Mon, 06 Jan 2025 18:25:38 +0000saderPetr Šrámek on the evolution of longevity clinics, the challenges faced in the industry and the need for a prevention-focused approach. The countdown to the Founders Longevity Forum Singapore has begun! Set to gather top minds from the worlds of...
The countdown to the Founders Longevity Forum Singapore has begun! Set to gather top minds from the worlds of science, healthcare and investment, this two-day event next month will delve into groundbreaking research and practical solutions for healthy aging. As interest in longevity accelerates worldwide, the forum aims to drive meaningful discussions, foster partnerships and showcase cutting-edge advancements in healthspan and vitality. With a strong focus on the Asia-Pacific region, it will also focus on Singapore’s emergence as a leading hub for innovation in addressing the challenges of aging.

Petr Šrámek, Cofounder, Chairman and Managing/General Partner at LongevityTech.Fund, will be a prominent attendee at the event. Renowned for his expertise in longevity-focused investments, Šrámek has played a pivotal role in identifying and funding innovative pre-clinical therapies with the potential to transform aging science. His leadership at LongevityTech.Fund has fostered groundbreaking advancements in the field, making him a prominent voice in longevity investment strategies.

Šrámek’s presentation on Investing in Pre-clinical Longevity Therapies will shed light on the financial and strategic considerations involved in accelerating early-stage therapies. This session promises to offer valuable insights into bridging the gap between cutting-edge research and real-world applications. Ahead of February’s Forum, we spoke with Šrámek to explore his vision for longevity investments, the role of venture capital in this field, and his thoughts on the future of pre-clinical therapies.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about LongevityTech.fund: https://www.longevitytech.fund/en/home]]>1252falsefullhttps://www.spreaker.com/episode/mindset-is-the-single-most-important-thing--74818154
The Roundtable of Longevity Clinics took place at the Buck Institute in California recently. Organized by the International Institute for Longevity, the event brought together leaders and innovators from all over the world intent on identifying effective diagnostics and recommendations for longevity-focused interventions, supplements, and therapies, exploring and implementing the latest longevity trends and solutions and establishing gold standards for longevity clinics, diagnostics, and interventions.

In attendance was entrepreneur, futurist and New York Times bestselling author Dr Peter Diamandis. Diamandis, who is also Founder & Executive Chairman of XPRIZE Foundation, sat down with Joanna Bensz of Longevity Center to share his thoughts on data, wearables, quantified self and really how AI is going to be a key tool in longevity, both at a macro level, but also at an n-of-1 level.

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about the Roundtable of Longevity Clinics: https://longevity-roundtable.com/

Video courtesy of International Institute for Longevity]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686616Fri, 03 Jan 2025 17:19:18 +0000saderIn conversation with Joanna Bensz, Peter Diamandis talks longevity clinics, use of wearables, motivation for change and longevity mindsets. The Roundtable of Longevity Clinics took place at the Buck Institute in California recently. Organized by the...
The Roundtable of Longevity Clinics took place at the Buck Institute in California recently. Organized by the International Institute for Longevity, the event brought together leaders and innovators from all over the world intent on identifying effective diagnostics and recommendations for longevity-focused interventions, supplements, and therapies, exploring and implementing the latest longevity trends and solutions and establishing gold standards for longevity clinics, diagnostics, and interventions.

In attendance was entrepreneur, futurist and New York Times bestselling author Dr Peter Diamandis. Diamandis, who is also Founder & Executive Chairman of XPRIZE Foundation, sat down with Joanna Bensz of Longevity Center to share his thoughts on data, wearables, quantified self and really how AI is going to be a key tool in longevity, both at a macro level, but also at an n-of-1 level.

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about the Roundtable of Longevity Clinics: https://longevity-roundtable.com/

Video courtesy of International Institute for Longevity]]>507falsefullhttps://www.spreaker.com/episode/the-next-frontier-of-longevity-human-healthspan-resilience--74818128
Founders Longevity Forum Singapore is only a couple of months away! Poised to bring together global leaders in longevity science, the two-day event will focus on the latest research and applications in healthy aging. With the growing global focus on longevity, this gathering provides a dynamic platform to showcase innovations and ignite partnerships that advance the pursuit of extended healthspan and vitality, and will also highlight Singapore's role as a hub for innovation in tackling aging-relating challenges.

Tina Woods, Executive Director of the International Institute of Longevity, will be a key participant at the event. Known for her dedication to advancing global longevity strategies, Woods has been instrumental in fostering collaborations between researchers, technology developers and healthcare providers, and her expertise will add depth to discussions on how to create scalable, evidence-based solutions for aging populations worldwide.

Longevity.Technology: Tina Woods' presentation with Jacqueline Poh, Managing Director of the Singapore Economic Development Board (EDB), on Governments Leading the Way is set to be a Forum highlight. Ahead of February's Forum, we sat down with Tina to get her thoughts on longevity clinics, the need for international standards and regulations and more.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about the International Institute of Longevity: https://l-institute.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686618Mon, 30 Dec 2024 16:28:26 +0000saderTina Woods on evidence-based practices, government policies on public health and why Singapore is a model for longevity initiatives. Founders Longevity Forum Singapore is only a couple of months away! Poised to bring together global leaders in...
Founders Longevity Forum Singapore is only a couple of months away! Poised to bring together global leaders in longevity science, the two-day event will focus on the latest research and applications in healthy aging. With the growing global focus on longevity, this gathering provides a dynamic platform to showcase innovations and ignite partnerships that advance the pursuit of extended healthspan and vitality, and will also highlight Singapore's role as a hub for innovation in tackling aging-relating challenges.

Tina Woods, Executive Director of the International Institute of Longevity, will be a key participant at the event. Known for her dedication to advancing global longevity strategies, Woods has been instrumental in fostering collaborations between researchers, technology developers and healthcare providers, and her expertise will add depth to discussions on how to create scalable, evidence-based solutions for aging populations worldwide.

Longevity.Technology: Tina Woods' presentation with Jacqueline Poh, Managing Director of the Singapore Economic Development Board (EDB), on Governments Leading the Way is set to be a Forum highlight. Ahead of February's Forum, we sat down with Tina to get her thoughts on longevity clinics, the need for international standards and regulations and more.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about the International Institute of Longevity: https://l-institute.com/]]>1057falsefullhttps://www.spreaker.com/episode/2025-will-be-a-big-year-for-longevity-clinics--74818167
Check out the interim results of our Longevity Clinics Survey 2024 – full results will be published in January 2025.

And, if you are part of a longevity clinical team, here is the chance for you to participate in the survey:
https://www.surveymonkey.com/r/longevityclinics2024

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686564Fri, 27 Dec 2024 18:03:21 +0000saderFor longevity clinics, it is time to get ready for 2025, which will see wider integration of recognized standards, wider use of AI in clinical decision making and debates around access to longevity and healthspan support for the less well-off. Check...
Check out the interim results of our Longevity Clinics Survey 2024 – full results will be published in January 2025.

And, if you are part of a longevity clinical team, here is the chance for you to participate in the survey:
https://www.surveymonkey.com/r/longevityclinics2024

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf]]>848falsefullhttps://www.spreaker.com/episode/exercise-is-great-for-longevity-we-can-make-it-work-even-better--74818133
Founders Longevity Forum is gearing up for its Singapore event next year, bringing leading voices from clinical innovation, academic research and investment to spotlight the rapidly evolving longevity sector. With a particular emphasis on advancements within the Asia-Pacific region, the forum promises a robust exchange of ideas and strategies aimed at reshaping healthspan and lifespan. As global interest in longevity intensifies, this event serves as a pivotal platform for uncovering breakthroughs and fostering collaboration among experts and visionaries.

Among the esteemed speakers is Dr Siobhan Mitchell, Chief Science Officer at MitoQ, the New Zealand-based biotech which developed a next-generation cell health molecule designed to penetrate deep within cells to reduce oxidative stress. This innovation supports the body's primary energy source – the mitochondria – aiming to improve energy levels, enhance exercise recovery and promote healthy aging.

Renowned for her work in advancing mitochondrial science, Dr Mitchell has played a key role in MitoQ's development of cutting-edge supplements designed to optimize energy production and combat oxidative stress at the cellular level. Mitchell is well placed to highlight the importance of mitochondria in supporting healthspan, and to bring into focus how innovative approaches can transform the way we age and live healthier, longer lives. Ahead of FLF SG, we sat down with her to discuss MitoQ’s research breakthroughs, the challenges of scaling supplement innovation and tailoring healthspan strategies to individual needs.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about MitoQ: https://www.mitoq.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686562Fri, 20 Dec 2024 15:58:27 +0000saderMitoQ's Dr Siobhan Mitchell on the role of mitochondria in healthspan, global longevity trends and the future of healthspan science. Founders Longevity Forum is gearing up for its Singapore event next year, bringing leading voices from clinical...
Founders Longevity Forum is gearing up for its Singapore event next year, bringing leading voices from clinical innovation, academic research and investment to spotlight the rapidly evolving longevity sector. With a particular emphasis on advancements within the Asia-Pacific region, the forum promises a robust exchange of ideas and strategies aimed at reshaping healthspan and lifespan. As global interest in longevity intensifies, this event serves as a pivotal platform for uncovering breakthroughs and fostering collaboration among experts and visionaries.

Among the esteemed speakers is Dr Siobhan Mitchell, Chief Science Officer at MitoQ, the New Zealand-based biotech which developed a next-generation cell health molecule designed to penetrate deep within cells to reduce oxidative stress. This innovation supports the body's primary energy source – the mitochondria – aiming to improve energy levels, enhance exercise recovery and promote healthy aging.

Renowned for her work in advancing mitochondrial science, Dr Mitchell has played a key role in MitoQ's development of cutting-edge supplements designed to optimize energy production and combat oxidative stress at the cellular level. Mitchell is well placed to highlight the importance of mitochondria in supporting healthspan, and to bring into focus how innovative approaches can transform the way we age and live healthier, longer lives. Ahead of FLF SG, we sat down with her to discuss MitoQ’s research breakthroughs, the challenges of scaling supplement innovation and tailoring healthspan strategies to individual needs.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about MitoQ: https://www.mitoq.com/]]>889falsefullhttps://www.spreaker.com/episode/xprize-healthspan-will-innovate-and-advance-the-field--74818164
Launched last year, the XPRIZE Healthspan is a $101 million global competition aimed at revolutionizing human aging. The winning team of must demonstrate that their solution restores muscle, cognitive and immune function by a minimum of 10 years, with a goal of 20 years, in people aged 50 to 80 years. Additionally, any treatment must take less than one year.

Submissions are flying in from all around the world, and with the Primary Registration Period closing tomorrow, we caught up with Dr Jamie Justice, Executive Vice President of the Health Domain at XPRIZE Foundation, to find out what has been happening so far – and something exciting happening in New York in 2025…

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about XPRIZE Healthspan: https://www.xprize.org/prizes/healthspan]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686610Thu, 19 Dec 2024 18:15:45 +0000saderFrom global reach to breadth of innovation and approach, Dr Jamie Justice talks XPRIZE Healthspan progress. Launched last year, the XPRIZE Healthspan is a $101 million global competition aimed at revolutionizing human aging. The winning team of must...
Launched last year, the XPRIZE Healthspan is a $101 million global competition aimed at revolutionizing human aging. The winning team of must demonstrate that their solution restores muscle, cognitive and immune function by a minimum of 10 years, with a goal of 20 years, in people aged 50 to 80 years. Additionally, any treatment must take less than one year.

Submissions are flying in from all around the world, and with the Primary Registration Period closing tomorrow, we caught up with Dr Jamie Justice, Executive Vice President of the Health Domain at XPRIZE Foundation, to find out what has been happening so far – and something exciting happening in New York in 2025…

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about XPRIZE Healthspan: https://www.xprize.org/prizes/healthspan]]>1519falsefullhttps://www.spreaker.com/episode/we-do-not-know-what-the-future-is-made-of--74818190
The longevity field was stirred in October 2024 by a provocative paper published in Nature Aging titled The Implausibility of Radical Life Extension in Humans in the 21st Century. Writen by S Jay Olshansky, Bradley J Willcox, Lloyd Demetrius and Hiram Beltrán-Sánchez, the paper explored demographic trends and mortality data to challenge one of the central ambitions of modern longevity science – extending human life far beyond current biological limits.

In the paper, the authors analyze life expectancy and mortality rates from the world’s longest-living populations, uncovering a marked deceleration in life expectancy gains since 1990. They argue that without revolutionary advancements in slowing biological aging, the likelihood of a significant leap in human lifespan – particularly the widespread survival to age 100 and beyond – is slim.

This conclusion has sparked heated discussions within longevity circles, raising critical questions about the gap between what is achievable in healthspan and the more aspirational moonshots of radical life extension – will extension be iterative or are we approaching a hard stop?

We sat down with Dr Eric Verdin, President and CEO of The Buck Institute to find out his view on the paper and the ensuing debate, and why focusing on the longevity paycheck could be a smarter strategy than playing the longevity lottery.

Read the paper discussed here: https://www.nature.com/articles/s43587-024-00702-3
---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about The Buck Institute: https://www.buckinstitute.org/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686592Wed, 11 Dec 2024 17:54:20 +0000saderDr Eric Verdin of The Buck Institute for Research on Aging on finding the longevity sweet spot between realism and optimism. The longevity field was stirred in October 2024 by a provocative paper published in Nature Aging titled The Implausibility of...
The longevity field was stirred in October 2024 by a provocative paper published in Nature Aging titled The Implausibility of Radical Life Extension in Humans in the 21st Century. Writen by S Jay Olshansky, Bradley J Willcox, Lloyd Demetrius and Hiram Beltrán-Sánchez, the paper explored demographic trends and mortality data to challenge one of the central ambitions of modern longevity science – extending human life far beyond current biological limits.

In the paper, the authors analyze life expectancy and mortality rates from the world’s longest-living populations, uncovering a marked deceleration in life expectancy gains since 1990. They argue that without revolutionary advancements in slowing biological aging, the likelihood of a significant leap in human lifespan – particularly the widespread survival to age 100 and beyond – is slim.

This conclusion has sparked heated discussions within longevity circles, raising critical questions about the gap between what is achievable in healthspan and the more aspirational moonshots of radical life extension – will extension be iterative or are we approaching a hard stop?

We sat down with Dr Eric Verdin, President and CEO of The Buck Institute to find out his view on the paper and the ensuing debate, and why focusing on the longevity paycheck could be a smarter strategy than playing the longevity lottery.

Read the paper discussed here: https://www.nature.com/articles/s43587-024-00702-3
---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about The Buck Institute: https://www.buckinstitute.org/]]>1142falsefullhttps://www.spreaker.com/episode/if-there-s-one-pill-for-longevity-it-s-exercise--74818198
In this interview, Kayla explains why regular physical activity is essential for both brain and body health. From improving blood flow to increasing dopamine levels, exercise offers incredible benefits that go beyond fitness.

Kayla dives into the science of how movement boosts energy, sharpens focus, and supports longevity markers like VO2 max, grip strength, and gait speed. She also shares why muscle is considered an organ of longevity and how building strength can help you stay healthier as you age.

Whether you’re just getting started or already an exercise enthusiast, Kayla’s practical advice will inspire you to make movement a daily habit. “I don’t have the energy not to work out,” she shares, emphasizing how exercise fuels both physical and mental resilience.

Want to know more about Kayla’s biohacking techniques, including hyperbaric oxygen therapy and red light therapy? Check out the full interview for more insights into her health optimization strategies.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Kayla: https://www.kaylabarnes.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686614Fri, 06 Dec 2024 15:00:55 +0000saderWhat’s the closest thing to a pill for longevity? According to biohacker and brain health expert Kayla Barnes-Lentz, it’s exercise. In this interview, Kayla explains why regular physical activity is essential for both brain and body health. From...
In this interview, Kayla explains why regular physical activity is essential for both brain and body health. From improving blood flow to increasing dopamine levels, exercise offers incredible benefits that go beyond fitness.

Kayla dives into the science of how movement boosts energy, sharpens focus, and supports longevity markers like VO2 max, grip strength, and gait speed. She also shares why muscle is considered an organ of longevity and how building strength can help you stay healthier as you age.

Whether you’re just getting started or already an exercise enthusiast, Kayla’s practical advice will inspire you to make movement a daily habit. “I don’t have the energy not to work out,” she shares, emphasizing how exercise fuels both physical and mental resilience.

Want to know more about Kayla’s biohacking techniques, including hyperbaric oxygen therapy and red light therapy? Check out the full interview for more insights into her health optimization strategies.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Kayla: https://www.kaylabarnes.com/]]>1441falsefullhttps://www.spreaker.com/episode/longevity-protocols-we-re-not-chasing-rainbows--74818180
The Founders Longevity Forum is set to make waves in Singapore, bringing together a distinguished lineup of global leaders in clinical innovation, academic research and investment. With a focus on advancing knowledge about the rapidly growing longevity sector, especially across the Asia-Pacific region, the event promises to foster dynamic discussions and collaboration. As interest in this field continues to surge globally, the forum will serve as a vital platform for exploring cutting-edge developments and strategies aimed at enhancing healthspan and lifespan.

Among the impressive roster of speakers is David Gobel, cofounder and CEO of the Methuselah Foundation, a nonprofit dedicated to extending the healthy human lifespan. Known for its ambitious goal of making “90 the new 50 by 2030,” the foundation has been a trailblazer in driving transformative research and initiatives in longevity science. Gobel’s leadership has steered the organization’s investments in innovative R&D projects, groundbreaking partnerships and incentive prizes that challenge conventional thinking about aging and human health.

As we gear up for Singapore, we'll be whetting your interest by bringing you a series of interviews with some of our speakers. We're kicking off with David Gobel, who shares shares insights on his work with the Methuselah Foundation, discusses longevity protocols and speaks candidly about his own experience of GLP1s.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Methuselah Foundation: https://www.mfoundation.org/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686605Fri, 29 Nov 2024 17:16:57 +0000saderMethuselah Foundation CEO David Gobel on why wild cards and binary answers make for interesting longevity bets. The Founders Longevity Forum is set to make waves in Singapore, bringing together a distinguished lineup of global leaders in clinical...
The Founders Longevity Forum is set to make waves in Singapore, bringing together a distinguished lineup of global leaders in clinical innovation, academic research and investment. With a focus on advancing knowledge about the rapidly growing longevity sector, especially across the Asia-Pacific region, the event promises to foster dynamic discussions and collaboration. As interest in this field continues to surge globally, the forum will serve as a vital platform for exploring cutting-edge developments and strategies aimed at enhancing healthspan and lifespan.

Among the impressive roster of speakers is David Gobel, cofounder and CEO of the Methuselah Foundation, a nonprofit dedicated to extending the healthy human lifespan. Known for its ambitious goal of making “90 the new 50 by 2030,” the foundation has been a trailblazer in driving transformative research and initiatives in longevity science. Gobel’s leadership has steered the organization’s investments in innovative R&D projects, groundbreaking partnerships and incentive prizes that challenge conventional thinking about aging and human health.

As we gear up for Singapore, we'll be whetting your interest by bringing you a series of interviews with some of our speakers. We're kicking off with David Gobel, who shares shares insights on his work with the Methuselah Foundation, discusses longevity protocols and speaks candidly about his own experience of GLP1s.

Find out more about Founders Longevity Forum Singapore:
https://founderslongevity.co/sg/#register

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Methuselah Foundation: https://www.mfoundation.org/]]>885falsefullhttps://www.spreaker.com/episode/nutrition-diseases-have-gone-from-deficiency-related-to-excess-related--74818155
Nutrition is one of the foundational pillars of longevity, shaping not just how long we live, but the quality of those years. The balance of what we eat – and how much – directly influences our healthspan, the period of life spent in good health. Overeating can lead to chronic conditions like obesity, diabetes and cardiovascular disease, while deficiencies in essential nutrients can weaken immunity, impair cellular repair and accelerate aging processes.

Striking the right nutritional balance is not merely about avoiding disease – it’s about fueling the body to function optimally, supporting energy, resilience and vitality at every stage of life. Understanding and optimizing nutrition is essential for anyone seeking to live healthier, longer lives.

Dr Michael Greger, a leading authority on evidence-based nutrition and the powerful role that diet plays in preventing chronic disease. He is also the founder of NutritionFacts.org, a science-based nonprofit organization that provides free updates on the latest in nutrition research via bite-sized videos, blogs, podcasts and infographics. We sat down with Dr Greger to find out more on the challenges and misconceptions surrounding nutrition and diet trends and the importance of eating well for longevity.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about NutritionFacts.org: https://nutritionfacts.org/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686584Tue, 26 Nov 2024 16:57:53 +0000saderDr Michael Greger on the modern diet's impact on longevity and the path to less inflammation and improved healthspan. Nutrition is one of the foundational pillars of longevity, shaping not just how long we live, but the quality of those years. The...
Nutrition is one of the foundational pillars of longevity, shaping not just how long we live, but the quality of those years. The balance of what we eat – and how much – directly influences our healthspan, the period of life spent in good health. Overeating can lead to chronic conditions like obesity, diabetes and cardiovascular disease, while deficiencies in essential nutrients can weaken immunity, impair cellular repair and accelerate aging processes.

Striking the right nutritional balance is not merely about avoiding disease – it’s about fueling the body to function optimally, supporting energy, resilience and vitality at every stage of life. Understanding and optimizing nutrition is essential for anyone seeking to live healthier, longer lives.

Dr Michael Greger, a leading authority on evidence-based nutrition and the powerful role that diet plays in preventing chronic disease. He is also the founder of NutritionFacts.org, a science-based nonprofit organization that provides free updates on the latest in nutrition research via bite-sized videos, blogs, podcasts and infographics. We sat down with Dr Greger to find out more on the challenges and misconceptions surrounding nutrition and diet trends and the importance of eating well for longevity.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about NutritionFacts.org: https://nutritionfacts.org/]]>1068falsefullhttps://www.spreaker.com/episode/ten-levels-of-longevity--74818096
In September, the Longevity Investors Conference was held in Gstaad, Switzerland; the conference brought together leading scientists, investors and innovators to discuss advancements in longevity science and investment opportunities, and it was also when we unveiled our Ten Levels of Longevity which aims to provide a structured perspective on the multifaceted approaches to enhancing human healthspan and lifespan and reflect the the importance of a holistic and tiered understanding in the pursuit of longevity.

The Ten Levels of Longevity framework offers a structured approach to understanding the diverse interventions and strategies aimed at extending human healthspan and lifespan. These levels encompass a spectrum from foundational lifestyle modifications to advanced biomedical therapies, providing a comprehensive roadmap for individuals and professionals navigating the evolving longevity landscape. By categorizing interventions into distinct stages, this framework facilitates clearer communication, targeted research and personalized application of longevity strategies.

Our thanks to Longevity Investors Conference for the video.
---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686554Wed, 20 Nov 2024 16:46:08 +0000saderLongevity.Technology CEO Phil Newman explains our new framework for categorizing and understanding the complexities of longevity. In September, the Longevity Investors Conference was held in Gstaad, Switzerland; the conference brought together...
In September, the Longevity Investors Conference was held in Gstaad, Switzerland; the conference brought together leading scientists, investors and innovators to discuss advancements in longevity science and investment opportunities, and it was also when we unveiled our Ten Levels of Longevity which aims to provide a structured perspective on the multifaceted approaches to enhancing human healthspan and lifespan and reflect the the importance of a holistic and tiered understanding in the pursuit of longevity.

The Ten Levels of Longevity framework offers a structured approach to understanding the diverse interventions and strategies aimed at extending human healthspan and lifespan. These levels encompass a spectrum from foundational lifestyle modifications to advanced biomedical therapies, providing a comprehensive roadmap for individuals and professionals navigating the evolving longevity landscape. By categorizing interventions into distinct stages, this framework facilitates clearer communication, targeted research and personalized application of longevity strategies.

Our thanks to Longevity Investors Conference for the video.
---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf]]>639falsefullhttps://www.spreaker.com/episode/the-nad-system-is-under-daily-attack-it-needs-boosting--74818201
Longevity.Technology has announced a new venture – the launch of its consumer products division, dedicated to science-backed longevity solutions. Our inaugural product, the FLT LONGEVITY supplement, showcases a unique blend of evidence-based ingredients aimed at enhancing healthspan and cellular vitality.

A major highlight of this launch is the partnership with ChromaDex, a leader in NAD+ research, to feature Niagen – ChromaDex's proprietary nicotinamide riboside (NR) – as the supplement's "hero" ingredient. Niagen has been shown to boost NAD+ levels, essential for cellular and metabolic functions, marking a strong foundation for the supplement's cellular health benefits.

Collaborating with leading suppliers and backed by human trials, Longevity.Technology emphasizes transparency and efficacy. By partnering with ChromaDex, a company known for its dedication to scientific rigor, we are demonstrating a commitment to bringing only the most effective, high-quality products to market. We sat down with one of the foremost experts in NAD+ research, Dr Charles Brenner, who is ChromaDex Chief Scientific Advisor, to find out more about his discovery that nicotinamide riboside is a precursor for NAD+, how NR affects aging and cellular health and Niagen’s potential for improving healthspan.

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y
Shop for FLT LONGEVITY – https://flt.life/

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf

More about ChromaDex: https://www.chromadex.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686593Fri, 15 Nov 2024 16:40:55 +0000saderChromaDex’s Dr Charles Brenner talks NAD+ and explains how Niagen enhances resilience against metabolic stress. Longevity.Technology has announced a new venture – the launch of its consumer products division, dedicated to science-backed longevity...
Longevity.Technology has announced a new venture – the launch of its consumer products division, dedicated to science-backed longevity solutions. Our inaugural product, the FLT LONGEVITY supplement, showcases a unique blend of evidence-based ingredients aimed at enhancing healthspan and cellular vitality.

A major highlight of this launch is the partnership with ChromaDex, a leader in NAD+ research, to feature Niagen – ChromaDex's proprietary nicotinamide riboside (NR) – as the supplement's "hero" ingredient. Niagen has been shown to boost NAD+ levels, essential for cellular and metabolic functions, marking a strong foundation for the supplement's cellular health benefits.

Collaborating with leading suppliers and backed by human trials, Longevity.Technology emphasizes transparency and efficacy. By partnering with ChromaDex, a company known for its dedication to scientific rigor, we are demonstrating a commitment to bringing only the most effective, high-quality products to market. We sat down with one of the foremost experts in NAD+ research, Dr Charles Brenner, who is ChromaDex Chief Scientific Advisor, to find out more about his discovery that nicotinamide riboside is a precursor for NAD+, how NR affects aging and cellular health and Niagen’s potential for improving healthspan.

---------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y
Shop for FLT LONGEVITY – https://flt.life/

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf

More about ChromaDex: https://www.chromadex.com/]]>915falsefullhttps://www.spreaker.com/episode/building-a-bridge-to-robust-and-validated-clinical-biomarkers--74818165
Antiaging treatments are on the verge of becoming commercially available, but the field still lacks standardized, clinically validated tools to accurately measure the aging process and assess the impact of interventions that aim to extend healthspan and lifespan. Establishing these standards is critical to understanding the biology of aging and ensuring the safety and success of future innovations, and as research advances, the need for reliable measurement tools grows, highlighting the importance of collaboration across disciplines. It is a good thing, then, that the Biomarkers of Aging Conference will shortly be upon us.

The Biomarkers of Aging Consortium’s upcoming event at Harvard addresses this need by bringing together leading scientists and industry experts to explore advancements in aging biomarkers and longevity interventions. This gathering fosters interdisciplinary collaboration, with sessions covering bioinformatics, open-source data sharing and innovative challenges (not to mention an interesting n=audience study!).

Through impactful discussions, the event aims to set new standards and advance research applications that could transform the management of aging and healthspan, bridging academic insights with practical applications for accelerated progress in the field. We sat down with two of the Consortium's Executive Committee, Drs Jesse Poganik and Mahdi Moqri to find out more.

More about the Biomarkers of Aging Consortium: https://www.agingconsortium.org/

The Biomarkers of Aging Conference runs 1st & 2nd November at The Joseph B Martin Conference Center, Harvard Medical School, Boston, Massachusetts.
Find out more here: https://www.agingconsortium.org/conference-2024

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686600Wed, 30 Oct 2024 14:27:50 +0000saderBiomarkers of Aging Conference aims to move needle on clinical use of biomarkers, with focus on translation, validation and standardization. Antiaging treatments are on the verge of becoming commercially available, but the field still lacks...
Antiaging treatments are on the verge of becoming commercially available, but the field still lacks standardized, clinically validated tools to accurately measure the aging process and assess the impact of interventions that aim to extend healthspan and lifespan. Establishing these standards is critical to understanding the biology of aging and ensuring the safety and success of future innovations, and as research advances, the need for reliable measurement tools grows, highlighting the importance of collaboration across disciplines. It is a good thing, then, that the Biomarkers of Aging Conference will shortly be upon us.

The Biomarkers of Aging Consortium’s upcoming event at Harvard addresses this need by bringing together leading scientists and industry experts to explore advancements in aging biomarkers and longevity interventions. This gathering fosters interdisciplinary collaboration, with sessions covering bioinformatics, open-source data sharing and innovative challenges (not to mention an interesting n=audience study!).

Through impactful discussions, the event aims to set new standards and advance research applications that could transform the management of aging and healthspan, bridging academic insights with practical applications for accelerated progress in the field. We sat down with two of the Consortium's Executive Committee, Drs Jesse Poganik and Mahdi Moqri to find out more.

More about the Biomarkers of Aging Consortium: https://www.agingconsortium.org/

The Biomarkers of Aging Conference runs 1st & 2nd November at The Joseph B Martin Conference Center, Harvard Medical School, Boston, Massachusetts.
Find out more here: https://www.agingconsortium.org/conference-2024

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf]]>1097falsefullhttps://www.spreaker.com/episode/skincare-powered-by-stem-cell-science--74818171
Aramore stands at the forefront of longevity science with a unique approach to skincare that combines rigorous research with cellular-level interventions. The company’s NAD+ Cell Energizing Lotion, developed by leading scientists from Harvard and MIT, uses a proprietary NAD+ complex that supports cellular health by stimulating energy production in skin cells, promoting skin health and resilience from the inside out. By working at the cellular level, the lotion stimulates metabolism, reinforces skin structure and combats visible aging signs such as wrinkles and loss of firmness, all while supporting the skin's natural barrier functions for long-lasting results.

Aramore’s dedication to innovation is reflected in their years of research to optimize NAD+ delivery through a topical solution. Recognizing that NAD+ molecules are challenging to absorb through the skin, they formulated a complex that includes both NAD+ precursors and essential nutrients to enhance cellular NAD+ synthesis. This advancement not only supports collagen production but also directly addresses the cellular energy decline associated with aging, setting a new standard for effective, science-backed skincare.

This commitment extends beyond skincare products alone. Aramore’s system includes supplements that work internally to support overall skin health, acknowledging the importance of a holistic approach to aging. By addressing both internal and external factors, Aramore has developed a comprehensive regimen that tackles intrinsic and extrinsic aging, underscoring their emphasis on clinically proven results and long-term skin vitality.

We sat down with Sarina Elmariah, Scientific Cofounder, Diana Saville, Cofounder and Head of Research, and Erin Cotter, CEO, to find out more.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Aramore: https://aramoreskincare.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686540Tue, 29 Oct 2024 17:16:42 +0000saderThe Aramore team explains why when it comes to skin health and longevity, it’s good to keep things topical. Aramore stands at the forefront of longevity science with a unique approach to skincare that combines rigorous research with cellular-level...
Aramore stands at the forefront of longevity science with a unique approach to skincare that combines rigorous research with cellular-level interventions. The company’s NAD+ Cell Energizing Lotion, developed by leading scientists from Harvard and MIT, uses a proprietary NAD+ complex that supports cellular health by stimulating energy production in skin cells, promoting skin health and resilience from the inside out. By working at the cellular level, the lotion stimulates metabolism, reinforces skin structure and combats visible aging signs such as wrinkles and loss of firmness, all while supporting the skin's natural barrier functions for long-lasting results.

Aramore’s dedication to innovation is reflected in their years of research to optimize NAD+ delivery through a topical solution. Recognizing that NAD+ molecules are challenging to absorb through the skin, they formulated a complex that includes both NAD+ precursors and essential nutrients to enhance cellular NAD+ synthesis. This advancement not only supports collagen production but also directly addresses the cellular energy decline associated with aging, setting a new standard for effective, science-backed skincare.

This commitment extends beyond skincare products alone. Aramore’s system includes supplements that work internally to support overall skin health, acknowledging the importance of a holistic approach to aging. By addressing both internal and external factors, Aramore has developed a comprehensive regimen that tackles intrinsic and extrinsic aging, underscoring their emphasis on clinically proven results and long-term skin vitality.

We sat down with Sarina Elmariah, Scientific Cofounder, Diana Saville, Cofounder and Head of Research, and Erin Cotter, CEO, to find out more.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Aramore: https://aramoreskincare.com/]]>1532falsefullhttps://www.spreaker.com/episode/we-need-to-science-the-hell-out-of-ovarian-longevity--74818214
Ovarian longevity, a critical subject affecting half of the world's population, is finally gaining attention due to its significant implications for fertility, menopause and women's overall health. With birth rates declining and women's healthspans increasing, scientists and investors are now focused on aligning menopause with this extended lifespan. However, the field faces several challenges, including limited knowledge about women's reproductive health, a broken drug discovery pipeline and a pressing need for better diagnostic and therapeutic solutions.

There are many advancing research areas in in the reproductive longevity field; advancements in genetic diagnostics and gene therapies offer new insights, while innovations such as induced pluripotent stem cells and 3D ovarian cell models hold promise for delaying menopause, extending fertility and addressing age-related diseases. However, there are the complexities of navigating regulatory pathways and the need for increased education, research funding and early intervention.

We sat down with Martin Varsavsky, Founder and Chairman of Gameto, and Stasa Stankovic, a reproductive geneticist and co-founder of OvartiX, to explore the future of ovarian aging and the critical need for a more profound understanding of how later menopause impacts women's health.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Gameto: https://www.gametogen.com/
More about OvartiX: https://ovartix.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686649Tue, 22 Oct 2024 14:30:35 +0000saderOn World Menopause Day, Martin Varsavsky and Stasa Stankovic discuss innovations and challenges in female reproductive longevity. Ovarian longevity, a critical subject affecting half of the world's population, is finally gaining attention due to its...
Ovarian longevity, a critical subject affecting half of the world's population, is finally gaining attention due to its significant implications for fertility, menopause and women's overall health. With birth rates declining and women's healthspans increasing, scientists and investors are now focused on aligning menopause with this extended lifespan. However, the field faces several challenges, including limited knowledge about women's reproductive health, a broken drug discovery pipeline and a pressing need for better diagnostic and therapeutic solutions.

There are many advancing research areas in in the reproductive longevity field; advancements in genetic diagnostics and gene therapies offer new insights, while innovations such as induced pluripotent stem cells and 3D ovarian cell models hold promise for delaying menopause, extending fertility and addressing age-related diseases. However, there are the complexities of navigating regulatory pathways and the need for increased education, research funding and early intervention.

We sat down with Martin Varsavsky, Founder and Chairman of Gameto, and Stasa Stankovic, a reproductive geneticist and co-founder of OvartiX, to explore the future of ovarian aging and the critical need for a more profound understanding of how later menopause impacts women's health.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Gameto: https://www.gametogen.com/
More about OvartiX: https://ovartix.com/]]>2866falsefullhttps://www.spreaker.com/episode/we-already-know-consumers-want-a-new-arena-of-healthcare--74818182
The Longevity Investors Conference (LIC) is set to return to the stunning Swiss town of Gstaad from 24th to 27th September, drawing an exclusive gathering of investors, scientists and entrepreneurs. This fifth edition promises an extended agenda packed with keynotes, panels and numerous networking opportunities. With a focus on cutting-edge innovations in healthspan, biotech and rejuvenation technologies, LIC aims to drive collaboration and spark dialogue between industry pioneers. Attendees will have the chance to engage with world-renowned longevity experts and dive deep into the latest scientific advancements shaping the future of healthy aging.

This year’s LIC stands out not only for its impressive lineup of speakers but also for its immersive experience, blending thought-provoking sessions with ample opportunities for relationship-building. From informal networking lunches to intimate evening receptions, the event fosters a unique atmosphere where participants can exchange insights, explore investment opportunities, and discuss emerging trends. With a growing emphasis on topics like AI applications in biohacking and the evolving longevity economy, LIC is poised to be a cornerstone event for the global longevity community, accelerating innovation and investment in the sector.

Longevity is very much focused on prevention, being, of course, far better than cure! One of the keenly-anticipated presentations speaks to this: Longevity Clinics: The Next Frontier in Preventive Care, which will be presented by Professors Andrea Maier and Evelyne Bischof. We sat down with Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research at National University of Singapore and Co-Director Centre for Healthy Longevity, Andrea B Maier to discuss the conference and more.

Find out more about Longevity Investors Conference here: https://www.longevityinvestors.ch/lic-2024

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686652Wed, 11 Sep 2024 17:02:24 +0000saderAhead of Longevity Investors Conference, Andrea Maier talks industry standards, building out clinical practice and longevity matchmaking. The Longevity Investors Conference (LIC) is set to return to the stunning Swiss town of Gstaad from 24th to 27th...
The Longevity Investors Conference (LIC) is set to return to the stunning Swiss town of Gstaad from 24th to 27th September, drawing an exclusive gathering of investors, scientists and entrepreneurs. This fifth edition promises an extended agenda packed with keynotes, panels and numerous networking opportunities. With a focus on cutting-edge innovations in healthspan, biotech and rejuvenation technologies, LIC aims to drive collaboration and spark dialogue between industry pioneers. Attendees will have the chance to engage with world-renowned longevity experts and dive deep into the latest scientific advancements shaping the future of healthy aging.

This year’s LIC stands out not only for its impressive lineup of speakers but also for its immersive experience, blending thought-provoking sessions with ample opportunities for relationship-building. From informal networking lunches to intimate evening receptions, the event fosters a unique atmosphere where participants can exchange insights, explore investment opportunities, and discuss emerging trends. With a growing emphasis on topics like AI applications in biohacking and the evolving longevity economy, LIC is poised to be a cornerstone event for the global longevity community, accelerating innovation and investment in the sector.

Longevity is very much focused on prevention, being, of course, far better than cure! One of the keenly-anticipated presentations speaks to this: Longevity Clinics: The Next Frontier in Preventive Care, which will be presented by Professors Andrea Maier and Evelyne Bischof. We sat down with Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research at National University of Singapore and Co-Director Centre for Healthy Longevity, Andrea B Maier to discuss the conference and more.

Find out more about Longevity Investors Conference here: https://www.longevityinvestors.ch/lic-2024

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>752falsefullhttps://www.spreaker.com/episode/four-fda-approved-drugs-decrease-overall-mortality-in-humans--74818114
Take a unique mix of investors, scientists and entrepreneurs, a longevity-focused agenda packed with keynotes, panels and networking and put them in a glorious Swiss setting and you have the Longevity Investors Conference.

Kicking off later this month on 24th September in Gstaad, this year's LIC boasts an extended agenda with numerous networking opportunities running over 2.5 days. LIC always boasts a stellar line-up of longevity key opinion leaders, and this means that program discusses the latest trends and developments, and connects investors with state-of-the-art scientific progress.

This is the fifth edition of LIC, and one person who has been at the conference year-on-year is Director of the Einstein Institute for Aging Research at Albert Einstein College of Medicine and President of the Academy for Health and Lifespan Research Nir Barzilai. Ahead of his LIC presentation on Can we grow older without growing sicker?, we sat down with Dr Barzilai to get his take on the conference, advancements in the longevity space and the three FDA-approved drugs out-performing GLP-1 inhibitors on the gerotherapeutic scale.

Find out more about Longevity Investors Conference here: https://www.longevityinvestors.ch/lic-2024

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686579Fri, 06 Sep 2024 16:57:16 +0000saderAhead of his appearance at Longevity Investors Conference, Nir Barzilai talks gerotherapeutics and choosing the right drugs for aging. Take a unique mix of investors, scientists and entrepreneurs, a longevity-focused agenda packed with keynotes,...
Take a unique mix of investors, scientists and entrepreneurs, a longevity-focused agenda packed with keynotes, panels and networking and put them in a glorious Swiss setting and you have the Longevity Investors Conference.

Kicking off later this month on 24th September in Gstaad, this year's LIC boasts an extended agenda with numerous networking opportunities running over 2.5 days. LIC always boasts a stellar line-up of longevity key opinion leaders, and this means that program discusses the latest trends and developments, and connects investors with state-of-the-art scientific progress.

This is the fifth edition of LIC, and one person who has been at the conference year-on-year is Director of the Einstein Institute for Aging Research at Albert Einstein College of Medicine and President of the Academy for Health and Lifespan Research Nir Barzilai. Ahead of his LIC presentation on Can we grow older without growing sicker?, we sat down with Dr Barzilai to get his take on the conference, advancements in the longevity space and the three FDA-approved drugs out-performing GLP-1 inhibitors on the gerotherapeutic scale.

Find out more about Longevity Investors Conference here: https://www.longevityinvestors.ch/lic-2024

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>1312falsefullhttps://www.spreaker.com/episode/there-s-a-tremendous-spectrum-of-pathologies-that-have-shown-success--74818194
Florida-based biotech BioXtek is pioneering the use of placental tissue-derived products in regenerative medicine. The company's proprietary BIOPUR process ensures the preservation of essential bioactive properties and has resulted in highly effective regenerative therapies using amniotic fluid and Wharton’s jelly, components that create an optimal anti-inflammatory and anti-fibrotic environment conducive to healing and regeneration.

BioXtek’s therapies are available as a variety of membrane patches derived from the human placental sac and tailored to meet different medical needs, from minor wounds to more complex healing requirements. These patches, available in single-layer to quad-layer configurations, leverage the synergy of bioactive molecules to enhance cell proliferation, angiogenesis and tissue regeneration while preventing fibrosis. Additionally, BioXtek is integrating advanced technologies like nanotechnology and AI-driven analytics to further refine the delivery and effectiveness of these therapies, positioning itself as a leader in the field of regenerative medicine that is bringing novel therapeutics to mainstream medicine.

We sat down with BioXtek’s CEO Dr Bruce Werber to find out more about innovating regeneration and proving that mechanism of action to the world.
---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about BioXtek: https://bioxtek.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686631Wed, 24 Jul 2024 16:35:42 +0000saderBioXtek CEO Dr Bruce Werber on a new healing paradigm that is going mainstream. Florida-based biotech BioXtek is pioneering the use of placental tissue-derived products in regenerative medicine. The company's proprietary BIOPUR process ensures the...
Florida-based biotech BioXtek is pioneering the use of placental tissue-derived products in regenerative medicine. The company's proprietary BIOPUR process ensures the preservation of essential bioactive properties and has resulted in highly effective regenerative therapies using amniotic fluid and Wharton’s jelly, components that create an optimal anti-inflammatory and anti-fibrotic environment conducive to healing and regeneration.

BioXtek’s therapies are available as a variety of membrane patches derived from the human placental sac and tailored to meet different medical needs, from minor wounds to more complex healing requirements. These patches, available in single-layer to quad-layer configurations, leverage the synergy of bioactive molecules to enhance cell proliferation, angiogenesis and tissue regeneration while preventing fibrosis. Additionally, BioXtek is integrating advanced technologies like nanotechnology and AI-driven analytics to further refine the delivery and effectiveness of these therapies, positioning itself as a leader in the field of regenerative medicine that is bringing novel therapeutics to mainstream medicine.

We sat down with BioXtek’s CEO Dr Bruce Werber to find out more about innovating regeneration and proving that mechanism of action to the world.
---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about BioXtek: https://bioxtek.com/]]>1247falsefullhttps://www.spreaker.com/episode/we-want-to-build-a-standard-here-that-can-be-accepted-anywhere--74818244
This year's developments in Vitalia, Roatán, Honduras captured the attention of the longevity world as the organizers set about transforming what began as a temporary venture into a groundbreaking permanent district within a special economic zone. Initially conceived as a pop-up city with a mission to foster a longevity network society, Vitalia, which is on the island of Roatán in Honduras, aims to revolutionize the biotech landscape by accelerating drug development and exploring life-extending innovations.

Over the course of its two-month run, which kicked off early in January, Vitalia hosted over 200 international participants who engaged in diverse themes ranging from longevity and human improvement to AI and technological progress. It was a convergence of minds and ideas has now laid the foundation for Vitalia to evolve into a permanent fixture, dedicated to advancing healthspan and lifespan through innovative biotech solutions.

Vitalia's transformation into a permanent district marks a significant leap towards creating a hub for longevity science and biotech. The event's success spotlights the island’s conducive environment for medical innovation, leveraging its progressive legal framework to support ambitious biotech endeavors. Discussions and activities during the pop-up city phase, such as the VitaDAO Life Extension Conference, highlighted the potential of decentralized longevity cities and the critical role of community in driving these advancements. With plans to establish multiple hubs globally, Vitalia is making significant progress towards its goal of extending human health and lifespan and is a case study for how to turn visionary concepts into tangible realities. We caught up with Vitalia CEO Niklas Anzinger to find out more.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Vitalia: https://vitalia.city/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686555Fri, 12 Jul 2024 16:18:35 +0000saderVitalia CEO Niklas Anzinger on the longevity city success story – community, credibility and crypto. This year's developments in Vitalia, Roatán, Honduras captured the attention of the longevity world as the organizers set about transforming what...
This year's developments in Vitalia, Roatán, Honduras captured the attention of the longevity world as the organizers set about transforming what began as a temporary venture into a groundbreaking permanent district within a special economic zone. Initially conceived as a pop-up city with a mission to foster a longevity network society, Vitalia, which is on the island of Roatán in Honduras, aims to revolutionize the biotech landscape by accelerating drug development and exploring life-extending innovations.

Over the course of its two-month run, which kicked off early in January, Vitalia hosted over 200 international participants who engaged in diverse themes ranging from longevity and human improvement to AI and technological progress. It was a convergence of minds and ideas has now laid the foundation for Vitalia to evolve into a permanent fixture, dedicated to advancing healthspan and lifespan through innovative biotech solutions.

Vitalia's transformation into a permanent district marks a significant leap towards creating a hub for longevity science and biotech. The event's success spotlights the island’s conducive environment for medical innovation, leveraging its progressive legal framework to support ambitious biotech endeavors. Discussions and activities during the pop-up city phase, such as the VitaDAO Life Extension Conference, highlighted the potential of decentralized longevity cities and the critical role of community in driving these advancements. With plans to establish multiple hubs globally, Vitalia is making significant progress towards its goal of extending human health and lifespan and is a case study for how to turn visionary concepts into tangible realities. We caught up with Vitalia CEO Niklas Anzinger to find out more.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Vitalia: https://vitalia.city/]]>1293falsefullhttps://www.spreaker.com/episode/device-that-reverses-alzheimer-s-cognitive-decline-may-also-increase-human-longevity--74818185
Fourteen years ago, scientists discovered exposing transgenic mice with Alzheimer’s to RF waves produced some exciting results; not only were the mice protected from further cognitive decline, but older mice even experienced a reversal of cognitive impairment. It will come as no surprise that the researchers set about leveraging this tech for a human approach, developing a treatment called Transcranial Radiofrequency Wave Treatment (TRFT). RF Longevity has realized this therapy in a device called MemorEM, a patented, noninvasive technology that has received Breakthrough Device designation from the US FDA as a potential treatment for Alzheimer’s in humans.

The MemorEM device delivers radiofrequency waves to the brain via eight transmitters embedded in a cap and a control box worn on the arm. Users wear the device at home for an hour a day, and experience no sound or sensation associated with the device – they can pretty much get on with anything during this time, although perhaps not grab a shower!

We sat down with Dr Gary Arendash, founder of RF Longevity, to find out more about MemorEM's potential for Alzheimer's therapy and lifespan extension and why all roads for a life extending intervention must go through preventing or lessening dementia.
---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about RF Longevity: https://rflongevity.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686606Wed, 10 Jul 2024 08:06:15 +0000saderRF Longevity Founder Gary Arendash talks immunity, cytokines and increasing human longevity through bioengineering with FDA breakthrough tech. Fourteen years ago, scientists discovered exposing transgenic mice with Alzheimer’s to RF waves produced...
Fourteen years ago, scientists discovered exposing transgenic mice with Alzheimer’s to RF waves produced some exciting results; not only were the mice protected from further cognitive decline, but older mice even experienced a reversal of cognitive impairment. It will come as no surprise that the researchers set about leveraging this tech for a human approach, developing a treatment called Transcranial Radiofrequency Wave Treatment (TRFT). RF Longevity has realized this therapy in a device called MemorEM, a patented, noninvasive technology that has received Breakthrough Device designation from the US FDA as a potential treatment for Alzheimer’s in humans.

The MemorEM device delivers radiofrequency waves to the brain via eight transmitters embedded in a cap and a control box worn on the arm. Users wear the device at home for an hour a day, and experience no sound or sensation associated with the device – they can pretty much get on with anything during this time, although perhaps not grab a shower!

We sat down with Dr Gary Arendash, founder of RF Longevity, to find out more about MemorEM's potential for Alzheimer's therapy and lifespan extension and why all roads for a life extending intervention must go through preventing or lessening dementia.
---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about RF Longevity: https://rflongevity.com/]]>1329falsefullhttps://www.spreaker.com/episode/i-want-a-translation-time-of-zero--74818187
Alden Scientific, a pioneering digital biology company, has emerged at the forefront of personalized healthcare by developing advanced individual predictions to manage health, disease and aging. Using sophisticated plasma proteomics, this innovative US startup has created AI models that can discern intricate connections necessary for an accurate assessment of an individual’s health and disease risk; these models evaluate over 200 different conditions, including major causes of morbidity and mortality such as Alzheimer’s disease, heart disease, diabetes and stroke. It is innovative technology that can empower individuals to comprehend the impact of various interventions on these health risks, offering a nuanced understanding of their overall well-being.

The quest to unravel the complexities of aging and age-related diseases demands an exhaustive analysis of numerous factors – ranging from genetics and the immune system to epigenetics and environmental influences. While AI has long been heralded for its potential to decode these intricate biological interrelations and catalyze a new era of healthcare, the industry has yet to witness the advent of tools that genuinely fulfill this promise. Alden Scientific's recent advancements, however, signify a substantial stride towards realizing this vision, potentially transforming how we approach and manage the multifaceted process of aging.

We sat down with Alden's CEO Jamie Heywood to discuss his motivations behind founding Alden Scientific, the company's groundbreaking approach to personalized health insights, and the innovative applications of their technology in both clinical and research settings.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Alden Scientific: https://www.aldenscientific.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686625Tue, 02 Jul 2024 15:54:00 +0000saderAlden Scientific CEO on creating a GPS for longevity and healthspan. Alden Scientific, a pioneering digital biology company, has emerged at the forefront of personalized healthcare by developing advanced individual predictions to manage health,...
Alden Scientific, a pioneering digital biology company, has emerged at the forefront of personalized healthcare by developing advanced individual predictions to manage health, disease and aging. Using sophisticated plasma proteomics, this innovative US startup has created AI models that can discern intricate connections necessary for an accurate assessment of an individual’s health and disease risk; these models evaluate over 200 different conditions, including major causes of morbidity and mortality such as Alzheimer’s disease, heart disease, diabetes and stroke. It is innovative technology that can empower individuals to comprehend the impact of various interventions on these health risks, offering a nuanced understanding of their overall well-being.

The quest to unravel the complexities of aging and age-related diseases demands an exhaustive analysis of numerous factors – ranging from genetics and the immune system to epigenetics and environmental influences. While AI has long been heralded for its potential to decode these intricate biological interrelations and catalyze a new era of healthcare, the industry has yet to witness the advent of tools that genuinely fulfill this promise. Alden Scientific's recent advancements, however, signify a substantial stride towards realizing this vision, potentially transforming how we approach and manage the multifaceted process of aging.

We sat down with Alden's CEO Jamie Heywood to discuss his motivations behind founding Alden Scientific, the company's groundbreaking approach to personalized health insights, and the innovative applications of their technology in both clinical and research settings.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Alden Scientific: https://www.aldenscientific.com/]]>1484falsefullhttps://www.spreaker.com/episode/there-is-a-need-for-academic-education-in-the-longevity-field--74818178
GCLS offers an Executive Master of Science in Longevity (EMSc Longevity), a distance learning program designed for professionals. With a curriculum covering the latest scientific findings on aging, health and longevity, the program aims to deepen knowledge and enhance credibility in the field. Designed both for practitioners seeking to improve longevity interventions and for financial and policy decision-makers who need longevity expertise for informed decisions, the online delivery allows students to balance their studies with their professional careers.

We sat down with Dominik Thor to discuss how this program addresses the biological mechanisms of aging, the various types of interventions, and the societal and financial implications of increased longevity.

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686588Wed, 12 Jun 2024 15:38:07 +0000saderThe Geneva College of Longevity Science (GCLS) is the first higher education institution dedicated solely to longevity science. Situated in Geneva, the college prides itself on Swiss academic standards, emphasizing scientific rigor and practical...
GCLS offers an Executive Master of Science in Longevity (EMSc Longevity), a distance learning program designed for professionals. With a curriculum covering the latest scientific findings on aging, health and longevity, the program aims to deepen knowledge and enhance credibility in the field. Designed both for practitioners seeking to improve longevity interventions and for financial and policy decision-makers who need longevity expertise for informed decisions, the online delivery allows students to balance their studies with their professional careers.

We sat down with Dominik Thor to discuss how this program addresses the biological mechanisms of aging, the various types of interventions, and the societal and financial implications of increased longevity.

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>638falsefullhttps://www.spreaker.com/episode/longevity-summit-dublin-looking-down-a-longevity-focused-lens--74818111
Next week's Longevity Summit Dublin, running from 13th to 16th June, promises to be a cornerstone event in the field of aging and longevity research. This summit aims to recognize and promote emerging developments in extending human healthspan by bringing together leading scientists, researchers and investors dedicated to tackling the challenges posed by diseases of aging – and aging itself.

https://longevitysummitdublin.com/

Featuring over 50 global pioneers, the conference will highlight the latest research and innovations in the longevity industry through keynote presentations by renowned experts and lively panels. The summit's carefully curated agenda will allow attendees to delve deeply into various pivotal topics, fostering a focused and comprehensive exploration of the most promising areas in longevity science.

Longevity A-list speakers attending include David Barzilai, Maria Blasco, Sebastian Brunemeier, Lynne Cox, Aaron Cravens, Walter Crompton, Aubrey de Grey, Peter Diamandis, Georg Fuellen, Alejandro Ocampo, Matthew ‘Oki’ O’Connor, Brian Kennedy, Melissa King, Mehmood Khan, Lou Hawthorne, Reason, Morten Scheibye-Knudsen, Björn Schumacher, Manuel Serrano, Stasa Stankovic, Andrew Steele and Alex Zhavoronkov (phew).

The Longevity Summit Dublin is not just a conference – it is a collaborative platform where evidence-based approaches and pragmatic solutions will be shared and discussed. By fostering an environment of knowledge exchange and collaboration, the event aims to play a pivotal role in advancing the frontiers of human healthspan extension; now in its third year, the conference has a reputation for catalyzing change in the longevity space, making waves with the Dublin Longevity Declaration last year.

For those committed to promoting healthier and longer lives through scientific innovation, this summit offers an unparalleled opportunity to engage with cutting-edge research and network with leaders in the field; we caught up with Martin O'Dea, CEO of Longevity Events Ltd and the principal organizer of the summit to find out more.

AND in partnership with Longevity Summit Dublin, we are delighted to offer Longevity.Technology readers a discount – please use the code FOUNDERSFORUM for 15% off the Longevity Summit Dublin full ticket price.
https://longevitysummitdublin.com/

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686615Fri, 07 Jun 2024 08:54:34 +0000saderLeading scientists and innovations will gather in Dublin next week to explore cutting-edge advancements in extending human healthspan. Next week's Longevity Summit Dublin, running from 13th to 16th June, promises to be a cornerstone event in the...
Next week's Longevity Summit Dublin, running from 13th to 16th June, promises to be a cornerstone event in the field of aging and longevity research. This summit aims to recognize and promote emerging developments in extending human healthspan by bringing together leading scientists, researchers and investors dedicated to tackling the challenges posed by diseases of aging – and aging itself.

https://longevitysummitdublin.com/

Featuring over 50 global pioneers, the conference will highlight the latest research and innovations in the longevity industry through keynote presentations by renowned experts and lively panels. The summit's carefully curated agenda will allow attendees to delve deeply into various pivotal topics, fostering a focused and comprehensive exploration of the most promising areas in longevity science.

Longevity A-list speakers attending include David Barzilai, Maria Blasco, Sebastian Brunemeier, Lynne Cox, Aaron Cravens, Walter Crompton, Aubrey de Grey, Peter Diamandis, Georg Fuellen, Alejandro Ocampo, Matthew ‘Oki’ O’Connor, Brian Kennedy, Melissa King, Mehmood Khan, Lou Hawthorne, Reason, Morten Scheibye-Knudsen, Björn Schumacher, Manuel Serrano, Stasa Stankovic, Andrew Steele and Alex Zhavoronkov (phew).

The Longevity Summit Dublin is not just a conference – it is a collaborative platform where evidence-based approaches and pragmatic solutions will be shared and discussed. By fostering an environment of knowledge exchange and collaboration, the event aims to play a pivotal role in advancing the frontiers of human healthspan extension; now in its third year, the conference has a reputation for catalyzing change in the longevity space, making waves with the Dublin Longevity Declaration last year.

For those committed to promoting healthier and longer lives through scientific innovation, this summit offers an unparalleled opportunity to engage with cutting-edge research and network with leaders in the field; we caught up with Martin O'Dea, CEO of Longevity Events Ltd and the principal organizer of the summit to find out more.

AND in partnership with Longevity Summit Dublin, we are delighted to offer Longevity.Technology readers a discount – please use the code FOUNDERSFORUM for 15% off the Longevity Summit Dublin full ticket price.
https://longevitysummitdublin.com/

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>558falsefullhttps://www.spreaker.com/episode/we-re-seeing-profound-reversal-of-a-number-of-conditions--74818208
Repair Biotechnologies is developing a novel approach to cholesterol management with its Cholesterol Degrading Platform (CDP); this innovative approach moves beyond conventional cholesterol-lowering strategies, aiming instead to degrade cholesterol at the cellular level.

The Syracuse, New York-based biotech is using unique lipid nanoparticle (LNP)-messenger RNA (mRNA) therapies designed to address the root causes of conditions stemming from localized cholesterol accumulation, setting a new standard in therapeutic interventions.
Unlike traditional methods that merely reduce LDL-cholesterol levels in the bloodstream, Repair Bio’s strategy targets the intracellular free cholesterol that is toxic to cells and a contributing factor in a variety of diseases. This approach not only promises to mitigate atherosclerosis but also shows potential in treating metabolic dysfunction-associated steatohepatitis (MASH), as evidenced by promising results in preclinical mouse models.

Atherosclerosis, marked by the buildup of arterial plaque, significantly impedes blood flow and is a major contributor to cardiovascular disease (CVD) – the leading cause of death worldwide. To address this pressing health burden, scientists at Repair Bio have developed a novel LNP-mRNA therapy, and in recent experiments, atherosclerotic mouse models treated with this therapy over a six-week period demonstrated promising results. It is an innovative approach that not only holds potential for mitigating atherosclerosis but also offers a pathway to reducing the global burden of CVD, ultimately saving lives and improving health outcomes.

The viability of this approach was further underscored when Repair Bio recently received favorable pre-IND feedback from the FDA, marking a significant milestone as the company prepares for clinical trials. We sat down with Reason, the Founder and CEO of Repair Bio, to find out more about the platform, upcoming clinical trials and tackling the Goldilocks problem in delivery systems.

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf

Find out more about Repair Biotechnologies and its novel platform here –
https://www.repairbiotechnologies.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686544Thu, 06 Jun 2024 15:07:27 +0000saderRepair Bio is harnessing gene therapy's potential to clear excess cholesterol with a platform that could reshape cardiovascular treatment. Repair Biotechnologies is developing a novel approach to cholesterol management with its Cholesterol Degrading...
Repair Biotechnologies is developing a novel approach to cholesterol management with its Cholesterol Degrading Platform (CDP); this innovative approach moves beyond conventional cholesterol-lowering strategies, aiming instead to degrade cholesterol at the cellular level.

The Syracuse, New York-based biotech is using unique lipid nanoparticle (LNP)-messenger RNA (mRNA) therapies designed to address the root causes of conditions stemming from localized cholesterol accumulation, setting a new standard in therapeutic interventions.
Unlike traditional methods that merely reduce LDL-cholesterol levels in the bloodstream, Repair Bio’s strategy targets the intracellular free cholesterol that is toxic to cells and a contributing factor in a variety of diseases. This approach not only promises to mitigate atherosclerosis but also shows potential in treating metabolic dysfunction-associated steatohepatitis (MASH), as evidenced by promising results in preclinical mouse models.

Atherosclerosis, marked by the buildup of arterial plaque, significantly impedes blood flow and is a major contributor to cardiovascular disease (CVD) – the leading cause of death worldwide. To address this pressing health burden, scientists at Repair Bio have developed a novel LNP-mRNA therapy, and in recent experiments, atherosclerotic mouse models treated with this therapy over a six-week period demonstrated promising results. It is an innovative approach that not only holds potential for mitigating atherosclerosis but also offers a pathway to reducing the global burden of CVD, ultimately saving lives and improving health outcomes.

The viability of this approach was further underscored when Repair Bio recently received favorable pre-IND feedback from the FDA, marking a significant milestone as the company prepares for clinical trials. We sat down with Reason, the Founder and CEO of Repair Bio, to find out more about the platform, upcoming clinical trials and tackling the Goldilocks problem in delivery systems.

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf

Find out more about Repair Biotechnologies and its novel platform here –
https://www.repairbiotechnologies.com/]]>807falsefullhttps://www.spreaker.com/episode/a-longevity-journey-we-are-amazed-all-the-time--74818132
The duo are also documenting their travels and interviews, creating a film called Beyond Time about their longevity journey and discoveries.

We met up with Marek and Alek Piotrowski in Singapore, and we were keen to find out more about their global expedition – an undertaking that should serve as a valuable contribution to the field of longevity research. Through their journey and interactions with experts worldwide, they are enhancing the conversation surrounding lifespan extension and health improvement. By raising awareness and facilitating discussion, the Piotrowskis are promoting a more informed understanding of longevity-related topics, ultimately encouraging greater engagement and collaboration within the scientific community.

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf

Follow Marek and Alek Piotrowski's longevity journey – https://longevityadvocate.com/beyondtime#hi-marek-alex-here]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686553Fri, 31 May 2024 15:51:15 +0000saderMarek and Alek Piotrowski are a father-and-son duo on a quest for longevity and radical life extension. The pair have embarked on a year-long trip around the world, investigating solutions that can help extend lifespan and healthspan and meeting up...
The duo are also documenting their travels and interviews, creating a film called Beyond Time about their longevity journey and discoveries.

We met up with Marek and Alek Piotrowski in Singapore, and we were keen to find out more about their global expedition – an undertaking that should serve as a valuable contribution to the field of longevity research. Through their journey and interactions with experts worldwide, they are enhancing the conversation surrounding lifespan extension and health improvement. By raising awareness and facilitating discussion, the Piotrowskis are promoting a more informed understanding of longevity-related topics, ultimately encouraging greater engagement and collaboration within the scientific community.

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter/X – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf

Follow Marek and Alek Piotrowski's longevity journey – https://longevityadvocate.com/beyondtime#hi-marek-alex-here]]>1132falsefullhttps://www.spreaker.com/episode/mitochondrial-restoration-therapy-could-be-launch-pad-for-longevity--74818174
Mitrix Bio recently announced the creation of a new subsidiary, Biotech Explorers, that is aiming to achieve a 130 year lifespan in humans. Initially focused on astronauts, and bringing benefits for those suffering from early-aging diseases, the trials will transplant bioreactor-grown mitochondria into volunteers to increase the number of functional mitochondria.

In addition to extended lifespan, Biotech Explorers also hopes to demonstrate rapid wound healing, enhanced radiation and infection resistance and muscle generation. Initially intended to make space travel less dangerous and debilitating, the implications for earthbound therapies are obvious. We sat down with Mitrix Bio CEO Tom Benson to find out more.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Mitrix Bio: https://www.mitrix.bio/
More about Biotech Explorers: https://www.explorers.bio/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686594Fri, 26 Apr 2024 16:24:59 +0000saderMitrix Bio CEO on how targeting increased longevity for astronauts could also pay dividends for those back on planet Earth. Mitrix Bio recently announced the creation of a new subsidiary, Biotech Explorers, that is aiming to achieve a 130 year...
Mitrix Bio recently announced the creation of a new subsidiary, Biotech Explorers, that is aiming to achieve a 130 year lifespan in humans. Initially focused on astronauts, and bringing benefits for those suffering from early-aging diseases, the trials will transplant bioreactor-grown mitochondria into volunteers to increase the number of functional mitochondria.

In addition to extended lifespan, Biotech Explorers also hopes to demonstrate rapid wound healing, enhanced radiation and infection resistance and muscle generation. Initially intended to make space travel less dangerous and debilitating, the implications for earthbound therapies are obvious. We sat down with Mitrix Bio CEO Tom Benson to find out more.

---------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about Mitrix Bio: https://www.mitrix.bio/
More about Biotech Explorers: https://www.explorers.bio/]]>1474falsefullhttps://www.spreaker.com/episode/longevity-supplements-are-going-mainstream--74818241
For some longevity supplement companies, their job is done when you buy their product; not Xandro, which takes a wraparound approach, sharing research on its ingredients for informed decision-making beforehand, and hosting a community that enables individuals from all walks of life that share a common passion for health and wellness.

Singapore-based Xandro wants to catalyze positive change in the longevity supplements industry with a brand that emphasizes accessibility, quality and community. With myriad supplements supporting everything from heart health to immunity, as well as combo packs that offer daily longevity and vitality care, Xandro wants to make optimizing healthspan a straightforward process that easily becomes part of a daily routine.

We sat down with Xandro’s Shantanu Kumar (CEO), Eugene He (Chief Advisor) and Toby Chin (Research scientist) and Dr Hishamuddin Badaruddin, a longevity medicine practitioner, to find out more about what makes this supplements company tick.

-------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about Xandro: https://xandrolab.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686545Wed, 24 Apr 2024 16:59:41 +0000saderXandro is on a mission to make science-based wellness nutrition accessible for everyone. For some longevity supplement companies, their job is done when you buy their product; not Xandro, which takes a wraparound approach, sharing research on its...
For some longevity supplement companies, their job is done when you buy their product; not Xandro, which takes a wraparound approach, sharing research on its ingredients for informed decision-making beforehand, and hosting a community that enables individuals from all walks of life that share a common passion for health and wellness.

Singapore-based Xandro wants to catalyze positive change in the longevity supplements industry with a brand that emphasizes accessibility, quality and community. With myriad supplements supporting everything from heart health to immunity, as well as combo packs that offer daily longevity and vitality care, Xandro wants to make optimizing healthspan a straightforward process that easily becomes part of a daily routine.

We sat down with Xandro’s Shantanu Kumar (CEO), Eugene He (Chief Advisor) and Toby Chin (Research scientist) and Dr Hishamuddin Badaruddin, a longevity medicine practitioner, to find out more about what makes this supplements company tick.

-------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about Xandro: https://xandrolab.com/]]>1453falsefullhttps://www.spreaker.com/episode/small-but-mighty-the-fatty-acid-that-packs-a-considerable-longevity-punch--74818138
Fatty15 is a longevity supplement centered around a very simple fatty acid that was discovered as a result of studying health data of US Navy dolphins and which has led to decades of accepted nutritional guidance being called into question. This super nutrient is called C15:0.

As a stable fatty acid, C15:0 is readily integrated into cell membranes, making cells more resilient against breakdown. It attenuates multiple hallmarks of aging, including cellular senescence, inflammaging, mitochondrial dysfunction and poor cellular signaling. 

Humans don’t make enough C15:0, so we need to get adequate amounts from our diet or through supplementation. However, saturated fats have been demonized for decades, being blamed for high cholesterol and heart disease. We sat down with Stephanie Venn-Watson, DVM, MPH, the Co-Founder and CEO of fatty15 to find out why the dietary guidelines on fatty acids need to be revisited, how the discovery of C15:0 and its longevity benefits came about, and the role C15:0 can play in menopause and more.

-------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about fatty15: https://fatty15.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686548Wed, 03 Apr 2024 16:29:21 +0000saderFatty15 CEO Stephanie Venn-Watson on why accidental discoveries can actually be the best ones when it comes to longevity. Fatty15 is a longevity supplement centered around a very simple fatty acid that was discovered as a result of studying health...
Fatty15 is a longevity supplement centered around a very simple fatty acid that was discovered as a result of studying health data of US Navy dolphins and which has led to decades of accepted nutritional guidance being called into question. This super nutrient is called C15:0.

As a stable fatty acid, C15:0 is readily integrated into cell membranes, making cells more resilient against breakdown. It attenuates multiple hallmarks of aging, including cellular senescence, inflammaging, mitochondrial dysfunction and poor cellular signaling. 

Humans don’t make enough C15:0, so we need to get adequate amounts from our diet or through supplementation. However, saturated fats have been demonized for decades, being blamed for high cholesterol and heart disease. We sat down with Stephanie Venn-Watson, DVM, MPH, the Co-Founder and CEO of fatty15 to find out why the dietary guidelines on fatty acids need to be revisited, how the discovery of C15:0 and its longevity benefits came about, and the role C15:0 can play in menopause and more.

-------

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about fatty15: https://fatty15.com/]]>1193falsefullhttps://www.spreaker.com/episode/longevity-center-an-integrated-longevity-journey--74818173
Longevity clinics are rapidly emerging as essential destinations for individuals invested in prolonging their health and vitality. With state-of-the-art equipment and a growing emphasis on holistic well-being, these clinics cater to those seeking to optimize their healthspan – the period of life spent in good health, free from chronic diseases and disabilities. Long gone are the days when healthcare was solely about treating illnesses – now, it is about proactive measures to prevent them.

Regular visits to these clinics are becoming routine for longevity enthusiasts, integrating seamlessly into their health regimens. Whether it's an annual check-up or more regular tracking of biomarkers and other diagnostics, these appointments serve as proactive steps towards understanding and enhancing one's healthspan by investigating everything from microbiomes to cognitive decline. It's no longer just about extending lifespan, but about ensuring that the years lived are vibrant, active and fulfilling.

Longevity.Technology CEO and founder Phil Newman undertook his first health assessment at Longevity Center's Warsaw clinic. The comprehensive assessment took approximately 5 hours, involved over 20 different tests.

To give an overview of Longevity Center’s comprehensive analysis of Phil’s health status, his assessment included:

An initial consultation
A biochemical panel including 47 different biomarkers
Measurement of telomere length
DNA testing
Ultrasound diagnostics
A WatchPat test to assess sleep quality test and a sleep consultation
A CNS cognitive function test
A dietitian consultation

The results and recommendations arising from this battery of tests were then discussed in depth in a summary consultation and a detailed Final Report was issued.


Find out more about Phil’s Longevity Center experience and what he discovered as a result of its comprehensive testing program in our video.


Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf


More about Longevity Center: https://longevity-center.eu/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686628Tue, 19 Mar 2024 16:51:10 +0000saderLongevity.Technology’s CEO Phil Newman tests his healthspan at a state-of-the-art clinic. Longevity clinics are rapidly emerging as essential destinations for individuals invested in prolonging their health and vitality. With state-of-the-art...
Longevity clinics are rapidly emerging as essential destinations for individuals invested in prolonging their health and vitality. With state-of-the-art equipment and a growing emphasis on holistic well-being, these clinics cater to those seeking to optimize their healthspan – the period of life spent in good health, free from chronic diseases and disabilities. Long gone are the days when healthcare was solely about treating illnesses – now, it is about proactive measures to prevent them.

Regular visits to these clinics are becoming routine for longevity enthusiasts, integrating seamlessly into their health regimens. Whether it's an annual check-up or more regular tracking of biomarkers and other diagnostics, these appointments serve as proactive steps towards understanding and enhancing one's healthspan by investigating everything from microbiomes to cognitive decline. It's no longer just about extending lifespan, but about ensuring that the years lived are vibrant, active and fulfilling.

Longevity.Technology CEO and founder Phil Newman undertook his first health assessment at Longevity Center's Warsaw clinic. The comprehensive assessment took approximately 5 hours, involved over 20 different tests.

To give an overview of Longevity Center’s comprehensive analysis of Phil’s health status, his assessment included:

An initial consultation
A biochemical panel including 47 different biomarkers
Measurement of telomere length
DNA testing
Ultrasound diagnostics
A WatchPat test to assess sleep quality test and a sleep consultation
A CNS cognitive function test
A dietitian consultation

The results and recommendations arising from this battery of tests were then discussed in depth in a summary consultation and a detailed Final Report was issued.


Find out more about Phil’s Longevity Center experience and what he discovered as a result of its comprehensive testing program in our video.


Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf


More about Longevity Center: https://longevity-center.eu/]]>184falsefullhttps://www.spreaker.com/episode/what-the-future-of-longevity-looks-like-with-lifeforce--74818144
Lifeforce is a functional healthcare company focusing on optimizing performance in mid-life. Encouraging clients to take a proactive approach to their healthspan, Lifeforce’s personalized plan combines biomarker testing, functional medicine doctors, certified health coaches, and advanced nutraceutical and hormone therapies. The company’s aim is to ensure its clients can look, feel and function at their best.

The driving force behind the company determined to put a “world-class longevity and performance doctor into every pocket in America” is Lifeforce president and cofounder Joel Jackson. His aim is to add an impressive 3.32 billion years of healthy life to America by making healthspan optimization straightforward, understandable and personalized. We sat down with Jackson to find out more about changing the fundamental way we age, unsustainable healthcare costs and navigating the longevity ecosystem.

Find out more about Lifeforce here: https://bit.ly/48WOInl

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686604Wed, 31 Jan 2024 13:53:46 +0000saderLifeforce cofounder on how increasing lifespan will change the way we treat disease and optimize healthspan. Lifeforce is a functional healthcare company focusing on optimizing performance in mid-life. Encouraging clients to take a proactive approach...
Lifeforce is a functional healthcare company focusing on optimizing performance in mid-life. Encouraging clients to take a proactive approach to their healthspan, Lifeforce’s personalized plan combines biomarker testing, functional medicine doctors, certified health coaches, and advanced nutraceutical and hormone therapies. The company’s aim is to ensure its clients can look, feel and function at their best.

The driving force behind the company determined to put a “world-class longevity and performance doctor into every pocket in America” is Lifeforce president and cofounder Joel Jackson. His aim is to add an impressive 3.32 billion years of healthy life to America by making healthspan optimization straightforward, understandable and personalized. We sat down with Jackson to find out more about changing the fundamental way we age, unsustainable healthcare costs and navigating the longevity ecosystem.

Find out more about Lifeforce here: https://bit.ly/48WOInl

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>956falsefullhttps://www.spreaker.com/episode/a-vaccine-for-aging-in-under-ten-years--74818115
Agemica is on a mission to create a vaccine for aging; its platform uses an AI-driven approach to seek out antiaging therapies that address root causes of aging and leverage those to prevent diseases of aging such as neurodegeneration, cardiovascular disease, immune system failure and cancer.

The company hopes its omics-based tech will extend both lifespan and healthspan, and the platform has already been validated in 17 cancer areas and predicted antiaging candidates that have higher efficacy, reduced side effects and lower chances of developing drug resistance.

Agemica's aim is to extend the number of indications of its candidates and pave the way, not only to better patient outcomes, but to therapies that hit the market much faster. We sat down with CEO and Cofounder Dr Ronjon Nag to find out how the platform works, its revolutionary potential and the diseases of aging Agemica has in its sights.

Visit Agemica here: https://agemica.com/

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686534Tue, 16 Jan 2024 17:22:19 +0000saderAgemica founder Ronjon Nag on the moonshot company he believes will develop a vaccine for aging and make a dramatic difference to lifespan and healthspan. Agemica is on a mission to create a vaccine for aging; its platform uses an AI-driven approach...
Agemica is on a mission to create a vaccine for aging; its platform uses an AI-driven approach to seek out antiaging therapies that address root causes of aging and leverage those to prevent diseases of aging such as neurodegeneration, cardiovascular disease, immune system failure and cancer.

The company hopes its omics-based tech will extend both lifespan and healthspan, and the platform has already been validated in 17 cancer areas and predicted antiaging candidates that have higher efficacy, reduced side effects and lower chances of developing drug resistance.

Agemica's aim is to extend the number of indications of its candidates and pave the way, not only to better patient outcomes, but to therapies that hit the market much faster. We sat down with CEO and Cofounder Dr Ronjon Nag to find out how the platform works, its revolutionary potential and the diseases of aging Agemica has in its sights.

Visit Agemica here: https://agemica.com/

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf]]>844falsefullhttps://www.spreaker.com/episode/therapeutic-plasma-exchange-a-new-therapeutic-modality-for-longevity--74818146
Therapeutic plasma exchange (TPE), also known as plasmapheresis, has been used to treat diseases such as Guillain-Barré syndrome and multiple sclerosis, but is also gaining traction as a longevity therapy. Research has shown that TPE can promote a shift towards a younger systemic proteome, including cells that exhibit reduced senescence and less DNA damage, as well as youthfully restoring pro-regenerative apoptotic regulators. Other benefits of TPE include an increase in the number of biomarkers of immune function, a reduction in the amount of neurodegeneration and cancer-related proteins and a decrease in inflammaging.

TPE involves drawing blood from a vein in the patient’s arm. A special machine separates the polluted plasma from the blood cells, and the aged, polluted plasma is discarded and replaced with clean, individualized, plasma-like replacement fluids, albumin, immunoglobins and other regeneration promoting factors. The new solution of freshly-cleaned blood is infused back into the patient’s body, supporting the body and brain’s ability to fight degeneration.

Alison Levitt, MD, is a doctor specializing in antiaging and regenerative medicine. We caught up with her at Healthy Longevity Clinic to find out more about TPE, the process and the benefits.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686556Tue, 02 Jan 2024 18:15:31 +0000saderHealthy Longevity Clinic’s Dr Alison Levitt on why spring cleaning your blood could be the best thing for longevity. Therapeutic plasma exchange (TPE), also known as plasmapheresis, has been used to treat diseases such as Guillain-Barré syndrome and...
Therapeutic plasma exchange (TPE), also known as plasmapheresis, has been used to treat diseases such as Guillain-Barré syndrome and multiple sclerosis, but is also gaining traction as a longevity therapy. Research has shown that TPE can promote a shift towards a younger systemic proteome, including cells that exhibit reduced senescence and less DNA damage, as well as youthfully restoring pro-regenerative apoptotic regulators. Other benefits of TPE include an increase in the number of biomarkers of immune function, a reduction in the amount of neurodegeneration and cancer-related proteins and a decrease in inflammaging.

TPE involves drawing blood from a vein in the patient’s arm. A special machine separates the polluted plasma from the blood cells, and the aged, polluted plasma is discarded and replaced with clean, individualized, plasma-like replacement fluids, albumin, immunoglobins and other regeneration promoting factors. The new solution of freshly-cleaned blood is infused back into the patient’s body, supporting the body and brain’s ability to fight degeneration.

Alison Levitt, MD, is a doctor specializing in antiaging and regenerative medicine. We caught up with her at Healthy Longevity Clinic to find out more about TPE, the process and the benefits.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>446falsefullhttps://www.spreaker.com/episode/get-interventions-to-market-and-to-people-faster-and-cheaper--74818177Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686565Wed, 20 Dec 2023 17:10:47 +0000sader------------------------------ Visit Longevity.Technology - https://bit.ly/3PwtH8Y Follow Longevity.Technology on: Twitter - https://bit.ly/3AMIXuq Facebook - https://bit.ly/3z8H1v5 Instagram - https://bit.ly/3IDvVRX Linkedin - https://bit.ly/3yIfDmfVisit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>881falsefullhttps://www.spreaker.com/episode/address-brain-aging-and-push-back-cognitive-decline--74818197
NAD+ plays a critical role in molecular pathways that keep our bodies running, growing and repairing. As well as NAD+ demonstrating some antiaging properties, raising the levels of this essential co-enzyme in the body shows promising results when it comes to the fight against age-related cognitive decline. However, levels of NAD+ diminish with age, and this is where NMN comes in. NMN – or nicotinamide mononucleotide – is a naturally-occurring direct precursor of NAD+; increasing the amount of NMN building blocks available encourages the body to up the levels of NAD+ and thus help stem cognitive decline.

As longevity supplements grow in popularity, so too do the number of products. While some are highly pure and of reputable provenance, others are less so. When Elena Seranova, who holds an MSc in Translational Neuroscience and a PhD in Stem Cell Biology and Autophagy, couldn’t find a reliable supplier of NMN for herself and her family, she started her own company. Now the company's product line has expanded to include NAD+ Brain, a nootropic designed to improve focus and concentration, slow down aging in the brain, guard the brain from oxidative stress and inflammation, and preserve NAD+ in the brain. We caught up with Dr Seranova to find out more about NMN Bio’s new product line.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686601Mon, 18 Dec 2023 17:52:13 +0000saderNMN Bio founder discusses new supplement NAD+ Brain and explains why optimizing for slower brain aging and reduced cognitive decline is a no brainer. NAD+ plays a critical role in molecular pathways that keep our bodies running, growing and...
NAD+ plays a critical role in molecular pathways that keep our bodies running, growing and repairing. As well as NAD+ demonstrating some antiaging properties, raising the levels of this essential co-enzyme in the body shows promising results when it comes to the fight against age-related cognitive decline. However, levels of NAD+ diminish with age, and this is where NMN comes in. NMN – or nicotinamide mononucleotide – is a naturally-occurring direct precursor of NAD+; increasing the amount of NMN building blocks available encourages the body to up the levels of NAD+ and thus help stem cognitive decline.

As longevity supplements grow in popularity, so too do the number of products. While some are highly pure and of reputable provenance, others are less so. When Elena Seranova, who holds an MSc in Translational Neuroscience and a PhD in Stem Cell Biology and Autophagy, couldn’t find a reliable supplier of NMN for herself and her family, she started her own company. Now the company's product line has expanded to include NAD+ Brain, a nootropic designed to improve focus and concentration, slow down aging in the brain, guard the brain from oxidative stress and inflammation, and preserve NAD+ in the brain. We caught up with Dr Seranova to find out more about NMN Bio’s new product line.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1138falsefullhttps://www.spreaker.com/episode/more-than-just-a-trip-the-longevity-potential-of-psychedelics--74818216
Terran Biosciences, a CNS-focused biotech platform company, is developing of transformative therapeutics and technologies for patients with neurological and psychiatric diseases. As well as targeting schizophrenia, Terran's novel drug Idazoxan (which it has licensed from Pierre Fabre and for which it holds the global development and commercialization rights) can be used to treat Alzheimer's and also comes as an extended-release version that enables once-daily dosing. A treatment for Parkinson’s psychosis is also in the pipeline.

Longevity.Technology: Terran has had a busy year; with an exclusive licensing deal with French pharma Pierre Fabre, the first cohort dosed in human clinical trial of its novel lead compound Idazoxan and a suite of IP publications all in the bag, Terran certainly isn't short of news for its festive round robin.

Terran has one of the largest psychedelic development programs in the industry, and is leveraging psychedelics with a long history of human use, including psilocybin, LSD and MDMA. It's no wonder, then, that that Terran had a significant presence at Wonderland earlier this year, and during the event, we were lucky enough to sit down with Terran’s founder and CEO, Sam Clark, MD PhD.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686650Wed, 13 Dec 2023 17:04:37 +0000saderTerran Biosciences founder on longevity-psychedelic crossovers, targeting neurodegeneration and making history. Terran Biosciences, a CNS-focused biotech platform company, is developing of transformative therapeutics and technologies for patients...
Terran Biosciences, a CNS-focused biotech platform company, is developing of transformative therapeutics and technologies for patients with neurological and psychiatric diseases. As well as targeting schizophrenia, Terran's novel drug Idazoxan (which it has licensed from Pierre Fabre and for which it holds the global development and commercialization rights) can be used to treat Alzheimer's and also comes as an extended-release version that enables once-daily dosing. A treatment for Parkinson’s psychosis is also in the pipeline.

Longevity.Technology: Terran has had a busy year; with an exclusive licensing deal with French pharma Pierre Fabre, the first cohort dosed in human clinical trial of its novel lead compound Idazoxan and a suite of IP publications all in the bag, Terran certainly isn't short of news for its festive round robin.

Terran has one of the largest psychedelic development programs in the industry, and is leveraging psychedelics with a long history of human use, including psilocybin, LSD and MDMA. It's no wonder, then, that that Terran had a significant presence at Wonderland earlier this year, and during the event, we were lucky enough to sit down with Terran’s founder and CEO, Sam Clark, MD PhD.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf]]>1014falsefullhttps://www.spreaker.com/episode/longevity-should-not-be-revolution-it-should-be-evolution--74818116
Recently, our CEO Phil Newman undertook his first health assessment at Warsaw's Longevity Center. The comprehensive assessment took approximately 5 hours, involved over 20 different tests, including a blood test analyzing more than 50 different biomarkers.

Longevity Center is all about prevention, detecting any potential risk factors and health dispositions so that targeted interventions can be made and made early. Using a suite of highly precise tools and tests, they detect the key risk factors for serious diseases and recommend interventions for maximizing healthspan.

But what does the patient journey at a longevity clinic really look like? Our intrepid CEO, armed with a full body stocking, finds out, as Longevity Center Medical Director of Male Health and Performance, Dr Robert Jarema, put his longevity through its paces.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686536Tue, 12 Dec 2023 14:03:54 +0000saderLongevity Center's Robert Jarema on how taking a comprehensive approach to healthspan can pay longevity dividends and why even small changes can make a big difference. Recently, our CEO Phil Newman undertook his first health assessment at Warsaw's...
Recently, our CEO Phil Newman undertook his first health assessment at Warsaw's Longevity Center. The comprehensive assessment took approximately 5 hours, involved over 20 different tests, including a blood test analyzing more than 50 different biomarkers.

Longevity Center is all about prevention, detecting any potential risk factors and health dispositions so that targeted interventions can be made and made early. Using a suite of highly precise tools and tests, they detect the key risk factors for serious diseases and recommend interventions for maximizing healthspan.

But what does the patient journey at a longevity clinic really look like? Our intrepid CEO, armed with a full body stocking, finds out, as Longevity Center Medical Director of Male Health and Performance, Dr Robert Jarema, put his longevity through its paces.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf]]>833falsefullhttps://www.spreaker.com/episode/there-will-be-a-point-where-we-solve-aging-this-decade-is-that-moment-in-time--74818181
On Wednesday, we reported on a new global competition announced at Global Healthspan Summit in Riyadh, Saudi Arabia. XPRIZE Healthspan aims to incentivize the development and testing of therapeutics to improve healthy aging, and it comes with an enormous encouragement – $101 million in prize money. The winning team will need to successfully develops a therapeutic that restores muscle, cognition and immune function by 20 years in older adults, and be able to demonstrate the results in a treatment period of one year or less.

Straight after the XPRIZE launch we were able to sit down with its founder Peter Diamandis and find out more about XPRIZE Healthspan’s evolution, how success will be measured and how he hopes it will break the mold in more ways than one.

-----------------------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686637Mon, 04 Dec 2023 16:50:06 +0000saderXPRIZE founder Peter Diamandis on the biggest prize the world has ever seen – and why a successful outcome will mean we’ll all be winners. On Wednesday, we reported on a new global competition announced at Global Healthspan Summit in Riyadh, Saudi...
On Wednesday, we reported on a new global competition announced at Global Healthspan Summit in Riyadh, Saudi Arabia. XPRIZE Healthspan aims to incentivize the development and testing of therapeutics to improve healthy aging, and it comes with an enormous encouragement – $101 million in prize money. The winning team will need to successfully develops a therapeutic that restores muscle, cognition and immune function by 20 years in older adults, and be able to demonstrate the results in a treatment period of one year or less.

Straight after the XPRIZE launch we were able to sit down with its founder Peter Diamandis and find out more about XPRIZE Healthspan’s evolution, how success will be measured and how he hopes it will break the mold in more ways than one.

-----------------------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>614falsefullhttps://www.spreaker.com/episode/our-vision-statement-is-clear-expand-healthy-lifespan-for-the-benefit-of-all--74818192
Next week, 100 international speakers and 1000 delegates will convene Riyadh at Hevolution’s inaugural Global Healthspan Summit. As well as unveiling significant investments in the longevity sector, the Summit aims to catalyze global collaboration around extending healthspan, accelerate scientific progress for a rapidly aging world.

Hevolution Foundation, which is delivering the summit, boasts an annual budget of up to $1 million. The Foundation invests in grants for aging research and pioneers impact investments in early-stage biotech, driving acceleration and progress in the field. The Foundation is hoping the summit will “serve as a seismic shift in how the world perceives and acts, catalyzing the discussion from lifespan to healthspan.” To find out more, we sat down with Hevolution’s CEO, Dr Mehmood Khan.

-----------------------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686567Thu, 23 Nov 2023 17:05:52 +0000saderAhead of the Global Healthspan Summit, Hevolution CEO Mehmood Khan updates on the Foundation’s progress and explains why nothing happens without talent. Next week, 100 international speakers and 1000 delegates will convene Riyadh at Hevolution’s...
Next week, 100 international speakers and 1000 delegates will convene Riyadh at Hevolution’s inaugural Global Healthspan Summit. As well as unveiling significant investments in the longevity sector, the Summit aims to catalyze global collaboration around extending healthspan, accelerate scientific progress for a rapidly aging world.

Hevolution Foundation, which is delivering the summit, boasts an annual budget of up to $1 million. The Foundation invests in grants for aging research and pioneers impact investments in early-stage biotech, driving acceleration and progress in the field. The Foundation is hoping the summit will “serve as a seismic shift in how the world perceives and acts, catalyzing the discussion from lifespan to healthspan.” To find out more, we sat down with Hevolution’s CEO, Dr Mehmood Khan.

-----------------------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>722falsefullhttps://www.spreaker.com/episode/improving-healthspan-and-longevity-can-be-just-like-riding-a-bike--74818184
High-intensity interval training (HIIT) has become very popular; alternating short periods of intense anaerobic exercise with recovery periods, it is designed to help to decrease body fat, increase strength and endurance, and improve healthspan in protocols that last approximately half-an-hour.

But these days, even finding half-an-hour can be tricky – enter CAROL Bike, an exercise bike designed around Reduced Exertion HIIT (REHIT) and AI-personalization, meaning an effective workout can be delivered in just 5 minutes.

Developed in collaboration with leading exercise researchers, CAROL Bike not only improves fitness, but increases VO₂, reduces blood pressure and decreases the risk of diabetes. Given CAROL Bike’s foundation being scientific studies, rather than just ‘feel the burn’ or ‘if it hurts, it must be working’, we were intrigued. We sat down with CAROL Bike’s cofounder and CEO Ulrich Dempfle, who leveraged his background in mechanical engineering to develop the world’s only Reduced Exertion HIIT (REHIT) bike.
-----------------------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686587Tue, 21 Nov 2023 17:17:58 +0000saderCAROL Bike CEO on the REHIT approach that can dial back the clock on your fitness potential by over a decade. High-intensity interval training (HIIT) has become very popular; alternating short periods of intense anaerobic exercise with recovery...
High-intensity interval training (HIIT) has become very popular; alternating short periods of intense anaerobic exercise with recovery periods, it is designed to help to decrease body fat, increase strength and endurance, and improve healthspan in protocols that last approximately half-an-hour.

But these days, even finding half-an-hour can be tricky – enter CAROL Bike, an exercise bike designed around Reduced Exertion HIIT (REHIT) and AI-personalization, meaning an effective workout can be delivered in just 5 minutes.

Developed in collaboration with leading exercise researchers, CAROL Bike not only improves fitness, but increases VO₂, reduces blood pressure and decreases the risk of diabetes. Given CAROL Bike’s foundation being scientific studies, rather than just ‘feel the burn’ or ‘if it hurts, it must be working’, we were intrigued. We sat down with CAROL Bike’s cofounder and CEO Ulrich Dempfle, who leveraged his background in mechanical engineering to develop the world’s only Reduced Exertion HIIT (REHIT) bike.
-----------------------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>920falsefullhttps://www.spreaker.com/episode/the-longevity-revolution-has-the-potential-to-transform-healthcare-in-our-lifetime--74818188

The Buck Institute is all about living better for longer – investigating and deciphering the biology of aging to end the threat of age-related disease. Aging is the number one risk factor for chronic disease, so the Buck deploys cutting edge science and technology and leading gerontologists in order to tackle it – but searching for immortality is definitely not something on its agenda.


The Buck Institute is headed up by Dr Eric Verdin; highly cited and with a Glenn Award for Research in Biological Mechanisms of Aging, over 210 scientific papers and more than 15 patents under his belt he is first and foremost a scientist. As longevity goes mainstream, gaining longer air time and more column inches, there is a danger that the more fringe or extreme areas of the field become the focus, rather than improving healthspan.


We sat down with Dr Verdin, President and CEO of The Buck Institute, to discuss these concerns and find out why searching for a philosopher’s stone might be good for Harry Potter but the wrong direction for geroscience.
-----------------------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686581Fri, 17 Nov 2023 16:33:34 +0000saderThe Buck Institute’s CEO Eric Verdin on why longevity research has transformative power, but the field must tread carefully between the hype and the noise. The Buck Institute is all about living better for longer – investigating and deciphering the...

The Buck Institute is all about living better for longer – investigating and deciphering the biology of aging to end the threat of age-related disease. Aging is the number one risk factor for chronic disease, so the Buck deploys cutting edge science and technology and leading gerontologists in order to tackle it – but searching for immortality is definitely not something on its agenda.


The Buck Institute is headed up by Dr Eric Verdin; highly cited and with a Glenn Award for Research in Biological Mechanisms of Aging, over 210 scientific papers and more than 15 patents under his belt he is first and foremost a scientist. As longevity goes mainstream, gaining longer air time and more column inches, there is a danger that the more fringe or extreme areas of the field become the focus, rather than improving healthspan.


We sat down with Dr Verdin, President and CEO of The Buck Institute, to discuss these concerns and find out why searching for a philosopher’s stone might be good for Harry Potter but the wrong direction for geroscience.
-----------------------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1196falsefullhttps://www.spreaker.com/episode/we-all-play-don-t-die-every-day-now-let-s-get-really-good-at-it--74818205
Longevity explorer Bryan Johnson looks forward to humanity’s next evolutionary chapter.

Bryan Johnson is the world’s most famous biohacker – and perhaps the “most measured man in human history”. He’s on a mission to maximally reverse the quantified biological age of each of his 70 organs, extending his lifespan and healthspan, and then roll out his protocol on a platform to ensure others can benefit from his experience, research and experimentation.

Johnson’s ethos can be summed up pretty neatly as don’t die, and to that end, he has written a book, or novel, to be more accurate, entitled Don’t Die, the uncorrected advanced reading version of which is downloadable as a free ebook from his website. Johnson’s nom de plume for this venture is Zero, described in the book as the “first individual H. sapiens to surpass five hundred years of age,” who dies in 2478 (in an accident, rather than from old age), just weeks away from “becoming Homo Deus.” Johnson credits Zero with the invention of Zeroism and the resurrection technology undie, as well as the fathering of “millions of biological and digital offspring who now live in the far reaches of the solar system and beyond”.

Because Don’t Die is a novel, Johnson can explore his philosophy in a different way, inviting us to observe the narrator, Scribe, on his last day on Earth, as he muses on humanity’s future evolution, the nature of death and free will and the impact of age reversal and programmable biology. Scribe is joined by a Pilgrim’s Progress-like cast of characters, including Cognitive Bias, Dark Humor and Game Play and Self Critical.

Johnson’s Blueprint started out as a science experiment to explore the future; he has since expanded it to be a plan for the future of humanity, a plan that is more than a health, science or data revolution. He now styles it as “a revolution of thought. Of action. Of actions not taken.” And Blueprint is also a character in Don’t Die. It was time to unpack Johnson’s philosophy in more detail, so we sat down with him to find out more about his book and what else is going on with him…


Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686646Tue, 07 Nov 2023 17:33:29 +0000saderGet the free e-ook - https://protocol.bryanjohnson.com/DONT-DIE-by-Zero Longevity explorer Bryan Johnson looks forward to humanity’s next evolutionary chapter. Bryan Johnson is the world’s most famous biohacker – and perhaps the “most measured man...
Longevity explorer Bryan Johnson looks forward to humanity’s next evolutionary chapter.

Bryan Johnson is the world’s most famous biohacker – and perhaps the “most measured man in human history”. He’s on a mission to maximally reverse the quantified biological age of each of his 70 organs, extending his lifespan and healthspan, and then roll out his protocol on a platform to ensure others can benefit from his experience, research and experimentation.

Johnson’s ethos can be summed up pretty neatly as don’t die, and to that end, he has written a book, or novel, to be more accurate, entitled Don’t Die, the uncorrected advanced reading version of which is downloadable as a free ebook from his website. Johnson’s nom de plume for this venture is Zero, described in the book as the “first individual H. sapiens to surpass five hundred years of age,” who dies in 2478 (in an accident, rather than from old age), just weeks away from “becoming Homo Deus.” Johnson credits Zero with the invention of Zeroism and the resurrection technology undie, as well as the fathering of “millions of biological and digital offspring who now live in the far reaches of the solar system and beyond”.

Because Don’t Die is a novel, Johnson can explore his philosophy in a different way, inviting us to observe the narrator, Scribe, on his last day on Earth, as he muses on humanity’s future evolution, the nature of death and free will and the impact of age reversal and programmable biology. Scribe is joined by a Pilgrim’s Progress-like cast of characters, including Cognitive Bias, Dark Humor and Game Play and Self Critical.

Johnson’s Blueprint started out as a science experiment to explore the future; he has since expanded it to be a plan for the future of humanity, a plan that is more than a health, science or data revolution. He now styles it as “a revolution of thought. Of action. Of actions not taken.” And Blueprint is also a character in Don’t Die. It was time to unpack Johnson’s philosophy in more detail, so we sat down with him to find out more about his book and what else is going on with him…


Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1858falsefullhttps://www.spreaker.com/episode/longevity-center-ceo-joanna-bensz-on-the-first-international-roundtable-of-longevity-clinic--74818127


Set to be a must-attend event for longevity-focused clinics, practitioners, businesses and investors interested in exploring and implementing the latest longevity trends and solutions, the Roundtable will bring together the world’s most prominent clinics to discuss cutting-edge trends and scientific knowledge in the field of healthspan extension and to foster networking with representatives of various products, biomarkers, diagnostic and technology providers. Speakers at the Roundtable, which is happening on 8th December, include David Sinclair, Joanna Bensz, Andrea Maier, Eric Verdin and David Karow.


Wellness tourism and longevity clinics are exploding spaces; clinics offer diagnostic testing, regimen advice, biomarker mapping, aging clock predictions and more. As the number of tests and interventions grows, so too, understandably, does the call for standards, and the Roundtable’s goal is meet that call, creating established gold standards for these practices. By bringing together a raft of experts and facilitating discussions on best practices for longevity testing and longevity-specific interventions, the Roundtable will define standards, identify effective diagnostics and and agree on recommendations for longevity-focused interventions, supplements and therapies.


Joanna Bensz, Founder and CEO, Longevity Center and International Institute of Longevity is one of those speaking at the Roundtable. We sat down with her to find out more.
Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf


More about Longevity Center: https://longevity-center.eu/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686640Tue, 07 Nov 2023 16:25:51 +0000saderNext month, the prestigious Buck Institute will play host to the first International Roundtable of Longevity Clinics. Set to be a must-attend event for longevity-focused clinics, practitioners, businesses and investors interested in exploring and...


Set to be a must-attend event for longevity-focused clinics, practitioners, businesses and investors interested in exploring and implementing the latest longevity trends and solutions, the Roundtable will bring together the world’s most prominent clinics to discuss cutting-edge trends and scientific knowledge in the field of healthspan extension and to foster networking with representatives of various products, biomarkers, diagnostic and technology providers. Speakers at the Roundtable, which is happening on 8th December, include David Sinclair, Joanna Bensz, Andrea Maier, Eric Verdin and David Karow.


Wellness tourism and longevity clinics are exploding spaces; clinics offer diagnostic testing, regimen advice, biomarker mapping, aging clock predictions and more. As the number of tests and interventions grows, so too, understandably, does the call for standards, and the Roundtable’s goal is meet that call, creating established gold standards for these practices. By bringing together a raft of experts and facilitating discussions on best practices for longevity testing and longevity-specific interventions, the Roundtable will define standards, identify effective diagnostics and and agree on recommendations for longevity-focused interventions, supplements and therapies.


Joanna Bensz, Founder and CEO, Longevity Center and International Institute of Longevity is one of those speaking at the Roundtable. We sat down with her to find out more.
Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf


More about Longevity Center: https://longevity-center.eu/]]>1004falsefullhttps://www.spreaker.com/episode/how-sports-medicine-can-maximize-the-longevity-runway--74818131
With a suite of state-of-the-art clinics, Longevity Center is opening the door on 'living better for longer' for its clients. Offering a wide range of longevity assessments and preventative check-ups, Longevity Center is grounded in geroscience research, as well as embracing a holistic mindset that acknowledges the importance of mental health and feeling well.

Longevity Center Switzerland is the company's third clinic, opened in Zurich earlier this year. Its team is headed by Medical Director Anna Erat MD PhD, whose clinical specialization spans preventive, sports and internal medicine, and whose clients include ice hockey team players, Formula 1 drivers and world-class Ironman triathletes. Erat also brings expertise in biomedicine, genetics, epidemiology and health systems management to her leadership of Longevity Center Switzerland, and we sat down with her to find out why optimizing for sports excellence is helping Longevity Center optimize healthspan for its clients.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about Longevity Center: https://longevity-center.eu/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686552Wed, 01 Nov 2023 15:37:12 +0000saderLongevity Center Zurich Medical Director Anna Erat joins us to discuss translating sports science into longevity and healthspan. With a suite of state-of-the-art clinics, Longevity Center is opening the door on 'living better for longer' for its...
With a suite of state-of-the-art clinics, Longevity Center is opening the door on 'living better for longer' for its clients. Offering a wide range of longevity assessments and preventative check-ups, Longevity Center is grounded in geroscience research, as well as embracing a holistic mindset that acknowledges the importance of mental health and feeling well.

Longevity Center Switzerland is the company's third clinic, opened in Zurich earlier this year. Its team is headed by Medical Director Anna Erat MD PhD, whose clinical specialization spans preventive, sports and internal medicine, and whose clients include ice hockey team players, Formula 1 drivers and world-class Ironman triathletes. Erat also brings expertise in biomedicine, genetics, epidemiology and health systems management to her leadership of Longevity Center Switzerland, and we sat down with her to find out why optimizing for sports excellence is helping Longevity Center optimize healthspan for its clients.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about Longevity Center: https://longevity-center.eu/]]>730falsefullhttps://www.spreaker.com/episode/are-supplements-the-key-to-unlocking-healthy-longevity--74818179
Next year sees the first global scientific conference focused solely on the role of supplements as a geroprotective intervention.

Happening at National University of Singapore, the conference will bring together leading scientists, clinicians, key opinion leaders, industry partners, consumer representatives and regulatory authorities to explore the immense potential of supplements in optimising the way we age. The speaker list already boasts David Sinclair, Brian Kennedy, Nir Barzilai, Andrea Maier, Greg Bailey and Brad Stanfield.

This conference can't come soon enough! The supplements space is exploding, with various products jostling for top spot when it comes to purity, bioavailability and synergy of ingredients, and the conference has set itself the task of separating hope from hype. Run by the Centre for Healthy Longevity, which is dedicated to advancing the science and application of supplements to optimise health and extend healthspan and lifespan, the events kick off with three days of workshops that form an intensive course on healthy longevity (26-28 February 2024). The week ends with the conference with Unlock Healthy Longevity: Supplements running on Thursday 29 February and Friday 1 March.

To find out more about what's involved, we sat down with Andrea Maier, Director of the Centre for Healthy Longevity, and Hans Meij, Director, NUS Academy for Healthy Longevity.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about the CHL Summit: https://chl-summit.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686622Fri, 27 Oct 2023 17:16:58 +0000saderA new conference is set to dive into the world of longevity supplements, from preclinical to clinical and from off the shelf to hyper-personalization. Next year sees the first global scientific conference focused solely on the role of supplements as...
Next year sees the first global scientific conference focused solely on the role of supplements as a geroprotective intervention.

Happening at National University of Singapore, the conference will bring together leading scientists, clinicians, key opinion leaders, industry partners, consumer representatives and regulatory authorities to explore the immense potential of supplements in optimising the way we age. The speaker list already boasts David Sinclair, Brian Kennedy, Nir Barzilai, Andrea Maier, Greg Bailey and Brad Stanfield.

This conference can't come soon enough! The supplements space is exploding, with various products jostling for top spot when it comes to purity, bioavailability and synergy of ingredients, and the conference has set itself the task of separating hope from hype. Run by the Centre for Healthy Longevity, which is dedicated to advancing the science and application of supplements to optimise health and extend healthspan and lifespan, the events kick off with three days of workshops that form an intensive course on healthy longevity (26-28 February 2024). The week ends with the conference with Unlock Healthy Longevity: Supplements running on Thursday 29 February and Friday 1 March.

To find out more about what's involved, we sat down with Andrea Maier, Director of the Centre for Healthy Longevity, and Hans Meij, Director, NUS Academy for Healthy Longevity.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about the CHL Summit: https://chl-summit.com/]]>1010falsefullhttps://www.spreaker.com/episode/i-want-medical-tourism-to-be-open-to-everyone-forever--74818195
Liz Parrish is the CEO of Seattle-based biotech BioViva, a company working to lengthen healthy human lifespans with gene therapy which includes both adeno-associated virus (AAV) and cytomegalovirus vector (CMV) approaches.

Parrish is passionate about reducing the suffering and death caused by cellular aging and its associated diseases. So much so, in fact, that she traveled to Colombia to test BioViva’s tech on herself in personalized N=1 research.

We sat down with Liz Parrish to find out her thoughts on patient advocacy, BioViva’s research into telomerase reverse transcriptase gene therapy and longevity medical tourism.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686530Tue, 26 Sep 2023 17:02:57 +0000saderBioViva’s CEO Liz Parrish on de-risking regulatory systems and creating evidence-based medicine from medical tourism. Liz Parrish is the CEO of Seattle-based biotech BioViva, a company working to lengthen healthy human lifespans with gene therapy...
Liz Parrish is the CEO of Seattle-based biotech BioViva, a company working to lengthen healthy human lifespans with gene therapy which includes both adeno-associated virus (AAV) and cytomegalovirus vector (CMV) approaches.

Parrish is passionate about reducing the suffering and death caused by cellular aging and its associated diseases. So much so, in fact, that she traveled to Colombia to test BioViva’s tech on herself in personalized N=1 research.

We sat down with Liz Parrish to find out her thoughts on patient advocacy, BioViva’s research into telomerase reverse transcriptase gene therapy and longevity medical tourism.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1056falsefullhttps://www.spreaker.com/episode/we-are-information-machines-and-it-s-time-to-renew-the-code--74818135
September is whizzing by, and that means that it's not long to go until the Longevity Investors Conference takes place in Switzerland. One of the speakers on Day 2 of this must-attend event is the philanthropist, entrepreneur and futurist David Gobel; the Methusaleh Foundation CEO will be presenting on  Lifting All Boats... Realizing precision personalized medicine via in vivitro modeling. An in vivitro approach combines traditional in vivo and in vitro methods, creating an 'in life in glass' platform.

Co-founded with Dane Gobel and Aubrey de Grey, the Methuselah Foundation is a medical charity based in Springfield, Virginia. The foundation has invested millions of dollars in the research and development of regenerative medicine, and uses its platform to promote public understanding of longevity and ways to extending the healthy human lifespan.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about Longevity Investors Conference: https://www.longevityinvestors.ch/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686559Wed, 20 Sep 2023 17:10:20 +0000saderMethuselah Foundation's CEO David Gobel on clinging to the longevity biotech mast while waiting for the rising tide. September is whizzing by, and that means that it's not long to go until the Longevity Investors Conference takes place in...
September is whizzing by, and that means that it's not long to go until the Longevity Investors Conference takes place in Switzerland. One of the speakers on Day 2 of this must-attend event is the philanthropist, entrepreneur and futurist David Gobel; the Methusaleh Foundation CEO will be presenting on  Lifting All Boats... Realizing precision personalized medicine via in vivitro modeling. An in vivitro approach combines traditional in vivo and in vitro methods, creating an 'in life in glass' platform.

Co-founded with Dane Gobel and Aubrey de Grey, the Methuselah Foundation is a medical charity based in Springfield, Virginia. The foundation has invested millions of dollars in the research and development of regenerative medicine, and uses its platform to promote public understanding of longevity and ways to extending the healthy human lifespan.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about Longevity Investors Conference: https://www.longevityinvestors.ch/]]>1175falsefullhttps://www.spreaker.com/episode/it-s-always-too-early-to-say-something-s-impossible--74818130
Think about genomic science, and you think about George Church. Dubbed the ‘father of genomics’, he helped to initiate the Human Genome Project, and he is Professor of Genetics at Harvard Medical School. He is also Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT) and leads Synthetic Biology at the Wyss Institute.

It’s not long, now, until RAADfest, and Professor Church is a keynote speaker, presenting on Technologies to radically alter our genomes: why and how?, and participating in a live Q&A. We sat down with him to discuss cellular reprogramming, the problem with biomarkers and gene therapy levers – and he also teased that he’ll be presenting some as-yet-unpublished data at RAADfest…

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about RAADfest: https://raadfest.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686574Wed, 06 Sep 2023 17:07:27 +0000saderGeorge Church on rewriting the genome, exponential synthetic biology and having a longevity methodology. Think about genomic science, and you think about George Church. Dubbed the ‘father of genomics’, he helped to initiate the Human Genome Project,...
Think about genomic science, and you think about George Church. Dubbed the ‘father of genomics’, he helped to initiate the Human Genome Project, and he is Professor of Genetics at Harvard Medical School. He is also Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT) and leads Synthetic Biology at the Wyss Institute.

It’s not long, now, until RAADfest, and Professor Church is a keynote speaker, presenting on Technologies to radically alter our genomes: why and how?, and participating in a live Q&A. We sat down with him to discuss cellular reprogramming, the problem with biomarkers and gene therapy levers – and he also teased that he’ll be presenting some as-yet-unpublished data at RAADfest…

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
LinkedIn - https://bit.ly/3yIfDmf

More about RAADfest: https://raadfest.com/]]>1516falsefullhttps://www.spreaker.com/episode/we-re-at-the-longevity-inflection-point-and-the-explosion-is-coming--74818151
It's not long to go, now, before the Longevity Investors Conference kicks off in Switerland. One of the speakers on day 2 of next month's event is Dr Greg Bailey, the Executive Chairman of Juvenescence who will be presenting on Biotech Investment Opportunities.

We recently covered the news that Serina Therapeutics and AgeX Therapeutics have entered into a merger agreement, so this is just one of the topics we were able to discuss with Dr Bailey, who also reveals why he feels like the warm-up band for The Rolling Stones. We also found out about the relaunch of Cognitive Switch, Juvenescence's ketone ester, why embracing prevention is so important and why founder scientists and institutions need to be treated fairly.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about Longevity Investors Conference: https://www.longevityinvestors.ch/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686642Thu, 31 Aug 2023 16:47:22 +0000saderJuvenescence's Executive Chairman Dr Greg Bailey on demographic timebombs, the biotech mafia and ensuring founders get to participate in the upside. It's not long to go, now, before the Longevity Investors Conference kicks off in Switerland. One of...
It's not long to go, now, before the Longevity Investors Conference kicks off in Switerland. One of the speakers on day 2 of next month's event is Dr Greg Bailey, the Executive Chairman of Juvenescence who will be presenting on Biotech Investment Opportunities.

We recently covered the news that Serina Therapeutics and AgeX Therapeutics have entered into a merger agreement, so this is just one of the topics we were able to discuss with Dr Bailey, who also reveals why he feels like the warm-up band for The Rolling Stones. We also found out about the relaunch of Cognitive Switch, Juvenescence's ketone ester, why embracing prevention is so important and why founder scientists and institutions need to be treated fairly.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about Longevity Investors Conference: https://www.longevityinvestors.ch/]]>1299falsefullhttps://www.spreaker.com/episode/longevity-to-a-sirtuin-extent--74818147
Not many companies style themselves as longevity-focused, but SIRTLab Corporation, a US Company with research laboratories in the Weizmann Science Park, Israel, is one that is very happy to do so. With a patented suite of advanced technologies to raise the specific and direct activity of the SIRT6 protein, SIRTLab has various age-related diseases in its sights, including liver disease, frailty, metabolic syndrome, neurodegeneration and inflammatory conditions.

Boasting leading geroscience researcher Dr Nir Barzilai as its Chief Medical Adviser, SIRTLab was founded by Boaz Misholi and Professor Haim Cohen, a world leader in research of SIRT6, who has seen over $40 million invested in his research. We caught up with Cohen to find out more about SIRT6 and the role of sirtuins in longevity.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686568Tue, 29 Aug 2023 17:48:59 +0000saderSIRTLab's Professor Haim Cohen on SIRT6 and its importance in longevity research. Not many companies style themselves as longevity-focused, but SIRTLab Corporation, a US Company with research laboratories in the Weizmann Science Park, Israel, is one...
Not many companies style themselves as longevity-focused, but SIRTLab Corporation, a US Company with research laboratories in the Weizmann Science Park, Israel, is one that is very happy to do so. With a patented suite of advanced technologies to raise the specific and direct activity of the SIRT6 protein, SIRTLab has various age-related diseases in its sights, including liver disease, frailty, metabolic syndrome, neurodegeneration and inflammatory conditions.

Boasting leading geroscience researcher Dr Nir Barzilai as its Chief Medical Adviser, SIRTLab was founded by Boaz Misholi and Professor Haim Cohen, a world leader in research of SIRT6, who has seen over $40 million invested in his research. We caught up with Cohen to find out more about SIRT6 and the role of sirtuins in longevity.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>578falsefullhttps://www.spreaker.com/episode/longevity-is-the-biggest-revolution-in-the-history-of-homo-sapiens-don-t-die--74818202
Bryan Johnson is the man behind Blueprint, a project that aims to measure all of his 70 organs – and then maximally reverse the quantified biological age of each. Described as the “most measured man in human history”, Johnson publicly documents his self-experimental protocols and results, allowing us to be passengers on his longevity journey. Two years and millions of dollars into that journey, Johnson has data demonstrating he has slowed his pace of aging by an equivalent 31 years, and now he is working on rolling out his algorithm to enable his followers to move from passenger to driver, taking up the Blueprint for themselves.

The term ‘biohacking’ could have been invented for Bryan Johnson. The multimillionaire tech entrepreneur makes no secret of the fact that he is spending $2 million a year, not only trying to keep the ravages of aging at bay, but to actively reverse his biological age. It’s no surprise then that Johnson is a featured speaker at this year’s RAADfest, the conference that puts super-longevity at the top of its agenda.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about RAADfest: https://raadfest.com/]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686541Fri, 25 Aug 2023 16:16:30 +0000saderBryan Johnson explains why longevity is here, why super-intelligence is right around the corner, and why when it comes to Blueprint, he is happiest in the trenches. Bryan Johnson is the man behind Blueprint, a project that aims to measure all of his...
Bryan Johnson is the man behind Blueprint, a project that aims to measure all of his 70 organs – and then maximally reverse the quantified biological age of each. Described as the “most measured man in human history”, Johnson publicly documents his self-experimental protocols and results, allowing us to be passengers on his longevity journey. Two years and millions of dollars into that journey, Johnson has data demonstrating he has slowed his pace of aging by an equivalent 31 years, and now he is working on rolling out his algorithm to enable his followers to move from passenger to driver, taking up the Blueprint for themselves.

The term ‘biohacking’ could have been invented for Bryan Johnson. The multimillionaire tech entrepreneur makes no secret of the fact that he is spending $2 million a year, not only trying to keep the ravages of aging at bay, but to actively reverse his biological age. It’s no surprise then that Johnson is a featured speaker at this year’s RAADfest, the conference that puts super-longevity at the top of its agenda.

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf

More about RAADfest: https://raadfest.com/]]>1702falsefullhttps://www.spreaker.com/episode/longevity-this-time-it-s-personal--74818143
NOVOS CEO and Founder Chris Mirabile on why ‘Younger For Longer’ is more than just a strapline.

NOVOS puts geroscience at the heart of its products; NOVOS Core is a patent-pending powdered formula containing 12 active longevity ingredients that target the hallmarks of aging. For customers that want a little additional pep in their longevity step, the company also offers NOVOS Boost, a capsule supplement containing high-purity microcrystalline nicotinamide mononucleotide (NMN), which harnesses the power of NAD+ to boost energy, metabolism and DNA repair.

And NOVOS puts its money where its mouth is – NOVOS Age is a powerful biological age test kit that allows customers to track how their lifestyle impacts their aging and discover if they are actually moving the needle on their longevity.

With four years of testing and formulating behind them, NOVOS is confident its products can slow down the pace of aging by targeting its root causes. The message is amplified with a comprehensive website that aims to educate and inform about healthy lifestyle choices for longevity and NOVOS Age includes a cutting-edge third-generation test that measures the pace of epigenetic aging, biological age and telomere length. We sat down with Founder and CEO Chris Mirabile to talk biological age reversal – staying Younger For Longer – and how you don’t have to be superhuman to achieve it.
------------------------------
Visit NOVOS - https://bit.ly/3NRtjnq
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686578Wed, 28 Jun 2023 12:49:17 +0000saderVisit NOVOS - https://bit.ly/3NRtjnq NOVOS CEO and Founder Chris Mirabile on why ‘Younger For Longer’ is more than just a strapline. NOVOS puts geroscience at the heart of its products; NOVOS Core is a patent-pending powdered formula containing 12...
NOVOS CEO and Founder Chris Mirabile on why ‘Younger For Longer’ is more than just a strapline.

NOVOS puts geroscience at the heart of its products; NOVOS Core is a patent-pending powdered formula containing 12 active longevity ingredients that target the hallmarks of aging. For customers that want a little additional pep in their longevity step, the company also offers NOVOS Boost, a capsule supplement containing high-purity microcrystalline nicotinamide mononucleotide (NMN), which harnesses the power of NAD+ to boost energy, metabolism and DNA repair.

And NOVOS puts its money where its mouth is – NOVOS Age is a powerful biological age test kit that allows customers to track how their lifestyle impacts their aging and discover if they are actually moving the needle on their longevity.

With four years of testing and formulating behind them, NOVOS is confident its products can slow down the pace of aging by targeting its root causes. The message is amplified with a comprehensive website that aims to educate and inform about healthy lifestyle choices for longevity and NOVOS Age includes a cutting-edge third-generation test that measures the pace of epigenetic aging, biological age and telomere length. We sat down with Founder and CEO Chris Mirabile to talk biological age reversal – staying Younger For Longer – and how you don’t have to be superhuman to achieve it.
------------------------------
Visit NOVOS - https://bit.ly/3NRtjnq
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1220falsefullhttps://www.spreaker.com/episode/sirt6-the-protein-that-talks-the-talk-and-walks-the-walk--74818210
Last month, US-Israeli startup SIRTLab announced the appointment of leading geroscience researcher Dr Nir Barzilai as its Chief Medical Adviser, adding additional longevity kudos to a company founded by Boaz Misholi and Professor Haim Cohen, a world leader in research of SIRT6, who has seen over $40 million invested in his research.

SIRTLab has the development of therapeutics that boost levels of SIRT6 in its sights, and given that SIRT6 has been shown to protect against aging-associated pathologies, including metabolic disease and cancer, and to promote longevity [1], it is no wonder that SIRTLab styles itself as “focused on longevity”. The company includes liver disease, frailty, metabolic syndrome, neurodegeneration and inflammatory conditions among its targets, and we grabbed some time with Nir Barzilai to find out more about his hopes for SIRT6 and how SIRTLab is moving forward.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686572Tue, 13 Jun 2023 16:51:34 +0000saderNir Barzilai on keeping longevity research relevant to humans, developing gerotherapeutics and making the best decisions. Last month, US-Israeli startup SIRTLab announced the appointment of leading geroscience researcher Dr Nir Barzilai as its Chief...
Last month, US-Israeli startup SIRTLab announced the appointment of leading geroscience researcher Dr Nir Barzilai as its Chief Medical Adviser, adding additional longevity kudos to a company founded by Boaz Misholi and Professor Haim Cohen, a world leader in research of SIRT6, who has seen over $40 million invested in his research.

SIRTLab has the development of therapeutics that boost levels of SIRT6 in its sights, and given that SIRT6 has been shown to protect against aging-associated pathologies, including metabolic disease and cancer, and to promote longevity [1], it is no wonder that SIRTLab styles itself as “focused on longevity”. The company includes liver disease, frailty, metabolic syndrome, neurodegeneration and inflammatory conditions among its targets, and we grabbed some time with Nir Barzilai to find out more about his hopes for SIRT6 and how SIRTLab is moving forward.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1007falsefullhttps://www.spreaker.com/episode/navigate-the-emerging-field-of-longevity--74818203
Full steam ahead as Investing in Longevity course live and open for booking.

The wait is over! A brand-new, specially-designed course is ready to assist in navigating the transformative industry of longevity, an industry set to revolutionize the world, presenting both challenges and remarkable opportunities for investors and participants alike.

Investing in a new mega-trend can be daunting, as entering an unfamiliar market requires a comprehensive understanding of new terminologies, scientific advancements, risks and potential opportunities. Investing in Longevity 101 is designed to address these needs.

The landscape is accelerating – supplement manufacturers, clinics, and biomarker vendors already generating revenues and raising capital, and a multitude of longevity biotechs are progressing steadily through clinical trial phases, with an increasing number reaching human trials. Myriad others are hot on their heels, actively seeking significant investments to sustain their progress and expedite their journey to the clinic or market. Longevity is a field of vast potential, but education is the key to unlocking its opportunities. By truly understanding this dynamic field – pitfalls, opportunities and trends – investors can benefit from this incredible potential while contributing much-needed investments to the longevity sector.

This online course is tailored to cater to a diverse audience of venture capitalists, fund managers, angel investors, pharma executives and biotech professionals, medical doctors pursuing continuing medical education, entrepreneurs, medical students, scientists, &c. The course welcomes all those eager to explore the potential of longevity and is part of a series of longevity education courses launched by Longevity Education Hub. We gathered the course founders – Evelyne Bischof, Phil Newman, Ricardo Gaminha Pacheco, Jiayi Song and Alex Zhavoronkov – round a virtual table to find out more.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686580Thu, 08 Jun 2023 14:01:03 +0000saderInvesting in longevity is live! Check it out here - http://bit.ly/45VKg7x Full steam ahead as Investing in Longevity course live and open for booking. The wait is over! A brand-new, specially-designed course is ready to assist in navigating the...
Full steam ahead as Investing in Longevity course live and open for booking.

The wait is over! A brand-new, specially-designed course is ready to assist in navigating the transformative industry of longevity, an industry set to revolutionize the world, presenting both challenges and remarkable opportunities for investors and participants alike.

Investing in a new mega-trend can be daunting, as entering an unfamiliar market requires a comprehensive understanding of new terminologies, scientific advancements, risks and potential opportunities. Investing in Longevity 101 is designed to address these needs.

The landscape is accelerating – supplement manufacturers, clinics, and biomarker vendors already generating revenues and raising capital, and a multitude of longevity biotechs are progressing steadily through clinical trial phases, with an increasing number reaching human trials. Myriad others are hot on their heels, actively seeking significant investments to sustain their progress and expedite their journey to the clinic or market. Longevity is a field of vast potential, but education is the key to unlocking its opportunities. By truly understanding this dynamic field – pitfalls, opportunities and trends – investors can benefit from this incredible potential while contributing much-needed investments to the longevity sector.

This online course is tailored to cater to a diverse audience of venture capitalists, fund managers, angel investors, pharma executives and biotech professionals, medical doctors pursuing continuing medical education, entrepreneurs, medical students, scientists, &c. The course welcomes all those eager to explore the potential of longevity and is part of a series of longevity education courses launched by Longevity Education Hub. We gathered the course founders – Evelyne Bischof, Phil Newman, Ricardo Gaminha Pacheco, Jiayi Song and Alex Zhavoronkov – round a virtual table to find out more.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1083falsefullhttps://www.spreaker.com/episode/it-s-a-brave-new-world-but-longevity-needs-to-stay-in-the-realm-of-the-credible--74818199
ARDD Conference Chairs Alex Zhavoronkov and Morten Scheibye-Knudsen talk megatrends, altruism and longevity.

The largest conference on aging in the biopharmaceutical industry is set to take place 28 August – 1 September 2023 on-site in Copenhagen and online. Leaders in the aging and longevity field will come together to impart and discuss the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions – it’s one of the must-attend events in the longevity space.

As Alex Zhavoronkov says, ARDD is ‘truly the go-to place for investors and biotechnology companies and academics to come together and help build the industry’. We grabbed some time with Zhavoronkov and fellow conference Chair Morten Scheibye-Knudsen to find out some of the conference’s forthcoming highlights and why ARDD 10 is set to be the best year yet.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686538Wed, 07 Jun 2023 17:01:57 +0000saderVisit ARDD - https://agingpharma.org/ ARDD Conference Chairs Alex Zhavoronkov and Morten Scheibye-Knudsen talk megatrends, altruism and longevity. The largest conference on aging in the biopharmaceutical industry is set to take place 28 August – 1...
ARDD Conference Chairs Alex Zhavoronkov and Morten Scheibye-Knudsen talk megatrends, altruism and longevity.

The largest conference on aging in the biopharmaceutical industry is set to take place 28 August – 1 September 2023 on-site in Copenhagen and online. Leaders in the aging and longevity field will come together to impart and discuss the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions – it’s one of the must-attend events in the longevity space.

As Alex Zhavoronkov says, ARDD is ‘truly the go-to place for investors and biotechnology companies and academics to come together and help build the industry’. We grabbed some time with Zhavoronkov and fellow conference Chair Morten Scheibye-Knudsen to find out some of the conference’s forthcoming highlights and why ARDD 10 is set to be the best year yet.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1504falsefullhttps://www.spreaker.com/episode/unlocking-longevity-potential-glycanage-s-approach-to-longevity-healthspan-and-menopause--74818200Longevity.Technology audience can benefit from 10% off at GlycanAge – shop now using the code LONGEVITYTECHNOLOGY

A change in mindset from treatment to prevention is required – and GlycanAge can help.

GlycanAge analyzes levels of low-grade chronic inflammation, using the data to calculate a person’s biological age, doing so by analyzing glycans on the main protein of the immune system – immunoglobulin G. Having this data can empower users to optimize their health, wellness and longevity, check lifestyle interventions are making a difference and personalize menopause management.

There’s a lot of confusion about aging clocks – who should be using them? Is one better than another? How should I use the data? We sat down with three people from GlycanAge – Nikolina Lauc, Co-Founder and CEO, Dr Lucija Sironic, MD, Longevity Consultant and Dr Marina Kavur, PhD, Head of R&D – to discuss communication around aging clocks, how we define biological age, and how we measure and adjust it. We also discussed menopause, HRT and andropause.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686635Thu, 01 Jun 2023 16:29:18 +0000saderVisit GlycanAge: https://bit.ly/45Jhg2q Longevity.Technology audience can benefit from 10% off at GlycanAge – shop now using the code LONGEVITYTECHNOLOGY A change in mindset from treatment to prevention is required – and GlycanAge can help....Longevity.Technology audience can benefit from 10% off at GlycanAge – shop now using the code LONGEVITYTECHNOLOGY

A change in mindset from treatment to prevention is required – and GlycanAge can help.

GlycanAge analyzes levels of low-grade chronic inflammation, using the data to calculate a person’s biological age, doing so by analyzing glycans on the main protein of the immune system – immunoglobulin G. Having this data can empower users to optimize their health, wellness and longevity, check lifestyle interventions are making a difference and personalize menopause management.

There’s a lot of confusion about aging clocks – who should be using them? Is one better than another? How should I use the data? We sat down with three people from GlycanAge – Nikolina Lauc, Co-Founder and CEO, Dr Lucija Sironic, MD, Longevity Consultant and Dr Marina Kavur, PhD, Head of R&D – to discuss communication around aging clocks, how we define biological age, and how we measure and adjust it. We also discussed menopause, HRT and andropause.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>2215falsefullhttps://www.spreaker.com/episode/a-strong-patent-portfolio-delivers-a-competitive-edge-in-the-longevity-space--74818183We write a great deal about supplements – new ones coming to market, ingredient synergies, clinical trials, &c. If a company has spent time and money developing a product, the last thing they want to see is someone ripping off its hard work and leveraging its IP for someone else’s benefit. One company who really knows its onions when it comes to IP is ChromaDex, developers of Niagen, the ingredient that makes up the best-selling supplement Tru Niagen.

Philip Redpath, Director of R&D at ChromaDex, and Aron Erickson, VP of R&D at ChromaDex, join us from their lab in Longmont to talk IP, explain why longevity supplement companies need a strong patent portfolio, types of patents applied for and patenting GRAS compounds – a patent masterclass, if you will.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686576Wed, 31 May 2023 18:02:16 +0000saderClimbing the intellectual property ladder the ChromaDex way. We write a great deal about supplements – new ones coming to market, ingredient synergies, clinical trials, &c. If a company has spent time and money developing a product, the last thing...We write a great deal about supplements – new ones coming to market, ingredient synergies, clinical trials, &c. If a company has spent time and money developing a product, the last thing they want to see is someone ripping off its hard work and leveraging its IP for someone else’s benefit. One company who really knows its onions when it comes to IP is ChromaDex, developers of Niagen, the ingredient that makes up the best-selling supplement Tru Niagen.

Philip Redpath, Director of R&D at ChromaDex, and Aron Erickson, VP of R&D at ChromaDex, join us from their lab in Longmont to talk IP, explain why longevity supplement companies need a strong patent portfolio, types of patents applied for and patenting GRAS compounds – a patent masterclass, if you will.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1004falsefullhttps://www.spreaker.com/episode/juvenescence-think-aging-up-rather-than-disease-down--74818209Back in January, we reported that leading longevity biotech Juvenescence had appointed Dr Richard Marshall CBE as CEO. As well bringing fifteen years’ GSK experience to the role, Marshall was also latterly Senior VP, Global Head of Development, Respiratory & Immunology at AstraZeneca.

Juvenescence is focused on antiaging research and the development of therapeutics to combat age-related diseases. Its various collaborations and subsidiaries enable it to explore diverse approaches, including small molecules, gene therapies and regenerative medicine, to address the challenges of aging and redefine the possibilities of healthy aging.

In appointing a CEO with an impressive Big Pharma track record, Juvenescence continues its commitment, not only to to novel and innovative therapeutics, but to moving antiaging drugs through human trials and into the clinic. We sat down with Dr Marshall to find out why having diversity of pipeline and thinking is so key to success, what Juvenescence’s USP is, and why, when it comes to supplements, we need to watch this space!
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686563Wed, 24 May 2023 16:47:53 +0000saderNew CEO set to Marshall longevity with a pipeline that delivers immediate therapeutic benefit, but always has an eye on a future preventative angle. Back in January, we reported that leading longevity biotech Juvenescence had appointed Dr Richard...Back in January, we reported that leading longevity biotech Juvenescence had appointed Dr Richard Marshall CBE as CEO. As well bringing fifteen years’ GSK experience to the role, Marshall was also latterly Senior VP, Global Head of Development, Respiratory & Immunology at AstraZeneca.

Juvenescence is focused on antiaging research and the development of therapeutics to combat age-related diseases. Its various collaborations and subsidiaries enable it to explore diverse approaches, including small molecules, gene therapies and regenerative medicine, to address the challenges of aging and redefine the possibilities of healthy aging.

In appointing a CEO with an impressive Big Pharma track record, Juvenescence continues its commitment, not only to to novel and innovative therapeutics, but to moving antiaging drugs through human trials and into the clinic. We sat down with Dr Marshall to find out why having diversity of pipeline and thinking is so key to success, what Juvenescence’s USP is, and why, when it comes to supplements, we need to watch this space!
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1583falsefullhttps://www.spreaker.com/episode/leveraging-the-power-of-senolytics-to-eliminate-senescence-cells--74818215
Combilytics is on a mission to leverage the power of senolytics through natural compound supplements and specific dosing.

Combilytics – a portmanteau derived from combination and senolytics – is the company behind EternLFX, a supplement designed to target and eliminate senescent cells. These cells are ones that have stopped growing and dividing, but didn’t get the ‘time to die’ memo, and instead hang around, emitting toxic chemicals and encouraging other cells to turn to the dark side that is senescence. Combilytics’ senolytic supplement contains fisetin and quercetin, as well as six different ingredients intended to boost the formula’s bioavailability (green tea extract ECGC, ginger root extract, black pepper fruit extract, grapefruit extract, licorice fruit extract and bromelain).

What sets EternLFX apart on the shelf is its meticulous dosing program which is based around active and inactive cycles and depends on your age and weight.

Steve Matheson, Combilytics CEO, was intrigued by a ‘zombie cells’ headline back in 2019. Having read studies showing that senolytics can eliminate senescent cells in humans, he set about developing a formula that would take quality ingredients, leverage their senolytic ability, and extend the healthspan of his customers. We sat down with Steve to learn more about his inspiration and direction.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686634Mon, 22 May 2023 14:42:17 +0000saderVisit Combilytics - https://bit.ly/3MOZy6c Combilytics is on a mission to leverage the power of senolytics through natural compound supplements and specific dosing. Combilytics – a portmanteau derived from combination and senolytics – is the company...
Combilytics is on a mission to leverage the power of senolytics through natural compound supplements and specific dosing.

Combilytics – a portmanteau derived from combination and senolytics – is the company behind EternLFX, a supplement designed to target and eliminate senescent cells. These cells are ones that have stopped growing and dividing, but didn’t get the ‘time to die’ memo, and instead hang around, emitting toxic chemicals and encouraging other cells to turn to the dark side that is senescence. Combilytics’ senolytic supplement contains fisetin and quercetin, as well as six different ingredients intended to boost the formula’s bioavailability (green tea extract ECGC, ginger root extract, black pepper fruit extract, grapefruit extract, licorice fruit extract and bromelain).

What sets EternLFX apart on the shelf is its meticulous dosing program which is based around active and inactive cycles and depends on your age and weight.

Steve Matheson, Combilytics CEO, was intrigued by a ‘zombie cells’ headline back in 2019. Having read studies showing that senolytics can eliminate senescent cells in humans, he set about developing a formula that would take quality ingredients, leverage their senolytic ability, and extend the healthspan of his customers. We sat down with Steve to learn more about his inspiration and direction.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1626falsefullhttps://www.spreaker.com/episode/investing-in-longevity-101--74818234
Investing in a new mega trend can be challenging; as well as entering a new market, there is a great deal to learn and understand – new terminology, new science, new risks and new opportunities.

Investing in Longevity 101 is a new online course designed to help investors, and all those interested in participating in this new economy, to navigate the sector – this includes entrepreneurs, executives, clinicians, policy makers, &c.

Launching shortly, the course content for Investing in Longevity 101 addresses both longevity biotech and non-biotech, reflecting the current segmentation of the longevity market.

There are companies like supplement manufacturers, clinics and biomarker vendors that are raising capital and generating revenues today, and there are longevity biotechs that are progressing through clinical trial phases – a growing number of them ‘in human’. Plus, there are myriad companies not far behind, all looking for multiple millions in investment that can help them maintain their progress and accelerate to clinic or market.

Education is key, and really understanding the longevity space will help investors benefit from its incredible opportunities – and help longevity benefit from much-needed investment. We gathered the course founders – Evelyne Bischof, Phil Newman, Ricardo Gaminha Pacheco, Jiayi Song and Alex Zhavoronkov – round a virtual table to find out more.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686551Fri, 12 May 2023 16:33:57 +0000saderA new course will help navigate emerging field of longevity – an industry that is going to change the world. Investing in a new mega trend can be challenging; as well as entering a new market, there is a great deal to learn and understand – new...
Investing in a new mega trend can be challenging; as well as entering a new market, there is a great deal to learn and understand – new terminology, new science, new risks and new opportunities.

Investing in Longevity 101 is a new online course designed to help investors, and all those interested in participating in this new economy, to navigate the sector – this includes entrepreneurs, executives, clinicians, policy makers, &c.

Launching shortly, the course content for Investing in Longevity 101 addresses both longevity biotech and non-biotech, reflecting the current segmentation of the longevity market.

There are companies like supplement manufacturers, clinics and biomarker vendors that are raising capital and generating revenues today, and there are longevity biotechs that are progressing through clinical trial phases – a growing number of them ‘in human’. Plus, there are myriad companies not far behind, all looking for multiple millions in investment that can help them maintain their progress and accelerate to clinic or market.

Education is key, and really understanding the longevity space will help investors benefit from its incredible opportunities – and help longevity benefit from much-needed investment. We gathered the course founders – Evelyne Bischof, Phil Newman, Ricardo Gaminha Pacheco, Jiayi Song and Alex Zhavoronkov – round a virtual table to find out more.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1079falsefullhttps://www.spreaker.com/episode/getting-comfortable-with-senotherapeutics--74818229
UNITY Biotech is a company working on therapeutics to slow, halt or reverse diseases of aging. With an initial focus on age-related eye diseases and neurological conditions, UNITY is in the happy position of having recently announced positive results from the long-term follow-up of its Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME).

We sat down with Anirvan Ghosh, the CEO of UNITY Biotechnology to find out more about the recent trial and its results, what’s next for UNITY and what excites him about the senotherapeutic space.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686570Wed, 10 May 2023 18:05:26 +0000saderUNITY Biotech’s CEO on data that builds conviction and pioneering novel treatment paradigms. UNITY Biotech is a company working on therapeutics to slow, halt or reverse diseases of aging. With an initial focus on age-related eye diseases and...
UNITY Biotech is a company working on therapeutics to slow, halt or reverse diseases of aging. With an initial focus on age-related eye diseases and neurological conditions, UNITY is in the happy position of having recently announced positive results from the long-term follow-up of its Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME).

We sat down with Anirvan Ghosh, the CEO of UNITY Biotechnology to find out more about the recent trial and its results, what’s next for UNITY and what excites him about the senotherapeutic space.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>908falsefullhttps://www.spreaker.com/episode/new-longevity-conference-will-span-research-to-evidence-based-clinical-practice--74818218
Sheba Longevity Conference will formally open hospital’s dedicated longevity center, facilitating a shift in Israel’s national health policy.

Next week will see the first Sheba Longevity Conference, a meeting that will bring together all relevant stakeholders in the multidisciplinary field of longevity medicine, providing a forum for showcasing outstanding research and scientific breakthroughs. The conference will also include the opening ceremony of the public academic hospital longevity center at Sheba Hospital.

The conference aims to foster collaborations that will accelerate the translation of scientific discoveries into clinical practices and facilitate a shift in Israel’s national healthy longevity policy. The event will also include an exhibition space for sponsors, partners and industry representatives to promote dialogue and showcase their work.

Kirkland, Rando, Barzilai, Maier, Zhavoronkov, Verdin, Mannick… the Sheba Longevity Conference has bagged some longevity A-listers who will be discussing senescence, geroscience, global longevity, aging clocks and more. We sat down with one of the founders of Sheba Longevity, Dr Evelyne Bischof to find out more.

Visit Sheba Longevity Conference - https://bit.ly/41btRId
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686583Thu, 04 May 2023 16:30:48 +0000saderVisit Sheba Longevity Conference - https://bit.ly/41btRId Sheba Longevity Conference will formally open hospital’s dedicated longevity center, facilitating a shift in Israel’s national health policy. Next week will see the first Sheba Longevity...
Sheba Longevity Conference will formally open hospital’s dedicated longevity center, facilitating a shift in Israel’s national health policy.

Next week will see the first Sheba Longevity Conference, a meeting that will bring together all relevant stakeholders in the multidisciplinary field of longevity medicine, providing a forum for showcasing outstanding research and scientific breakthroughs. The conference will also include the opening ceremony of the public academic hospital longevity center at Sheba Hospital.

The conference aims to foster collaborations that will accelerate the translation of scientific discoveries into clinical practices and facilitate a shift in Israel’s national healthy longevity policy. The event will also include an exhibition space for sponsors, partners and industry representatives to promote dialogue and showcase their work.

Kirkland, Rando, Barzilai, Maier, Zhavoronkov, Verdin, Mannick… the Sheba Longevity Conference has bagged some longevity A-listers who will be discussing senescence, geroscience, global longevity, aging clocks and more. We sat down with one of the founders of Sheba Longevity, Dr Evelyne Bischof to find out more.

Visit Sheba Longevity Conference - https://bit.ly/41btRId
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>443falsefullhttps://www.spreaker.com/episode/the-longevity-tech-that-shows-insane-promise-with-aubrey-de-grey--74818160
Aubrey de Grey explains why the time is right to be extremely ambitious and audacious when it comes to longevity research.

August will see the second annual Longevity Summit take place in Dublin. Packed with keynote presentations by leading experts in the aging field, the summit will showcase some of the latest – and most exciting – research and innovations in the longevity space.

One of the Longevity Summit's most-anticipated speakers is eminent gerontologist Dr Aubrey de Grey. Since the launch of the Longevity Escape Velocity Foundation, which Dr de Grey announced at Dublin last year, news on progress of its flagship research programme Robust Mouse Rejuvenation has been keenly awaited, as has further details on its research into transplants on demand.

Visit Longevity Summit Dublin - https://bit.ly/44ciTF5
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686596Wed, 03 May 2023 17:07:31 +0000saderVisit Longevity Summit Dublin - https://bit.ly/44ciTF5 Aubrey de Grey explains why the time is right to be extremely ambitious and audacious when it comes to longevity research. August will see the second annual Longevity Summit take place in...
Aubrey de Grey explains why the time is right to be extremely ambitious and audacious when it comes to longevity research.

August will see the second annual Longevity Summit take place in Dublin. Packed with keynote presentations by leading experts in the aging field, the summit will showcase some of the latest – and most exciting – research and innovations in the longevity space.

One of the Longevity Summit's most-anticipated speakers is eminent gerontologist Dr Aubrey de Grey. Since the launch of the Longevity Escape Velocity Foundation, which Dr de Grey announced at Dublin last year, news on progress of its flagship research programme Robust Mouse Rejuvenation has been keenly awaited, as has further details on its research into transplants on demand.

Visit Longevity Summit Dublin - https://bit.ly/44ciTF5
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>821falsefullhttps://www.spreaker.com/episode/aubrey-de-grey-on-longevity-summit-dublin-2023-and-what-it-means-for-the-longevity-movement--74818224
Kicking off in August, the 2023 Longevity Summit Dublin is set to recognize emerging research developments to extend human healthspan by gathering together some of the world's leading scientists. A showcase for the most up-to-date research and innovations in the longevity industry, the summit will feature keynote presentations by leading experts in the aging field.

With over 40 global pioneering scientists, researchers and investors packed into four days of sharing knowledge, identifying opportunities and networking, Longevity Summit Dublin is one of the must-attend dates of the longevity calendar. Eminent gerontologist Dr Aubrey de Grey is speaking at the conference, and we sat down with him to find out what attendees can expect this year.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686620Mon, 01 May 2023 14:38:56 +0000saderVisit Longevity Summit Dublin - https://bit.ly/44ciTF5 Kicking off in August, the 2023 Longevity Summit Dublin is set to recognize emerging research developments to extend human healthspan by gathering together some of the world's leading scientists....
Kicking off in August, the 2023 Longevity Summit Dublin is set to recognize emerging research developments to extend human healthspan by gathering together some of the world's leading scientists. A showcase for the most up-to-date research and innovations in the longevity industry, the summit will feature keynote presentations by leading experts in the aging field.

With over 40 global pioneering scientists, researchers and investors packed into four days of sharing knowledge, identifying opportunities and networking, Longevity Summit Dublin is one of the must-attend dates of the longevity calendar. Eminent gerontologist Dr Aubrey de Grey is speaking at the conference, and we sat down with him to find out what attendees can expect this year.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>605falsefullhttps://www.spreaker.com/episode/a-guide-to-healthy-interventions-that-works-for-you--74818220
The process of aging is the accumulation of damage to your body over time due to a long-term overactive immune system.

Knowing your biological age can help you determine whether your current lifestyle is optimal or if changes are needed.

GlycanAge takes a different approach to metabolic age
Is inflammation the enemy? It looks like the jury is still undecided – and with good reason.

Inflammation is essential to evolution – put simply, we cannot survive without it. According to GlycanAge founder Professor Gordan Lauc, it is a process by which the body kills invaders: bacteria and viruses – inflammation is a go-to defence against these threats.

However, this comes at a cost – in this battle of warding off the enemy, we destroy a bit of ourselves, and that’s where physical manifestations of pain, and redness or swollenness, flag up to us that something is going wrong.

But what about low-grade inflammation that we can’t feel but is damaging us all the same?

Read the full article here - https://longevity.technology/lifestyle/glycanage-gives-you-a-guide-to-health-interventions-that-work-for-you/

Visit GlycanAge - https://bit.ly/41gW41f
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686643Tue, 18 Apr 2023 12:39:19 +0000saderVisit Glycanage - https://bit.ly/41gW41f The process of aging is the accumulation of damage to your body over time due to a long-term overactive immune system. Knowing your biological age can help you determine whether your current lifestyle is...
The process of aging is the accumulation of damage to your body over time due to a long-term overactive immune system.

Knowing your biological age can help you determine whether your current lifestyle is optimal or if changes are needed.

GlycanAge takes a different approach to metabolic age
Is inflammation the enemy? It looks like the jury is still undecided – and with good reason.

Inflammation is essential to evolution – put simply, we cannot survive without it. According to GlycanAge founder Professor Gordan Lauc, it is a process by which the body kills invaders: bacteria and viruses – inflammation is a go-to defence against these threats.

However, this comes at a cost – in this battle of warding off the enemy, we destroy a bit of ourselves, and that’s where physical manifestations of pain, and redness or swollenness, flag up to us that something is going wrong.

But what about low-grade inflammation that we can’t feel but is damaging us all the same?

Read the full article here - https://longevity.technology/lifestyle/glycanage-gives-you-a-guide-to-health-interventions-that-work-for-you/

Visit GlycanAge - https://bit.ly/41gW41f
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>2624falsefullhttps://www.spreaker.com/episode/from-the-cradle-to-the-grave-the-long-way-round--74818213
The International Longevity Summit is a conference set to leverage the dynamics of diversity, inclusivity and innovation to foster a revolution in African longevity – afrolongevity – and biotech.

Running over two full days, the ILS is set to provide relevant insights into the longevity space, education, investment opportunities and excellent networking opportunities all in the wonderful setting of the Cradle of Humankind Heritage Site in Johannesburg, South Africa.

Supported by South African Tourism, South African Airways, Longevity Escape Velocity Foundation, SENS Research Foundation and GlycanAge, among others, the conference will bring together the world’s top longevity KOLs, institutional and private investors, family offices and funds. Confirmed speakers include Aubrey de Grey, Andrea Maier, Evelyne Yehudit Bishof, Natasha Vita-More, Jyothi Devakumar, Alexandra Bause and José Luis Cordeiro.

Africa is often referred to as the Cradle of Humankind, and now with an inspirational summit seeking to explore strategies for accelerated implementation of longevity science and integration of innovation in clinical care pathways and healthcare ecosystems to shape our further evolution, perhaps it might also soon be the Cradle of Longevity. ILS has a bigger vision than just life extension; it is seeking to create momentum to not only improve the quality of life in Africa, but to demonstrate on an international stage just what the world can learn from Africa and to prioritize longevity as a fundamental element of human development.

By focusing on Convergence, Investment, Innovation and Translation, the conference aims to refine and augment conventional approaches in scientific discovery, research and development, as well as illustrate and facilitate unconventional approaches for exponential advancement and discovery. We sat down with Ósìnàkáchì Ákùmà Kálù, Founder of Transdisciplinary Agora for Future Discussions ( TAFFDs ), the body behind the conference, and speaker at ILS to find out more.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686639Wed, 12 Apr 2023 17:22:20 +0000saderNew conference seeks to explore research, strategies and education that will close the life expectancy gap on the African continent. The International Longevity Summit is a conference set to leverage the dynamics of diversity, inclusivity and...
The International Longevity Summit is a conference set to leverage the dynamics of diversity, inclusivity and innovation to foster a revolution in African longevity – afrolongevity – and biotech.

Running over two full days, the ILS is set to provide relevant insights into the longevity space, education, investment opportunities and excellent networking opportunities all in the wonderful setting of the Cradle of Humankind Heritage Site in Johannesburg, South Africa.

Supported by South African Tourism, South African Airways, Longevity Escape Velocity Foundation, SENS Research Foundation and GlycanAge, among others, the conference will bring together the world’s top longevity KOLs, institutional and private investors, family offices and funds. Confirmed speakers include Aubrey de Grey, Andrea Maier, Evelyne Yehudit Bishof, Natasha Vita-More, Jyothi Devakumar, Alexandra Bause and José Luis Cordeiro.

Africa is often referred to as the Cradle of Humankind, and now with an inspirational summit seeking to explore strategies for accelerated implementation of longevity science and integration of innovation in clinical care pathways and healthcare ecosystems to shape our further evolution, perhaps it might also soon be the Cradle of Longevity. ILS has a bigger vision than just life extension; it is seeking to create momentum to not only improve the quality of life in Africa, but to demonstrate on an international stage just what the world can learn from Africa and to prioritize longevity as a fundamental element of human development.

By focusing on Convergence, Investment, Innovation and Translation, the conference aims to refine and augment conventional approaches in scientific discovery, research and development, as well as illustrate and facilitate unconventional approaches for exponential advancement and discovery. We sat down with Ósìnàkáchì Ákùmà Kálù, Founder of Transdisciplinary Agora for Future Discussions ( TAFFDs ), the body behind the conference, and speaker at ILS to find out more.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>841falsefullhttps://www.spreaker.com/episode/could-mitochondrial-therapy-tackle-aging-from-the-inside-out--74818189
Visit Mitrix Bio - https://mitrix.bio/

DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the company mentioned in this article to support its current funding round. Qualifying investors can find out more via the Longevity.Technology investment portal.

We recently brought you an interview with Tom Benson, the CEO and Founder of Californian longevity biotech start-up Mitrix Bio, in which we discussed how energy is the headline and why it will take a major intervention to win the Degeneration Game. Today, it’s the turn of mitochondrial medicine and its applications, from bolstering immunity to slowing skin aging.

Mitochondria are organelles that play a critical role in energy production and metabolism, as well as other cellular functions, such as calcium homeostasis, apoptosis and reactive oxygen species (ROS) signaling. Mitochondrial dysfunction has been implicated in the pathogenesis of numerous age-related diseases, including neurodegenerative disorders, metabolic syndrome, cancer and cardiovascular disease.

Mitochondrial decline with age is characterized by a decrease in both the number and function of mitochondria, resulting in reduced ATP production and increased ROS generation, which can lead to oxidative stress and damage to cellular components. It is no wonder, then, that research is seeking a way to both preserve mitochondrial function and to maintain mitochondrial numbers, both of which are crucial for healthy aging and the prevention of age-related diseases. What if technology could harness the body’s method for transporting and releasing fresh mitochondria? We sat down with Tom Benson to find out just how important mitochondria are.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686623Thu, 06 Apr 2023 15:30:17 +0000saderMitrix Bio CEO and Founder on how mitochondria affect everything, everywhere, all at once. Visit Mitrix Bio - https://mitrix.bio/ DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the company mentioned in...
Visit Mitrix Bio - https://mitrix.bio/

DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the company mentioned in this article to support its current funding round. Qualifying investors can find out more via the Longevity.Technology investment portal.

We recently brought you an interview with Tom Benson, the CEO and Founder of Californian longevity biotech start-up Mitrix Bio, in which we discussed how energy is the headline and why it will take a major intervention to win the Degeneration Game. Today, it’s the turn of mitochondrial medicine and its applications, from bolstering immunity to slowing skin aging.

Mitochondria are organelles that play a critical role in energy production and metabolism, as well as other cellular functions, such as calcium homeostasis, apoptosis and reactive oxygen species (ROS) signaling. Mitochondrial dysfunction has been implicated in the pathogenesis of numerous age-related diseases, including neurodegenerative disorders, metabolic syndrome, cancer and cardiovascular disease.

Mitochondrial decline with age is characterized by a decrease in both the number and function of mitochondria, resulting in reduced ATP production and increased ROS generation, which can lead to oxidative stress and damage to cellular components. It is no wonder, then, that research is seeking a way to both preserve mitochondrial function and to maintain mitochondrial numbers, both of which are crucial for healthy aging and the prevention of age-related diseases. What if technology could harness the body’s method for transporting and releasing fresh mitochondria? We sat down with Tom Benson to find out just how important mitochondria are.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>532falsefullhttps://www.spreaker.com/episode/longevity-real-estate-built-on-prevention-and-detection--74818156
Fountain Life is on a mission to change healthcare from reactive to proactive and from amelioration to prevention with an innovative, fully-integrated platform that aims to deliver best-in-class predictive, preventative, personalized and data-driven health.

With founding partners that include Peter Diamandis, Tony Robbins, Robert Hariri, and William Kapp, and the Buck Institute's Eric Verdin, on its medical advisory board, Fountain Life has an impeccable pedigree. The company has already opened four precision diagnostic testing centers, including its latest in Lake Nona, Florida, with centers in California, New Delhi, Dubai and Toronto coming soon.

Longevity is often described as a journey, but the destination is pretty important, too! By partnering with real estate developers, hospitality management companies and other wellness-oriented businesses, Fountain Life aims to create innovative healthcare destinations where a spa-like experience is seamlessly interwoven with cutting edge tech that delivers precision diagnostic testing, and where prevention and healthspan are as much key tenets of the community as green spaces and well-designed layouts.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686597Wed, 05 Apr 2023 15:43:09 +0000saderFountain Life COO talks master-planned communities that focus on longevity and healthspan from the get-go. Fountain Life is on a mission to change healthcare from reactive to proactive and from amelioration to prevention with an innovative,...
Fountain Life is on a mission to change healthcare from reactive to proactive and from amelioration to prevention with an innovative, fully-integrated platform that aims to deliver best-in-class predictive, preventative, personalized and data-driven health.

With founding partners that include Peter Diamandis, Tony Robbins, Robert Hariri, and William Kapp, and the Buck Institute's Eric Verdin, on its medical advisory board, Fountain Life has an impeccable pedigree. The company has already opened four precision diagnostic testing centers, including its latest in Lake Nona, Florida, with centers in California, New Delhi, Dubai and Toronto coming soon.

Longevity is often described as a journey, but the destination is pretty important, too! By partnering with real estate developers, hospitality management companies and other wellness-oriented businesses, Fountain Life aims to create innovative healthcare destinations where a spa-like experience is seamlessly interwoven with cutting edge tech that delivers precision diagnostic testing, and where prevention and healthspan are as much key tenets of the community as green spaces and well-designed layouts.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>910falsefullhttps://www.spreaker.com/episode/why-finding-out-your-glycanage-could-put-more-time-on-the-clock--74818207
Visit Glycanage - https://glycanage.com/

Glycans are important, but often overlooked building blocks of life; the surfaces of all cells are covered with a thick layer of glycans and they are linked to the aging of our immune system, meaning that they can reveal how we are changing on the inside.

Glycans attach to immunoglobulins and analysis of this can play a role in determining biological age; GlycanAge, which was founded by Professor Gordan Lauc, analyses the level of low-grade chronic inflammation in order to calculate a person’s biological age, by analysing glycans on the main protein of the immune system – immunoglobulin G.

Changes in glycan composition can regulate inflammatory responses, aid viral immune escape, regulate apoptosis and promote cancer cell metastasis. Glycans integrate genetic, epigenetic and environmental information into physiological processes that are vital in all aspects of health and disease, so by unlocking the potential of the human glycome, GlycanAge is enabling its customers to better navigate biological age diagnostics and disease prevention. To find out more about the GlycanAge test, we sat down with Professor Lauc.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686633Thu, 23 Mar 2023 18:12:39 +0000saderGlycanAge founder Gordan Lauc on understanding the role inflammation plays in healthspan and longevity – and testing it. Visit Glycanage - https://glycanage.com/ Glycans are important, but often overlooked building blocks of life; the surfaces of...
Visit Glycanage - https://glycanage.com/

Glycans are important, but often overlooked building blocks of life; the surfaces of all cells are covered with a thick layer of glycans and they are linked to the aging of our immune system, meaning that they can reveal how we are changing on the inside.

Glycans attach to immunoglobulins and analysis of this can play a role in determining biological age; GlycanAge, which was founded by Professor Gordan Lauc, analyses the level of low-grade chronic inflammation in order to calculate a person’s biological age, by analysing glycans on the main protein of the immune system – immunoglobulin G.

Changes in glycan composition can regulate inflammatory responses, aid viral immune escape, regulate apoptosis and promote cancer cell metastasis. Glycans integrate genetic, epigenetic and environmental information into physiological processes that are vital in all aspects of health and disease, so by unlocking the potential of the human glycome, GlycanAge is enabling its customers to better navigate biological age diagnostics and disease prevention. To find out more about the GlycanAge test, we sat down with Professor Lauc.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1309falsefullhttps://www.spreaker.com/episode/why-energy-could-be-the-key-to-longevity--74818233
DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the company mentioned in this video to support its current funding round. Qualifying investors can find out more via the Longevity.Technology investment portal - https://longevity.technology/investment/dashboard/

Last week, we brought you an interview with Tom Benson, the CEO and Founder of Californian longevity biotech start-up Mitrix Bio, in which we discussed mitochondrial dysfunction and the mitochondrial cycle. Today, it’s the turn of longevity interventions and predictions, the role of mitochondrial DNA – and a guest appearance from David and Goliath.

Mitochondrial dysfunction has been implicated in dozens of chronic diseases from Alzheimer’s to CVD and from frailty to immune senescence. Mitrix Bio is targeting that dysfunction with its novel mitlets platform, and when it comes to learning more mitochondria, Mitrix’s founder Tom Benson is a compelling teacher.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686577Thu, 23 Mar 2023 17:23:48 +0000saderMitrix Bio CEO and Founder on energy is the headline and why it will take a major intervention to win the Degeneration Game. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the company mentioned in this...
DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the company mentioned in this video to support its current funding round. Qualifying investors can find out more via the Longevity.Technology investment portal - https://longevity.technology/investment/dashboard/

Last week, we brought you an interview with Tom Benson, the CEO and Founder of Californian longevity biotech start-up Mitrix Bio, in which we discussed mitochondrial dysfunction and the mitochondrial cycle. Today, it’s the turn of longevity interventions and predictions, the role of mitochondrial DNA – and a guest appearance from David and Goliath.

Mitochondrial dysfunction has been implicated in dozens of chronic diseases from Alzheimer’s to CVD and from frailty to immune senescence. Mitrix Bio is targeting that dysfunction with its novel mitlets platform, and when it comes to learning more mitochondria, Mitrix’s founder Tom Benson is a compelling teacher.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>609falsefullhttps://www.spreaker.com/episode/what-happens-when-bad-guy-cells-have-a-change-of-heart--74818230
Atherosclerosis is a killer, and while the risk factors can be lowered by healthy lifestyle choices and lipid-lowering agents such as statins, a new approach is needed to address the root-cause of this disease. Cyclarity Therapeutics has developed a new platform aiming to make a significant dent in cardiovascular disease’s ranking as the world’s number one killer by reducing incidences of heart attack and stroke.

Cyclarity, the company behind the platform, is tackling atherosclerosis by using custom-engineered cyclodextrins to capture, and remove from cells, oxidised cholesterol derivatives. Unchecked, oxidised low-density lipoprotein cholesterol (oxLDL) is taken up by macrophages resulting in a foamy cytoplasmic froth that causes cell death. These dead cells form a necrotic core that can rupture leading to a thrombosis, heart attack or stroke, and if that isn't dangerous enough, oxLDL triggers an inflammatory response that can grow and loosen those plaques, leading to the same devastating events.

We sat down with Cyclarity's Vice President of Biology, Dr Daniel M Clemens, to find out more about the company's lead candidate and how it works.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686613Thu, 16 Mar 2023 17:13:56 +0000saderHow Cyclarity is targeting atherosclerosis and giving the body the means to reverse disease from the inside out. Atherosclerosis is a killer, and while the risk factors can be lowered by healthy lifestyle choices and lipid-lowering agents such as...
Atherosclerosis is a killer, and while the risk factors can be lowered by healthy lifestyle choices and lipid-lowering agents such as statins, a new approach is needed to address the root-cause of this disease. Cyclarity Therapeutics has developed a new platform aiming to make a significant dent in cardiovascular disease’s ranking as the world’s number one killer by reducing incidences of heart attack and stroke.

Cyclarity, the company behind the platform, is tackling atherosclerosis by using custom-engineered cyclodextrins to capture, and remove from cells, oxidised cholesterol derivatives. Unchecked, oxidised low-density lipoprotein cholesterol (oxLDL) is taken up by macrophages resulting in a foamy cytoplasmic froth that causes cell death. These dead cells form a necrotic core that can rupture leading to a thrombosis, heart attack or stroke, and if that isn't dangerous enough, oxLDL triggers an inflammatory response that can grow and loosen those plaques, leading to the same devastating events.

We sat down with Cyclarity's Vice President of Biology, Dr Daniel M Clemens, to find out more about the company's lead candidate and how it works.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>430falsefullhttps://www.spreaker.com/episode/home-longevity-testing-that-democratizes-access-to-your-biological-data--74818134
Analyzing biomarkers to provide practical actionable insights from objective data.

With labs in Salt Lake City in the US and Geneva in Switzerland, Biostarks is a company built on advanced, innovative blood testing solutions for athletes. Now it is leveraging that experience and knowledge with a suite of cutting-edge tech that individuals can use to optimize their health and performance.

The Biostarks team of scientists and physicians can analyze a wide range of biomarkers, from hormones to nutrients, and provide actionable insights into an individual's health status and performance potential. Through easy-to-use self-collection biomarker test kits that can be conveniently performed at home, individuals can monitor their health and track their progress in real-time, empowering them to make informed decisions about their diet, exercise and lifestyle choices.

Biostarks does not outsource its testing to third party labs, but instead conducts testing at its own accredited laboratories; the team uses a unique proprietary algorithm and results platform to generate rigorous, precise results, and with a sports test kit and nutrition test kit already on the market and a longevity test kit available for pre-order on Indiegogo, we wanted to find out more! We sat down with Pierre-Edouard Sottas, Founder and Chief Scientific Officer at Biostarks to discover more about the company and how it is hoping to move the needle on longevity testing.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686611Wed, 15 Mar 2023 17:20:21 +0000saderVisit Biostarks - http://bit.ly/3JgaTJP Analyzing biomarkers to provide practical actionable insights from objective data. With labs in Salt Lake City in the US and Geneva in Switzerland, Biostarks is a company built on advanced, innovative blood...
Analyzing biomarkers to provide practical actionable insights from objective data.

With labs in Salt Lake City in the US and Geneva in Switzerland, Biostarks is a company built on advanced, innovative blood testing solutions for athletes. Now it is leveraging that experience and knowledge with a suite of cutting-edge tech that individuals can use to optimize their health and performance.

The Biostarks team of scientists and physicians can analyze a wide range of biomarkers, from hormones to nutrients, and provide actionable insights into an individual's health status and performance potential. Through easy-to-use self-collection biomarker test kits that can be conveniently performed at home, individuals can monitor their health and track their progress in real-time, empowering them to make informed decisions about their diet, exercise and lifestyle choices.

Biostarks does not outsource its testing to third party labs, but instead conducts testing at its own accredited laboratories; the team uses a unique proprietary algorithm and results platform to generate rigorous, precise results, and with a sports test kit and nutrition test kit already on the market and a longevity test kit available for pre-order on Indiegogo, we wanted to find out more! We sat down with Pierre-Edouard Sottas, Founder and Chief Scientific Officer at Biostarks to discover more about the company and how it is hoping to move the needle on longevity testing.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>663falsefullhttps://www.spreaker.com/episode/stressed-tissue-and-cellular-burn-out-enter-the-mitochondrial-cycle--74818211
DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the company mentioned in this article to support its current funding round. Qualifying investors can find out more via the Longevity.Technology investment portal - https://longevity.technology/investment/dashboard/

Mitochondrial dysfunction has been implicated in dozens of chronic diseases from Alzheimer's to CVD and from frailty to immune senescence. Californian longevity biotech start-up Mitrix Bio is targeting that dysfunction with its novel mitlets platform.

To tackle something, you have to understand it. We sat down with Mitrix Bio CEO and founder Tom Benson to get the lowdown on mitochondria, mitochondrial dysfunction and the mitochondrial cycle. It turns out that when it comes to mitochondrial replication, sometimes slow and steady really does win the longevity race.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686569Tue, 14 Mar 2023 17:55:55 +0000saderMitrix Bio CEO and Founder on mitochondrial degradation – and how it drives aging and lifespan. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the company mentioned in this article to support its current...
DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has been contracted by the company mentioned in this article to support its current funding round. Qualifying investors can find out more via the Longevity.Technology investment portal - https://longevity.technology/investment/dashboard/

Mitochondrial dysfunction has been implicated in dozens of chronic diseases from Alzheimer's to CVD and from frailty to immune senescence. Californian longevity biotech start-up Mitrix Bio is targeting that dysfunction with its novel mitlets platform.

To tackle something, you have to understand it. We sat down with Mitrix Bio CEO and founder Tom Benson to get the lowdown on mitochondria, mitochondrial dysfunction and the mitochondrial cycle. It turns out that when it comes to mitochondrial replication, sometimes slow and steady really does win the longevity race.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>441falsefullhttps://www.spreaker.com/episode/bringing-biological-age-tracking-to-the-masses-with-michael-geer-co-founder-of-humanity--74818217
Recent research has demonstrated that an estimation of biological age can be made from any blood test panel, meaning that an accurate, scalable, affordable test of biological age will be available to pretty much anyone who wants one, something that could have enormous impact for preventative healthcare and people taking charge of their own longevity trajectory.

While the publication has not yet been peer-reviewed and is still in preprint, we were keen to find out more straightaway, so we reached out to Michael Geer, co-founder of Humanity, an app that monitors your rate of aging, and one of the paper's authors, and sat down with him to find out more about the platform and what it could mean for longevity.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686647Wed, 01 Mar 2023 13:21:12 +0000saderHumanity Co-founder Michael Geer on using AI / machine learning to bring better health outcomes to everybody – and why building models in the open speeds adoption. Recent research has demonstrated that an estimation of biological age can be made from...
Recent research has demonstrated that an estimation of biological age can be made from any blood test panel, meaning that an accurate, scalable, affordable test of biological age will be available to pretty much anyone who wants one, something that could have enormous impact for preventative healthcare and people taking charge of their own longevity trajectory.

While the publication has not yet been peer-reviewed and is still in preprint, we were keen to find out more straightaway, so we reached out to Michael Geer, co-founder of Humanity, an app that monitors your rate of aging, and one of the paper's authors, and sat down with him to find out more about the platform and what it could mean for longevity.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>515falsefullhttps://www.spreaker.com/episode/designing-a-molecule-for-longevity-with-amelia-anderson-co-founder-cyclarity--74818227
Cyclarity Therapeutics is targeting atherosclerosis and hoping to do something about cardiovascular disease’s ranking as the world’s number one killer by reducing incidences of heart attack and stroke through a simple and affordable preventive therapy.

The company’s platform uses rationally-designed cyclodextrin molecules that remove arterial plaque by clearing the non-degradable oxidised cholesterol that accumulates within cells in the arterial walls.

We wanted to find out more about how these molecules were designed, so we sat down with Head of Scientific Computing & Co-Founder Amelia Anderson to find out more about how it all works. Plus she let us road-test her VR program!
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686561Thu, 23 Feb 2023 12:21:39 +0000saderFrom machine learning to virtual reality, Cyclarity is leveraging the key tools in the fight against atherosclerosis. Cyclarity Therapeutics is targeting atherosclerosis and hoping to do something about cardiovascular disease’s ranking as the world’s...
Cyclarity Therapeutics is targeting atherosclerosis and hoping to do something about cardiovascular disease’s ranking as the world’s number one killer by reducing incidences of heart attack and stroke through a simple and affordable preventive therapy.

The company’s platform uses rationally-designed cyclodextrin molecules that remove arterial plaque by clearing the non-degradable oxidised cholesterol that accumulates within cells in the arterial walls.

We wanted to find out more about how these molecules were designed, so we sat down with Head of Scientific Computing & Co-Founder Amelia Anderson to find out more about how it all works. Plus she let us road-test her VR program!
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>454falsefullhttps://www.spreaker.com/episode/dr-rand-mcclain-discusses-age-as-a-biomarker-for-healthcare--74818228
McClain's new book Cheating Death:The New Science of Living Longer and Better is out on 7 March, and in it, McClain reveals his strategies for longevity and discusses what the future of regenerative medicine holds. These topics are right in our sweet spot, so we were delighted to sit down with Dr McClain to find out more.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686653Mon, 20 Feb 2023 18:42:35 +0000saderDr Rand McClain is a key figure in the world of longevity therapies and innovative antiaging solutions. However, he is also keen to convey that he is not just a doctor – he's also a patient. In his new book, McClain details how his past health battles...
McClain's new book Cheating Death:The New Science of Living Longer and Better is out on 7 March, and in it, McClain reveals his strategies for longevity and discusses what the future of regenerative medicine holds. These topics are right in our sweet spot, so we were delighted to sit down with Dr McClain to find out more.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>744falsefullhttps://www.spreaker.com/episode/muhdo-2-0-is-taking-personalised-longevity-to-a-new-level--74818221

Muhdo is on a mission to personalize wellness through a digital health and testing ecosystem that is driven by big data and diagnostics. A saliva test generates a DNA health profile and biological age and epigenetic profile, and the app-based platform integrates epigenetics, genetics, health, fitness, nutrition, cognitive testing, facial tracking and wellbeing to generate an individual longitudinal health data proposition that aims to help individuals reduce the risk of future adverse health issues by providing them with the tools and knowledge to live healthier lifestyles.


Muhdo 2.0 enables a user to calculate eight different age clocks through genetic analysis, in-app gamification and face scanning. The clocks calculate the user’s age for skin, eyes, memory and hearing, as well generating a pro- and anti-inflammatory score.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686566Fri, 17 Feb 2023 17:11:36 +0000saderMuhdo launches app upgrade and Helixer personalised supplements that combine DNA data with over 850,000 epigenetic markers. Muhdo is on a mission to personalize wellness through a digital health and testing ecosystem that is driven by big data and...

Muhdo is on a mission to personalize wellness through a digital health and testing ecosystem that is driven by big data and diagnostics. A saliva test generates a DNA health profile and biological age and epigenetic profile, and the app-based platform integrates epigenetics, genetics, health, fitness, nutrition, cognitive testing, facial tracking and wellbeing to generate an individual longitudinal health data proposition that aims to help individuals reduce the risk of future adverse health issues by providing them with the tools and knowledge to live healthier lifestyles.


Muhdo 2.0 enables a user to calculate eight different age clocks through genetic analysis, in-app gamification and face scanning. The clocks calculate the user’s age for skin, eyes, memory and hearing, as well generating a pro- and anti-inflammatory score.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y


Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>559falsefullhttps://www.spreaker.com/episode/keeping-it-real-srf-s-goal-of-real-longevity-therapies-for-everyone--74818237
The SENS Research Foundation (SRF) is a non-profit organisation on a mission to transform the way the world researches and treats age-related disease. Focusing on a damage repair paradigm for treating the diseases of aging, SRF promotes and supports scientific research, advocacy and education, training researchers to support a growing regenerative medicine field. By supporting research projects at universities and institutes around the world, SRF hopes to realise its goal of curing such age-related diseases as macular degeneration, heart disease, cancer and Alzheimer’s disease.

As well as its research focus, SRF also educates, informing the wider public about how to tackle the economic and political issues that stem from an aging world population through its advocacy campaigns and educational programmes.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686638Tue, 07 Feb 2023 13:49:47 +0000saderThe SENS Research Foundation on the thrill of research and the importance of nurturing longevity start-ups. The SENS Research Foundation (SRF) is a non-profit organisation on a mission to transform the way the world researches and treats age-related...
The SENS Research Foundation (SRF) is a non-profit organisation on a mission to transform the way the world researches and treats age-related disease. Focusing on a damage repair paradigm for treating the diseases of aging, SRF promotes and supports scientific research, advocacy and education, training researchers to support a growing regenerative medicine field. By supporting research projects at universities and institutes around the world, SRF hopes to realise its goal of curing such age-related diseases as macular degeneration, heart disease, cancer and Alzheimer’s disease.

As well as its research focus, SRF also educates, informing the wider public about how to tackle the economic and political issues that stem from an aging world population through its advocacy campaigns and educational programmes.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>929falsefullhttps://www.spreaker.com/episode/the-elegant-solution-to-one-of-the-world-s-biggest-problems-atherosclerosis-with-dr-oki-o-connor--74818212
Cyclarity Therapeutics is on a mission to deliver affordable therapy for the world's number one killer – cardiovascular disease. Its novel cyclodextrin targets atherosclerosis, removing arterial plaque by clearing the non-degradable oxidised cholesterol that accumulates within cells in the arterial walls.

With in-human clinical trials likely to start this year, Cyclarity is rapidly progressing its cyclodextrin drug for atherosclerosis towards market. We caught up with its CEO of Scientific Affairs, Dr Matthew 'Oki' O'Connor to find out more about the company's platform, its cyclodextrin drug and his views on the current market.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686617Wed, 01 Feb 2023 12:01:08 +0000saderDr Oki O'Connor on Cyclarity's elegant solution to one of the world's biggest problems – atherosclerosis. Cyclarity Therapeutics is on a mission to deliver affordable therapy for the world's number one killer – cardiovascular disease. Its novel...
Cyclarity Therapeutics is on a mission to deliver affordable therapy for the world's number one killer – cardiovascular disease. Its novel cyclodextrin targets atherosclerosis, removing arterial plaque by clearing the non-degradable oxidised cholesterol that accumulates within cells in the arterial walls.

With in-human clinical trials likely to start this year, Cyclarity is rapidly progressing its cyclodextrin drug for atherosclerosis towards market. We caught up with its CEO of Scientific Affairs, Dr Matthew 'Oki' O'Connor to find out more about the company's platform, its cyclodextrin drug and his views on the current market.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>632falsefullhttps://www.spreaker.com/episode/dr-elizabeth-yurth-on-why-we-should-no-longer-accept-that-joint-aging-is-inevitable--74818232
With the rise in people taking a more active interest in their health and healthspan, we were delighted to Dr Yurth a.bout her innovative longevity practice.

Visit spermidineLIFE to learn more - https://bit.ly/3Hhqs3Z

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686533Fri, 20 Jan 2023 10:08:24 +0000saderWe chat to Dr Elizabeth Yurth, Founder of the Boulder Longevity Institute and a double board-certified physician in Physical Medicine & Rehabilitation and Antiaging/Regenerative Medicine with more than 30 years of clinical experience. With the...
With the rise in people taking a more active interest in their health and healthspan, we were delighted to Dr Yurth a.bout her innovative longevity practice.

Visit spermidineLIFE to learn more - https://bit.ly/3Hhqs3Z

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>730falsefullhttps://www.spreaker.com/episode/the-youthful-side-of-longevity-with-andrea-olsen-ceo-youth-longevity-association--74818222

The Youth Longevity Association was founded to introduce driven high school students into an international community of inspired researchers to advance longevity research, fostering long-term links and collaborations the space. YLA trains its members through various age-research education programmes and large-scale team projects, preparing them for professional work experience recruitment. They welcome exceptional high schoolers to their team to start their careers early and increase the world’s longevity, step by step.

The YLA is a terrific idea; longevity is an accelerating space, but many research areas are still in their infancy, with their potential benefits not being realised for decades, the youth are who will ultimately benefit. Add to that the importance of embedding healthy living practices from the get-go and attracting top talent to the field of geroscience and the YLA becomes a no-brainer. As well as funding longevity research, the YLA offers its members the chance to participate in group projects, hackathons and essay competitions, and to train with longevity experts in order to be recruited by laboratories and organisations in the longevity field!

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686549Wed, 18 Jan 2023 17:56:57 +0000saderAndrea Olsen on how the Youth Longevity Association is spreading awareness of longevity. The Youth Longevity Association was founded to introduce driven high school students into an international community of inspired researchers to advance...

The Youth Longevity Association was founded to introduce driven high school students into an international community of inspired researchers to advance longevity research, fostering long-term links and collaborations the space. YLA trains its members through various age-research education programmes and large-scale team projects, preparing them for professional work experience recruitment. They welcome exceptional high schoolers to their team to start their careers early and increase the world’s longevity, step by step.

The YLA is a terrific idea; longevity is an accelerating space, but many research areas are still in their infancy, with their potential benefits not being realised for decades, the youth are who will ultimately benefit. Add to that the importance of embedding healthy living practices from the get-go and attracting top talent to the field of geroscience and the YLA becomes a no-brainer. As well as funding longevity research, the YLA offers its members the chance to participate in group projects, hackathons and essay competitions, and to train with longevity experts in order to be recruited by laboratories and organisations in the longevity field!

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>575falsefullhttps://www.spreaker.com/episode/university-of-colorado-boulder-experts-on-role-mitochondria-play-in-keeping-healthy--74818145
We chat to two integrative physiology professors about their studies on MitoQ and heart health, and the role mitochondria play in keeping healthy.

Cardiovascular health is a major concern and understandably people are looking for ways to maintain a healthy lifestyle.

We all know how hard our hearts work beating 24/7. The energy powering our hearts and carrying our blood away from and back to the heart comes from mitochondria, the powerhouses of the cells. Mitochondria convert glucose and oxygen to cellular energy and they work hardest in the cardiovascular system, but mitochondria numbers diminish with age, and mitochondrial dysfunction increases. 

Doug Seals PhD and Matthew Rossman PhD are integrative physiology professors at the University of Colorado Boulder. Having headed up a fascinating study on heart health and MitoQ in 2018, they have built on the the positive results with a much-larger scale clinical trial, again focused on MitoQ and heart health. Our hearts skipped a metaphorical beat at the chance to discuss the dangers of oxidative stress with them, and find out more about keeping the cardiovascular system healthy.

Visit MitoQ to learn more - https://bit.ly/3V1M1KS

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686550Tue, 17 Jan 2023 18:13:02 +0000saderVisit MitoQ - https://bit.ly/3V1M1KS We chat to two integrative physiology professors about their studies on MitoQ and heart health, and the role mitochondria play in keeping healthy. Cardiovascular health is a major concern and understandably...
We chat to two integrative physiology professors about their studies on MitoQ and heart health, and the role mitochondria play in keeping healthy.

Cardiovascular health is a major concern and understandably people are looking for ways to maintain a healthy lifestyle.

We all know how hard our hearts work beating 24/7. The energy powering our hearts and carrying our blood away from and back to the heart comes from mitochondria, the powerhouses of the cells. Mitochondria convert glucose and oxygen to cellular energy and they work hardest in the cardiovascular system, but mitochondria numbers diminish with age, and mitochondrial dysfunction increases. 

Doug Seals PhD and Matthew Rossman PhD are integrative physiology professors at the University of Colorado Boulder. Having headed up a fascinating study on heart health and MitoQ in 2018, they have built on the the positive results with a much-larger scale clinical trial, again focused on MitoQ and heart health. Our hearts skipped a metaphorical beat at the chance to discuss the dangers of oxidative stress with them, and find out more about keeping the cardiovascular system healthy.

Visit MitoQ to learn more - https://bit.ly/3V1M1KS

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>790falsefullhttps://www.spreaker.com/episode/longevity-medicine-education-at-a-grassroots-level-will-effect-global-change--74818231
Earlier today we covered the news that the Longevity Education Hub is expanding the reach of its longevity medicine courses by releasing Spanish and Portuguese versions, with other languages also in the pipeline.

Education is, of course, key to longevity, but it is not simply knowing that diet and exercise are important, or that supplements can help prevent age-related decline. Rather the field of longevity medicine turns preventative medicine up to 11, aiming not just to prevent disease, but to keep the patient at the age of optimal performance in the context of their entire lifespan.

By designing and making available longevity medicine courses, the Longevity Education Hub aims to bridge the gap between laboratory science and medicine, providing updates on the latest advances in aging research and AI, and preparing the physicians for new types of clinical trials and patient management. Longevity medicine is fast-evolving, so online courses can help physicians keep up-to-date with novel quantitative and quantified indicators of aging, such as deep aging clocks, and learn how measuring and tracking biomarkers can compress morbidity, helping their patients extend both their lifespan and their healthspan.

And to expand our own education, we sat down with Course Author Evelyne Bischof, MD, Course Author, Chinese Course Co-Author Christine Huang, MD, and Volunteer, MSD CME Coordinator Ricardo Gaminha Pacheco, MD.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686648Tue, 10 Jan 2023 17:43:58 +0000saderOnline courses, integration with medical faculties and local chapter initiatives aim to embed longevity medicine into medical education and training. Earlier today we covered the news that the Longevity Education Hub is expanding the reach of its...
Earlier today we covered the news that the Longevity Education Hub is expanding the reach of its longevity medicine courses by releasing Spanish and Portuguese versions, with other languages also in the pipeline.

Education is, of course, key to longevity, but it is not simply knowing that diet and exercise are important, or that supplements can help prevent age-related decline. Rather the field of longevity medicine turns preventative medicine up to 11, aiming not just to prevent disease, but to keep the patient at the age of optimal performance in the context of their entire lifespan.

By designing and making available longevity medicine courses, the Longevity Education Hub aims to bridge the gap between laboratory science and medicine, providing updates on the latest advances in aging research and AI, and preparing the physicians for new types of clinical trials and patient management. Longevity medicine is fast-evolving, so online courses can help physicians keep up-to-date with novel quantitative and quantified indicators of aging, such as deep aging clocks, and learn how measuring and tracking biomarkers can compress morbidity, helping their patients extend both their lifespan and their healthspan.

And to expand our own education, we sat down with Course Author Evelyne Bischof, MD, Course Author, Chinese Course Co-Author Christine Huang, MD, and Volunteer, MSD CME Coordinator Ricardo Gaminha Pacheco, MD.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>992falsefullhttps://www.spreaker.com/episode/cyclarity-s-guardians-are-leading-the-battle-against-atherosclerosis--74818239
Cyclarity Therapeutics has atherosclerosis firmly in its sights; with tech that removes arterial plaque by clearing the non-degradable oxidised cholesterol that accumulates within cells in the arterial walls, the company is well-placed to deliver its long-term goal of simple and affordable preventive therapy for the world.

Cardiovascular disease is the world's number one killer, but many people don't even know they have atherosclerosis as the first indication can often be a fatal or life-impacting event such as a heart attack or stroke. The first true disease-modifying treatment, Cyclarity's rationally-designed cyclodextrin molecule (UDP003) is set to change all that.

We're excited by Cyclarity's platform, so we were delighted to sit down with CEO of Corporate Affairs Mike Kope, CEO of Scientific Affairs Dr Matthew ‘Oki’ O’Connor, Director of Biology Dr Daniel M Clemens and Head of Scientific Computing & Co-Founder Amelia Anderson to find out more about how it all works.

Visit Cyclarity - https://cyclaritytx.com/

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686602Tue, 10 Jan 2023 14:10:23 +0000saderHow a novel cyclodextrin platform is tacking bad guy cells and reinvigorating them to be guardians of the immune system. Cyclarity Therapeutics has atherosclerosis firmly in its sights; with tech that removes arterial plaque by clearing the...
Cyclarity Therapeutics has atherosclerosis firmly in its sights; with tech that removes arterial plaque by clearing the non-degradable oxidised cholesterol that accumulates within cells in the arterial walls, the company is well-placed to deliver its long-term goal of simple and affordable preventive therapy for the world.

Cardiovascular disease is the world's number one killer, but many people don't even know they have atherosclerosis as the first indication can often be a fatal or life-impacting event such as a heart attack or stroke. The first true disease-modifying treatment, Cyclarity's rationally-designed cyclodextrin molecule (UDP003) is set to change all that.

We're excited by Cyclarity's platform, so we were delighted to sit down with CEO of Corporate Affairs Mike Kope, CEO of Scientific Affairs Dr Matthew ‘Oki’ O’Connor, Director of Biology Dr Daniel M Clemens and Head of Scientific Computing & Co-Founder Amelia Anderson to find out more about how it all works.

Visit Cyclarity - https://cyclaritytx.com/

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1307falsefullhttps://www.spreaker.com/episode/what-is-mitoq-and-why-does-your-body-need-it-with-the-sheeky-science-show--74818149
The unique formula of MitoQ targets cell stress, helping you feel more energetic, recover faster from exercise and age more gracefully - so you can live life to the fullest.

You nourish your cells when you breathe and eat. Free radicals are also created – bursts of oxygen molecules that stress cells. As you get older and especially as life becomes more intense, your natural resistance to free radicals slows down. MitoQ is bioengineered to get deep inside cells and neutralise them.

You're investing in your cellular health every time you take MitoQ. The possibilities are endless when you're in charge of your health.

To learn about MitoQ visit https://bit.ly/3V1M1KS

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686571Mon, 09 Jan 2023 17:09:14 +0000saderVisit MitoQ - https://bit.ly/3V1M1KS The unique formula of MitoQ targets cell stress, helping you feel more energetic, recover faster from exercise and age more gracefully - so you can live life to the fullest. You nourish your cells when you...
The unique formula of MitoQ targets cell stress, helping you feel more energetic, recover faster from exercise and age more gracefully - so you can live life to the fullest.

You nourish your cells when you breathe and eat. Free radicals are also created – bursts of oxygen molecules that stress cells. As you get older and especially as life becomes more intense, your natural resistance to free radicals slows down. MitoQ is bioengineered to get deep inside cells and neutralise them.

You're investing in your cellular health every time you take MitoQ. The possibilities are endless when you're in charge of your health.

To learn about MitoQ visit https://bit.ly/3V1M1KS

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>374falsefullhttps://www.spreaker.com/episode/possibilities-of-longevity-to-physicians-and-wellness-professionals-with-yakov-ozer--74818162
The Healthy Longevity Guide is a global education platform for health and wellness professionals interested in healthy longevity and healthy lifespan extension. It believes that the exceptional progress in the science of understanding aging, the stride in prevention and rejuvenation technologies, together with the global demographic trend of population aging, have created a new global challenge for all of us, and so it is on a mission to empower one million health and wellness professionals to provide healthy longevity guidance to billions of people worldwide, and aiming to build a solid bridge to longevity expertise for those professionals.

The Healthy Longevity Guide’s CEO Yakov Ozer is a digital health enthusiast, and he brings that enthusiasm to HLG’s drive to empower health and wellness professionals with unique, actionable and science-based education in healthy aging.

We caught up with Ozer to find out more about the Healthy Longevity Guide and where it fits in an accelerating sector.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686624Wed, 21 Dec 2022 16:57:16 +0000saderOn a mission to empower one million health professionals and bring healthy longevity to billions. The Healthy Longevity Guide is a global education platform for health and wellness professionals interested in healthy longevity and healthy lifespan...
The Healthy Longevity Guide is a global education platform for health and wellness professionals interested in healthy longevity and healthy lifespan extension. It believes that the exceptional progress in the science of understanding aging, the stride in prevention and rejuvenation technologies, together with the global demographic trend of population aging, have created a new global challenge for all of us, and so it is on a mission to empower one million health and wellness professionals to provide healthy longevity guidance to billions of people worldwide, and aiming to build a solid bridge to longevity expertise for those professionals.

The Healthy Longevity Guide’s CEO Yakov Ozer is a digital health enthusiast, and he brings that enthusiasm to HLG’s drive to empower health and wellness professionals with unique, actionable and science-based education in healthy aging.

We caught up with Ozer to find out more about the Healthy Longevity Guide and where it fits in an accelerating sector.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>919falsefullhttps://www.spreaker.com/episode/the-reality-of-spermidine-supplementation-with-dr-halland-chen--74818236
All this background is useful if you are wondering if supplements are right for you and if so, which ones to take. However, having a professional perspective is always useful, and founder of Impact Health Dr Halland Chen MD is a Double Board-Certified doctor who is a Partnered Practitioner of spermidineLIFE. We caught up with Dr Chen to find out what it is like practising at the cutting edge of longevity medicine, and what are some of the most promising interventions he recommends to his patients.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686626Tue, 06 Dec 2022 17:55:22 +0000saderSpermidine is a popular longevity supplement – and with good reason, as it has antiaging properties and can suppress inflammation and oxidation. Studies have shown the interestingly-named polyamine can increase lifespan in animal models, and research...
All this background is useful if you are wondering if supplements are right for you and if so, which ones to take. However, having a professional perspective is always useful, and founder of Impact Health Dr Halland Chen MD is a Double Board-Certified doctor who is a Partnered Practitioner of spermidineLIFE. We caught up with Dr Chen to find out what it is like practising at the cutting edge of longevity medicine, and what are some of the most promising interventions he recommends to his patients.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>402falsefullhttps://www.spreaker.com/episode/tackling-atherosclerosis-through-disease-reversal-with-mike-kope-co-ceo-cyclarity-therapeutics--74818223
Cyclarity Therapeutics is on a mission to develop technology to treat, cure and reverse atherosclerosis. The company's tech, rationally-designed cyclodextrin molecules that remove arterial plaque by clearing the non-degradable oxidised cholesterol that accumulates within cells in the arterial walls, could make a significant dent in cardiovascular disease's ranking as the world's number one killer by reducing incidences of heart attack and stroke.

Michael Kope, who was also Founding CEO of SENS Research Foundation, is the Co-Founder and Co-CEO of Cyclarity Therapeutics. Cyclarity is spearheading true disease-modifying treatments for age-related diseases and doing it with simple and direct interventions, so we were delighted to catch up with Michael and discuss his biotech company and its work.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686598Wed, 16 Nov 2022 17:25:12 +0000saderCyclarity CEO talks about tackling oxidised cholesterol and taking on the world's biggest killer. Cyclarity Therapeutics is on a mission to develop technology to treat, cure and reverse atherosclerosis. The company's tech, rationally-designed...
Cyclarity Therapeutics is on a mission to develop technology to treat, cure and reverse atherosclerosis. The company's tech, rationally-designed cyclodextrin molecules that remove arterial plaque by clearing the non-degradable oxidised cholesterol that accumulates within cells in the arterial walls, could make a significant dent in cardiovascular disease's ranking as the world's number one killer by reducing incidences of heart attack and stroke.

Michael Kope, who was also Founding CEO of SENS Research Foundation, is the Co-Founder and Co-CEO of Cyclarity Therapeutics. Cyclarity is spearheading true disease-modifying treatments for age-related diseases and doing it with simple and direct interventions, so we were delighted to catch up with Michael and discuss his biotech company and its work.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>747falsefullhttps://www.spreaker.com/episode/dr-evelyne-bischof-on-longevity-education-and-embedding-longevity-medicine-into-clinical-practice--74818240
The goal of compressing morbidity and maximising healthspan is one that needs to be championed by physicians and healthcare systems, but there is a lack of knowledge of longevity science among healthcare professionals with the consequences of aging often accepted rather than tackled or avoided. But a longevity medicine revolution is brewing, and Dr Bischof is a key architect of the coming change. We jumped at the change to sit down with her and discover more about embedding longevity medicine in clinical practice.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686547Tue, 15 Nov 2022 17:58:27 +0000saderEvelyne Bischof is Longevity physician at Human Longevity, Chief associate physician internal medicine at Renji Hospital of Jiaotong University School of Medicine and Associate professor Shanghai University of Medicine. She is a doctor who is deeply...
The goal of compressing morbidity and maximising healthspan is one that needs to be championed by physicians and healthcare systems, but there is a lack of knowledge of longevity science among healthcare professionals with the consequences of aging often accepted rather than tackled or avoided. But a longevity medicine revolution is brewing, and Dr Bischof is a key architect of the coming change. We jumped at the change to sit down with her and discover more about embedding longevity medicine in clinical practice.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>916falsefullhttps://www.spreaker.com/episode/making-longevity-tangible-for-everybody-as-soon-as-possible-with-marc-p-bernegger--74818219
Over the last couple of weeks, we've brought you a series of interviews that we undertook while we were at the Longevity Investors Conference last month. Held in Gstaad in Switzerland, the LIC is the world’s leading and most private longevity-focused investors-only conference, showcasing longevity investment opportunities and the exciting directions in which the field is accelerating.

LIC goes from strength-to-strength, and one of the reasons the conference is so successful is its founders, Marc P Bernegger and Tobias Reichmuth.

Serial-tech entrepreneur Bernegger has been following developments in the field of longevity since 2009; besides co-founding the longevity company-builder Maximon and the Longevity Investors Conference, he is involved in the crypto hedge fund AltAlpha Digital and is among others on the board of CfC St. Moritz and the Swiss Blockchain Federation. Bernegger brings a wealth of experience to LIC, so we were glad to sit down with him to discuss how crypto intersects with longevity and building a bridge between research and the market.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686560Wed, 09 Nov 2022 17:04:13 +0000saderMarc P Bernegger discusses building a bridge between amazing lab-based research and the creation of a successful longevity company. Over the last couple of weeks, we've brought you a series of interviews that we undertook while we were at...
Over the last couple of weeks, we've brought you a series of interviews that we undertook while we were at the Longevity Investors Conference last month. Held in Gstaad in Switzerland, the LIC is the world’s leading and most private longevity-focused investors-only conference, showcasing longevity investment opportunities and the exciting directions in which the field is accelerating.

LIC goes from strength-to-strength, and one of the reasons the conference is so successful is its founders, Marc P Bernegger and Tobias Reichmuth.

Serial-tech entrepreneur Bernegger has been following developments in the field of longevity since 2009; besides co-founding the longevity company-builder Maximon and the Longevity Investors Conference, he is involved in the crypto hedge fund AltAlpha Digital and is among others on the board of CfC St. Moritz and the Swiss Blockchain Federation. Bernegger brings a wealth of experience to LIC, so we were glad to sit down with him to discuss how crypto intersects with longevity and building a bridge between research and the market.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>592falsefullhttps://www.spreaker.com/episode/tobias-reichmuth-the-longevity-market-starts-now--74818225
We were lucky enough to attend the Longevity Investors Conference last month; this key event attracts those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. To put it succinctly, as MIT Tech Review did recently, LIC "brings academic scientists and biotech companies together with deep-pocketed investors. We’re talking millionaires and billionaires."

One of the driving forces behind the Longevity Investors Conference is Dr Tobias Reichmuth; a company-builder since the age of 21, Reichmuth has invested in more than 20 startups and is one of the founding partners of Maximon, the longevity company building. Along with his Maximon colleague Marc P Bernegger, Riechmuth launched the Longevity Investors Conference, and we couldn't pass up the chance to grab some time with him to discuss the current longevity market.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686591Fri, 04 Nov 2022 17:49:13 +0000saderDr Tobias Reichmuth talks taking hardcore science to market without biotech approval risk and the catalyst that is translational research. We were lucky enough to attend the Longevity Investors Conference last month; this key event attracts those...
We were lucky enough to attend the Longevity Investors Conference last month; this key event attracts those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. To put it succinctly, as MIT Tech Review did recently, LIC "brings academic scientists and biotech companies together with deep-pocketed investors. We’re talking millionaires and billionaires."

One of the driving forces behind the Longevity Investors Conference is Dr Tobias Reichmuth; a company-builder since the age of 21, Reichmuth has invested in more than 20 startups and is one of the founding partners of Maximon, the longevity company building. Along with his Maximon colleague Marc P Bernegger, Riechmuth launched the Longevity Investors Conference, and we couldn't pass up the chance to grab some time with him to discuss the current longevity market.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>615falsefullhttps://www.spreaker.com/episode/dr-brian-kennedy-validating-aging-interventions-and-why-rapamycin-is-the-gold-standard--74818243
Brian Kennedy is one of the busiest people in the longevity business, with fingers in many of the most interesting antiaging pies. He was at the Longevity Investors Conference recently, discussing some of the latest discoveries in longevity research and giving a longevity industry overview.

The Longevity Investors Conference (LIC) is the world’s leading and most private longevity-focused investors-only conference. Providing relevant insights into the fast-growing field of longevity, the conference also offers expert education and investment opportunities, as well as fostering excellent networking opportunities. It was our privilege to attend and talk to so many key opinion leaders.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686603Thu, 03 Nov 2022 17:49:49 +0000saderDr Brian Kennedy explains why verifying longevity interventions work is key and why the transition to human trials is so important. Brian Kennedy is one of the busiest people in the longevity business, with fingers in many of the most interesting...
Brian Kennedy is one of the busiest people in the longevity business, with fingers in many of the most interesting antiaging pies. He was at the Longevity Investors Conference recently, discussing some of the latest discoveries in longevity research and giving a longevity industry overview.

The Longevity Investors Conference (LIC) is the world’s leading and most private longevity-focused investors-only conference. Providing relevant insights into the fast-growing field of longevity, the conference also offers expert education and investment opportunities, as well as fostering excellent networking opportunities. It was our privilege to attend and talk to so many key opinion leaders.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>576falsefullhttps://www.spreaker.com/episode/dr-charles-brenner-longevity-is-not-a-simple-engineering-problem--74818226
The Longevity Investors Conference is a key event for those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. The world's leading and most private longevity-focused investors-only conference, LIC attracts some of the most prominent thought leaders.

One of those thought leaders is Charles Brenner, the biochemist whose work on nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism, includes the discovery of nicotinamide riboside (NR) kinase pathway and the resulting tech that led to the development of NR as an NAD-booster.

As Eric Verdin did recently, Brenner is one for driving the longevity debate, even if it causes more than a few ripples, and in cautioning against overstating progress, he is a significant calibration point for our industry (Twitter wars, notwithstanding). We were able to grab a few moments with Brenner at LIC to find out more about his thoughts on the current state of play.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686630Wed, 02 Nov 2022 17:12:37 +0000saderDr Charles Brenner on the longevity understanding disconnect, the best interventions for longevity, and the NR trials he'd like to see. The Longevity Investors Conference is a key event for those interested in learning about longevity investment...
The Longevity Investors Conference is a key event for those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. The world's leading and most private longevity-focused investors-only conference, LIC attracts some of the most prominent thought leaders.

One of those thought leaders is Charles Brenner, the biochemist whose work on nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism, includes the discovery of nicotinamide riboside (NR) kinase pathway and the resulting tech that led to the development of NR as an NAD-booster.

As Eric Verdin did recently, Brenner is one for driving the longevity debate, even if it causes more than a few ripples, and in cautioning against overstating progress, he is a significant calibration point for our industry (Twitter wars, notwithstanding). We were able to grab a few moments with Brenner at LIC to find out more about his thoughts on the current state of play.
------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>390falsefullhttps://www.spreaker.com/episode/aubrey-de-grey-on-longevity-at-scale--74818169
The Longevity Investors Conference is quickly turning into one of the highlights in the longevity calendar, and we were delighted to be able to interview some of the speakers in a few 'backstage' moments.

Held in the exclusive location of Gstaad in Switzerland, The Longevity Investors Conference (LIC) is the world’s leading and most private longevity-focused investors-only conference. Providing relevant insights into the fast-growing field of longevity, the conference also offers expert education and investment opportunities, as well as fostering excellent networking opportunities. Dr Aubrey de Grey was in Gstaad to address the conference on rejuvenation biotechnology as well as being part of a panel discussing where crypto meets longevity.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686645Fri, 28 Oct 2022 13:53:54 +0000saderNew foundation aims for scientific and rhetorical value – and to run the debug cycle for longevity research. The Longevity Investors Conference is quickly turning into one of the highlights in the longevity calendar, and we were delighted to be able...
The Longevity Investors Conference is quickly turning into one of the highlights in the longevity calendar, and we were delighted to be able to interview some of the speakers in a few 'backstage' moments.

Held in the exclusive location of Gstaad in Switzerland, The Longevity Investors Conference (LIC) is the world’s leading and most private longevity-focused investors-only conference. Providing relevant insights into the fast-growing field of longevity, the conference also offers expert education and investment opportunities, as well as fostering excellent networking opportunities. Dr Aubrey de Grey was in Gstaad to address the conference on rejuvenation biotechnology as well as being part of a panel discussing where crypto meets longevity.

------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>656falsefullhttps://www.spreaker.com/episode/eric-verdin-talks-nmn-and-longevity-supplements--74818235
With so many longevity supplements jostling for space on crowded shelves, it can be hard to know what you should be taking or, indeed, if you should be taking anything at all. The answer to both these questions lies in science, and it's good to know there are supplements available that are backed by rigorous clinical trials and supported by advanced research.

One of these is Elevant; preclinically and clinically tested (and with no fewer than 11 clinical trials underway), Elevant's proprietary, pharma-grade NMN-C is backed by clinical trials that are the most extensive in-human NMN research programme to date.

Elevant partnered with the renowned Buck Institute for Research on Aging to create and test NMN-C. We spoke to Dr Eric Verdin, President of The Buck Institute, recently to find out more about Elevant and the research behind it.

Visit Elevant - https://bit.ly/3gfm36H
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686595Tue, 18 Oct 2022 08:48:13 +0000saderIf our final readout is lifespan and healthspan, how can we improve the numbers? With so many longevity supplements jostling for space on crowded shelves, it can be hard to know what you should be taking or, indeed, if you should be taking anything...
With so many longevity supplements jostling for space on crowded shelves, it can be hard to know what you should be taking or, indeed, if you should be taking anything at all. The answer to both these questions lies in science, and it's good to know there are supplements available that are backed by rigorous clinical trials and supported by advanced research.

One of these is Elevant; preclinically and clinically tested (and with no fewer than 11 clinical trials underway), Elevant's proprietary, pharma-grade NMN-C is backed by clinical trials that are the most extensive in-human NMN research programme to date.

Elevant partnered with the renowned Buck Institute for Research on Aging to create and test NMN-C. We spoke to Dr Eric Verdin, President of The Buck Institute, recently to find out more about Elevant and the research behind it.

Visit Elevant - https://bit.ly/3gfm36H
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>434falsefullhttps://www.spreaker.com/episode/are-aging-clocks-telling-the-right-time-eric-verdin-president-buck-institute--74818238
Eric's keynote was fascinating, and we were lucky enough to follow it up with an interview where we could further explore his position on aging clocks and the implications of some new studies in which he and the Buck have been involved.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686542Mon, 17 Oct 2022 16:50:04 +0000saderThe Rejuvenation Startup Summit is one of the key events in the longevity calendar; kicking things off with the opening keynote was Eric Verdin, CEO and President of the Buck Institute for Research on Aging. Eric's keynote was fascinating, and we...
Eric's keynote was fascinating, and we were lucky enough to follow it up with an interview where we could further explore his position on aging clocks and the implications of some new studies in which he and the Buck have been involved.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>666falsefullhttps://www.spreaker.com/episode/aubrey-de-grey-on-why-aubrey-3-0-is-about-racing-towards-milestones-and-a-brand-new-foundation--74823363
But most excitingly, Dr de Grey used the platform of Longevity Summit Dublin to launch his new foundation; its Board of Directors already boasts Greg Grinberg as Executive Chair, Daria Khaltourina, Martin O'Dea (also Events Director), Gennady Stolyarov and David Wood.

Dr de Grey has always been a passionate advocate of longevity research and biotechnology, so it's no surprise his energy and enthusiasm has driven him to create a new foundation.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686543Wed, 21 Sep 2022 16:18:53 +0000saderCo-founder of the SENS Foundation, Dr Aubrey de Grey is the co-organiser of this week's Longevity Summit Dublin 2022; he was keynote speaker at this week's summit, speaking on Robust Mouse Rejuvenation: real soon now? and featuring on the panel...
But most excitingly, Dr de Grey used the platform of Longevity Summit Dublin to launch his new foundation; its Board of Directors already boasts Greg Grinberg as Executive Chair, Daria Khaltourina, Martin O'Dea (also Events Director), Gennady Stolyarov and David Wood.

Dr de Grey has always been a passionate advocate of longevity research and biotechnology, so it's no surprise his energy and enthusiasm has driven him to create a new foundation.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>812falsefullhttps://www.spreaker.com/episode/ian-white-we-re-right-on-the-precipice-of-fundamental-changes-in-longevity-research--74823046
Dr Ian White, President and CSO, NeoBiosis, is considered a leading expert in the field of aging and regenerative medicine with 20 years’ experience working with stem cells, regenerative cells and tissue regeneration. At the vanguard of regenerative medicine, Dr White is ideally placed to discuss The universal laws of aging and how humans are uniquely prepared to reject them at the upcoming RAADFest conference.

RAADFest 2022 kicks off on 6 October; featuring four days of all-new content that promises to “fuel your future” and RAADFest aims to bring attendees to the cutting edge of longevity. While much scientific progress is iterative and measured in small steps, giant leaps are needed to inspire and propel the sector, so ahead of RAADFest, we caught up with Ian White for a video interview in which he shares his views on how research on perinatal tissue is contributing to the fight for longevity and how the field of regenerative medicine is accelerating.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686585Fri, 16 Sep 2022 15:18:29 +0000saderDr Ian White explains how research focused on the very start of life can play a role in extending it. Dr Ian White, President and CSO, NeoBiosis, is considered a leading expert in the field of aging and regenerative medicine with 20 years’ experience...
Dr Ian White, President and CSO, NeoBiosis, is considered a leading expert in the field of aging and regenerative medicine with 20 years’ experience working with stem cells, regenerative cells and tissue regeneration. At the vanguard of regenerative medicine, Dr White is ideally placed to discuss The universal laws of aging and how humans are uniquely prepared to reject them at the upcoming RAADFest conference.

RAADFest 2022 kicks off on 6 October; featuring four days of all-new content that promises to “fuel your future” and RAADFest aims to bring attendees to the cutting edge of longevity. While much scientific progress is iterative and measured in small steps, giant leaps are needed to inspire and propel the sector, so ahead of RAADFest, we caught up with Ian White for a video interview in which he shares his views on how research on perinatal tissue is contributing to the fight for longevity and how the field of regenerative medicine is accelerating.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>737falsefullhttps://www.spreaker.com/episode/human-longevity-trials-and-aging-with-dr-brian-kennedy--74823009
Alpha-ketoglutarate (AKG) is used by cells during growth and in healing from injuries; studies have shown it may be effective in treating osteoporosis, preventing a decline in protein synthesis, reducing frailty and, in some mammalian studies; even extending lifespan. has gone one step further, adding calcium to produce LifeAKG™, a patent-pending, highly bioavailable and ultra pure CaAKG supplement, backed by extensive research and double-blind placebo-controlled clinical trials.

Brian Kennedy PhD, who was the Buck Institute’s second CEO, serves as Rejuvant's Scientific Advisor; he is also a member of the Board. Currently, Dr Kennedy is Professor and Director of the Center for Healthy Aging at the National University of Singapore, and with a plethora of widely-cited papers on aging and longevity under his belt, he is regarded as an expert in the science of gerontology.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686546Thu, 15 Sep 2022 16:42:38 +0000saderDr Brian Kennedy on Rejuvant, human longevity trials, aging optimally and why individual response to intervention is key. Alpha-ketoglutarate (AKG) is used by cells during growth and in healing from injuries; studies have shown it may be effective in...
Alpha-ketoglutarate (AKG) is used by cells during growth and in healing from injuries; studies have shown it may be effective in treating osteoporosis, preventing a decline in protein synthesis, reducing frailty and, in some mammalian studies; even extending lifespan. has gone one step further, adding calcium to produce LifeAKG™, a patent-pending, highly bioavailable and ultra pure CaAKG supplement, backed by extensive research and double-blind placebo-controlled clinical trials.

Brian Kennedy PhD, who was the Buck Institute’s second CEO, serves as Rejuvant's Scientific Advisor; he is also a member of the Board. Currently, Dr Kennedy is Professor and Director of the Center for Healthy Aging at the National University of Singapore, and with a plethora of widely-cited papers on aging and longevity under his belt, he is regarded as an expert in the science of gerontology.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>489falsefullhttps://www.spreaker.com/episode/unlocking-the-power-of-cell-derived-medicines-with-dr-alex-schueller-cellvie-s-ceo--74822998
Mitochondria play a crucial role in the aging process, activating factors and metabolic pathways involved in longevity. Their dysfunction impacts on both lifespan and healthspan, and whilst they have been identified as disease targets for some time, mitochondria have proven difficult to treat.

The founders of cellvie wondered if it were possible, as they put it, to leverage one of the cornerstones of evolution – to replace and augment damaged mitochondria. And so, the concept of Therapeutic Mitochondria Transplantation was born. TMT holds the potential of sustainably affecting mitochondria function, and reinvigorating or amplifying the cellular energy metabolism – and having raised $5 million in Kizoo-led seed funding, cellvie is on the way to turning that possibility into a reality.

Dr Alex Schueller, Cellvie's CEO, will be speaking at Berlin’s Rejuvenation Startup Summit (14-15 October 2022), as part of an all-star line-up that includes Michael Greve, Eric Verdin, Brian Kennedy, Michael Sidler, Christian Angermayer and our own Phil Newman. Hosted by the Forever Healthy Foundation, this vibrant networking event aims to accelerate the development of the rejuvenation biotech industry.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686573Wed, 14 Sep 2022 16:18:00 +0000saderThe biotech platform that is leveraging one of the cornerstones of evolution – mitochondria. Mitochondria play a crucial role in the aging process, activating factors and metabolic pathways involved in longevity. Their dysfunction impacts on both...
Mitochondria play a crucial role in the aging process, activating factors and metabolic pathways involved in longevity. Their dysfunction impacts on both lifespan and healthspan, and whilst they have been identified as disease targets for some time, mitochondria have proven difficult to treat.

The founders of cellvie wondered if it were possible, as they put it, to leverage one of the cornerstones of evolution – to replace and augment damaged mitochondria. And so, the concept of Therapeutic Mitochondria Transplantation was born. TMT holds the potential of sustainably affecting mitochondria function, and reinvigorating or amplifying the cellular energy metabolism – and having raised $5 million in Kizoo-led seed funding, cellvie is on the way to turning that possibility into a reality.

Dr Alex Schueller, Cellvie's CEO, will be speaking at Berlin’s Rejuvenation Startup Summit (14-15 October 2022), as part of an all-star line-up that includes Michael Greve, Eric Verdin, Brian Kennedy, Michael Sidler, Christian Angermayer and our own Phil Newman. Hosted by the Forever Healthy Foundation, this vibrant networking event aims to accelerate the development of the rejuvenation biotech industry.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>818falsefullhttps://www.spreaker.com/episode/mount-everest-summiteer-jatin-chaudhary-on-improving-the-quality-of-mitochondria-with-urolithin-a--74823037
As part of his preparation for the monumental climb, Chaudhary worked on improving the quality of his mitochondria with urolithin A, using a supplement called Mitopure, which, Jatin says was the X-factor he was looking for.

We sat down with Jatin Chaudhary to find out more about how researching mitochondria played a part in his incredible achievement and what it feels like to be on top of the world.
--------------------------------
Visit Mitopure Timeline - https://bit.ly/3dV6zUk
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686599Mon, 05 Sep 2022 16:32:50 +0000saderJatin Chaudhary summited Mount Everest in the morning hours of 12th May 2022; he was the first person from the remote district of Kutch in India to have scaled the mountain. The 43-year-old software development manager was aware that at his age, time...
As part of his preparation for the monumental climb, Chaudhary worked on improving the quality of his mitochondria with urolithin A, using a supplement called Mitopure, which, Jatin says was the X-factor he was looking for.

We sat down with Jatin Chaudhary to find out more about how researching mitochondria played a part in his incredible achievement and what it feels like to be on top of the world.
--------------------------------
Visit Mitopure Timeline - https://bit.ly/3dV6zUk
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>528falsefullhttps://www.spreaker.com/episode/longevity-it-s-waiting-for-the-netflix-moment-dr-michael-sidler--74823007Michael Sidler, PhD, is a passionate investor, coach and supporter of startups and the whole ecosystem that surrounds them. He is co-founder and partner at Redalpine, a seed stage VC that invests in high tech companies in ICT and life sciences.

Michael Sidler is one of the speakers lined up for Berlin’s Rejuvenation Startup Summit (14-15 October 2022), which is hosted by the Forever Healthy Foundation. This vibrant networking event aims to accelerate the development of the rejuvenation biotech industry, and Sidler will be joining an all-star line-up that includes Michael Greve, Eric Verdin, Brian Kennedy, Christian Angermayer and our own Phil Newman.

Ahead of the Summit, we caught up with Michael Sidler for a video interview in which he shares his views on the intersection of tech and life sciences, the Garnter Hype Cycle and why a new paradigm for clinical trials is needed.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686654Thu, 25 Aug 2022 13:08:36 +0000saderDr Michael Sidler discusses the questions raised by longevity investment, why it’s time to frame a positive narrative for the sector and why longevity clinical trials need a new paradigm. Michael Sidler, PhD, is a passionate investor, coach and...Michael Sidler, PhD, is a passionate investor, coach and supporter of startups and the whole ecosystem that surrounds them. He is co-founder and partner at Redalpine, a seed stage VC that invests in high tech companies in ICT and life sciences.

Michael Sidler is one of the speakers lined up for Berlin’s Rejuvenation Startup Summit (14-15 October 2022), which is hosted by the Forever Healthy Foundation. This vibrant networking event aims to accelerate the development of the rejuvenation biotech industry, and Sidler will be joining an all-star line-up that includes Michael Greve, Eric Verdin, Brian Kennedy, Christian Angermayer and our own Phil Newman.

Ahead of the Summit, we caught up with Michael Sidler for a video interview in which he shares his views on the intersection of tech and life sciences, the Garnter Hype Cycle and why a new paradigm for clinical trials is needed.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>841falsefullhttps://www.spreaker.com/episode/improving-your-metabolic-fitness-by-tracking-glucose-biomarkers-with-mohit-kumar-ceo-ultrahuman--74822933
Ultrahuman is going from metabolic fitness strength to metabolic fitness strength. In 2022, we have covered its acquisition of wearables company LazyCo the roster of tech investors and founders investing in its Series A and the launch of the world’s first smart ring with a focus on metabolism.

Ultrahuman; newest wearable is the Ultrahuman Ring, a metabolism-tracking wearable that measures movement, sleep and the body’s energy dynamics coupled with intelligent activity or recuperating recommendations, in real-time; this allows users to balance and take control of their health.

The metabolic health crisis is one of the largest healthcare crises in existence today; with over a billion people globally suffering from a metabolic health disorder, these disorders contribute to almost 85% of all chronic diseases in the world. Wearables (and their associated platforms) can inform lifestyle choices by helping people understand how food and exercise affect their metabolic health, leading to improved eating habits and increased activity levels.

--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686641Thu, 25 Aug 2022 10:48:41 +0000saderUltrahuman CEO on investing in better choices for a healthier, longer life. Ultrahuman is going from metabolic fitness strength to metabolic fitness strength. In 2022, we have covered its acquisition of wearables company LazyCo the roster of tech...
Ultrahuman is going from metabolic fitness strength to metabolic fitness strength. In 2022, we have covered its acquisition of wearables company LazyCo the roster of tech investors and founders investing in its Series A and the launch of the world’s first smart ring with a focus on metabolism.

Ultrahuman; newest wearable is the Ultrahuman Ring, a metabolism-tracking wearable that measures movement, sleep and the body’s energy dynamics coupled with intelligent activity or recuperating recommendations, in real-time; this allows users to balance and take control of their health.

The metabolic health crisis is one of the largest healthcare crises in existence today; with over a billion people globally suffering from a metabolic health disorder, these disorders contribute to almost 85% of all chronic diseases in the world. Wearables (and their associated platforms) can inform lifestyle choices by helping people understand how food and exercise affect their metabolic health, leading to improved eating habits and increased activity levels.

--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>707falsefullhttps://www.spreaker.com/episode/what-s-urolithin-a-and-can-it-stimulate-mitophagy-and-increase-muscle-endurance--74822972
Urolithin A is produced by bacteria in the gut microbiome, making it a postbiotic. It is synthesised after eating certain foods that are high in ellagitannins, part of a family of bioactive polyphenols found in berries, nuts and most famously, pomegranates.

There's a lot to be said for healthy eating and ensuring a varied diet that benefits from as many advantageous compounds as possible. However, simply loading up your shopping cart with pomegranates won't automatically confer the benefits of urolithin A on you; your gut needs to have the correct microbiome environment to be able to make sufficient quantities of urolithin A, and not everyone can do that.

Specifically, people who have more bacteria from the Clostridiales and Ruminococcaceae families living in their gut can produce urolithin A (these people are often termed "producers"). In fact, few as 1 in 3 people produce enough urolithin A! The only way to ensure you are getting enough urolithin A is from direct supplementation.

--------------------------------
Visit Mitopure Timeline - https://bit.ly/3dV6zUk
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686537Wed, 24 Aug 2022 11:29:19 +0000saderThe naturally-occurring antiaging compound that improves mitochondrial and muscle function giving you faster recovery and more energy. Urolithin A is produced by bacteria in the gut microbiome, making it a postbiotic. It is synthesised after eating...
Urolithin A is produced by bacteria in the gut microbiome, making it a postbiotic. It is synthesised after eating certain foods that are high in ellagitannins, part of a family of bioactive polyphenols found in berries, nuts and most famously, pomegranates.

There's a lot to be said for healthy eating and ensuring a varied diet that benefits from as many advantageous compounds as possible. However, simply loading up your shopping cart with pomegranates won't automatically confer the benefits of urolithin A on you; your gut needs to have the correct microbiome environment to be able to make sufficient quantities of urolithin A, and not everyone can do that.

Specifically, people who have more bacteria from the Clostridiales and Ruminococcaceae families living in their gut can produce urolithin A (these people are often termed "producers"). In fact, few as 1 in 3 people produce enough urolithin A! The only way to ensure you are getting enough urolithin A is from direct supplementation.

--------------------------------
Visit Mitopure Timeline - https://bit.ly/3dV6zUk
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>309falsefullhttps://www.spreaker.com/episode/naveen-jain-longevity-is-for-the-common-good--74823101
Naveen Jain is an entrepreneur and philanthropist driven to solve the world’s biggest challenges through innovation. A keen interest in moonshots – he's written a book on the subject – makes him ideally placed to discuss "The moonshot to cure aging" at the upcoming RAADFest conference.

RAADFest 2022 kicks off on 6 October and features four days of all-new content that promises to “fuel your future” and bring you to the cutting edge of longevity. While much scientific progress is iterative and measured in small steps, giant leaps are needed to inspire and propel the sector, with RAADFest fast approaching, we caught up with Naveen Jain for a video interview in which he shares his views on the role of the wellness industry, how longevity is growing as a sector and why we need to be mindful of our pact with microbes.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686636Tue, 23 Aug 2022 15:38:14 +0000saderAhead of RAADFest 2022, we chat to Viome CEO and founder Naveen Jain about why longevity needs lofty goals – and why we're all in it together. Naveen Jain is an entrepreneur and philanthropist driven to solve the world’s biggest challenges through...
Naveen Jain is an entrepreneur and philanthropist driven to solve the world’s biggest challenges through innovation. A keen interest in moonshots – he's written a book on the subject – makes him ideally placed to discuss "The moonshot to cure aging" at the upcoming RAADFest conference.

RAADFest 2022 kicks off on 6 October and features four days of all-new content that promises to “fuel your future” and bring you to the cutting edge of longevity. While much scientific progress is iterative and measured in small steps, giant leaps are needed to inspire and propel the sector, with RAADFest fast approaching, we caught up with Naveen Jain for a video interview in which he shares his views on the role of the wellness industry, how longevity is growing as a sector and why we need to be mindful of our pact with microbes.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>851falsefullhttps://www.spreaker.com/episode/martin-o-dea-longevity-is-burning-bright-in-ireland--74822997
Ireland is a focus for longevity science, research and investment and next month’s Longevity Summit Dublin promises to celebrate and explore new frontiers in longevity, biotech and rejuvenation. With a roster of longevity thought leaders (including Aubrey de Grey, Mike West, Matthew O’Connor, Brian Kennedy, Oliver Zolman, Andrea Maier, David Gobel, Alexey Strygin, Jim Mellon…) and a Welcome Gala it is a must see event for anyone in the sector.

Ahead of Longevity Summit Dublin (which runs 18-20 September), our editor-in-chief Phil Newman caught up with Longevity Events CEO and Summit organiser Martin O’Dea for a video interview in which he shares his views on Ireland’s contribution to the longevity economy and why it is such a successful jumping-off point for so many industries and biotechs and big pharma pivoting to longevity.
--------------------------------
Visit Longevity Summit Dublin - https://longevitysummitdublin.com/
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686535Fri, 19 Aug 2022 15:59:56 +0000saderLongevity Events CEO on why the Celtic Tiger is outsizing longevity in Ireland. Ireland is a focus for longevity science, research and investment and next month’s Longevity Summit Dublin promises to celebrate and explore new frontiers in longevity,...
Ireland is a focus for longevity science, research and investment and next month’s Longevity Summit Dublin promises to celebrate and explore new frontiers in longevity, biotech and rejuvenation. With a roster of longevity thought leaders (including Aubrey de Grey, Mike West, Matthew O’Connor, Brian Kennedy, Oliver Zolman, Andrea Maier, David Gobel, Alexey Strygin, Jim Mellon…) and a Welcome Gala it is a must see event for anyone in the sector.

Ahead of Longevity Summit Dublin (which runs 18-20 September), our editor-in-chief Phil Newman caught up with Longevity Events CEO and Summit organiser Martin O’Dea for a video interview in which he shares his views on Ireland’s contribution to the longevity economy and why it is such a successful jumping-off point for so many industries and biotechs and big pharma pivoting to longevity.
--------------------------------
Visit Longevity Summit Dublin - https://longevitysummitdublin.com/
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>715falsefullhttps://www.spreaker.com/episode/christian-angermayer-on-longevity-and-biotech-investment--74822968One of the speakers at October’s Rejuvenation Startup Summit in Berlin is the entrepreneur and investor, Christian Angermayer.

With more than $3 billion under management through his Apeiron Investment Group, Angermayer is a major figure in the longevity sector through his platform biotech companies Cambrian and Rejuveron – building on his belief that everyone wants to live healthier, happier and longer lives.

Ahead of Berlin’s meeting, our editor-in-chief caught up with Angermayer for a video interview in which he shares his views on subjects ranging from longevity investing, the biotech market, and what’s happening with his $200 million SPAC with David Sinclair and Peter Attia
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686651Tue, 16 Aug 2022 14:12:55 +0000saderChristian Angermayer, founder of talks longevity investment, optimism on SPAC deal and light at the end of the tunnel for the biotech market. One of the speakers at October’s Rejuvenation Startup Summit in Berlin is the entrepreneur and investor,...One of the speakers at October’s Rejuvenation Startup Summit in Berlin is the entrepreneur and investor, Christian Angermayer.

With more than $3 billion under management through his Apeiron Investment Group, Angermayer is a major figure in the longevity sector through his platform biotech companies Cambrian and Rejuveron – building on his belief that everyone wants to live healthier, happier and longer lives.

Ahead of Berlin’s meeting, our editor-in-chief caught up with Angermayer for a video interview in which he shares his views on subjects ranging from longevity investing, the biotech market, and what’s happening with his $200 million SPAC with David Sinclair and Peter Attia
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>865falsefullhttps://www.spreaker.com/episode/michael-antonov-longevity-is-all-about-tackling-true-unknowns--74822952Michael Antonov is a serial entrepreneur and philanthropist who is passionate about challenging the problem of aging. From Co-founder and CTO of Scaleform, a user interface software company, whose product is embedded into hundreds of computer, console and mobile games, Antonov went on to co-found Oculus, where as Chief Software Architect, he helped revive the virtual reality industry. Oculus was acquired by Facebook, and Antonov has moved on to found Formic Ventures, a diversified VC that makes early-stage investments in biotech start-ups.

Longevity.Technology: Whether it’s debugging biology, or applying rigorous logic to decide on an intervention, Michael Antonov takes an analytical approach to decision making, but his philosophy is broader than that. Committed to innovation and to reinvention, his VC Formic is all about providing people with the right tools to leverage technology, and by doing so, try to expand human lifespan and accelerate the development of human progress by fighting entropy itself.

Check out our fascinating interview with Michael Antonov, in which we find out more about applying software logic to challenge aging, the appeal of cellular reprogramming and understanding the spin when investing in supplements.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686558Thu, 11 Aug 2022 13:09:08 +0000saderThe Co-founder of Formic Ventures is using logic and innovation to drive the longevity sector forward. Michael Antonov is a serial entrepreneur and philanthropist who is passionate about challenging the problem of aging. From Co-founder and CTO of...Michael Antonov is a serial entrepreneur and philanthropist who is passionate about challenging the problem of aging. From Co-founder and CTO of Scaleform, a user interface software company, whose product is embedded into hundreds of computer, console and mobile games, Antonov went on to co-found Oculus, where as Chief Software Architect, he helped revive the virtual reality industry. Oculus was acquired by Facebook, and Antonov has moved on to found Formic Ventures, a diversified VC that makes early-stage investments in biotech start-ups.

Longevity.Technology: Whether it’s debugging biology, or applying rigorous logic to decide on an intervention, Michael Antonov takes an analytical approach to decision making, but his philosophy is broader than that. Committed to innovation and to reinvention, his VC Formic is all about providing people with the right tools to leverage technology, and by doing so, try to expand human lifespan and accelerate the development of human progress by fighting entropy itself.

Check out our fascinating interview with Michael Antonov, in which we find out more about applying software logic to challenge aging, the appeal of cellular reprogramming and understanding the spin when investing in supplements.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>983falsefullhttps://www.spreaker.com/episode/sergey-young-breaking-the-barrier-of-maximum-lifespan--74823063
Sergey Young, the longevity investor and founder of the Longevity Vision Fund is on a mission to extend healthy lifespans of at least one billion people. His new book, Growing Young, is released on 24th August and is already rising up the Amazon charts.

“It’s been amazing three years journey,” Young told Longevity.Technology. “I spent hours and days in different labs in the best clinics in the world and best academic institutions. I even talked to Peter Jackson! I’m very excited to share with everyone, so every reader can start their longevity journey today.”

Check out our fascinating interview with Sergey Young, in which we find out more about his new book and his take on the current longevity space.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686619Thu, 11 Aug 2022 13:07:53 +0000saderAhead of the launch of his new book Growing Young, Sergey Young joins us for a video interview to discuss longevity horizons, personal health strategies and disruptive tech – and how we are moving towards radically extending our lifespan and...
Sergey Young, the longevity investor and founder of the Longevity Vision Fund is on a mission to extend healthy lifespans of at least one billion people. His new book, Growing Young, is released on 24th August and is already rising up the Amazon charts.

“It’s been amazing three years journey,” Young told Longevity.Technology. “I spent hours and days in different labs in the best clinics in the world and best academic institutions. I even talked to Peter Jackson! I’m very excited to share with everyone, so every reader can start their longevity journey today.”

Check out our fascinating interview with Sergey Young, in which we find out more about his new book and his take on the current longevity space.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>932falsefullhttps://www.spreaker.com/episode/guy-perelmuter-deep-tech-is-the-key-driver-for-longevity--74823068
Guy Perelmuter is the award-winning author of Present Future, a book about understanding how technology has shaped the world and the constant changes we experience as a species. It is about making sure we understand the origins of some of the key technologies that are transforming the modern world and their impacts on society, the economy and the environment.

And, of course, an enormous disruptor of society is the quest for longevity – living longer and living more healthily, with the debilitating diseases of aging consigned to the history books.

Guy joined me to discuss the nature of change and the future of technology.

--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686632Thu, 11 Aug 2022 13:06:51 +0000saderDeep tech disruption can change life expectancy and mindset – author Guy Perelmuter explains how. Guy Perelmuter is the award-winning author of Present Future, a book about understanding how technology has shaped the world and the constant changes we...
Guy Perelmuter is the award-winning author of Present Future, a book about understanding how technology has shaped the world and the constant changes we experience as a species. It is about making sure we understand the origins of some of the key technologies that are transforming the modern world and their impacts on society, the economy and the environment.

And, of course, an enormous disruptor of society is the quest for longevity – living longer and living more healthily, with the debilitating diseases of aging consigned to the history books.

Guy joined me to discuss the nature of change and the future of technology.

--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>875falsefullhttps://www.spreaker.com/episode/aubrey-de-grey-on-why-the-methuselarity-will-happen-by-2035-and-why-it-will-be-free--74822980
Then we went one better and interviewed Dr Aubrey de Grey, founder and Chief Science Officer of SENS Research Foundation and member of our Advisory Panel. Dr de Grey also contributed the foreword for the above report. We asked him the same six questions (and a few of our own) and he gave some pretty fascinating answers – candid and on camera.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686607Thu, 11 Aug 2022 13:05:17 +0000saderAs part of Longevity.Technology’s research for our senotherapeutics report, we conducted a survey on a panel of 18 researchers and executives, all experts in the senotherapeutics field. This survey was designed to derive well informed insights on the...
Then we went one better and interviewed Dr Aubrey de Grey, founder and Chief Science Officer of SENS Research Foundation and member of our Advisory Panel. Dr de Grey also contributed the foreword for the above report. We asked him the same six questions (and a few of our own) and he gave some pretty fascinating answers – candid and on camera.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1610falsefullhttps://www.spreaker.com/episode/epigenetic-testing-promoting-healthy-longevity-with-erin-sharoni-foxo-technologies--74822974
Biotech company FOXO is aiming to make longevity science fundamental to life insurance by applying epigenetic science and AI to commercialise saliva-based biomarkers, and the company has recently appointed Erin Sharoni as Chief Product Officer of FOXO LIFE, a life insurance company that is powered by molecular health technology.

Erin Sharoni directs FOXO’s consumer-based health and wellness research objectives, which aim to provide consumers with a compelling user experience; with the worlds of epigenetic testing, personalised health and hyper-individualised insurance premiums colliding, we wanted to find out more about what epigenetic tests mean for insurance – and for longevity.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686621Thu, 21 Jul 2022 10:47:59 +0000saderErin Sharoni of FOXO on using epigenetic testing to optimise longevity and wellbeing. Biotech company FOXO is aiming to make longevity science fundamental to life insurance by applying epigenetic science and AI to commercialise saliva-based...
Biotech company FOXO is aiming to make longevity science fundamental to life insurance by applying epigenetic science and AI to commercialise saliva-based biomarkers, and the company has recently appointed Erin Sharoni as Chief Product Officer of FOXO LIFE, a life insurance company that is powered by molecular health technology.

Erin Sharoni directs FOXO’s consumer-based health and wellness research objectives, which aim to provide consumers with a compelling user experience; with the worlds of epigenetic testing, personalised health and hyper-individualised insurance premiums colliding, we wanted to find out more about what epigenetic tests mean for insurance – and for longevity.
--------------------------------
Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>1383falsefullhttps://www.spreaker.com/episode/dr-frank-lipman-explains-the-importance-of-nmn-and-nad--74823020
Longevity.Technology recommends Elevant: a clinically-tested, high purity supplement, that works directly within your cells to boost energy. Boom!

Dr Frank Lipman is one of longevity's trailblazers; the founder of the Eleven Eleven Wellness Center and New York Times best-selling author of seven books, he is passionate about health being a synergy of physical, mental, emotional, spiritual and social wellbeing and advocates for the journey towards it taking a holistic approach that embraces a variety of disciplines.

Dr Lipman recommends Elevant NMN-C to some of his patients and also takes it himself; recently, we were fortunate enough to sit down with Dr Lipman to talk about his proactive and preventative approach to longevity.

Use the code LT20 to get 20% off any Elevant NMN supplement.
Visit Elevant - https://bit.ly/3RI3u9C

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686590Mon, 18 Jul 2022 15:45:24 +0000saderFrom working at a cellular level to playing a part in holistic longevity strategy, Dr Frank Lipman explains the value of Elevant's NMN-C. Longevity.Technology recommends Elevant: a clinically-tested, high purity supplement, that works directly within...
Longevity.Technology recommends Elevant: a clinically-tested, high purity supplement, that works directly within your cells to boost energy. Boom!

Dr Frank Lipman is one of longevity's trailblazers; the founder of the Eleven Eleven Wellness Center and New York Times best-selling author of seven books, he is passionate about health being a synergy of physical, mental, emotional, spiritual and social wellbeing and advocates for the journey towards it taking a holistic approach that embraces a variety of disciplines.

Dr Lipman recommends Elevant NMN-C to some of his patients and also takes it himself; recently, we were fortunate enough to sit down with Dr Lipman to talk about his proactive and preventative approach to longevity.

Use the code LT20 to get 20% off any Elevant NMN supplement.
Visit Elevant - https://bit.ly/3RI3u9C

Visit Longevity.Technology - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>633falsefullhttps://www.spreaker.com/episode/longeveron-s-dr-joshua-hare-talks-frailty-alzheimer-s-and-cell-therapy-clinical-trials--74823054
With work ongoing to advance clinical research in Alzheimer's using a cell therapy approach and to develop a regenerative medicine approach for intervention and treatment of frailty, we sat down with Dr Hare to find out more about Longeveron and its lead investigational product Lomecel-B, which is derived from culture-expanded medicinal signalling cells (also called mesenchymal stromal cells, or MSCs).

Visit us - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686608Fri, 15 Jul 2022 11:26:56 +0000saderLongeveron is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Double board-certified cardiologist Dr Joshua Hare co-founded Longeveron as a spin-out from the University of Miami...
With work ongoing to advance clinical research in Alzheimer's using a cell therapy approach and to develop a regenerative medicine approach for intervention and treatment of frailty, we sat down with Dr Hare to find out more about Longeveron and its lead investigational product Lomecel-B, which is derived from culture-expanded medicinal signalling cells (also called mesenchymal stromal cells, or MSCs).

Visit us - https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter - https://bit.ly/3AMIXuq
Facebook - https://bit.ly/3z8H1v5
Instagram - https://bit.ly/3IDvVRX
Linkedin - https://bit.ly/3yIfDmf]]>865falsefullhttps://www.spreaker.com/episode/winning-strategy-performance-coach-david-bailey-discusses-tour-de-france-and-urolithin-a--74823014
David Bailey, PhD, is a performance consultant in World Tour cycling; he manages performance projects focused on athlete physical preparation, equipment development, sports nutrition and related performance interventions that target success at World Tour level.]]>https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686531Wed, 29 Jun 2022 14:30:34 +0000saderRacing for longevity – from honing performance to maximising muscle recovery, the Tour de France is a strategic battle for cyclist and team. David Bailey, PhD, is a performance consultant in World Tour cycling; he manages performance projects focused...
David Bailey, PhD, is a performance consultant in World Tour cycling; he manages performance projects focused on athlete physical preparation, equipment development, sports nutrition and related performance interventions that target success at World Tour level.]]>611falsefullhttps://www.spreaker.com/episode/urolithin-a-the-small-molecule-that-packs-a-big-punch--74823030https://app.pigeonpod.cloud/feed/2094987252491399169/episode/2094987462993686609Wed, 23 Mar 2022 16:47:58 +0000saderWe talk to Chris Rinsch the CEO of Amazentis to find out more about Mitopure, the urolithin A longevity supplement you need to know about.717falsefull